

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 November 2002 (28.11.2002)

PCT

(10) International Publication Number
WO 02/094770 A2(51) International Patent Classification⁷: C07C 317/32,
C07D 209/88, 215/36, 209/08, 333/34, 271/06, C07C
323/62, 317/44, C07D 213/30, 263/22, 257/04, 213/82,
213/61, 213/70, 213/38, 277/46, 257/06, 277/34, 211/46,
A61K 31/10, A61P 13/00

(21) International Application Number: PCT/JP02/04865

(22) International Filing Date: 20 May 2002 (20.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PR5232 24 May 2001 (24.05.2001) AU
PR9780 28 December 2001 (28.12.2001) AU
PS0799 28 February 2002 (28.02.2002) AU

(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SAKURAI, Minoru [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). WASHIZUKA, Kenichi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). HAMASHIMA, Hitoshi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). TOMISHIMA, Yasuyo [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka

541-8514 (JP). IMANISHI, Masashi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). KAYAKIRI, Hiroshi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). TANIGUCHI, Kiyoshi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). TAKAMURA, Fujiko [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(74) Agent: TABUSHI, Eiji; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.





(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: AMINOALCOHOL DERIVATIVES



(57) Abstract: The present invention relates to a compound formula wherein R¹ is phenyl, pyridyl, etc., each of which may be substituted with one or two substituent(s); R² is hydrogen, an amino protective group, etc.; R³ and R⁴ are each independently hydrogen, lower alkyl or hydroxy(lower)alkyl; R⁵ is aryl, ar(lower)alkyl, etc., each of which may be substituted with one, two or three substituent(s); R⁸ is hydrogen or halogen, X is a single bond or O-CH₂-, and n is 0, 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.

WO 02/094770 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DESCRIPTION

AMINOALCOHOL DERIVATIVES

5 TECHNICAL FIELD

This invention relates to new aminoalcohol derivatives and salts thereof which are beta-3 (β_3) adrenergic receptor agonists and useful as a medicament.

10 DISCLOSURE OF INVENTION

This invention relates to new aminoalcohol derivatives which are β_3 adrenergic receptor agonists and salts thereof.

More particularly, it relates to new aminoalcohol derivatives and salts thereof which have gut sympathomimetic, 15 anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence, anti-pollakiuria activities, anti-diabetes and anti-obesity, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment 20 and/or prevention of gastro-intestinal disorders caused by smooth muscle contractions in a human being or an animal.

One object of this invention is to provide new and useful aminoalcohol derivatives and salts thereof which have gut sympathomimetic, anti-ulcerous, lipolytic, anti-urinary 25 incontinence, anti-pollakiuria activities, anti-diabetes and anti-obesity.


Another object of this invention is to provide processes for the preparation of said aminoalcohol derivatives and salts thereof.

30 A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said aminoalcohol derivatives and salts thereof.

Still further object of this invention is to provide a 35 therapeutical method for the treatment and/or prevention of aforesaid diseases in a human being or an animal, using said

aminoalcohol derivatives and salts thereof.


The object aminoalcohol derivatives of this invention are new and can be represented by compound of the following
5 formula [II]:



10


wherein

R¹ is phenyl, pyridyl, indolyl or carbazolyl, each of which may be substituted with one or two same or different substituent(s) selected from a group consisting of halogen; hydroxy; benzyloxy; nitro; cyano; mono(or di or tri)halo(lower)alkyl; and (lower alkylsulfonyl)amino, R² is hydrogen, [5-(lower alkyl)-2-oxo-1,3-dioxol-4-yl](lower)alkoxycarbony or an amino protective group, R³ and R⁴ are each independently hydrogen, lower alkyl or hydroxy(lower)alkyl,



R⁵ is aryl, ar(lower)alkyl, a heterocyclic group or lower alkyl, each of which may be substituted with one, two or three same or different substituent(s) selected from a group consisting of halogen; hydroxy; cyano; amino(hydroxyimino)methyl; phenyl optionally substituted with carboxy or lower alkoxy carbonyl; phenoxy optionally substituted with halogen; lower alkoxy optionally substituted with hydroxy, amino, cyano, carboxy, carbamoyl, mono(or di)(lower)alkylcarbamoyl, lower alkoxy carbonyl, cyclo(lower)alkyloxy carbonyl, hydroxy(lower)alkoxy carbonyl,

di[(lower)alkoxy](lower)alkoxycarbonyl,
 pyridyl(lower)alkoxycarbonyl, phenyl or tetrazolyl;
 mono(or di or tri)halo(lower)alkoxy; lower alkyl
 optionally substituted with carboxy, lower
 5 alkoxy, dioxothiazolidinyl or
 dioxothiazolidinylidene; lower alkenyl optionally
 substituted with carboxy or lower alkoxy; carbonyl;
 oxadiazolyl optionally substituted with lower alkyl;
 tetrazolyl; triazolylthio; lower alkanoyl; carboxy;
 10 lower alkoxy; carbamoyl optionally substituted
 with one or two same or different substituent(s)
 selected from a group consisting of lower alkyl, lower
 alkoxy, carboxy(lower)alkyl, lower
 alkoxy(lower)alkyl, tetrazolyl, thiazolyl
 15 optionally substituted with lower alkyl, oxazolyl
 optionally substituted with lower alkyl, oxadiazolyl,
 lower alkylsulfonyl and phenylsulfonyl;
 (hydroxypiperidino)carbonyl; (2,4-dioxo-1,3-
 thiazolidin-5-ylidene)methyl; and amino optionally
 20 substituted with one or two same or different
 substituent(s) selected from a group consisting of
 lower alkyl, lower alkanoyl, benzoyl, pyridylcarbonyl,
 lower alkylsulfonyl, phenylsulfonyl, carbamoyl, lower
 alkylcarbamoyl, phenylcarbamoyl, lower alkoxy
 25 and phenoxy, carbonyl,
 or




in which R^6 and R^7 are each independently hydrogen,
 carboxy or lower alkoxy, carbonyl,
 35 R^8 is hydrogen or halogen,

X is a single bond or $-O-CH_2-$, and
 n is 0, 1 or 2,
 or a salt thereof.

5 According to this invention, the object compounds can
 be prepared by processes which are illustrated in the
 following schemes.

Process 1

10




[II]

[III]

or a salt thereof

or a salt thereof

15




[I]

or a salt thereof

20

Process 2

25




[Ia]

or a salt thereof

30



elimination reaction
 of the amino
 protective group



[Ib]

or a salt thereof

35

Process 3

15 wherein R^1 , R^2 , R^3 , R^4 , $\text{C}(\text{R}^5)(\text{R}^8)$, R^5 , R^8 , X and n are each as defined above,

R_a^2 is [5-(lower alkyl)-2-oxo-1,3-dioxol-4-yl](lower)alkoxycarbonyl or an amino protective group,

20 R^9 is lower alkyl optionally substituted with hydroxy, amino, cyano, carboxy, carbamoyl, mono(or di)(lower)alkylcarbamoyl, lower alkoxycarbonyl, cyclo(lower)alkyloxycarbonyl, hydroxy(lower)alkoxycarbonyl, di[(lower)alkoxy](lower)alkoxycarbonyl, pyridyl(lower)alkoxycarbonyl, phenyl or tetrazolyl, and

Y is halogen.

30

As to the starting compounds [II], [III], [Ia], [Ic] and [IV], some of them are novel and can be prepared by the procedures described in the Preparations and Examples mentioned later or a conventional manner.

35

In the above and subsequent description of the present specification, suitable examples of the various definition to be included within the scope of the invention are explained in detail in the following.

5

The term "lower" is intended to mean a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise indicated.

10

Suitable "lower alkyl" and "lower alkyl" moiety in the terms of "(lower alkylsulfonyl)amino", "di(lower)alkyl-carbamoyl", etc. may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 15 1-methylpentyl, tert-pentyl, neo-pentyl, hexyl, isohexyl and the like, in which more preferable one is C₁-C₄ alkyl, and the most preferable one is methyl.

20

Suitable "lower alkenyl" may include vinyl, 1-(or 2)-propenyl, 1-(or 2- or 3-)butenyl, 1-(or 2- or 3- or 4)-pentenyl, 1-(or 2- or 3- or 4- or 5-)hexenyl, methylvinyl, ethylvinyl, 1-(or 2- or 3-)methyl-1-(or 2-)propenyl, 1-(or 2- or 3-)ethyl-1-(or 2-)propenyl, 1-(or 2- or 3- or 4-)methyl-1-(or 2- or 3-)butenyl and the like, in which more 25 preferable one may be C₂-C₄ alkenyl.

30

Suitable "cyclo(lower)alkyl" moiety in the term of "cyclo(lower)alkyloxycarbonyl" may include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, in which more preferable one is cyclo(C₃-C₆)alkyl, and the most preferable one is cyclohexyl.

35

Suitable "lower alkoxy" and "lower alkoxy" moiety in the terms of "mono(or di or tri)(lower)alkoxy" and "lower alkoxycarbonyl" may include methoxy, ethoxy, propoxy,

isopropoxy, butoxy, iso-butoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy and the like, in which preferable one is C₁-C₄ alkoxy, and the most preferable one is methoxy or ethoxy.

5

Suitable "lower alkanoyl" may include formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl and the like, in which preferable one is C₂-C₄ alkanoyl, and the most preferable one is formyl.

10

Suitable "halogen" may be fluoro, chloro, bromo and iodo, in which preferable one is chloro.

15

Suitable "aryl" and "aryl" moiety in the term of "ar(lower)alkyl" may include phenyl, naphthyl, anthryl and the like, in which the preferred one may be phenyl.

20

Suitable example of "heterocyclic group" may include unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 1H-1,2,4-triazolyl, 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl or 2H-1,2,3-triazolyl), tetrazolyl (e.g. 1H-1,2,3,4-tetrazolyl, 2H-1,2,3,4-tetrazolyl, etc.), etc.;

25

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, azetidyl, etc.;

30

unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indoliziny, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, etc.;

35

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, morpholino, etc.;

10 unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;

20 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example thiazolidinyl, thiomorpholinyl, thiomorpholino, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s), for example, thienyl, dihydrodithiynyl, dihydrodithionyl, etc.;

30 unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, imidazothiadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, furyl etc.;

35 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen

atom(s), for example, tetrahydrofuran, tetrahydropyran, dioxacyclopentane, dioxacyclohexane, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom and 1 or 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;

unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s), for example benzothienyl, benzodithiyl, etc.;

unsaturated condensed heterocyclic group containing an oxygen atom and 1 or 2 sulfur atom(s), for example, benzoxathiinyl, etc.; and the like.

Suitable "mono(or di or tri)halo(lower)alkoxy" may include chloromethoxy, dichloromethoxy, trichloromethoxy, bromomethoxy, dibromomethoxy, tribromomethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 1 or 2-chloroethoxy, 1 or 2-bromoethoxy, 1 or 2-fluoroethoxy, 1,1-difluoroethoxy, 2,2-difluoroethoxy and the like, in which more preferable one is mono(or di or tri)halo(C₁-C₄)alkoxy, and the most preferable one is difluoromethoxy.

Suitable example of "amino protective group" moiety may be common amino protective group such as substituted or unsubstituted lower alkanoyl [e.g. formyl, acetyl, propionyl, trifluoroacetyl, etc.], phthaloyl, lower alkoxy carbonyl [e.g. tert-butoxycarbonyl, tert-amylloxycarbonyl, etc.], substituted or unsubstituted aralkyloxycarbonyl [e.g. benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.], substituted or unsubstituted arenesulfonyl [e.g. benzenesulfonyl, tosyl, etc.], nitrophenylsulfenyl, ar(lower)alkyl [e.g. trityl, benzyl, etc.], and the like, in which preferable one is benzyl.

Suitable salts of the object aminoalcohol derivative

[I] are pharmaceutically acceptable salts and include conventional non-toxic salts such as an inorganic acid addition salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], an organic acid addition salt [e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartrate, citrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc., an alkali metal salt [e.g. sodium salt, potassium salt, etc.] or the like.

10 The Processes 1 to 3 for preparing the object compounds of the present invention are explained in detail in the following.

Process 1

15 The object compound [I] or a salt thereof can be prepared by reacting a compound [II] or a salt thereof with a compound [III] or a salt thereof.

Suitable salt of the compounds [II] and [III] may be the same as those exemplified for the compound [I].

20 The reaction is preferably carried out in the presence of a base such as an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g. magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], tri(lower)alkylamine [e.g. trimethylamine, triethylamine, etc.], picoline or the like.

25 The reaction is usually carried out in a conventional solvent, such as an alcohol [e.g. methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not adversely influence the reaction.

The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.

35 Process 2

The object compound [Ib] or a salt thereof can be prepared by subjecting a compound [Ia] or a salt thereof to elimination reaction of the amino protective group.

Suitable salts of the compounds [Ia] and [Ib] may be the same as those exemplified for the compound [I].

This reaction can be carried out in a similar manner to that of Example 8 or 9 mentioned below.

Process 3

The object compound [Id] or a salt thereof can be prepared by reacting a compound [Ic] or a salt thereof with a compound [IV] or a salt thereof.

Suitable salts of the compounds [Ic] and [IV] may be the same as those exemplified for the compound [I].

This reaction can be carried out in a similar manner to that of Example 19 or 21.

The compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like, and converted to the desired salt in conventional manners, if necessary.

It is to be noted that the compound [I] and the other compounds may include one or more stereoisomers due to asymmetric carbon atoms, and all of such isomers and mixture thereof are included within the scope of this invention.

It is further to be noted that isomerization or rearrangement of the object compound [I] may occur due to the effect of the light, acid base or the like, and the compound obtained as the result of said isomerization or rearrangement is also included within the scope of the present invention.

It is also to be noted that the solvating form of the compound [I] (e.g. hydrate, etc.) and any form of the crystal of the compound [I] are included within the scope of

the present invention.

The object compound [I] or a salt thereof possesses gut
sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic,
5 anti-urinary incontinence and anti-pollakiuria activities,
and are useful for the treatment and/or prevention of
gastro-intestinal disorders caused by smooth muscle
contractions in human beings or animals, and more
particularly for the treatment and/or prevention of spasm or
10 hyperanakinesia in case of irritable bowel syndrome,
gastritis, gastric ulcer, duodenal ulcer, enteritis,
cholecystopathy, cholangitis, urinary calculus and the like;
for the treatment and/or prevention of ulcer such as gastric
ulcer, duodenal ulcer, peptic ulcer, ulcer causes by non
15 steroidal anti-inflammatory drugs, or the like; for the
treatment and/or prevention of dysuria such as pollakiuria,
urinary incontinence or the like in case of nervous
pollakiuria, neurogenic bladder dysfunction, nocturia,
unstable bladder, cystospasm, chronic cystitis, chronic
20 prostatitis, prostatic hypertrophy or the like; for the
treatment and/or prevention of pancreatitis, obesity,
diabetes, glycosuria, hyperlipidemia, hypertension,
atherosclerosis, glaucoma, melancholia, depression or the
like; for the treatment and/or prevention of diseases as the
25 result of insulin resistance (e.g. hypertension,
hyperinsulinemia, etc.); for the treatment and/or prevention
of neurogenetic inflammation; and for reducing a wasting
condition, and the like.

Additionally, β_3 adrenergic receptor agonists are known
30 to lower triglyceride and cholesterol levels and to raise
high density lipoprotein levels in mammals (US Patent No.
5,451,677). Accordingly, the object compound [I] is useful
in the treatment and/or prevention of conditions such as
hyper-triglyceridaemia, hypercholesterolaemia and in
35 lowering high density lipoprotein levels as well as in the

treatment of atherosclerotic and cardiovascular diseases and relates conditions.

Moreover, the object compound [I] is useful for
5 inhibiting uterine contractions, preventing premature labor, and treating and preventing dysmenorrhea.

In order to show the usefulness of the compound [I] for the prophylactic and therapeutic treatment of above-
10 mentioned disease in human being or animals, the pharmacological test data of a representative compound thereof are shown in the following.

Test

15 Effect on the increase in intravesical pressure induced by carbachol in anesthetized dog

Test Compound

(1) (2S)-2-[(2S)-2-Hydroxy-3-phenoxypropyl amino]-3-[4-
20 (phenylsulfonyl)phenyl]-1-propanol (the object compound of Example 8 mentioned below)

Test Method

Female Beagle dogs weighing 8.0-15.0 kg were fasted for
25 24 hours and maintained under halothane anesthesia. A 12F Foley catheter was lubricated with water soluble jelly, inserted into the urethral orifice and advanced approximately 10 cm until the balloon tip was placed well inside the bladder. The balloon was then inflated with 5 ml
30 of room air and catheter slowly withdrawn just past the first resistance that is felt at the bladder neck. Urine was completely drained out through the catheter, and 30 ml of biological saline was infused. The catheter was connected to pressure transducer, and intravesical pressure
35 was continuously recorded. Intraduodenal administration of

test compound (I) inhibited carbachol (1.8 µg/kg)-induced increase in intravesical pressure (IVP).

Test Results

5

Treatment	% inhibition of carbachol-induced increase in IVP
Test Compound (I) (0.32 mg/kg)	30%

Preferred embodiments of the object compound [I] are as follows:

- 10 R¹ is phenyl, pyridyl, indolyl or carbazolyl, each of which may be substituted with one or two same or different substituent(s) selected from a group consisting of halogen (more preferably fluoro or chloro); hydroxy; benzyloxy; nitro; cyano; mono(or di or
- 15 tri)halo(lower)alkyl (more preferably mono(or di or tri)halo(C₁-C₄)alkyl, most preferably trifluoromethyl) and (lower alkylsulfonyl)amino (more preferably (C₁-C₄ alkylsulfonyl)amino, most preferably (methanesulfonyl)amino),
- 20 R² is hydrogen, [5-(lower alkyl)-2-oxo-1,3-dioxol-4-yl](lower)alkoxycarbonyl (more preferably [5-(C₁-C₄ alkyl)-2-oxo-1,3-dioxol-4-yl](C₁-C₄)-alkoxycarbonyl, most preferably (5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl), lower alkoxycarbonyl
- 25 (more preferably C₁-C₄ alkoxycarbonyl, most preferably tert-butoxycarbonyl) or ar(lower)alkyl (more preferably ar(C₁-C₄)alkyl, most preferably benzyl),
- R³ and R⁴ are each independently hydrogen, lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl) or
- 30 hydroxy(lower)alkyl (more preferably hydroxy(C₁-C₄)-alkyl, most preferably hydroxymethyl),

R⁵ is aryl (more preferably phenyl), ar(lower)alkyl (more preferably ar(C₁-C₄)alkyl, most preferably benzyl), a heterocyclic group (more preferably unsaturated 3 to 8-membered (more preferably 5 or 6-membered)

5 heteromonocyclic group containing 1 to 4 nitrogen atom(s), unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), unsaturated 3 to 8-membered (more preferably 5 or 6-membered)

10 heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) or unsaturated 3 to 8-membered (more preferably 5 or 6-membered)

15 heteromonocyclic group containing 1 or 2 sulfur atom(s), most preferably triazolyl (most preferably 1H-1,2,4-triazolyl), tetrazolyl (most preferably 1H-1,2,3,4-tetrazolyl), quinolyl, thiazolyl or thienyl) or lower alkyl (more preferably C₁-C₄ alkyl, most preferably propyl), each of which may be substituted with one, two or three same or different substituent(s) selected from

20 a group consisting of halogen (more preferably fluoro or chloro); hydroxy; cyano; amino(hydroxyimino)methyl; phenyl optionally substituted with carboxy or lower alkoxy carbonyl (more preferably C₁-C₄ alkoxy carbonyl, most preferably ethoxy carbonyl); phenoxy optionally substituted with halogen (more preferably fluoro);

25 lower alkoxy (more preferably C₁-C₄ alkoxy, most preferably methoxy, ethoxy or isopropoxy) optionally substituted with hydroxy, amino, cyano, carboxy, carbamoyl, mono(or di)(lower)alkylcarbamoyl (more preferably mono(or di)(C₁-C₄)alkylcarbamoyl, most


30 preferably methylcarbamoyl or dimethylcarbamoyl), lower alkoxy carbonyl (more preferably C₁-C₄ alkoxy carbonyl, most preferably methoxy carbonyl, ethoxy carbonyl, propoxy carbonyl, isopropoxy carbonyl or tert-butoxy carbonyl), cyclo(lower)alkyloxy carbonyl (more

35 preferably cyclo(C₃-C₆)alkyloxy carbonyl, most


preferably cyclohexyloxycarbonyl),
hydroxy(lower)alkoxycarbonyl (more preferably
hydroxy(C₁-C₄)alkoxycarbonyl, most preferably 2-
hydroxyethoxycarbonyl), di[(lower)alkoxy](lower)-
5 alkoxycarbonyl (more preferably di[(C₁-C₄)alkoxy]-
(C₁-C₄)alkoxycarbonyl, most preferably 2-ethoxy-1-
(ethoxymethyl)ethoxycarbonyl),
pyridyl(lower)alkoxycarbonyl (more preferably
pyridyl(C₁-C₄)alkoxycarbonyl, most preferably 2-
10 pyridylmethoxycarbonyl), phenyl or tetrazolyl (more
preferably 1H-1,2,3,4-tetrazolyl); mono(or di or
tri)halo(lower)alkoxy (more preferably mono(or di or
tri)halo(C₁-C₄)alkoxy, most preferably fluoromethoxy,
difluoromethoxy or trifluoromethoxy); lower alkyl (more
15 preferably C₁-C₄ alkyl, most preferably methyl or
ethyl) optionally substituted with carboxy, lower
alkoxycarbonyl (more preferably C₁-C₄ alkoxycarbonyl,
most preferably ethoxycarbonyl), dioxothiazolidinyl
(more preferably 2,4-dioxothiazolidinyl) or
20 dioxothiazolidinylidene (more preferably 2,4-
dioxothiazolidinylidene); lower alkenyl (more
preferably C₂-C₄ alkenyl, most preferably vinyl)
optionally substituted with carboxy or lower
alkoxycarbonyl (more preferably C₁-C₄ alkoxycarbonyl,
25 most preferably ethoxycarbonyl); oxadiazolyl (more
preferably 1,2,4-oxadiazolyl) optionally substituted
with lower alkyl (more preferably C₁-C₄ alkyl, most
preferably methyl); tetrazolyl (more preferably 1H-
1,2,3,4-tetrazolyl); triazolylthio (more preferably 1H-
30 1,2,4-triazol-3-ylthio); lower alkanoyl (more
preferably C₁-C₄ alkanoyl, most preferably formyl);
carboxy; lower alkoxycarbonyl (more preferably C₁-C₄
alkoxycarbonyl, most preferably ethoxycarbonyl);
carbamoyl optionally substituted with one or two same
35 or different substituent(s) selected from a group

consisting of lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl), lower alkoxy (more preferably C₁-C₄ alkoxy, most preferably methoxy), carboxy(lower)alkyl (more preferably carboxy(C₁-C₄)-alkyl, most preferably carboxymethyl or 2-carboxyethyl), lower alkoxy-carbonyl(lower)alkyl (more preferably C₁-C₄ alkoxy-carbonyl(C₁-C₄)-alkyl, most preferably ethoxy-carbonylmethyl or 2-(ethoxy-carbonyl)ethyl), thiazolyl optionally substituted with lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl), oxazolyl optionally substituted with lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl), oxaziazolyl (more preferably 1,2,4-oxaziazolyl), lower alkylsulfonyl (more preferably C₁-C₄ alkylsulfonyl, most preferably methanesulfonyl) and phenylsulfonyl; (hydroxypiperidino)carbonyl; (2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl; and amino optionally substituted with one or two same or different substituent(s) selected from a group consisting of lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl), lower alkanoyl (more preferably C₁-C₄ alkanoyl, most preferably acetyl), benzoyl, pyridylcarbonyl, lower alkylsulfonyl (more preferably C₁-C₄ alkylsulfonyl, most preferably methanesulfonyl), phenylsulfonyl, carbamoyl, lower alkylcarbamoyl (more preferably C₁-C₄ alkylcarbamoyl, most preferably methylcarbamoyl), phenylcarbamoyl, lower alkoxy-carbonyl (more preferably C₁-C₄ alkoxy-carbonyl, most preferably methoxy-carbonyl) and phenoxy-carbonyl,

or



or

in which R⁶ and R⁷ are

each independently hydrogen, carboxy or lower
alkoxycarbonyl (more preferably C₁-C₄ alkoxycarbonyl,
most preferably ethoxycarbonyl), and

5 R⁸ is hydrogen or halogen (more preferably chloro).

More preferred embodiments of the object compound [I]
are as follows:

10 R¹ is phenyl which may be substituted with one or two same
or different substituent(s) selected from a group
consisting of halogen (more preferably fluoro or
chloro); hydroxy; benzyloxy; nitro and (lower
alkylsulfonyl)amino (more preferably (C₁-C₄
15 alkylsulfonyl)amino, most preferably
(methanesulfonyl)amino),

R² is hydrogen or [5-(lower alkyl)-2-oxo-1,3-dioxol-4-
yl](lower)alkoxycarbonyl (more preferably [5-(C₁-C₄
alkyl)-2-oxo-1,3-dioxol-4-yl](C₁-C₄)alkoxycarbonyl,
20 most preferably (5-methyl-2-oxo-1,3-dioxol-4-
yl)methoxycarbonyl),

R³ and R⁴ are each independently hydrogen, lower alkyl (more
preferably C₁-C₄ alkyl, most preferably methyl) or
hydroxy(lower)alkyl (more preferably hydroxy(C₁-C₄)-
25 alkyl, most preferably hydroxymethyl),


R⁵ is phenyl, benzyl, triazolyl (more preferably 1H-1,2,4-
triazolyl), tetrazolyl (more preferably 1H-1,2,3,4-
tetrazolyl), quinolyl, thiazolyl, thienyl or lower
alkyl (more preferably C₁-C₄ alkyl, most preferably
30 propyl), each of which may be substituted with one, two
or three same or different substituent(s) selected from
a group consisting of halogen (more preferably fluoro
or chloro); hydroxy; cyano; amino(hydroxyimino)methyl;
phenyl optionally substituted with carboxy or lower
35 alkoxycarbonyl (more preferably C₁-C₄ alkoxycarbonyl,

most preferably ethoxycarbonyl); phenoxy optionally substituted with halogen (more preferably fluoro); lower alkoxy (more preferably C₁-C₄ alkoxy, most preferably methoxy, ethoxy or isopropoxy) optionally substituted with hydroxy, amino, cyano, carboxy, carbamoyl, mono(or di)(lower)alkylcarbamoyl (more preferably mono(or di)(C₁-C₄)alkylcarbamoyl, most preferably methylcarbamoyl or dimethylcarbamoyl), lower alkoxycarbonyl (more preferably C₁-C₄ alkoxycarbonyl, most preferably methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl or tert-butoxycarbonyl), cyclo(lower)alkyloxycarbonyl (more preferably cyclo(C₃-C₆)alkyloxycarbonyl, most preferably cyclohexyloxycarbonyl), hydroxy(lower)alkoxycarbonyl (more preferably hydroxy(C₁-C₄)alkoxycarbonyl, most preferably 2-hydroxyethoxycarbonyl), di[(lower)alkoxy]-(lower)alkoxycarbonyl (more preferably di[(C₁-C₄)-alkoxy](C₁-C₄)alkoxycarbonyl, most preferably 2-ethoxy-1-(ethoxymethyl)ethoxycarbonyl), pyridyl(lower)alkoxycarbonyl (more preferably pyridyl(C₁-C₄)alkoxycarbonyl, most preferably 2-pyridylmethoxycarbonyl), phenyl or tetrazolyl (more preferably 1H-1,2,3,4-tetrazolyl); mono(or di or tri)halo(lower)alkoxy (more preferably mono(or di or tri)halo(C₁-C₄)alkoxy, most preferably fluoromethoxy, difluoromethoxy or trifluoromethoxy); lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl or ethyl) optionally substituted with carboxy, lower alkoxycarbonyl (more preferably C₁-C₄ alkoxycarbonyl, most preferably ethoxycarbonyl), dioxothiazolidinyl (more preferably 2,4-dioxothiazolidinyl) or dioxothiazolidinylidene (more preferably 2,4-dioxothiazolidinylidene); lower alkenyl (more preferably C₂-C₄ alkenyl, most preferably vinyl)

optionally substituted with carboxy or lower
alkoxycarbonyl (more preferably C₁-C₄ alkoxycarbonyl,
most preferably ethoxycarbonyl); oxadiazolyl (more
preferably 1,2,4-oxadiazolyl) optionally substituted
5 with lower alkyl (more preferably C₁-C₄ alkyl, most
preferably methyl); tetrazolyl (more preferably 1H-
1,2,3,4-tetrazolyl); triazolylthio (more preferably 1H-
1,2,4-triazol-3-ylthio); lower alkanoyl (more
preferably C₁-C₄ alkanoyl, most preferably formyl);
10 carboxy; lower alkoxycarbonyl (more preferably C₁-C₄
alkoxycarbonyl, most preferably ethoxycarbonyl);
carbamoyl optionally substituted with one or two same
or different substituent(s) selected from a group
consisting of lower alkyl (more preferably C₁-C₄ alkyl,
15 most preferably methyl), lower alkoxy (more preferably
C₁-C₄ alkoxy, most preferably methoxy),
carboxy(lower)alkyl (more preferably carboxy(C₁-C₄)-
alkyl, most preferably carboxymethyl or 2-
carboxyethyl), lower alkoxycarbonyl(lower)alkyl (more
20 preferably C₁-C₄ alkoxycarbonyl(C₁-C₄)alkyl, most
preferably ethoxycarbonylmethyl or 2-
(ethoxycarbonyl)ethyl), thiazolyl optionally
substituted with lower alkyl (more preferably C₁-C₄
alkyl, most preferably methyl), oxazolyl optionally
25 substituted with lower alkyl (more preferably C₁-C₄
alkyl, most preferably methyl), oxaziazolyl (more
preferably 1,2,4-oxaziazolyl), lower alkylsulfonyl
(more preferably C₁-C₄ alkylsulfonyl, most preferably
methanesulfonyl) and phenylsulfonyl;
30 (hydroxypiperidino)carbonyl; (2,4-dioxo-1,3-
thiazolidin-5-ylidene)methyl; and
amino optionally substituted with one or two same or
different substituent(s) selected from a group
consisting of lower alkyl (more preferably C₁-C₄ alkyl,
35 most preferably methyl), lower alkanoyl (more

preferably C₁-C₄ alkanoyl, most preferably acetyl), benzoyl, pyridylcarbonyl, lower alkylsulfonyl (more preferably C₁-C₄ alkylsulfonyl, most preferably methanesulfonyl), phenylsulfonyl, carbamoyl, lower alkylcarbamoyl (more preferably C₁-C₄ alkylcarbamoyl, most preferably methylcarbamoyl), phenylcarbamoyl, lower alkoxy carbonyl (more preferably C₁-C₄ alkoxy carbonyl, most preferably methoxy carbonyl) and phenoxy carbonyl,

or




each independently hydrogen, carboxy or lower alkoxy carbonyl (more preferably C₁-C₄ alkoxy carbonyl, most preferably ethoxy carbonyl), and

R⁸ is hydrogen or halogen (more preferably chloro).

More preferred embodiments of the object compound [I] are as follows:

R¹ is phenyl which may be substituted with halogen,

R² is hydrogen,




R⁵ is phenyl which may be substituted with one, two or three same or different substituent(s) selected from a group consisting of halogen; hydroxy; cyano; amino(hydroxyimino)methyl; phenyl optionally substituted with carboxy or lower alkoxy carbonyl; phenoxy optionally substituted with halogen; lower alkoxy optionally substituted with hydroxy, amino,

cyano, carboxy, carbamoyl, mono(or
 di)(lower)alkoxycarbamoyl, lower alkoxycarbonyl,
 cyclo(lower)alkyloxycarbonyl,
 hydroxy(lower)alkoxycarbonyl,
 5 di[(lower)alkoxy](lower)alkoxycarbonyl,
 pyridyl(lower)alkoxycarbonyl, phenyl or tetrazolyl;
 mono(or di or tri)halo(lower)alkoxy; lower alkyl
 optionally substituted with carboxy, lower
 alkoxycarbonyl, dioxothiazolidinyl or
 10 dioxothiazolidinylidene; lower alkenyl optionally
 substituted with carboxy or lower alkoxycarbonyl;
 oxadiazolyl optionally substituted with lower alkyl;
 tetrazolyl; triazolylthio; lower alkanoyl; carboxy;
 lower alkoxycarbonyl; carbamoyl optionally substituted
 15 with one or two same or different substituent(s)
 selected from a group consisting of lower alkyl, lower
 alkoxy, carboxy, lower alkoxycarbonyl, thiazolyl
 optionally substituted with lower alkyl, oxazolyl
 optionally substituted with lower alkyl, oxadiazolyl,
 20 lower alkylsulfonyl or phenylsulfonyl; and amino
 optionally substituted with one or two same or
 different substituent(s) selected from a group
 consisting of lower alkyl and lower alkanoyl,
 R⁸ is hydrogen,
 25 X is a single bond, and
 n is 1.

More preferred embodiments of the object compound [I]
 are as follows:

30 R¹ is phenyl which may be substituted with halogen,
 R² is hydrogen,



- R³ and R⁴ are each hydrogen,
R⁵ is phenyl substituted with lower alkoxy optionally
substituted with a substituent selected from a group
consisting of hydroxy, amino, cyano, carboxy, carbamoyl,
5 mono(or di)(lower)alkoxycarbamoyl, lower alkoxycarbonyl,
cyclo(lower)alkyloxycarbonyl,
hydroxy(lower)alkoxycarbonyl,
di[(lower)alkoxy](lower)alkoxycarbonyl,
pyridyl(lower)alkoxycarbonyl, phenyl and tetrazolyl,
10 R⁸ is hydrogen,
X is a single bond, and
n is 1.

- The following Preparations and Examples are given for
15 the purpose of illustrating this invention.

Preparation 1

- Under nitrogen, to a solution of tert-butyl (S)-2-
hydroxy-1-(4-hydroxybenzyl)ethylcarbamate (24 g) in
20 dichloromethane (500 ml) were added 2,2-dimethoxypropane (34
ml) and p-toluenesulfonic acid monohydrate (1.7 g) at room
temperature, and the mixture was stirred at the same
temperature for 60 hours. The resulting mixture was poured
into saturated aqueous sodium hydrogencarbonate and the
25 aqueous mixture was extracted with ethyl acetate. The
organic layer was washed with brine, dried over anhydrous
magnesium sulfate and evaporated under reduced pressure to
get a solid. Trituration with hexane followed by collection
and dryness in vacuo gave tert-butyl (S)-4-(4-
30 hydroxybenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
(22 g).

NMR (DMSO-d₆, δ): 1.3-1.55 (15H, m), 2.4-2.6 (1H, m),
2.8-2.95 (1H, m), 3.6-4.0 (3H, m), 6.69 (2H, d,
J=8.2Hz), 6.98 (2H, d, J=8.4Hz)

Preparation 2

Under nitrogen, to a solution of tert-butyl (S)-4-(4-hydroxybenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (10 g) in dichloromethane (100 ml) were added 2,6-lutidine (4.2 ml) and trifluoromethanesulfonic anhydride (6.0 ml) at 5°C and the mixture was stirred at the same temperature for 80 minutes. The resulting mixture was poured into ice-cold 0.1N hydrochloric acid and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate, water and brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 10:1) to give tert-butyl (S)-2,2-dimethyl-4-[4-[[trifluoromethyl)sulfonyl]oxy]benzyl]-1,3-oxazolidine-3-carboxylate (13 g).

NMR (CDCl₃, δ): 1.35-1.7 (15H, m), 2.65-2.85 (1H, m), 3.05-3.3 (1H, m), 3.7-4.2 (3H, m), 7.15-7.4 (4H, m)

Preparation 3

Under nitrogen, to a solution of benzenethiol (0.94 ml) in tetrahydrofuran (30 ml) was added dropwise butyllithium (1.52M in hexane, 6.0 ml) in acetone-dry ice bath, and the mixture was stirred at the same temperature for 20 minutes. Under nitrogen, to a solution of tert-butyl (S)-2,2-dimethyl-4-[4-[[trifluoromethyl)sulfonyl]oxy]benzyl]-1,3-oxazolidine-3-carboxylate (3.6 g), lithium chloride (770 mg) and tetrakis(triphenylphosphine)palladium(0) (1.9 g) in tetrahydrofuran (40 ml) was added the above prepared solution at room temperature, and the mixture was refluxed for 40 minutes. The mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. The residue was

purified by column chromatography on silica gel
(hexane:ethyl acetate = 20:1 to 10:1) to give tert-butyl
(S)-2,2-dimethyl-4-[4-(phenylthio)benzyl]-1,3-oxazolidine-3-
carboxylate (1.8 g).

5 NMR (CDCl₃, δ): 1.4-1.7 (15H, m), 2.55-2.75 (1H, m),
3.0-3.25 (1H, m), 3.7-4.2 (3H, m), 7.1-7.4 (9H, m)

Preparation 4

The following compounds were obtained according to a
10 similar manner to that of Preparation 3.

(1) tert-Butyl (S)-4-[4-[(4-methoxyphenyl)thio]benzyl]-2,2-
dimethyl-1,3-oxazolidine-3-carboxylate

15 NMR (CDCl₃, δ): 1.4-1.6 (15H, m), 2.5-2.8 (1H, m), 3.0-
3.3 (1H, m), 3.7-4.2 (6H, m), 6.85-7.5 (8H, m)
(+)ESI-MS (m/z): 452 (M+Na)⁺

(2) tert-Butyl (S)-4-[4-[(4-fluorophenyl)thio]benzyl]-2,2-
dimethyl-1,3-oxazolidine-3-carboxylate

20 NMR (CDCl₃, δ): 1.4-1.65 (15H, m), 2.6-2.75 (1H, m),
3.0-3.25 (1H, m), 3.7-4.2 (3H, m), 6.95-7.5 (8H,
m)
(+)ESI-MS (m/z): 440 (M+Na)⁺

25 (3) tert-Butyl (S)-2,2-dimethyl-4-[4-(2-
thienylthio)benzyl]-1,3-oxazolidine-3-carboxylate

NMR (CDCl₃, δ): 1.4-1.7 (15H, m), 2.55-2.7 (1H, m),
2.95-3.25 (1H, m), 3.65-4.15 (3H, m), 7.05-7.5 (7H,
m)
30 (+)ESI-MS (m/z): 428 (M+H)⁺

Preparation 5

Under nitrogen at 5°C, to a solution of tert-butyl (S)-
2,2-dimethyl-4-[4-(phenylthio)benzyl]-1,3-oxazolidine-3-
35 carboxylate (230 mg) in dichloromethane (10 ml) were added

sodium hydrogen carbonate (170 mg) and m-chloroperbenzoic acid (300 mg) and the mixture was stirred at the same temperature for 1 hour. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 10:1 to 4:1) to give tert-butyl (S)-2,2-dimethyl-4-[4-(phenylsulfonyl)benzyl]-1,3-oxazolidine-3-carboxylate (250 mg).

NMR (CDCl₃, δ): 1.35-1.6 (9H, m), 2.65-2.8 (1H, m),
3.05-3.3 (1H, m), 3.6-3.8 (2H, m), 3.9-4.2 (1H, m),
7.25-7.6 (5H, m), 7.8-8.0 (4H, m)

(+)ESI-MS (m/z): 454 (M+Na)⁺

Preparation 6

The following compounds were obtained according to a similar manner to that of Preparation 5.

(1) tert-Butyl (S)-4-[4-[(4-methoxyphenyl)sulfonyl]benzyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate

NMR (CDCl₃, δ): 2.65-2.8 (1H, m), 3.05-3.3 (1H, m),
3.65-3.85 (2H, m), 3.84 (3H, s), 3.9-4.2 (1H, m),
6.9-7.05 (2H, m), 7.3-7.5 (2H, m), 7.75-7.9 (4H, m)

(+)ESI-MS (m/z): 484 (M+Na)⁺

(2) tert-Butyl (S)-4-[4-[(4-fluorophenyl)sulfonyl]benzyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate

NMR (CDCl₃, δ): 1.4-1.7 (15H, m), 2.7-2.85 (1H, m),
3.05-3.3 (1H, m), 3.65-3.85 (2H, m), 3.9-4.15 (1H, m),
7.1-7.45 (4H, m), 7.8-8.0 (4H, m)

(+)ESI-MS (m/z): 472 (M+Na)⁺

(3) tert-Butyl (S)-2,2-dimethyl-4-[4-(2-thienylsulfonyl)benzyl]-1,3-oxazolidine-3-carboxylate
NMR (CDCl₃, δ): 1.4-1.65 (15H, m), 2.7-2.85 (1H, m),
3.05-3.3 (1H, m), 3.65-3.85 (2H, m), 3.9-4.2 (1H,
5 m), 7.05-7.1 (1H, m), 7.3-7.45 (1H, m), 7.6-7.75
(1H, m), 7.85-7.95 (1H, m)
(+)ESI-MS (m/z): 460 (M+Na)⁺

Preparation 7

10 To a solution of (S)-2,2-dimethyl-4-[4-(phenylsulfonyl)benzyl]-1,3-oxazolidine-3-carboxylate (230 mg) in a mixture of 1,4-dioxane (1 ml) and methanol (1 ml) was added 4N hydrogen chloride in 1,4-dioxane (2 ml) at room temperature, and the mixture was stirred at the same
15 temperature for 2.5 hours. After evaporation under reduced pressure, the residue was dried in vacuo to give (S)-2-amino-3-[4-(phenylsulfonyl)phenyl]-1-propanol hydrochloride (190 mg).

NMR (DMSO-d₆, δ): 2.9-3.0 (2H, m), 3.2-3.6 (3H, m),
20 7.5-8.2 (9H, m)
(+)ESI-MS (m/z): 292 (M-HCl+H)⁺

Preparation 8

The following compounds were obtained according to a
25 similar manner to that of Preparation 7.

(1) (S)-2-Amino-3-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1-propanol hydrochloride

NMR (DMSO-d₆, δ): 2.9-2.95 (2H, m), 3.25-3.6 (3H, m),
30 3.83 (3H, s), 7.13 (2H, d, J=8.9Hz), 7.50 (2H, d,
J=8.2Hz), 7.85-7.95 (4H, m)
(+)APCI-MS (m/z): 322 (M-HCl+H)⁺

(2) (S)-2-Amino-3-[4-[(4-fluorophenyl)sulfonyl]phenyl]-1-propanol hydrochloride
35

NMR (DMSO- d_6 , δ): 2.8-3.1 (2H, m), 3.2-3.6 (3H, m),
7.4-7.65 (4H, m), 7.9-8.3 (4H, m)
(+)APCI-MS (m/z): 310 (M-HCl+H)⁺

5 (3) (S)-2-Amino-3-[4-(2-thienylsulfonyl)phenyl]-1-propanol
hydrochloride

NMR (DMSO- d_6 , δ): 2.9-3.2 (2H, m), 3.25-3.6 (3H, m),
7.24 (1H, dd, J=3.8, 4.9Hz), 7.57 (2H, d, J=8.3Hz),
7.86 (1H, dd, J=1.3, 3.8Hz), 7.94 (2H, d, J=8.3Hz),
10 8.10 (1H, dd, J=1.3, 4.9Hz)
(+)ESI-MS (m/z): 298 (M-HCl+H)⁺

(4) (S)-2-Amino-3-[4-(4-quinolinylsulfonyl)phenyl]-1-
propanol dihydrochloride

15 NMR (DMSO- d_6 , δ): 2.9-3.0 (2H, m), 3.3-3.8 (3H, m),
7.55 (2H, d, J=8.3Hz), 7.75-8.1 (7H, m), 8.15-8.25
(1H, m), 8.26 (1H, d, J=4.4Hz), 8.55-8.65 (1H, m),
9.23 (1H, d, J=4.4Hz)
(+)APCI-MS (m/z): 343 (M-2HCl+H)⁺

20

Preparation 9

Under nitrogen at 5°C, to a solution of (S)-2-amino-3-
[4-(phenylsulfonyl)phenyl]-1-propanol hydrochloride (410 mg)
in methanol (10 ml) was added sodium methoxide (28% in
25 methanol, 0.24 ml), and the mixture was stirred at the same
temperature for 20 minutes. After removal of the insoluble
materials by filtration, the filtrate was evaporated and
dried in vacuo. A mixture of the residue and benzaldehyde
(0.13 ml) in toluene (10 ml) in the presence of a catalytic
30 amount of p-toluenesulfonic acid monohydrate was refluxed
for 1.5 hours to remove water as the toluene azeotrope.
After removal of toluene by evaporation, to a solution of
the residue in methanol (5 ml) was added sodium borohydride
(47 mg) under nitrogen at 5°C, and the mixture was stirred
35 at room temperature for 1.5 days. The resulting mixture was

poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:methanol = 100:1 to 30:1) to give (S)-2-(benzylamino)-3-[4-(phenylsulfonyl)-phenyl]-1-propanol (270 mg).

NMR (CDCl₃, δ): 2.7-3.0 (3H, m), 3.25-3.35 (1H, m),
3.55-3.7 (1H, m), 3.76 (2H, s), 7.1-7.35 (7H, m),
7.45-7.65 (3H, m), 7.8-8.0 (4H, m)
(+)APCI-MS (m/z): 382 (M+H)⁺

Preparation 10

To an ice-cooled mixture of (R)-1-(4-benzyloxy-3-nitrophenyl)-2-bromoethanol (140.86 g, 87.3%ee), pyridine (65 ml) and 4-(dimethylamino)pyridine (2.44 g) in toluene (705 ml) was added (1S)-(-)-camphanic chloride (95.21 g) in portions over 15 minutes. The mixture was stirred at room temperature for 22 hours. The mixture was cooled with an ice bath and partitioned between toluene and water. The organic layer was separated, washed twice with water (430 ml), once with sodium hydrogen carbonate solution (430 ml), once with brine (430 ml), dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residual oil was crystallized from ethyl acetate (107 ml) - 2-propanol (1070 ml) to give crude (1S,4R)-camphanic acid (R)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethyl ester (193.48 g) as a white powder.

NMR (CDCl₃, δ): 1.02 (3H, s), 1.07 (3H, s), 1.13 (3H, s), 1.60-1.80 (1H, m), 1.85-2.12 (2H, m), 2.32-2.56 (1H, m), 3.52-3.80 (2H, m, AB of ABX), 5.25 (2H, s), 6.07 (1H, dd, J=8, 5Hz, X of ABX), 7.15 (1H, d, J=9Hz), 7.28-7.52 (5H, m), 7.57 (1H, dd, J=9, 2Hz), 7.89 (1H, d, J=2Hz)

MS (m/z): 554, 556 (M+Na)⁺

Preparation 11

The crude powder of (245.78 g) of (1S,4R)-camphanic
5 acid (R)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethyl ester,
the object compound in Preparation 10 was recrystallized
from ethyl acetate (490 ml) - hexane (740 ml) to give pure
ester (186.23 g) as white crystals. The diastereomeric
excess of the product was determined to be 98.2%de by HPLC
10 analysis using a chiral stationary phase column (Daicel
CHIRALPAK AD, 4.6x250 mm, hexane/2-propanol = 50/50). The
second crop was obtained from the mother liquor by the same
method (37.84 g, 97.6%de).

Mp: 149-150°C

15

Preparation 12

To an ice-cooled solution of (1S,4R)-camphanic acid
(R)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethyl ester (229.14
g, 98%de) in tetrahydrofuran (460 ml) - methanol (460 ml)
20 was added dropwise 6N sodium hydroxide solution (158 ml)
over 10 minutes. The mixture was stirred at room
temperature for 1 hour. The mixture was cooled with an ice
bath and partitioned between toluene and water. The organic
layer was separated, washed twice with water (460 ml), once
25 with brine (460 ml), dried over magnesium sulfate, and
filtered. The filtrate was concentrated to give a solid.
The solid was recrystallized from ethyl acetate (120 ml) -
hexane (820 ml) to give (R)-(4-benzyloxy-3-
nitrophenyl)oxirane (110.80 g) as a white powder. The
30 enantiomeric excess of the product was determined to be
98.2%ee by HPLC analysis using a chiral stationary phase
column (Daicel CHIRALPAK AS, 4.6x250 mm, hexane/2-propanol =
70/30).

NMR (CDCl₃, δ): 2.76 (1H, dd, J=5, 2Hz), 3.16 (1H, dd,
35 J=5, 4Hz), 3.85 (1H, dd, J=4, 2Hz), 5.24 (2H, s),

7.10 (1H, d, J=9Hz), 7.25-7.52 (6H, m), 7.78 (1H, d, J=2Hz)

MS (m/z): 294 (M+Na)⁺

5 Preparation 13

Under nitrogen, to a solution of triisopropylsilane (0.48 g) in tetrahydrofuran (10 ml) was added dropwise butyllithium (1.54M in hexane, 1.6 ml) in acetone-dry ice bath, and the mixture was stirred at the same temperature
10 for 15 minutes. After removal of the cooling bath, to this one were added a solution of tert-butyl (S)-2,2-dimethyl-4-[4-[(trifluoromethyl)sulfonyl]oxy]benzyl]-1,3-oxazolidine-3-carboxylate (1.0 g) in tetrahydrofuran (4 ml) and tetrakis(triphenylphosphine)palladium(0) (0.26 g), and the
15 mixture was refluxed for 4.5 hours. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure.
20 The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 20:1 to 10:1) to give tert-butyl (S)-2,2-dimethyl-4-[4-[(triisopropylsilyl)thio]benzyl]-1,3-oxazolidine-3-carboxylate (280 mg).

NMR (CDCl₃, δ): 1.0-1.35 (21H, m), 1.45-1.7 (15H, m),
25 2.5-2.7 (1H, m), 3.0-3.25 (1H, m), 3.65-4.2 (3H, m), 7.0-7.15 (2H, m), 7.35-7.5 (2H, m)

(+)ESI-MS (m/z): 346 (M-ⁱPr₃Si+2H)⁺

Preparation 14

30 Under nitrogen at room temperature, to a solution of tert-butyl (S)-2,2-dimethyl-4-[4-[(triisopropylsilyl)thio]benzyl]-1,3-oxazolidine-3-carboxylate (270 mg) in N,N-dimethylformamide (5 ml) were added cesium fluoride (92 mg) and 4-chloroquinoline (99 mg), and the mixture was stirred
35 at the same temperature for 12 hours. The resulting mixture

was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure.

- 5 The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 3:1 to 2:1) to give tert-butyl (S)-2,2-dimethyl-4-[4-(4-quinolinylthio)benzyl]-1,3-oxazolidine-3-carboxylate (180 mg).

10 NMR (CDCl₃, δ): 1.45-1.7 (15H, m), 2.7-2.9 (1H, m), 3.1-3.3 (1H, m), 3.7-4.3 (3H, m), 6.76 (1H, d, J=4.6Hz), 7.25-7.4 (2H, m), 7.45-7.8 (4H, m), 8.09 (1H, d, J=8.3Hz), 8.22 (1H, d, J=7.6Hz), 8.58 (1H, d, J=4.8Hz)
(+)ESI-MS (m/z): 451 (M+H)⁺

15

Preparation 15

- Under nitrogen, to a solution of tert-butyl (S)-2,2-dimethyl-4-[4-(4-quinolinylthio)benzyl]-1,3-oxazolidine-3-carboxylate (140 mg) in dichloromethane (2 ml) were added
20 acetic acid (1 ml) and m-chloroperbenzoic acid (110 mg) at 5°C, and the mixture was stirred at the same temperature for 30 minutes. The mixture was poured into a mixture of water and ethyl acetate and the mixture was made alkaline with aqueous 5N sodium hydroxide. After separation, the organic
25 layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 1:1) to give tert-butyl (S)-2,2-dimethyl-4-[4-(4-quinolinyl-
30 sulfonyl)benzyl]-1,3-oxazolidine-3-carboxylate (51 mg).

35 NMR (CDCl₃, δ): 1.3-1.6 (15H, m), 2.7-2.95 (1H, m), 3.05-3.3 (1H, m), 3.8-4.15 (3H, m), 7.3-7.5 (2H, m), 7.6-7.85 (2H, m), 7.9-8.05 (2H, m), 8.1-8.25 (2H, m), 8.67 (1H, d, J=8.4Hz), 9.12 (1H, d, J=4.4Hz)

(+)ESI-MS (m/z): 505 (M+Na)⁺

Preparation 16

Under nitrogen at room temperature, to a solution of 4-fluorobenzaldehyde (3.0 g) in N,N-dimethylformamide (60 ml) was added 4-methoxybenzenethiol (3.3 ml) and potassium carbonate (3.7 g), and the mixture was stirred at 120°C for 6 hours. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 10:1) to give 4-[(4-methoxyphenyl)thio]benzaldehyde (4.9 g).

NMR (CDCl₃, δ): 3.86 (3H, s), 6.95-7.0 (2H, m), 7.1-7.2 (2H, m), 7.45-7.5 (2H, m), 7.65-7.7 (2H, m), 9.89 (1H, s)

(+)APCI-MS (m/z): 245 (M+H)⁺

Preparation 17

The following compounds were obtained according to a similar manner to that of Preparation 16.

(1) 4-[(3-Methoxyphenyl)thio]benzaldehyde

NMR (CDCl₃, δ): 3.81 (3H, s), 6.9-7.0 (1H, m), 7.05-7.15 (2H, m), 7.25-7.4 (3H, m), 7.7-7.8 (2H, m), 9.92 (1H, s)

(+)APCI-MS (m/z): 245 (M+H)⁺

(2) 4-[(2-Methoxyphenyl)thio]benzaldehyde

NMR (CDCl₃, δ): 3.82 (3H, s), 6.95-7.1 (2H, m), 7.15-7.25 (2H, m), 7.4-7.55 (2H, m), 7.65-7.75 (2H, m), 9.90 (1H, s)

(+)APCI-MS (m/z): 245 (M+H)⁺

(3) 4-[(3,4-Dimethoxyphenyl)thio]benzaldehyde

NMR (CDCl₃, δ): 3.87 (3H, s), 3.94 (3H, s), 6.94 (1H, d, J=8.3Hz), 7.05 (1H, d, J=2.0Hz), 7.1-7.25 (3H, m), 7.65-7.8 (2H, m), 9.89 (1H, s)

5 (+)ESI-MS (m/z): 297 (M+Na)⁺.

Preparation 18

Under nitrogen at 5°C, to a solution of 4-[(4-methoxyphenyl)thio]benzaldehyde (4.8 g) in dichloromethane
10 (100 ml) was added m-chloroperbenzoic acid (11 g), and the mixture was stirred at the same temperature for 2.5 hours. The resulting mixture was poured into saturated aqueous sodium hydrogen carbonate and the aqueous mixture was
15 successively with saturated aqueous sodium hydrogen carbonate and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure followed by dryness to give 4-[(4-methoxyphenyl)sulfonyl]benzaldehyde (5.3 g).

20 NMR (CDCl₃, δ): 3.85 (3H, s), 6.95-7.05 (2H, m), 7.85-8.1 (6H, m), 10.07 (1H, s)
(+)APCI-MS (m/z): 277 (M+H)⁺

Preparation 19

Under nitrogen at 5°C, to a solution of tert-butyl N-benzyl-N-[2-[4-[(4-methoxyphenyl)thio]phenyl]ethyl]-
25 carbamate (1.3 g) in dichloromethane (25 ml) was added m-chloroperbenzoic acid (1.5 g), and the mixture was stirred at the same temperature for 45 minutes. The mixture was poured into aqueous sodium thiosulfate and the aqueous
30 mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate twice and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure followed by dryness to give t-butyl N-benzyl-N-[2-[4-[(4-
35 methoxyphenyl)sulfonyl]phenyl]ethyl]carbamate (1.5 g).

(+)ESI-MS (m/z): 504 (M+Na)⁺

Preparation 20

The following compounds were obtained according to a
5 similar manner to that of Preparation 19.

(1) tert-Butyl N-benzyl-N-[2-[4-[[4-(4-
fluorophenoxy)phenyl]sulfonyl]phenyl]ethyl]carbamate
(+)ESI-MS (m/z): 584 (M+Na)⁺

10

(2) tert-Butyl N-benzyl-N-[2-[4-[(3-
methoxyphenyl)sulfonyl]phenyl]ethyl]carbamate
(+)ESI-MS (m/z): 504 (M+Na)⁺

15

(3) tert-Butyl N-benzyl-N-[2-[4-[(3-
hydroxyphenyl)sulfonyl]phenyl]ethyl]carbamate
NMR (CDCl₃, δ): 1.38 (9H, br s), 2.7-2.9 (2H, m), 3.25-
3.5 (2H, m), 4.37 (2H, br s), 6.95-7.05 (1H, m),
7.15-7.5 (10H, m), 7.75-7.85 (2H, m)
20 (+)ESI-MS (m/z): 490 (M+Na)⁺

(4) tert-Butyl N-benzyl-N-[2-[4-[[3-(4-
fluorophenoxy)phenyl]sulfonyl]phenyl]ethyl]carbamate
(+)ESI-MS (m/z): 584 (M+Na)⁺

25

(5) tert-Butyl N-benzyl-N-[2-[4-[(2-
methoxyphenyl)sulfonyl]phenyl]ethyl]carbamate
(+)ESI-MS (m/z): 504 (M+Na)⁺

30

(6) tert-Butyl N-benzyl-N-[2-[4-[(2-
hydroxyphenyl)sulfonyl]phenyl]ethyl]carbamate
(+)ESI-MS (m/z): 490 (M+Na)⁺

35

(7) Ethyl [2-[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)-
amino]ethyl]phenyl]sulfonyl]phenoxy]acetate

NMR (CDCl₃, δ): 1.23 (3H, t, J=7.1Hz), 1.43 (9H, s),
2.7-2.95 (2H, br s), 3.25-3.5 (2H, br s), 4.19 (2H,
q, J=7.1Hz), 4.25-4.45 (1H, m), 4.59 (2H, s),
6.75-6.85 (1H, m), 7.1-7.35 (8H, m), 7.45-7.55 (1H,
5 m), 7.9-8.0 (2H, m), 8.15-8.2 (1H, m)
(+)ESI-MS (m/z): 576 (M+Na)⁺

(8) tert-Butyl N-benzyl-N-[2-[4-[[2-(4-
fluorophenoxy)phenyl]sulfonyl]phenyl]ethyl]carbamate
10 NMR (CDCl₃, δ): 1.42 (9H, br s), 2.65-2.9 (2H, m),
3.25-3.5 (2H, m), 4.25-4.5 (2H, m), 6.65-6.8 (3H,
m), 6.85-7.0 (2H, m), 7.05-7.5 (9H, m), 7.8-7.95
(2H, m), 8.2-8.3 (1H, m)
(+)APCI-MS (m/z): 462 (M-Boc+2H)⁺

15 (9) tert-Butyl N-benzyl-N-[2-[4-[(3,4-
dimethoxyphenyl)sulfonyl]phenyl]ethyl]carbamate
NMR (CDCl₃, δ): 1.39 (9H, br s), 2.7-2.95 (2H, m),
3.25-3.5 (2H, m), 3.90 (3H, s), 3.91 (3H, s),
20 4.25-4.5 (2H, m), 6.91 (1H, d, J=8.5Hz), 7.1-7.4
(8H, m), 7.5-7.6 (1H, m), 7.75-7.85 (2H, m)
(+)APCI-MS (m/z): 534 (M+Na)⁺

Preparation 21

25 Under nitrogen at 5°C, to a suspension of
(methoxymethyl)triphenylphosphonium chloride (2.5 g) in
tetrahydrofuran (10 ml) was added potassium tert-butoxide
(0.74 g) by portions with care, and the mixture was stirred
at room temperature for 30 minutes. To this one was added
30 4-[(4-methoxyphenyl)sulfonyl]benzaldehyde (0.91 g) in
tetrahydrofuran (10 ml), and the mixture was stirred at room
temperature for 12 hours. The resulting mixture was poured
into water and the aqueous mixture was extracted in ethyl
acetate. The organic layer was washed with brine, dried over
35 anhydrous magnesium sulfate and evaporated under reduced

pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 3:1 to 1:1) to give 1-methoxy-4-[[4-(2-methoxyethenyl)phenyl]sulfonyl]benzene (0.89 g).

5 (+)-APCI-MS (m/z): 305 (M+H)⁺

Preparation 22

Under nitrogen at room temperature, to a solution of 1-methoxy-4-[[4-(2-methoxyethenyl)phenyl]sulfonyl]benzene (400
10 mg) in dichloromethane (4 ml) was added formic acid (2 ml), and the mixture was refluxed for 10 hours. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous
15 magnesium sulfate and evaporated under reduced pressure followed by dryness to give crude [4-[(4-methoxyphenyl)sulfonyl]phenyl]acetaldehyde which was used in the next step.

Preparation 23

A mixture of (S)-2-(phenoxyethyl)oxirane (3.0 g) and 28% ammonium hydroxide (15 ml) in ethanol (30 ml) was sealed at room temperature for 12 hours. After evaporation under reduced pressure, the residue was dissolved into a mixture
25 of ethyl acetate and methanol followed by addition of 4N hydrogen chloride in 1,4-dioxane. After being stirred for 12 hours, the precipitates were collected by filtration followed by being washed with ethyl acetate and dryness to give (S)-1-amino-3-phenoxy-2-propanol hydrochloride (3.4 g).

30 (+)-ESI-MS (m/z): 168 (M-HCl+H)⁺

Preparation 24

Under nitrogen at room temperature, to a solution of 4-
[(4-methoxyphenyl)thio]benzaldehyde (5.1 g) in methanol (51
35 ml) were added nitromethane (1.7 ml), acetic acid (0.60 ml)

and butylamine (1.0 ml), and the mixture was stirred at the same temperature overnight to give a precipitate. Water (51 ml) was poured into the resulting mixture and the mixture was stirred for 30 minutes. The deposit was collected by
5 filtration and the filter cake was washed with water followed by air-drying to give 1-methoxy-4-[[4-(2-nitroethenyl)phenyl]thio]benzene (5.4 g).

NMR (CDCl₃, δ): 3.86 (3H, s), 6.9-7.15 (4H, m), 7.3-7.6 (5H, m), 7.85-7.95 (1H, m)
10 (+)ESI-MS (m/z): 310 (M+Na)⁺

Preparation 25

The following compounds were obtained according to a similar manner to that of Preparation 24.

15

(1) 1-Methoxy-3-[[4-(2-nitroethenyl)phenyl]thio]benzene
NMR (CDCl₃, δ): 3.80 (3H, s), 6.85-7.15 (3H, m), 7.2-7.55 (6H, m), 7.9-8.0 (1H, m)
(+)ESI-MS (m/z): 310 (M+Na)⁺

20

(2) 1-Methoxy-2-[[4-(2-nitroethenyl)phenyl]thio]benzene
NMR (DMSO-d₆, δ): 3.78 (3H, s), 6.95-7.25 (4H, m), 7.35-7.55 (2H, m), 7.7-7.85 (2H, m), 8.0-8.25 (2H, m)
m)

25

(+)APCI-MS (m/z): 288 (M+H)⁺

30

(3) 1,2-Dimethoxy-4-[[4-(2-nitroethenyl)phenyl]thio]benzene
NMR (CDCl₃, δ): 3.88 (3H, s), 3.94 (3H, s), 6.85-7.0 (1H, m), 7.0-7.25 (4H, m), 7.35-7.4 (2H, m), 7.45-7.6 (1H, m), 7.9-8.0 (1H, m)
(+)ESI-MS (m/z): 340 (M+Na)⁺

Preparation 26

Under nitrogen at 5°C, to a suspension of
35 lithiumaluminum hydride (3.2 g) in tetrahydrofuran (80 ml)

was added dropwise 1-methoxy-4-[[4-(2-nitroethenyl)phenyl]-thio]benzene (4.8 g) in tetrahydrofuran (50 ml), and the mixture was refluxed for 6.5 hours. The resulting mixture was cooled to 5°C, and to this one was added sodium fluoride (14 g) followed by water (4.5 ml) dropwise carefully. The mixture was vigorously stirred at room temperature for 30 minutes. The precipitate was removed by filtration, and the filter cake was washed with a mixture of ethyl acetate and ethanol (95:5). The filtrate was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (40 ml) and cooled to 5°C. To this one was added 4N hydrogen chloride in 1,4-dioxane (8.4 ml) and the mixture was stirred at room temperature for 30 minutes to deposit the corresponding salt followed by collection by filtration. The filter cake was washed with ethyl acetate and dissolved in a mixture of ethyl acetate and 1N sodium hydroxide. After separation, the organic layer was dried over anhydrous magnesium sulfate, evaporated under reduced pressure and dried to give 2-[4-[(4-methoxyphenyl)thio]phenyl]ethylamine (2.0 g).

NMR (CDCl₃, δ): 2.69 (2H, t, J=6.8Hz), 2.93 (2H, t, J=6.8Hz), 3.81 (3H, s), 6.85-6.95 (2H, m), 7.05-7.2 (4H, m), 7.35-7.45 (2H, m)
(+)APCI-MS (m/z): 260 (M+H)⁺

Preparation 27

The following compounds were obtained according to a similar manner to that of preparation 26.

(1) 2-[4-[(3-Methoxyphenyl)thio]phenyl]ethylamine
NMR (CDCl₃, δ): 2.74 (2H, t, J=6.9Hz), 2.97 (2H, t, J=6.9Hz), 3.75 (3H, s), 6.7-6.9 (3H, m), 7.1-7.4 (5H, m)
(+)ESI-MS (m/z): 260 (M+H)⁺

(2) 2-[4-[(2-Methoxyphenyl)thio]phenyl]ethylamine

NMR (CDCl₃, δ): 2.74 (2H, t, J=6.6Hz), 2.9-3.05 (2H, m),
3.88 (3H, s), 6.8-7.4 (8H, m)
(+)APCI-MS (m/z): 260 (M+H)⁺

5

(3) 2-[4-[(3,4-Dimethoxyphenyl)thio]phenyl]ethylamine

NMR (DMSO-d₆, δ): 2.45-2.8 (4H, m), 3.72 (3H, s), 3.77
(3H, s), 6.9-7.2 (7H, m)
(+)ESI-MS (m/z): 290 (M+H)⁺

10

Preparation 28

Under nitrogen at room temperature, to a solution of 2-[4-[(4-methoxyphenyl)thio]phenyl]ethylamine (2.0 g) in dichloromethane (20 ml) was added benzaldehyde (0.78 ml),
15 and the mixture was stirred at the same temperature for 20 minutes. To this one was added toluene and evaporated under reduced pressure. Under nitrogen at 5°C, to a solution of the residue in tetrahydrofuran (20 ml) was added sodium borohydride (0.32 g) followed by methanol (10 ml) dropwise
20 and the mixture was stirred at room temperature for 40 minutes. The resulting mixture was poured into a mixture of ethyl acetate and water and stirred for 10 minutes. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under
25 reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:methanol = 100:1 to 20:1) to give N-benzyl-N-[2-[4-[(4-methoxyphenyl)thio]phenyl]ethyl]amine (2.0 g).

NMR (CDCl₃, δ): 2.7-2.9 (4H, m), 3.81 (2H, s), 3.83 (3H, s), 6.85-6.95 (2H, m), 7.05-7.45 (11H, m)
30 (+)APCI-MS (m/z): 350 (M+H)⁺

Preparation 29

The following compounds were obtained according to a
35 similar manner to that of Preparation 28.

- (1) N-Benzyl-N-[2-[4-[(3-methoxyphenyl)thio]phenyl]ethyl]-
amine
NMR (CDCl₃, δ): 2.75-3.0 (4H, m), 3.78 (3H, s), 3.80
5 (2H, s), 6.7-6.95 (3H, m), 7.1-7.4 (10H, m)
(+)APCI-MS (m/z): 350 (M+H)⁺
- (2) N-Benzyl-N-[2-[4-[(2-methoxyphenyl)thio]phenyl]ethyl]-
amine
10 NMR (CDCl₃, δ): 2.75-2.95 (4H, m); 3.84 (2H, s), 3.87
(3H, s), 6.75-6.9 (2H, m), 6.95-7.05 (1H, m),
7.15-7.4 (10H, m)
(+)APCI-MS (m/z): 350 (M+H)⁺
- 15 (3) N-Benzyl-N-[2-[4-[(3,4-dimethoxyphenyl)thio]-
phenyl]ethyl]amine
NMR (CDCl₃, δ): 2.7-2.95 (4H, m), 3.79 (2H, s), 3.82
(3H, s), 3.88 (3H, s), 6.84 (1H, d, J=8.3Hz),
6.95-7.4 (11H, m)
20 (+)ESI-MS (m/z): 380 (M+H)⁺

Preparation 30

- Under nitrogen at room temperature, to a solution of N-
benzyl-N-[2-[4-[(4-methoxyphenyl)thio]phenyl]ethyl]amine
25 (1.0 g) in tetrahydrofuran (10 ml) was added di-tert-butyl
dicarbonate (0.69 g) in tetrahydrofuran (2 ml), and the
mixture was stirred at the same temperature for 1.5 hours.
The resulting mixture was poured into saturated aqueous
sodium hydrogen carbonate and the aqueous mixture was
30 extracted with ethyl acetate. The organic layer was washed
with brine, dried over anhydrous magnesium sulfate and
evaporated under reduced pressure followed by dryness to
give tert-butyl N-benzyl-N-[2-[4-[(4-methoxyphenyl)thio]-
phenyl]ethyl]carbamate (1.3 g).
35 (+)ESI-MS (m/z): 472 (M+H)⁺

Preparation 31

The following compounds were obtained according to a similar manner to that of Preparation 30.

5

(1) tert-Butyl N-benzyl-N-[2-[4-[(4-hydroxyphenyl)thio]phenyl]ethyl]carbamate

NMR (CDCl₃, δ): 1.45 (9H, s), 2.6-2.85 (2H, m), 3.25-3.45 (2H, m), 4.3-4.45 (2H, m), 6.75-6.85 (2H, m), 6.9-7.4 (11H, m)

10

(+)ESI-MS (m/z): 458 (M+Na)⁺

(2) tert-Butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(4-cyanophenyl)thio]phenyl]ethyl]carbamate

15

(+)ESI-MS (m/z): 531, 533 (M+Na)⁺

(3) tert-Butyl N-benzyl-N-[2-[4-[(3-methoxyphenyl)thio]phenyl]ethyl]carbamate

(+)ESI-MS (m/z): 472 (M+Na)⁺

20

(4) tert-Butyl N-benzyl-N-[2-[4-[(3-hydroxyphenyl)thio]phenyl]ethyl]carbamate

NMR (CDCl₃, δ): 1.45 (9H, br s), 2.7-2.85 (2H, m), 3.3-3.5 (2H, m), 4.37 (2H, s), 6.55-6.7 (2H, m), 6.75-6.85 (1H, m), 7.05-7.4 (10H, m)

25

(+)ESI-MS (m/z): 458 (M+Na)⁺

(5) tert-Butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(3-cyanophenyl)thio]phenyl]ethyl]carbamate

30

NMR (CDCl₃, δ): 1.4-1.55 (9H, m), 2.65-2.9 (2H, m), 3.2-3.4 (4H, m), 4.8-4.95 (1H, m), 7.0-7.5 (12H, m)

(+)ESI-MS (m/z): 531, 533 (M+Na)⁺

35

(6) tert-Butyl N-benzyl-N-[2-[4-[(2-

methoxyphenyl]thio]phenyl]ethyl]carbamate
(+)ESI-MS (m/z): 472 (M+Na)⁺

5 (7) tert-Butyl N-benzyl-N-[2-[4-[(2-hydroxyphenyl)thio]phenyl]ethyl]carbamate
NMR (CDCl₃, δ): 1.43 (9H, br s), 2.6-2.85 (2H, m), 3.2-3.45 (2H, m), 4.25-4.45 (2H, m), 6.85-7.6 (13H, m)
(+)ESI-MS (m/z): 458 (M+Na)⁺

10 (8) tert-Butyl N-benzyl-N-[2-[4-[(3,4-dimethoxyphenyl)thio]phenyl]ethyl]carbamate
NMR (CDCl₃, δ): 1.45 (9H, br s), 2.6-2.85 (2H, m), 3.2-3.5 (2H, m), 3.82 (3H, s), 3.88 (3H, s), 4.25-4.45 (2H, m), 6.83 (1H, d, J=8.3Hz), 6.95-7.4 (11H, m)
15 (+)ESI-MS (m/z): 502 (M+Na)⁺

Preparation 32

At room temperature, to a solution of N-benzyl-N-[2-[4-(4-methoxybenzenesulfonyl)phenyl]ethyl]carbamic acid tert-butyl ester (1.5 g) in ethyl acetate (10 ml) was added 4N
20 hydrogen chloride in 1,4-dioxane (10 ml), and the mixture was stirred at the same temperature for 1 hour to give a precipitate. The precipitate was collected by filtration and washed with ethyl acetate followed by dissolution in a
25 mixture of saturated aqueous sodium hydrogen carbonate and ethyl acetate. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure followed by dryness to
30 give N-benzyl-N-[2-[4-(4-methoxybenzenesulfonyl)-phenyl]ethyl]amine (0.92 g).

NMR (CDCl₃, δ): 3.8-3.95 (4H, m), 3.80 (2H, s), 3.83 (3H, s), 6.9-7.0 (2H, m), 7.15-7.35 (7H, m), 7.75-7.9 (4H, m)
(+)APCI-MS (m/z): 382 (M+H)⁺

Preparation 33

The following compounds were obtained according to a similar manner to that of Preparation 32.

- 5 (1) N-Benzyl-N-[2-[4-[[4-(4-fluorophenoxy)phenyl]-sulfonyl]phenyl]ethyl]amine.
NMR (CDCl₃, δ): 2.8-2.95 (4H, m), 3.79 (2H, s), 6.9-7.4 (13H, m), 7.75-7.9 (4H, m)
(+)APCI-MS (m/z): 462 (M+H)⁺
- 10 (2) N-Benzyl-N-[2-[4-[(3-methoxyphenyl)sulfonyl]phenyl]ethyl]amine
NMR (CDCl₃, δ): 2.8-2.95 (4H, m), 3.78 (2H, s), 3.84 (3H, s), 7.05-7.1 (1H, m), 7.15-7.55 (10H, m),
15 7.85-7.9 (2H, m)
(+)APCI-MS (m/z): 382 (M+H)⁺
- (3) 3-[[4-[2-(Benzylamino)ethyl]phenyl]sulfonyl]phenol
NMR (CDCl₃, δ): 2.7-3.0 (4H, m), 3.81 (2H, s), 6.9-7.0 (1H, m), 7.1-7.5 (10H, m), 7.75-7.85 (2H, m)
20 (-)APCI-MS (m/z): 366 (M-H)⁻
- (4) N-Benzyl-N-[2-[4-[[3-(4-fluorophenoxy)phenyl]-sulfonyl]phenyl]ethyl]amine
25 NMR (CDCl₃, δ): 2.8-3.0 (4H, m), 3.79 (2H, s), 6.9-7.65 (15H, m), 7.75-7.9 (2H, m)
(+)APCI-MS (m/z): 462 (M+H)⁺
- (5) N-Benzyl-N-[2-[4-[(2-methoxyphenyl)sulfonyl]phenyl]ethyl]amine
30 NMR (CDCl₃, δ): 2.8-3.0 (4H, m), 3.76 (3H, s), 3.79 (2H, s), 6.85-6.95 (1H, m), 7.05-7.35 (8H, m), 7.45-7.65 (1H, m), 7.85-7.95 (2H, m), 8.1-8.2 (1H, m)
(+)APCI-MS (m/z): 382 (M+H)⁺
- 35

- (6) 2-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]phenol
NMR (DMSO-d₆, δ): 2.65-2.9 (4H, m), 3.72 (2H, s), 6.8-
7.05 (3H, m), 7.1-7.65 (7H, m), 7.7-7.9 (3H, m)
(+)ESI-MS (m/z): 368 (M+H)⁺

5

- (7) Ethyl [2-[[4-[2-(benzylamino)ethyl]phenyl]-
sulfonyl]phenoxy]acetate
NMR (CDCl₃, δ): 1.23 (3H, t, J=7.1Hz), 2.85-2.95 (4H,
m), 3.79 (2H, s), 4.18 (2H, q, J=7.1Hz), 4.60 (2H,
s), 6.75-6.85 (1H, m), 7.15-7.35 (8H, m), 7.45-
7.55 (1H, m), 7.95-8.05 (2H, m), 8.15-8.25 (1H, m)
(+)APCI-MS (m/z): 454 (M+H)⁺

10

- (8) N-Benzyl-N-[2-[4-[[2-(4-fluorophenoxy)phenyl]-
sulfonyl]phenyl]ethyl]amine
NMR (CDCl₃, δ): 2.8-2.9 (4H, m), 3.80 (2H, s), 6.65-6.8
(3H, m), 6.85-7.0 (2H, m), 7.15-7.55 (9H, m),
7.85-7.95 (2H, m), 8.2-8.3 (1H, m)
(+)APCI-MS (m/z): 462 (M+H)⁺

15

20

- (9) N-Benzyl-N-[2-[4-[(3,4-dimethoxyphenyl)sulfonyl]-
phenyl]ethyl]amine
NMR (CDCl₃, δ): 2.8-3.0 (4H, m), 3.78 (2H, s), 3.91 (6H,
m), 6.92 (1H, d, J=8.5Hz), 7.2-7.4 (8H, m), 7.5-
7.6 (1H, m), 7.75-7.9 (2H, m)
(+)ESI-MS (m/z): 412 (M+H)⁺

25

Preparation 34

- Under nitrogen at 5°C, to a solution of N-benzyl-N-[2-
[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amine (400 mg) in
dichloromethane (10 ml) was added 1M boron tribromide in
dichloromethane (5.1 ml), and the mixture was stirred at the
same temperature for 12 hours. The mixture was evaporated
under reduced pressure. The residue was dissolved in a
mixture of dichloromethane and saturated aqueous sodium

35

hydrogen carbonate. After separation, the organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure followed by dryness to give 4-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]phenol (400 mg).

- 5 NMR (DMSO- d_6 , δ): 2.65-2.9 (4H, m), 3.68 (2H, s), 6.85-6.95 (2H, m), 7.1-7.45 (7H, m), 7.7-7.85 (4H, m)
(+)APCI-MS (m/z): 368 (M+H)⁺

Preparation 35

- 10 The following compounds were obtained according to a similar manner to that of Preparation 34.

(1) 4-[[4-[2-(Benzylamino)ethyl]phenyl]thio]phenol

- 15 NMR (DMSO- d_6 , δ): 2.65-2.75 (4H, m), 3.71 (2H, s), 6.75-6.85 (2H, m), 6.95-7.35 (11H, m)
(+)APCI-MS (m/z): 336 (M+H)⁺

(2) 3-[[4-[2-(Benzylamino)ethyl]phenyl]thio]phenol

- 20 NMR (DMSO- d_6 , δ): 2.7-2.85 (4H, m), 3.74 (2H, s), 7.55-7.75 (3H, m), 7.05-7.4 (10H, m)
(+)APCI-MS (m/z): 336 (M+H)⁺

(3) 2-[[4-[2-(Benzylamino)ethyl]phenyl]thio]phenol

- 25 NMR (CDCl₃, δ): 2.65-2.95 (4H, m), 3.78 (2H, s), 6.8-7.6 (13H, m)
(+)APCI-MS (m/z): 336 (M+H)⁺

Preparation 36

- 30 To a solution of tert-butyl N-benzyl-N-[2-[4-[(4-hydroxyphenyl)thio]phenyl]ethyl]carbamate (200 mg) in dichloromethane (6 ml) were added 4-fluorophenylboronic acid (130 mg), copper(II) acetate (83 mg), molecular sieves 4 Å (200 mg) and pyridine (0.19 ml) at room temperature, and the mixture was stirred at the same temperature of 7 days. The
35 insoluble materials were removed by filtration with celite.

The filtrate was poured into 0.1N hydrochloric acid and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 20:1 to 10:1) to give tert-butyl N-benzyl-N-[2-[4-[[4-(4-fluorophenoxy)phenyl]thio]phenyl]ethyl]carbamate (95 mg).

10 NMR (CDCl₃, δ): 1.45 (9H, s), 2.65-2.9 (2H, m), 3.25-3.5 (2H, m), 4.3-4.45 (2H, m), 6.85-7.4 (17H, m)
(+)ESI-MS (m/z): 552 (M+Na)⁺

Preparation 37

15 The following compounds were obtained according to a similar manner to that of Preparation 36.

(1) tert-Butyl N-benzyl-N-[2-[4-[[3-(4-fluorophenoxy)phenyl]thio]phenyl]ethyl]carbamate

20 NMR (CDCl₃, δ): 1.46 (9H, br s), 2.65-2.9 (2H, m), 3.25-3.5 (2H, m), 4.3-4.45 (2H, m), 6.7-7.4 (17H, m)
(+)ESI-MS (m/z): 552 (M+Na)⁺

25 (2) tert-Butyl N-benzyl-N-[2-[4-[[2-(4-fluorophenoxy)phenyl]thio]phenyl]ethyl]carbamate

NMR (CDCl₃, δ): 1.47 (9H, br s), 2.65-2.9 (2H, m), 3.25-3.5 (2H, m), 4.25-4.45 (2H, m), 6.8-7.4 (17H, m)
30 (+)ESI-MS (m/z): 552 (M+Na)⁺

Preparation 38

Under nitrogen at 5°C, to a suspension of sodium hydride (60% in oil, 7.9 g) in N,N-dimethylformamide (100 ml) was added methyl 4-hydroxyphenylacetate (30 g) in N,N-

35

dimethylformamide (55 ml), and the mixture was stirred at room temperature for 1 hour followed by cooling to 5°C. To this one was added dimethylthiocarbamoyl chloride (25 g) in N,N-dimethylformamide (55 ml), and the mixture was stirred at 45°C for 2 hours. The resulting mixture was poured into water and the organic layer was extracted with a mixture of hexane and ethyl acetate (1:1). The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (toluene:ethyl acetate = 20:1) to give methyl [4-[[[(dimethylamino)thiocarbonyl]oxy]phenyl]acetate (34 g).

NMR (CDCl₃, δ): 3.33 (3H, s), 3.45 (3H, s), 3.63 (2H, s), 3.70 (3H, s), 6.95-7.05 (2H, m), 7.25-7.35 (2H, m)

(+)ESI-MS (m/z): 276 (M+Na)⁺

Preparation 39

Under nitrogen, a mixture of methyl [4-[[[(dimethylamino)thiocarbonyl]oxy]phenyl]acetate (34 g) in diphenyl ether (100 ml) was stirred at 240°C for 29 hours. The resulting mixture was purified by column chromatography on silica gel (hexane:ethyl acetate = 10:1 to 2:1) to give methyl [4-[[[(dimethylamino)carbonyl]thio]phenyl]acetate (25 g).

NMR (CDCl₃, δ): 3.05 (6H, br s), 3.63 (2H, s), 3.68 (3H, s), 7.25-7.35 (2H, m), 7.4-7.5 (2H, m)

(+)ESI-MS (m/z): 276 (M+Na)⁺

Preparation 40

Under nitrogen, to a solution of methyl [4-[[[(dimethylamino)carbonyl]thio]phenyl]acetate (25 g) in ethanol (200 ml) was added potassium hydroxide (27 g) in water (100 ml), and the mixture was refluxed for 4 hours. The resulting mixture was cooled to 5°C, and to this one was

added concentrated hydrochloric acid (40 ml) and water (20 ml). The mixture was stirred at the same temperature for 30 minutes to give a precipitate. The precipitate was collected by filtration and washed with water followed by dryness to give (4-mercaptophenyl)acetic acid (8.6 g).

(-)ESI-MS (m/z): 167 (M-H)⁻

Preparation 41

Under nitrogen at room temperature, to a suspension of (4-mercaptophenyl)acetic acid (1.0 g) in ethanol (20 ml) was added 4N hydrogen chloride in 1,4-dioxane (2 ml), and the mixture was stirred at the same temperature for 12 hours. The resulting mixture was evaporated under reducer pressure followed by dryness to give ethyl (4-mercaptophenyl)acetate (1.2 g).

NMR (CDCl₃, δ): 1.24 (3H, t, J=7.1Hz), 3.55 (2H, s), 4.14 (2H, q, J=7.1Hz), 7.1-7.3 (4H, m)

(-)APCI-MS (m/z): 195 (M-H)⁻

Preparation 42

Under nitrogen at room temperature, to a solution of ethyl (4-meraptophenyl)acetate (540 mg) in N,N-dimethylformamide (10 ml) were added 4-fluorobenzonitrile (370 mg) and potassium carbonate (570 mg), and the mixture was stirred at 120°C for 11 hours. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 20:1 to 10:1) to give ethyl [4-[(4-cyanophenyl)thio]phenyl]acetate (590 mg).

NMR (CDCl₃, δ): 1.28 (3H, t, J=7.1Hz), 3.66 (2H, s), 4.19 (2H, q, J=7.1Hz), 7.15-7.2 (2H, m), 7.3-7.4 (2H, m), 7.4-7.55 (4H, m)

(-)APCI-MS (m/z): 296 (M-H)⁻

Preparation 43

The following compound was obtained according to a
5 similar manner to that of preparation 42.

Ethyl [4-[(3-cyanophenyl)thio]phenyl]acetate

NMR (CDCl₃, δ): 1.27 (3H, t, J=7.1Hz), 3.64 (2H, s),
4.18 (2H, q, J=7.1Hz), 7.25-7.5 (8H, m)

10 (+)APCI-MS (m/z): 298 (M+H)⁺

Preparation 44

At 5°C, to a suspension of ethyl [4-[(4-
cyanophenyl)thio]phenyl]acetate (570 mg) in a mixture of
15 ethanol (8.5 ml) and tetrahydrofuran (2 ml) was added 1N
sodium hydroxide (1.9 ml), and the mixture was stirred at
room temperature for 3 hours. After cooling to 5°C, to this
one was added 1N hydrochloric acid (1.9 ml), and the mixture
was evaporated under reduced pressure followed by dryness to
20 give [4-[(4-cyanophenyl)thio]phenyl]acetic acid (620 mg).

NMR (DMSO-d₆, δ): 3.66 (2H, s), 7.15-7.3 (2H, m), 7.35-
7.55 (4H, m), 7.75-7.85 (2H, m)

(+)ESI-MS (m/z): 292 (M+Na)⁺

25 Preparation 45

The following compound was obtained according to a
similar manner to that of Preparation 44.

[4-[(3-Cyanophenyl)thio]phenyl]acetic acid

30 NMR (DMSO-d₆, δ): 3.61 (2H, s), 7.25-7.6 (6H, m), 7.65-
7.8 (2H, m)

(+)ESI-MS (m/z): 292 (M+Na)⁺

Preparation 46

35 Under nitrogen at 5°C, to a solution of [4-[(4-

cyanophenyl)thio]phenyl]acetic acid (610 mg) in N,N-dimethylformamide (10 ml) were added (R)-2-amino-1-(3-chlorophenyl)ethanol hydrochloride (520 mg), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (380 mg) and 1-hydroxybenzotriazol (330 mg), and the mixture was stirred at room temperature for 12 hours. The resulting mixture was poured into 0.1N hydrochloric acid and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water, 0.1N sodium hydroxide, water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure followed by dryness to give N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-2-[4-[(4-cyanophenyl)thio]phenyl]acetamide (800 mg).

NMR (CDCl₃, δ): 3.25-3.4 (1H, m), 3.58 (2H, s), 3.6-3.8 (1H, m), 4.8-4.9 (1H, m), 7.15-7.35 (8H, m), 7.4-7.55 (4H, m)
(+)ESI-MS (m/z): 445, 447 (M+Na)⁺

Preparation 47

The following compound was obtained according to a similar manner to that of Preparation 46.

N-[(R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-2-[4-[(3-cyanophenyl)thio]phenyl]acetamide
NMR (CDCl₃, δ): 3.25-3.4 (1H, m), 3.59 (2H, s), 3.6-3.8 (1H, m), 4.75-4.9 (1H, m), 7.1-7.55 (12H, m)
(-)APCI-MS (m/z): 420, 422 (M-H)⁻

Preparation 48

Under nitrogen at 5°C, to a solution of N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-2-[4-[(4-cyanophenyl)thio]phenyl]acetamide (760 mg) in tetrahydrofuran (15 ml) was added borane-methyl sulfide complex (0.51 ml), and the mixture was stirred at room temperature for 12 hours. To the resulting mixture was added methanol and the mixture was

evaporated under reduced pressure. The residue was dissolved in acetic acid (5 ml) and stirred at 60°C for 8 hours. The mixture was evaporated under reduced pressure. The residue was dissolved in a mixture of saturated aqueous sodium hydrogen carbonate and ethyl acetate. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:methanol = 100:1 to 30:1) to give 4-[[4-[2-[[[R]-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]thio]benzonitrile (190 mg).
(+)APCI-MS (m/z): 409, 411 (M+H)⁺

Preparation 49

The following compound was obtained according to a similar manner to that of Preparation 48.

3-[[4-[2-[[[R]-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]thio]benzonitrile
NMR (CDCl₃, δ): 2.6-3.1 (6H, m), 4.6-4.8 (2H, m), 7.0-7.75 (12H, m)
(+)APCI-MS (m/z): 409, 411 (M+H)⁺

Preparation 50

The following compound was obtained according to a similar manner to that of Example 21.

Ethyl [2-[[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)-amino]ethyl]phenyl]thio]phenoxy]acetate
NMR (CDCl₃, δ): 1.29 (3H, t, J=7.2Hz), 1.47 (9H, br s), 2.65-2.9 (2H, m), 3.25-3.5 (2H, m), 4.25 (2H, q, J=7.2Hz), 4.25-4.55 (1H, m), 4.68 (2H, s), 6.7-7.4 (8H, m)
(+)ESI-MS (m/z): 544 (M+Na)⁺

Example 1

Under nitrogen, to a solution of (S)-2-amino-3-[4-(phenylsulfonyl)phenyl]-1-propanol hydrochloride (63 mg) in ethanol (5 ml) were added N,N-diisopropylethylamine (50 μ l) and (S)-2-[(4-fluorophenoxy)methyl]oxirane (58 mg) at room temperature, and the mixture was refluxed overnight. After removal of the solvent in vacuo, the residue was dissolved in a mixture of water and ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by thin layer silica gel chromatography (chloroform:methanol = 5:1) to give (2S)-2-[[[(2S)-3-(4-fluorophenoxy)-2-hydroxypropyl]amino]-3-[4-(phenylsulfonyl)phenyl]-1-propanol (38 mg).

NMR (DMSO- d_6 , δ): 2.55-2.8 (5H, m), 3.7-3.9 (3H, m), 6.8-6.95 (2H, m), 7.05-7.2 (2H, m), 7.44 (2H, d, $J=8.3$ Hz), 7.5-7.7 (3H, m), 7.81 (2H, d, $J=8.3$ Hz), 7.9-8.0 (2H, m)
(+)APCI-MS (m/z): 460 (M+H)⁺

Example 2

The following compounds were obtained according to a similar manner to that of Example 1.

(1) (2S)-2-[[[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-3-[4-(phenylsulfonyl)phenyl]-1-propanol
NMR (DMSO- d_6 , δ): 2.6-3.0 (5H, m), 3.1-3.4 (2H, m), 3.9-4.2 (3H, m), 6.63 (1H, d, $J=7.8$ Hz), 7.05-7.15 (2H, m), 7.25-7.8 (10H, m), 7.85-7.95 (2H, m), 8.21 (1H, d, $J=7.8$ Hz)
(+)APCI-MS (m/z): 531 (M+H)⁺

(2) (2S)-2-[[[(2S)-3-(4-Fluorophenoxy)-2-hydroxypropyl]amino]-3-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1-propanol

NMR (CD₃OD, δ): 2.65-3.0 (5H, m), 3.3-3.65 (2H, m),
3.75-4.1 (6H, m), 6.8-7.15 (6H, m), 7.43 (2H, d,
J=8.0Hz), 7.75-7.9 (4H, m)
(+)ESI-MS (m/z): 490 (M+H)⁺

5

(3) (2S)-2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-
3-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1-propanol
NMR (CD₃OD, δ): 2.7-3.0 (5H, m), 3.3-3.65 (2H, m), 3.84
(3H, s), 4.65-4.75 (1H, m), 7.0-7.45 (8H, m),
7.75-7.9 (4H, m)
(+)ESI-MS (m/z): 476, 478 (M+H)⁺

10

(4) (2S)-2-[[(2S)-2-Hydroxy-3-phenoxypropyl]amino]-3-[4-(4-
quinolinylsulfonyl)phenyl]-1-propanol
NMR (DMSO-d₆, δ): 2.5-2.8 (5H, m), 3.1-3.4 (2H, m),
3.7-3.9 (3H, m), 6.8-7.0 (3H, m), 7.2-7.35 (2H, m),
7.46 (2H, d, J=8.4Hz), 7.7-7.95 (4H, m), 8.15-8.25
(2H, m), 8.5-8.6 (1H, m), 9.22 (1H, d, J=4.4Hz)
(+)APCI-MS (m/z): 493 (M+H)⁺

15

20

Example 3

To a solution of (2S)-2-[N-benzyl-N-[(2R)-2-[4-(benzyloxy)-3-nitrophenyl]-2-hydroxyethyl]amino]-3-[4-(phenylsulfonyl)phenyl]-1-propanol (100 mg) in a mixture of
25 ethanol (6 ml) and water (2 ml) were added powdered iron (26 mg) and ammonium chloride (4 mg) at room temperature, and the mixture was refluxed for 1 hour. Insoluble materials were filtered off. The filtrate was evaporated under reduced pressure. The residue was dissolved in a mixture of
30 saturated aqueous sodium hydrogen carbonate and ethyl acetate. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated in reduced pressure. Under nitrogen at 5°C, to a solution of the residue in dichloromethane (5 ml) were added pyridine
35 (19 μ l) and methanesulfonyl chloride (13 μ l) and the mixture

was stirred at the same temperature for 5 hours. The resulting mixture was poured into saturated aqueous sodium hydrogen carbonate and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:ethyl acetate = 100:1) to give N-[5-[(1R)-2-[N-benzyl-N-[(1S)-2-hydroxy-1-[4-(phenylsulfonyl)benzyl]ethyl]amino]-1-hydroxyethyl]-2-(benzyloxy)phenyl]methanesulfonamide (60 mg).

NMR (CDCl₃, δ): 2.5-3.1 (8H, m), 3.3-3.55 (2H, m), 3.65-3.9 (2H, m), 4.5-4.6 (1H, m), 5.10 (2H, s), 6.95-7.6 (18H, m), 7.80 (2H, d, J=8.3Hz), 7.9-8.0 (2H, m)

(+)ESI-MS (m/z): 701 (M+H)⁺

Example 4

Under nitrogen, a mixture of (S)-2-(benzylamino)-3-[4-(phenylsulfonyl)phenyl]-1-propanol (100 mg) and (S)-2-(phenoxymethyl)oxirane (39 mg) in ethanol (10 ml) was refluxed for 24 hours. The resulting mixture was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel (chloroform:ethyl acetate = 20:1 to 5:1) to give (2S)-2-[N-benzyl-N-((2S)-2-hydroxy-3-phenoxypropyl)amino]-3-[4-(phenylsulfonyl)phenyl]-1-propanol (100 mg).

NMR (CDCl₃, δ): 2.5-3.25 (6H, m), 3.4-3.7 (3H, m), 3.75-4.0 (3H, m), 6.8-7.0 (3H, m), 7.1-7.35 (9H, m), 7.45-7.65 (3H, m), 7.75-8.0 (4H, m)

(+)APCI-MS (m/z): 532 (M+H)⁺

Example 5

The following compound was obtained according to a similar manner to that of Example 4.

(2S)-2-[N-Benzyl-N-[(2R)-2-[4-(benzyloxy)-3-nitrophenyl]-2-hydroxyethyl]amino]-3-[4-(phenylsulfonyl)-phenyl]-1-propanol

NMR (CDCl₃, δ): 2.6-2.75 (2H, m), 2.8-2.95 (2H, m),
5 3.1-3.25 (1H, m), 3.5-3.9 (4H, m), 4.4-4.5 (1H, m),
5.22 (2H, s), 7.0-7.6 (17H, m), 7.7-8.0 (5H, m)
(+)APCI-MS (m/z): 653 (M+H)⁺

Example 6

10 Under nitrogen, a mixture of N-benzyl-N-[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amine (150 mg) and (S)-2-[(4-fluorophenoxy)methyl]oxirane (79 mg) in ethanol (5 ml) was refluxed for 47 hours. The resulting mixture was
15 evaporated under reduced pressure and the residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 3:1 to 1:1) to give (S)-1-[N-benzyl-N-[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-(4-fluorophenoxy)-2-propanol (230 mg).

NMR (CDCl₃, δ): 2.65-2.9 (6H, m), 3.5-3.85 (7H, m),
20 3.9-4.05 (1H, m), 6.75-6.85 (2H, m), 6.9-7.05 (3H, m), 7.1-7.3 (8H, m), 7.75-7.9 (4H, m)
(+)APCI-MS (m/z): 550 (M+H)⁺

Example 7

25 The following compounds were obtained according to a similar manner to that of Example 6.

(1) (S)-1-[N-Benzyl-N-[2-[4-[(4-methoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-3-(1H-indol-4-yloxy)-2-propanol

30 NMR (CDCl₃, δ): 2.7-2.9 (6H, m), 3.55-3.85 (2H, m),
3.82 (3H, s), 4.05-4.2 (3H, m), 6.45-6.5 (1H, m),
6.55-6.6 (1H, m), 6.85-7.3 (10H, m), 7.7-7.9 (4H, m)
(+)APCI-MS (m/z): 571 (M+H)⁺

- (2) (S)-1-[N-Benzyl-N-[2-[4-[(4-methoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-3-(9H-carbazol-4-yloxy)-2-propanol
NMR (CDCl₃, δ): 2.7-3.0 (6H, m), 3.55-3.9 (2H, m), 3.81 (3H, s), 4.15-4.3 (3H, m), 6.63 (1H, d, J=7.9Hz),
5 6.85-7.45 (11H, m), 7.7-7.9 (4H, m), 8.09 (1H, br s), 8.23 (1H, d, J=7.7Hz)
(+)APCI-MS (m/z): 621 (M+H)⁺
- (3) 4-[[4-[2-[N-Benzyl-N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenol
10 NMR (CDCl₃, δ): 2.5-2.95 (6H, m), 3.5-3.95 (2H, m), 4.55-4.65 (1H, m), 6.85-6.95 (2H, m), 7.1-7.4 (11H, m), 7.75-7.9 (4H, m)
(+)ESI-MS (m/z): 522, 524 (M+H)⁺
- (4) (R)-2-[N-Benzyl-N-[2-[4-[[4-(4-fluorophenoxy)phenyl]-sulfonyl]phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol
NMR (CDCl₃, δ): 2.5-2.9 (6H, m), 3.5-3.9 (2H, m), 4.55-4.7 (1H, m), 6.95-7.35 (17H, m), 7.75-7.9 (4H, m)
20 (+)ESI-MS (m/z): 616, 618 (M+H)⁺
- (5) (S)-1-[N-Benzyl-N-[2-[4-[(3-methoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-3-phenoxy-2-propanol
NMR (CDCl₃, δ): 2.65-2.9 (6H, m), 3.55-3.85 (2H, m),
25 3.84 (3H, s), 3.85-4.1 (3H, m), 6.85-7.55 (16H, m), 7.75-7.85 (2H, m)
(+)APCI-MS (m/z): 532 (M+H)⁺
- (6) (S)-1-[N-Benzyl-N-[2-[4-[(3-methoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-3-(4-fluorophenoxy)-2-propanol
30 NMR (CDCl₃, δ): 2.65-2.9 (6H, m), 3.5-4.05 (8H, m), 6.75-6.85 (2H, m), 6.9-7.3 (10H, m), 7.35-7.55 (3H, m), 7.75-7.85 (2H, m)
(+)APCI-MS (m/z): 550 (M+H)⁺

- (7) (R)-2-[N-Benzyl-N-[2-[4-[(3-methoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol
NMR (CDCl₃, δ): 2.5-2.95 (6H, m), 3.45-3.95 (2H, m),
3.87 (3H, s), 4.55-4.65 (1H, m), 7.05-7.55 (15H, m), 7.8-7.85 (2H, m)
(+)APCI-MS (m/z): 536, 538 (M+H)⁺
- (8) 3-[[4-[2-[N-Benzyl-N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenol
NMR (CDCl₃, δ): 2.45-3.0 (6H, m), 3.5-4.0 (2H, m),
4.45-4.55 (1H, m), 6.9-7.45 (14H, m), 7.5-7.55 (1H, m), 7.8-7.9 (2H, m)
(+)APCI-MS (m/z): 522, 524 (M+H)⁺
- (9) (R)-2-[N-Benzyl-N-[2-[4-[(2-methoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol
NMR (CDCl₃, δ): 2.5-3.0 (6H, m), 3.5-3.95 (2H, m), 3.75 (3H, s), 4.55-4.65 (1H, m), 6.85-6.9 (1H, m),
7.05-7.35 (12H, m), 7.45-7.6 (1H, m), 7.8-7.9 (2H, m), 8.1-8.2 (1H, m)
(+)APCI-MS (m/z): 536, 538 (M+H)⁺
- (10) 2-[[4-[2-[N-Benzyl-N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenol
NMR (DMSO-d₆, δ): 2.55-2.8 (6H, m), 3.55-3.8 (2H, m),
4.6-4.75 (1H, m), 6.85-7.55 (14H, m), 7.7-7.8 (2H, m), 7.85-7.9 (1H, m)
(+)APCI-MS (m/z): 522, 524 (M+H)⁺
- (11) Ethyl [2-[[4-[2-[N-benzyl-N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate
NMR (CDCl₃, δ): 1.26 (3H, t, J=7.1Hz), 2.5-2.95 (6H, m),
3.5-3.95 (2H, m), 4.19 (2H, q, J=7.1Hz), 4.5-4.65 (3H, m), 6.75-6.85 (1H, m), 7.1-7.35 (12H, m),

7.45-7.55 (1H, m), 7.9-8.0 (2H, m), 8.15-8.25 (1H, m)

(+)APCI-MS (m/z): 608, 610 (M+H)⁺

5 (12) (R)-2-[N-Benzyl-N-[2-[4-[(3,4-dimethoxyphenyl)-sulfonyl]phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol
NMR (CDCl₃, δ): 2.5-2.95 (6H, m), 3.5-3.95 (2H, m),
3.90 (3H, s), 3.91 (3H, s), 4.55-4.65 (1H, m),
6.92 (1H, d, J=8.5Hz), 7.1-7.4 (12H, m), 7.5-7.6
10 (1H, m), 7.75-7.85 (2H, m)
(+)ESI-MS (m/z): 566, 568 (M+H)⁺

(13) (R)-2-[N-Benzyl-N-[2-[4-[[2-(4-fluorophenoxy)phenyl]-sulfonyl]phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol
15 NMR (CDCl₃, δ): 2.5-2.95 (6H, m), 3.5-3.95 (2H, m),
4.55-4.7 (1H, m), 6.65-6.8 (3H, m), 6.85-7.0 (2H, m),
7.1-7.35 (12H, m), 7.4-7.55 (1H, m), 7.8-7.9
(2H, m), 8.2-8.3 (1H, m)
(+)ESI-MS (m/z): 616, 618 (M+H)⁺

20 (14) (S)-1-[N-Benzyl-N-[2-[4-[(3,4-dimethoxyphenyl)-sulfonyl]phenyl]ethyl]amino]-3-phenoxy-2-propanol
NMR (CDCl₃, δ): 2.65-2.9 (6H, m), 3.55-3.85 (2H, m),
3.85-4.1 (3H, m), 3.90 (3H, s), 3.91 (3H, s),
25 6.85-7.0 (3H, m), 7.1-7.4 (11H, m), 7.5-7.6 (1H, m),
7.75-7.85 (2H, m)
(+)ESI-MS (m/z): 562 (M+H)⁺

Example 8

30 A mixture of (2S)-2-[N-benzyl-N-((2S)-2-hydroxy-3-phenoxypropyl)amino]-3-[4-(phenylsulfonyl)phenyl]-1-propanol
(96 mg) and 10% palladium on activated carbon (50% wet, 30 mg) in methanol (5 ml) was stirred at room temperature in
the presence of hydrogen at an atmospheric pressure for 7.5
35 hours. After filtration, the filtrate was evaporated under

reduced pressure followed by trituration with hexane and dryness in vacuo to give (2S)-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-[4-(phenylsulfonyl)phenyl]-1-propanol (42 mg).

5 NMR (DMSO- d_6 , δ): 2.5-2.9 (5H, m), 3.15-3.55 (2H, m), 3.6-3.95 (3H, m), 6.8-7.0 (3H, m), 7.2-7.35 (2H, m), 7.44 (2H, d, $J=8.3$ Hz), 7.55-7.7 (3H, m), 7.80 (2H, d, $J=8.3$ Hz), 7.85-8.0 (2H, m)
(+)APCI-MS (m/z): 442 (M+H)⁺

10

Example 9

A mixture of N-[5-[(1R)-2-[N-benzyl-N-[(1S)-2-hydroxy-1-[4-(phenylsulfonyl)benzyl]ethyl]amino]-1-hydroxyethyl]-2-(benzyloxy)phenyl]methanesulfonamide (57 mg) and 10%
15 palladium on activated carbon (50% wet, 50 mg) in methanol (3 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 3 hours. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by thin layer silica gel
20 chromatography (chloroform:methanol = 3:1) to give N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[(1S)-2-hydroxy-1-[4-(phenylsulfonyl)benzyl]ethyl]amino]ethyl]phenyl]-methanesulfonamide (17 mg).

25 NMR (DMSO- d_6 , δ): 2.4-2.8 (5H, m), 2.91 (3H, s), 3.05-3.6 (2H, m), 4.35-4.45 (1H, m), 6.80 (1H, d, $J=8.2$ Hz), 6.9-7.0 (1H, m), 7.16 (1H, m), 7.41 (2H, d, $J=8.2$ Hz), 7.55-7.75 (3H, m), 7.82 (2H, d, $J=8.1$ Hz), 7.9-8.0 (2H, m)
(+)APCI-MS (m/z): 521 (M+H)⁺

30

Example 10

A mixture of (S)-1-[N-benzyl-N-[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-(4-fluorophenoxy)-2-propanol (220 mg), 10% palladium on
35 activated carbon (50% wet, 110 mg) and hydrogen chloride-

methanol reagent 10 (Tokyo Kasei, 0.24 ml) in methanol (5 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 2 hours. After filtration, the filtrate was evaporated and dryness in vacuo gave (S)-1-(4-fluorophenoxy)-3-[[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-2-propanol hydrochloride (160 mg).

NMR (DMSO-d₆, δ): 2.85-3.25 (6H, m), 3.82 (3H, s), 3.85-3.95 (2H, m), 4.0-4.2 (1H, m), 6.85-7.0 (2H, m), 7.05-7.2 (4H, m), 7.49 (2H, d, J=8.4Hz), 7.85-7.95 (4H, m)
(+)APCI-MS (m/z): 460 (M-HCl+H)⁺

Example 11

The following compounds were obtained according to a similar manner to that of Example 10.

(1) (2S)-1-(9H-Carbazol-4-yloxy)-3-[[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-2-propanol hydrochloride
NMR (DMSO-d₆, δ): 2.95-3.4 (6H, m), 3.82 (3H, s), 4.15-4.45 (3H, m), 6.69 (1H, d, J=7.8Hz), 7.05-7.15 (4H, m), 7.25-7.55 (5H, m), 7.85-7.9 (4H, m), 8.21 (1H, d, J=7.7Hz), 11.29 (1H, s)
(+)APCI-MS (m/z): 531 (M-HCl+H)⁺

(2) (S)-1-[[2-[4-[(3-Methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-phenoxy-2-propanol hydrochloride
NMR (DMSO-d₆, δ): 2.95-3.3 (6H, m), 3.83 (3H, s), 3.9-4.0 (2H, m), 4.1-4.25 (1H, m), 6.85-7.0 (3H, m), 7.2-7.35 (3H, m), 7.4-7.6 (5H, m), 7.9-8.0 (2H, m)
(+)APCI-MS (m/z): 442 (M-HCl+H)⁺

(3) (S)-1-(4-Fluorophenoxy)-3-[[2-[4-[(3-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-2-propanol hydrochloride

NMR (DMSO- d_6 , δ): 3.95-3.5 (6H, m), 3.83 (3H, s), 3.9-4.0 (2H, m), 4.1-4.25 (1H, m), 6.9-7.0 (2H, m), 7.05-7.3 (3H, m), 7.4-7.6 (5H, m), 7.9-8.0 (2H, m)
(+)APCI-MS (m/z): 460 (M-HCl+H)⁺

5

Example 12

Under nitrogen, to a solution of (S)-2-amino-3-[4-(4-methoxybenzenesulfonyl)phenyl]propan-1-ol hydrochloride (70 mg) in ethanol (5 ml) was added sodium methoxide (28% in methanol, 41 μ l) at 5°C. After being stirred at room temperature for 20 minutes, to this one was added (S)-2-(phoxymethyl)oxirane (32.3 mg), and the solution was refluxed overnight. The mixture was diluted with chloroform and insoluble materials were removed by filtration. The filtrate was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel (chloroform/methanol = 20:1 to 10:1) to give (2S)-2-((2S)-2-hydroxy-3-phenoxypropylamino)-3-[4-(4-methoxybenzenesulfonyl)phenyl]propan-1-ol (36 mg).

20

Example 13

The following compounds were obtained according to a similar manner to that of Example 12.

25 (1) (2S)-2-(((2S)-2-Hydroxy-3-phenoxypropyl)amino)-3-[4-(2-thienylsulfonyl)phenyl]-1-propanol

NMR (DMSO- d_6 , δ): 2.5-2.8 (5H, m), 3.1-3.4 (2H, m), 3.7-3.9 (3H, m), 6.85-7.0 (3H, m), 7.15-7.35 (3H, m), 7.46 (2H, d, J=8.4Hz), 7.75-7.9 (3H, m), 8.05 (1H, dd, J=1.3, 4.9Hz)

30

(+)ESI-MS (m/z): 448 (M+H)⁺

(2) (2S)-3-[4-[(4-Fluorophenyl)sulfonyl]phenyl]-2-(((2S)-2-hydroxy-3-phenoxypropyl)amino)-1-propanol

35

NMR (DMSO- d_6 , δ): 2.55-2.8 (5H, m), 3.1-3.4 (2H, m),

3.7-3.95 (3H, m), 6.85-7.0 (3H, m), 7.25-7.55 (6H, m), 7.81 (2H, d, J=8.3Hz), 7.95-8.1 (2H, m)
(+)APCI-MS (m/z): 460 (M+H)⁺

5 Example 14

Under nitrogen at room temperature, to a solution of [4-[(4-methoxyphenyl)sulfonyl]phenyl]acetaldehyde (190 mg) in 1,2-dichloroethane (5 ml) were added (S)-1-amino-3-phenoxy-2-propanol hydrochloride (150 mg), sodium triacetoxyborohydride (350 mg) and acetic acid (0.11 ml), and the mixture was stirred at the same temperature for 9 hours. The resulting mixture was poured into a mixture of 1N sodium hydroxide and ethyl acetate, and the mixture was stirred for 30 minutes. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:methanol = 30:1 to 15:1) followed by treatment with 4N hydrogen chloride in 1,4-dioxane to give (S)-1-[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-phenoxy-2-propanol hydrochloride (57 mg).

NMR (DMSO-d₆, δ): 2.95-3.4 (6H, m), 3.82 (3H, s), 3.9-4.0 (2H, m), 4.1-4.2 (1H, m), 6.9-7.0 (3H, m), 7.1-7.2 (2H, m), 7.25-7.4 (2H, m), 7.45-7.6 (2H, m), 7.8-7.95 (4H, m)
(+)APCI-MS (m/z): 442 (M-HCl+H)⁺

Example 15

The following compound was obtained according to a similar manner to that of Example 14.

(R)-1-(3-Chlorophenyl)-2-[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride

NMR (DMSO-d₆, δ): 2.9-3.4 (6H, m), 3.82 (3H, s), 4.9-5.05 (1H, m), 7.1-7.2 (2H, m), 7.3-7.55 (6H, m),

7.85-7.95 (4H, m)

(+)APCI-MS (m/z): 446, 448 (M-HCl+H)⁺

Example 16

5 A mixture of (S)-1-[N-benzyl-N-[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-(1H-indol-4-yloxy)-2-propanol (140 mg) and 10% palladium on activated carbon (50% wet, 70 mg) in methanol (3 ml) and chlorobenzene (3 ml) was stirred at room temperature in the presence of
10 hydrogen at an atmospheric pressure for 1 hour. After filtration, the filtrate was evaporated under reduced pressure and triturated with hexane followed by dryness to give (S)-1-(1H-indol-4-yloxy)-3-[[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-2-propanol hydrochloride (120
15 mg).

NMR (DMSO-d₆, δ): 2.9-3.7 (6H m), 3.81 (3H, s), 3.95-4.45 (3H, m), 6.45-7.55 (9H, m), 7.8-7.95 (4H, m)

(+)ESI-MS (m/z): 481 (M-HCl+H)⁺

20 Example 17

A mixture of 4-[[4-[2-[N-benzyl-N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenol (86 mg) and 10% palladium on activated carbon (50% wet, 43 mg) in a mixture of methanol (2 ml) and
25 chlorobenzene (2 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 2 hours. After filtration, the filtrate was evaporated under reduced pressure. The residue was dissolved in a mixture of saturated aqueous sodium hydrogen carbonate and ethyl
30 acetate. After separation, the organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:methanol = 20:1 to 8:1) followed by treatment with 4N hydrogen chloride in 1,4-dioxane and
35 dryness to give 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-

hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenol
hydrochloride (35 mg).

NMR (DMSO- d_6 , δ): 2.9-3.6 (6H, m), 4.85-5.0 (1H, m),
6.85-7.0 (2H, m), 7.2-7.55 (6H, m), 7.7-7.9 (4H,
5 m)
(+)ESI-MS (m/z): 432, 434 (M-HCl+H)⁺

Example 18

The following compounds were obtained according to a
10 similar manner to that of Example 17.

(1) (R)-1-(3-Chlorophenyl)-2-[[2-[4-[(4-ethoxyphenyl)-
sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride
NMR (DMSO- d_6 , δ): 1.32 (3H, t, J=6.9Hz), 2.95-3.4 (6H,
15 m), 4.10 (2H, q, J=6.9Hz), 7.05-7.15 (2H, m), 7.3-
7.55 (6H, m), 7.8-7.95 (4H, m)
(+)APCI-MS (m/z): 460, 462 (M-HCl+H)⁺

(2) Methyl [4-[[4-[2-[(R)-2-(3-chlorophenyl)-2-
20 hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-
acetate
NMR (DMSO- d_6 , δ): 2.6-2.8 (6H, m), 3.69 (3H, s), 4.5-
4.65 (1H, m), 4.92 (2H, s), 7.05-7.15 (2H, m),
7.2-7.45 (6H, m), 7.75-7.9 (4H, m)
25 (+)APCI-MS (m/z): 504, 506 (M+H)⁺

(3) Methyl [3-[[4-[2-[(R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-
acetate
30 NMR (DMSO- d_6 , δ): 2.55-2.8 (6H, m), 3.69 (3H, s), 4.5-
4.65 (1H, m), 4.93 (2H, s), 7.2-7.6 (10H, m), 7.8-
7.9 (2H, m)
(+)APCI-MS (m/z): 504, 506 (M+H)⁺

35 (4) (R)-1-(3-Chlorophenyl)-2-[[2-[4-[[4-(4-fluorophenoxy)-

phenyl]sulfonyl]phenyl]ethyl]amino]ethanol
hydrochloride

NMR (DMSO-d₆, δ): 2.9-3.45 (6H, m), 4.85-5.0 (1H, m),
7.05-7.6 (12H, m), 7.85-8.0 (4H, m)

5 (+)APCI-MS (m/z): 526, 528 (M-HCl+H)⁺

(5) (R)-1-(3-Chlorophenyl)-2-[[2-[4-[(3-methoxyphenyl)-
sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride

NMR (DMSO-d₆, δ): 2.95-3.3 (6H, m), 3.83 (3H, s), 4.85-
10 5.0 (1H, m), 7.2-7.6 (10H, m), 7.9-8.0 (2H, m)

(+)APCI-MS (m/z): 446, 448 (M-HCl+H)⁺

(6) 3-[[4-[2-[[[(R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]ethyl]phenyl]sulfonyl]phenol hydrochloride

15 NMR (DMSO-d₆, δ): 2.9-3.5 (6H, m), 4.85-5.0 (1H, m),
7.0-7.1 (1H, m), 7.2-7.6 (9H, m), 7.85-7.95 (2H,
m)

(+)APCI-MS (m/z): 432, 434 (M-HCl+H)⁺

20 (7) (R)-1-(3-Chlorophenyl)-2-[[2-[4-[(3-ethoxyphenyl)-
sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride

NMR (DMSO-d₆, δ): 1.33 (3H, t, J=6.9Hz), 2.9-3.4 (6H,
m), 4.10 (2H, q, J=6.9Hz), 4.9-5.0 (1H, m), 7.15-
7.6 (10H, m), 7.9-8.0 (2H, m)

25 (+)ESI-MS (m/z): 460, 462 (M-HCl+H)⁺

(8) (R)-2-[N-Benzyl-N-[2-[4-[[3-(4-fluorophenoxy)phenyl]-
sulfonyl]phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol

30 NMR (CDCl₃, δ): 2.55-2.95 (6H, m), 3.5-3.95 (2H, m),
4.55-4.65 (1H, m), 6.9-7.65 (19H, m), 7.75-7.85
(2H, m)

(+)ESI-MS (m/z): 616, 618 (M+H)⁺

(9) (R)-1-(3-Chlorophenyl)-2-[[2-[4-[[3-(4-fluorophenoxy)-
phenyl]sulfonyl]phenyl]ethyl]amino]ethanol

35

hydrochloride

NMR (DMSO- d_6 , δ): 2.95-3.5 (6H, m), 4.85-5.05 (1H, m),
7.1-7.75 (14H, m), 7.85-8.0 (2H, m)
(+)ESI-MS (m/z): 526, 528 (M-HCl+H)⁺

5

(10) (R)-1-(3-Chlorophenyl)-2-[[2-[4-[(2-methoxyphenyl)-
sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride

NMR (DMSO- d_6 , δ): 3.0-3.45 (6H, m), 3.74 (3H, s), 4.9-
5.0 (1H, m), 7.1-7.25 (2H, m), 7.3-7.55 (6H, m),
10 7.6-7.75 (1H, m), 7.8-7.9 (2H, m), 7.95-8.05 (1H,
m)
(+)APCI-MS (m/z): 446, 448 (M-HCl+H)⁺

(11) 2-[[4-[2-[[[(R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]ethyl]phenyl]sulfonyl]phenol] hydrochloride

NMR (DMSO- d_6 , δ): 2.8-3.55 (6H, m), 4.85-5.05 (1H, m),
15 6.85-7.1 (2H, m), 7.2-7.6 (7H, m), 7.8-8.0 (3H, m)
(+)ESI-MS (m/z): 432, 434 (M-HCl+H)⁺

20 (12) Ethyl [2-[[4-[2-[[[(R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-
acetate

NMR (CDCl₃, δ): 1.16 (3H, t, J=7.1Hz), 2.55-2.9 (6H, m),
4.12 (2H, q, J=7.1Hz), 4.55-4.65 (1H, m), 4.81 (2H,
25 s), 7.05-7.45 (8H, m), 7.55-7.7 (1H, m), 7.85-7.95
(2H, m), 7.95-8.05 (1H, m)
(+)APCI-MS (m/z): 518, 520 (M+H)⁺

(13) (R)-1-(3-Chlorophenyl)-2-[[2-[4-[[2-(4-fluorophenoxy)-
phenyl]sulfonyl]phenyl]ethyl]amino]ethanol
hydrochloride

NMR (DMSO- d_6 , δ): 2.95-3.7 (6H, m), 4.85-5.05 (1H, m),
30 6.3-6.4 (1H, m), 6.65-6.8 (2H, m), 6.8-6.95 (1H,
m), 7.1-7.25 (2H, m), 7.25-7.55 (6H, m), 7.6-7.75
35 (1H, m), 7.8-7.9 (2H, m), 8.2-8.3 (1H, m)

(+)APCI-MS (m/z): 526, 528 (M-HCl+H)⁺

(14) (R)-1-(3-Chlorophenyl)-2-[[2-[4-[(3,4-dimethoxyphenyl)-sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride

5 NMR (DMSO-d₆, δ): 2.95-3.45 (6H, m), 3.82 (3H, s), 3.83 (3H, s), 4.85-5.0 (1H, m), 7.15 (1H, d, J=8.6Hz), 7.3-7.6 (8H, m), 7.85-8.0 (2H, m)

(+)ESI-MS (m/z): 476, 478 (M-HCl+H)⁺

10 Example 19

Under nitrogen at 5°C, to a suspension of sodium hydride (60% in oil, 8.4 mg) in N,N-dimethylformamide (3 ml) was added 4-[[4-(2-[N-benzyl-N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl)sulfonyl]phenol (100 mg),
15 and the mixture was stirred at the same temperature for 30 minutes. To this one was added ethyl iodide (17 µl), and the mixture was stirred at room temperature for 1.5 days. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer
20 was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 5:1 to 3:1) to give (R)-2-[N-benzyl-N-[2-[4-[(4-ethoxyphenyl)sulfonyl]phenyl]-ethyl]amino]-1-(3-chlorophenyl)ethanol (81 mg).
25

NMR (CDCl₃, δ): 1.41 (3H, t, J=7.0Hz), 2.5-2.95 (6H, m), 3.5-3.95 (2H, m), 4.05 (2H, q, J=7.0Hz), 4.55-4.7 (1H, m), 6.9-7.0 (2H, m), 7.1-7.4 (11H, m), 7.75-7.9 (4H, m)

30 (+)APCI-MS (m/z): 550, 552 (M+H)⁺

Example 20

The following compound was obtained according to a similar manner to that of Example 19.

(R)-2-[N-Benzyl-N-[2-[4-[(3-ethoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol

NMR (CDCl₃, δ): 1.41 (3H, t, J=7.0Hz), 2.55-2.95 (6H, m), 3.5-3.95 (2H, m), 4.06 (2H, q, J=7.0Hz), 4.55-4.7 (1H, m), 7.0-7.55 (15H, m), 7.75-7.9 (2H, m)
(+)APCI-MS (m/z): 550, 552 (M+H)⁺

Example 21

Under nitrogen at 5°C, to a suspension of sodium hydride (60% in oil, 17 mg) in N,N-dimethylformamide (3 ml) was added 4-[[4-[2-[N-benzyl-N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenol (200 mg), and the mixture was stirred at the same temperature for 30 minutes. To this one was added ethyl bromoacetate (47 μl), and the mixture was stirred at 5°C for 5 hours. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 5:1 to 2:1) to give ethyl [4-[[4-[2-[N-benzyl-N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate (200 mg).

NMR (CDCl₃, δ): 1.28 (3H, t, J=7.2Hz), 2.55-2.9 (6H, m), 3.5-3.95 (2H, m), 4.26 (2H, q, J=7.2Hz), 4.55-4.65 (1H, m), 4.63 (2H, s), 6.9-7.0 (2H, m), 7.1-7.35 (11H, m), 7.75-7.9 (4H, m)
(+)APCI-MS (m/z): 608, 610 (M+H)⁺

Example 22

The following compound was obtained according to a similar manner to that of Example 21.

Ethyl [3-[[4-[2-[N-benzyl-N-[(R)-2-(3-chlorophenyl)-2-

hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate

NMR (CDCl₃, δ): 1.28 (3H, t, J=7.1Hz), 2.5-2.95 (6H, m),
3.5-3.95 (2H, m), 4.26 (2H, q, J=7.1Hz), 4.55-4.65
(1H, m), 4.64 (2H, s), 7.05-7.6 (15H, m), 7.75-
7.85 (2H, m)

5

(+)APCI-MS (m/z): 608, 610 (M+H)⁺

Example 23

At room temperature, to a solution of methyl [4-[[4-[2-
[[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-
sulfonyl]phenoxy]acetate (32 mg) in ethanol (2 ml) was added
1N sodium hydroxide (62 μl), and the mixture was stirred at
the same temperature for 4.5 hours. The resulting mixture
was evaporated under reduced pressure and dried to give
sodium [4-[[4-[2-[[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-
amino]ethyl]phenyl]sulfonyl]phenoxy]acetate (34 mg).

15

NMR (DMSO-d₆, δ): 2.55-2.85 (6H, m), 4.15 (2H, s),
4.55-4.65 (1H, m), 6.85-6.95 (2H, m), 7.2-7.45 (6H,
m), 7.7-7.9 (4H, m)

20

(+)ESI-MS (m/z): 512, 514 (M+H)⁺

Example 24

The following compounds were obtained according to a
similar manner to that of Example 23.

25

(1) Sodium [3-[[4-[2-[[(R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-
acetate

NMR (DMSO-d₆, δ): 2.55-2.85 (6H, m), 4.14 (2H, s),
4.55-4.7 (1H, m), 7.0-7.1 (1H, m), 7.2-7.5 (9H, m),
7.75-7.9 (2H, m)

30

(+)ESI-MS (m/z): 512, 514 (M+H)⁺

(2) Sodium [2-[[4-[2-[[(R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-

35

acetate

NMR (DMSO- d_6 , δ): 2.45-2.9 (6H, m), 4.03 (2H, s), 4.5-4.65 (1H, m), 6.85-7.6 (9H, m), 7.85-8.0 (3H, m)
(+)ESI-MS (m/z): 512, 514 (M+H)⁺

5

Example 25

At room temperature, to a solution of methyl [4-[[4-[2-[[[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]phenoxy]acetate (28 mg) in ethanol (2 ml) was added
10 3.95N hydrogen chloride in ethanol (1 ml), and the mixture was allowed to stand at the same temperature for 2 hours. The resulting mixture was evaporated under reduced pressure and dried to give ethyl [4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
15 hydrochloride (31 mg).

NMR (DMSO- d_6 , δ): 1.20 (3H, t, J=7.1Hz), 2.95-3.3 (6H, m), 4.16 (2H, q, J=7.1Hz), 4.85-5.0 (1H, m), 4.91 (2H, s), 7.1-7.2 (2H, m), 7.3-7.55 (6H, m), 7.8-7.95 (4H, m)
20 (+)ESI-MS (m/z): 518, 520 (M-HCl+H)⁺

Example 26

The following compounds were obtained according to a similar manner to that of Example 25.

25

(1) Ethyl [3-[[4-[2-[[[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate hydrochloride

NMR (DMSO- d_6 , δ): 1.19 (3H, t, J=7.1Hz), 2.9-3.6 (6H, m), 4.16 (2H, q, J=7.1Hz), 4.85-5.0 (3H, m), 7.2-7.6 (10H, m), 7.9-8.0 (2H, m)
30 (+)ESI-MS (m/z): 518, 520 (M-HCl+H)⁺

(2) Ethyl [2-[[4-[2-[[[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-
35

acetate hydrochloride

NMR (DMSO-d₆, δ): 1.17 (3H, t, J=7.1Hz), 2.95-3.5 (6H, m), 4.13 (2H, q, J=7.1Hz), 4.83 (2H, s), 4.85-5.0 (1H, m), 7.05-7.5 (8H, m), 7.55-7.7 (1H, m), 7.9-8.1 (3H, m)

(+)APCI-MS (m/z): 518, 520 (M-HCl+H)⁺

Example 27

Under nitrogen at 5°C, to a solution of tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(4-cyanophenyl)thio]phenyl]ethyl]carbamate (240 mg) in dichloromethane (10 ml) was added m-chloroperbenzoic acid (320 mg), and the mixture was stirred at room temperature for 7 hours. The resulting mixture was poured into aqueous sodium thiosulfate, and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 3:1 to 1:1) to give tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(4-cyanophenyl)sulfonyl]phenyl]ethyl]carbamate (91 mg).

(+)ESI-MS (m/z): 563, 565 (M+Na)⁺

Example 28

The following compound was obtained according to a similar manner to that of Example 27.

tert-Butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(3-cyanophenyl)sulfonyl]phenyl]ethyl]carbamate

NMR (CDCl₃, δ): 1.36 (9H, br s), 2.7-3.0 (2H, m), 3.2-3.5 (4H, m), 4.75-4.9 (1H, m), 7.15-7.4 (6H, m), 7.55-7.7 (1H, m), 7.75-7.9 (3H, m), 8.1-8.25 (2H, m)

(+)ESI-MS (m/z): 563, 565 (M+Na)⁺

Example 29

Under nitrogen at room temperature, to a solution of
5 tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-
[4-[(4-cyanophenyl)sulfonyl]phenyl]ethyl]carbamate (86 mg)
in ethanol (5 ml) were added hydroxylamine hydrochloride (12
mg) and potassium carbonate (27 mg), and the mixture was
10 refluxed for 7 hours. The resulting mixture was cooled to
room temperature and diluted with dichloromethane. The
mixture was filtrated through a bed of silica gel and the
silica gel was washed with a mixture of dichloromethane and
methanol (10:1). The filtrate was evaporated under reduced
pressure and dried to give tert-butyl N-[2-[4-[[4-
15 [amino(hydroxyimino)methyl]phenyl]sulfonyl]phenyl]ethyl]-N-
[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (86 mg).

(+)ESI-MS (m/z): 596, 598 (M+Na)⁺

Example 30

20 The following compound was obtained according to a
similar manner to that of Example 29.

tert-Butyl N-[2-[4-[[3-[amino(hydroxyimino)methyl]-
phenyl]sulfonyl]phenyl]ethyl]-N-[(R)-2-(3-chlorophenyl)-2-
25 hydroxyethyl]carbamate

NMR (CDCl₃, δ): 1.36 (9H, br s), 2.7-2.95 (2H, m), 3.1-
3.5 (4H, m), 4.7-4.85 (1H, m), 7.1-8.15 (12H, m)

(+)ESI-MS (m/z): 596, 598 (M+Na)⁺

30 Example 31

Under nitrogen at 5°C, to a solution of tert-butyl N-[2-
[4-[[4-[amino(hydroxyimino)methyl]phenyl]sulfonyl]-
phenyl]ethyl]-N-[(R)-2-(3-chlorophenyl)-2-
hydroxyethyl]carbamate (83 mg) in pyridine (2 ml) was added
35 dropwise acetyl chloride (11 μl), and the mixture was stirred

at room temperature for 1.5 hours followed by being refluxed for 3 hours. The resulting mixture was evaporated under reduced pressure. The residue was dissolved in a mixture of water and ethyl acetate. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 2:1 to 1:1) to give tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]sulfonyl]phenyl]ethyl]-carbamate (33 mg).

NMR (CDCl₃, δ): 1.34 (9H, br s), 2.67 (3H, s), 2.65-2.95 (2H, m), 3.1-3.45 (4H, m), 4.75-4.9 (1H, m), 7.15-7.35 (6H, m), 7.85-7.9 (2H, m), 7.95-8.05 (2H, m), 8.15-8.2 (2H, m)
(+)ESI-MS (m/z): 620, 622 (M+Na)⁺

Example 32

The following compound was obtained according to a similar manner to that of Example 31.

tert-Butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]sulfonyl]phenyl]ethyl]carbamate

NMR (CDCl₃, δ): 1.32 (9H, br s), 2.65-2.95 (2H, m), 2.67 (3H, s), 3.15-4.45 (4H, m), 4.8-4.9 (1H, m), 7.1-7.4 (6H, m), 7.55-7.65 (1H, m), 7.85-7.95 (2H, m), 8.0-8.1 (1H, m), 8.2-8.3 (1H, m), 8.6-8.65 (1H, m)
(+)ESI-MS (m/z): 620, 622 (M+Na)⁺

Example 33

At room temperature, to a solution of tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]sulfonyl]phenyl]ethyl]-

carbamate (29 mg) in ethyl acetate (1 ml) was added 4N hydrogen chloride in 1,4-dioxane (1 ml), and the mixture was stirred at the same temperature for 3.5 hours to give a precipitate. The precipitate was collected by filtration and dried to give (R)-1-(3-chlorophenyl)-2-[[2-[4-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]sulfonyl]phenyl]ethyl]-amino]ethanol dihydrochloride (14 mg).

NMR (DMSO-d₆, δ): 2.68 (3H, s), 2.9-3.4 (6H, m), 4.85-5.0 (1H, m), 7.3-7.45 (4H, m), 7.54 (2H, d, J=8.4Hz), 7.98 (2H, d, J=8.4Hz), 8.1-8.25 (4H, m)
(+)ESI-MS (m/z): 489, 500 (M-2HCl+H)⁺

Example 34

The following compound was synthesized according to a similar manner to that of Example 33.

(R)-1-(3-Chlorophenyl)-2-[[2-[4-[[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]sulfonyl]phenyl]ethyl]amino]ethanol dihydrochloride

NMR (DMSO-d₆, δ): 2.70 (3H, s), 2.9-3.4 (6H, m), 4.85-5.0 (1H, m), 7.3-7.6 (6H, m), 7.75-7.9 (1H, m), 7.95-8.05 (2H, m), 8.15-8.35 (2H, m), 8.4-8.45 (1H, m)
(+)ESI-MS (m/z): 498, 500 (M-2HCl+H)⁺

Example 35

A mixture of (S)-1-[N-benzyl-N-[2-[4-[(3,4-dimethoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-phenoxy-2-propanol (250 mg) and 10% palladium on activated carbon (50% wet, 130 mg) in methanol (5 ml) was stirred room temperature in the presence of hydrogen at an atmospheric pressure for 2 hours. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:methanol = 50:1 to 20:1) followed by treatment with hydrogen chloride-methanol

reagent 10 (Tokyo Kasei) and dryness to give (S)-1-[[2-[4-
[(3,4-dimethoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-
phenoxy-2-propanol hydrochloride (180 mg).

5 NMR (DMSO- d_6 , δ): 2.9-3.5 (6H, m), 3.82 (3H, s), 3.83
(3H, s), 3.9-4.0 (2H, m), 4.05-4.25 (1H, m), 6.85-
7.0 (3H, m), 7.15 (1H, d, $J=8.5\text{Hz}$), 7.25-7.6 (6H,
m), 7.85-8.0 (2H, m)
(+)ESI-MS (m/z): 472 ($M\text{-HCl}+\text{H}$)⁺

10 Preparation 51

The following compounds were obtained according to a
similar manner to that of Preparation 2.

(1) 3-[[4-[2-[N-Benzyl-N-(tert-butoxycarbonyl)amino]ethyl]-
15 phenyl]thiolphenyl trifluoromethanesulfonate
NMR (CDCl_3 , δ): 1.47 (9H, s), 2.80 (2H, br s), 3.39 (2H,
br s), 4.38 (2H, br s), 6.95-7.45 (13H, m)
(+)APCI-MS (m/z): 590 ($M+\text{Na}$)⁺

20 (2) 4-[[4-[2-[N-Benzyl-N-(tert-butoxycarbonyl)amino]ethyl]-
phenyl]thiolphenyl trifluoromethanesulfonate
NMR (CDCl_3 , δ): 1.47 (9H, s), 2.78 (2H, m), 3.39 (2H,
m), 4.38 (2H, m), 7.05-7.40 (13H, m)
(+)APCI-MS (m/z): 590 ($M+\text{Na}$)⁺

25 (3) 4-[[4-[(2R)-2-[(2,2,2-Trifluoroacetyl)amino]propyl]-
phenyl]sulfonyl]phenyl trifluoromethanesulfonate
NMR (CDCl_3 , δ): 1.23 (3H, d, $J=7\text{Hz}$), 2.87 (1H, dd, $J=14$,
7Hz), 2.98 (1H, dd, $J=14$, 6Hz), 4.28 (1H, m), 6.08
30 (1H, br d, $J=7\text{Hz}$), 7.36 (2H, d, $J=7\text{Hz}$), 7.42 (2H,
d, $J=7\text{Hz}$), 7.90 (2H, d, $J=7\text{Hz}$), 8.03 (2H, d,
 $J=7\text{Hz}$)
(+)APCI-MS (m/z): 542 ($M+\text{Na}$)⁺

35 Preparation 52

A mixture of 3-[[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)amino]ethyl]phenyl]thio]phenyl trifluoromethanesulfonate (521 mg), palladium(II) acetate (22 mg), 1,3-bis(diphenylphosphino)propane (46 mg), ethanol (2.1 ml), and triethylamine (0.4 ml) in N,N-dimethylformamide (4.2 ml) was heated to 60°C under carbon monoxide (1 atm) atmosphere for 5.5 hours. After being allowed to cool to room temperature, the mixture was partitioned between hexane/ethyl acetate (1/3) and water. The organic layer was separated, washed successively with water, brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give ethyl 3-[[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)amino]ethyl]phenyl]thio]benzoate (389 mg) as a colorless oil.

NMR (CDCl₃, δ): 1.36 (3H, t, J=7Hz), 1.46 (9H, s), 2.76 (2H, br s), 3.36 (2H, br s), 4.34 (2H, q, J=7Hz), 4.36 (2H, br s), 6.95-7.50 (11H, m), 7.87 (1H, d, J=7Hz), 7.98 (1H, s)

(+)APCI-MS (m/z): 514 (M+Na)⁺

Preparation 53

The following compounds were obtained according to a similar manner to that of Preparation 19.

- (1) Ethyl 3-[[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)amino]ethyl]phenyl]sulfonyl]benzoate
- NMR (CDCl₃, δ): 1.38 (9H, s), 1.40 (3H, t, J=7Hz), 2.81 (2H, br s), 3.35 (2H, br s), 4.38 (2H, br s), 4.40 (2H, q, J=7Hz), 7.00-7.45 (7H, m), 7.58 (1H, t, J=8Hz), 7.86 (2H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.22 (1H, d, J=8Hz), 8.57 (1H, s)
- (+)APCI-MS (m/z): 546 (M+Na)⁺
- (2) Ethyl 4-[[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)-

amino]ethyl]phenyl]sulfonyl]benzoate

NMR (CDCl₃, δ): 1.38 (3H, t, J=7Hz), 1.39 (9H, s), 2.80
(2H, br s), 3.35 (2H, br s), 4.36 (2H, br s), 4.39
(2H, q, J=7Hz), 7.00-7.45 (7H, m), 7.84 (2H, d,
5 J=8Hz), 7.98 (2H, d, J=8Hz), 8.14 (2H, d, J=8Hz)
(+)APCI-MS (m/z): 546 (M+Na)⁺

Preparation 54

The following compounds were obtained according to a
10 similar manner to that of Preparation 32.

(1) Ethyl 3-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-
benzoate

NMR (CDCl₃, δ): 1.40 (3H, t, J=7Hz), 2.86 (4H, m), 3.78
15 (2H, s), 4.40 (2H, q, J=7Hz), 7.10-7.43 (7H, m),
7.58 (1H, t, J=8Hz), 7.87 (2H, d, J=8Hz), 8.11 (1H,
d, J=8Hz), 8.22 (1H, d, J=8Hz), 8.58 (1H, s)
(+)APCI-MS (m/z): 424 (M+H)⁺

20 (2) Ethyl 4-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-
benzoate

NMR (CDCl₃, δ): 1.38 (3H, t, J=7Hz), 2.87 (4H, m), 3.74
(2H, s), 4.39 (2H, q, J=7Hz), 7.10-7.45 (7H, m),
7.86 (2H, d, J=8Hz), 7.99 (2H, d, J=8Hz), 8.15 (2H,
25 d, J=8Hz)
(+)APCI-MS (m/z): 424 (M+H)⁺

Preparation 55

The following compounds were obtained according to a
30 similar manner to that of Preparation 52.

(1) Ethyl 4-[[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)amino]-
ethyl]phenyl]thio]benzoate

NMR (CDCl₃, δ): 1.36 (3H, t, J=7Hz), 1.47 (9H, s), 2.80
35 (2H, br s), 3.39 (2H, br s), 4.34 (2H, q, J=7Hz),

4.36 (2H, br s), 7.00-7.50 (12H, m), 7.88 (1H, d, J=7Hz)

(+)APCI-MS (m/z): 514 (M+Na)⁺

- 5 (2) Ethyl 4-[[4-[(2R)-2-[(trifluoroacetyl)amino]propyl]-phenyl]sulfonyl]benzoate

NMR (CDCl₃, δ): 1.21 (3H, d, J=7Hz), 1.39 (3H, t, J=7Hz), 2.84 (1H, dd, J=14, 7Hz), 2.98 (1H, dd, J=14, 6Hz), 4.26 (1H, m), 4.39 (2H, q, J=7Hz) 6.08 (1H, br d, J=7Hz), 7.33 (2H, d, J=8Hz), 7.89 (2H, d, J=7Hz), 7.99 (2H, d, J=7Hz), 8.16 (2H, d, J=8Hz)

(+)APCI-MS (m/z): 466 (M+Na)⁺

15 Preparation 56

To a solution of ethyl 4-[[4-[(2R)-2-[(trifluoroacetyl)amino]propyl]phenyl]sulfonyl]benzoate (1.58 g) in ethanol (16 ml) was added 1N sodium hydroxide solution (8.6 ml), and the mixture was heated to 50°C for 3 hours. After the solvent was evaporated, and the residue was dissolved in 4 M hydrogen chloride/ethanol (16 ml) and kept at room temperature for 7 days. The solvent was evaporated, and the residue was partitioned between ethyl acetate and sodium hydrogen carbonate solution. The organic layer was washed with brine, dried over magnesium sulfate. Filtration followed by evaporation gave ethyl 4-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]benzoate (1.09 g) as an off-white powder.

NMR (DMSO-d₆, δ): 1.11 (3H, d, J=6Hz), 1.32 (3H, t, J=7Hz), 2.81 (1H, dd, J=13, 8Hz), 3.07 (1H, dd, J=13, 6Hz), 3.28-3.58 (1H, m), 4.34 (2H, q, J=7Hz), 7.54 (2H, d, J=8Hz), 7.80-8.40 (8H, m)

(+)APCI-MS (m/z): 348 (M+H)⁺

35 Preparation 57

The following compounds were obtained according to a similar manner to that of Preparation 68.

- (1) N-[2-[4-[(3-Chloro-4-methoxyphenyl)sulfonyl]-phenyl]ethyl]-2,2,2-trifluoroacetamide
5 (+)APCI-MS (m/z): 444 (M+Na)⁺
- (2) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1-methylethyl]acetamide
10 (+)APCI-MS (m/z): 424 (M+Na)⁺

Preparation 58

The following compounds were obtained according to a similar manner to that of Preparation 34.

- 15 (1) N-[2-[4-[(3-Chloro-4-hydroxyphenyl)sulfonyl]-phenyl]ethyl]-2,2,2-trifluoroacetamide
NMR (CDCl₃, δ): 2.95 (2H, t, J=7.1Hz), 3.61 (2H, q-like, J=6.8Hz), 6.16 (1H, br s), 6.39 (1H, br s), 7.11
20 (1H, d, J=8.6Hz), 7.34 (2H, d, J=8.3Hz), 7.75 (1H, dd, J=8.6, 2.3Hz), 7.87 (2H, d, J=8.3Hz), 7.93 (1H, d, J=2.3Hz)
(+)APCI-MS (m/z): 430 (M+Na)⁺
- 25 (2) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(4-hydroxyphenyl)sulfonyl]phenyl]-1-methylethyl]acetamide
(+)APCI-MS (m/z): 410 (M+Na)⁺
- (3) 2,2,2-Trifluoro-N-[2-[4-[(4-hydroxyphenyl)sulfonyl]-phenyl]-1,1-dimethylethyl]acetamide
30 MS (m/z): 402 (M+H)
- (4) N-[(1R)-2-[4-[(3-Chloro-4-hydroxyphenyl)sulfonyl]-phenyl]-1-methylethyl]-2,2,2-trifluoroacetamide
35 NMR (CDCl₃, δ): 1.20 (3H, d, J=3Hz), 2.80-3.00 (2H, m),

4.20-4.40 (1H, m), 7.00-7.10 (2H, m), 7.20-7.35
(2H, m), 7.80-7.95 (4H, m)

5 (5) 2,2,2-Trifluoro-N-[2-[4-[(4-hydroxy-3-methylphenyl)sulfonyl]phenyl]ethyl]acetamide
MS (m/z): 388 (M+H)

10 (6) 2,2,2-Trifluoro-N-[2-[4-[(3-fluoro-4-hydroxyphenyl)sulfonyl]phenyl]ethyl]acetamide
MS (m/z): 389 (M-H)

15 (7) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(3-hydroxyphenyl)sulfonyl]phenyl]-1-methylethyl]acetamide
MS (m/z): 376 (M+H)

Preparation 59

To a solution of N-[2-[4-[(3-chloro-4-hydroxyphenyl)sulfonyl]phenyl]ethyl]-2,2,2-trifluoroacetamide (687 mg) in N,N-dimethylformamide (7.0 ml) was added potassium carbonate (279 mg) at room temperature and the resulting suspension was stirred at the same temperature for 40 minutes. To the mixture was added chloroacetic acid tert-butyl ester (290 µl) and the mixture was stirred at room temperature for 23 hours. The mixture was quenched by the addition of water (20 ml) and extracted with ethyl acetate (20 ml x 1, 5 ml x 1). The combined extracts were washed with water (20 ml x 2) and brine (20 ml x 1) and dried over magnesium sulfate. Filtration followed by evaporation gave brown foam (716 mg). The crude product was chromatographed on silica gel (eluent: hexane/ethyl acetate) to give tert-butyl [2-chloro-4-[[4-[2-[(trifluoroacetyl)amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate (502 mg) as white foam.

(+)APCI-MS (m/z): 544 (M+Na)⁺

35 Preparation 60

To a suspension of tert-butyl [2-chloro-4-[[4-[2-
[(trifluoroacetyl)amino]ethyl]phenyl]sulfonyl]phenoxy]-
acetate (496 mg) in methanol (10.0 ml) was added 1N sodium
hydroxide solution (2.85 ml) at room temperature and the
5 mixture was stirred at the same temperature for 5 hours.
The mixture was quenched by the addition of 1N hydrochloric
acid (1.9 ml) and the solvent was removed by evaporation.
The residual solid was suspended in 4N hydrogen chloride in
ethanol (10 ml) and the suspension was stirred at room
10 temperature overnight. The solvent was removed by
evaporation and the residual white solid was suspended in
ethyl acetate (10 ml). To the suspension were added a
saturated aqueous sodium hydrogen carbonate solution (5 ml)
and water (5 ml) and the whole was stirred vigorously. The
15 organic layer was separated and the aqueous layer was
extracted with ethyl acetate (10 ml x 2). The combined
extracts were washed with brine (5 ml) and dried over
magnesium sulfate. Filtration followed by evaporation gave
ethyl [4-[[4-(2-aminoethyl)phenyl]sulfonyl]-2-
20 chlorophenoxy]acetate (398 mg) as a pale yellow paste.
(+)APCI-MS (m/z): 398 (M+H)⁺

Preparation 61

To a solution of N-[2-[4-[(3-chloro-4-hydroxyphenyl)-
25 sulfonyl]phenyl]ethyl]-2,2,2-trifluoroacetamide (874 mg) in
methanol (8.0 ml) was added 1N sodium hydroxide solution
(6.43 ml) and the solution was stirred at room temperature
for 1 hour. To the solution was added 1N hydrochloric acid
(4.29 ml) and the mixture was stirred at room temperature
30 for 1 hour. The precipitates were collected by filtration,
washed with a small portion of methanol, and dried under
reduced pressure to give 4-[[4-(2-aminoethyl)phenyl]-
sulfonyl]-2-chlorophenol (595 mg) as a white powder.
(+)APCI-MS (m/z): 312 (M+H)⁺

Preparation 62

To a solution of 2,2,2-trifluoro-N-[(1R)-1-methyl-2-phenylethyl]acetamide (10.0 g) in chloroform (100 ml) was added chlorosulfonic acid (50 ml) dropwise under 5°C over 90 minutes. The solution was stirred at the same temperature for 1 hour and at room temperature overnight. The reaction mixture was carefully added dropwise to a stirred mixture of water (150 ml) and chloroform (50 ml) under ice-water cooling. The organic layer was separated and washed with water (200 ml x 1) and dried over magnesium sulfate. Filtration followed by evaporation gave a white solid (14.2 g). The solid was chromatographed on silica gel (eluent: hexane/ethyl acetate) to give 4-[(2R)-2-[(trifluoroacetyl)-aminopropyl]benzenesulfonyl chloride (11.5 g) as a white solid.

NMR (CDCl₃, δ): 1.27 (3H, d, J=6.7Hz), 2.92 (1H, dd, J=7.3, 13.6Hz), 3.07 (1H, dd, J=6.1, 13.6Hz), 4.32 (1H, h, J=7.0Hz), 6.19 (1H, br), 7.44 (2H, d, J=8.5Hz), 8.00 (2H, d, J=8.5Hz)

Preparation 63

To a solution of 2,2,2-trifluoro-N-[(1R)-2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1-methylethyl]acetamide (500 mg) in a mixed solvent of methanol (5.0 ml) and water (1.5 ml) was added potassium carbonate (344 mg) and the mixture was stirred at room temperature for 30 minutes. The mixture was warmed to 50°C and stirred for 6 hours. After cooling to room temperature, the solvent was removed by evaporation. The residue was dissolved in ethyl acetate (20 ml) and washed with brine (5 ml x 1). The aqueous washing was extracted with ethyl acetate (5 ml x 2). The organic layers were combined and dried over magnesium sulfate. Filtration followed by evaporation gave (2R)-1-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-2-propanamine (342 mg) as a white solid.

(+)APCI-MS (m/z): 306 (M+H)⁺

Preparation 64

The following compound was obtained according to a similar manner to that of Preparation 59.

5

tert-Butyl [4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-propyl]phenyl]sulfonyl]phenoxy]acetate
(+)APCI-MS (m/z): 524 (M+Na)⁺

10 Preparation 65

To a solution of tert-butyl [4-[[4-[(2R)-2-[(trifluoroacetyl)amino]propyl]phenyl]sulfonyl]phenoxy]acetate (1.46 g) in a mixed solvent of methanol (15 ml) and water (5 ml) was added potassium carbonate (805 mg) and the solution was stirred at 50°C for 2 hours. To the solution was added 1N sodium hydroxide (2.91 ml) and the mixture was stirred at the same temperature for 6 hours. After cooling to room temperature, the solvent was removed by evaporation. The residue was dissolved in 4N hydrogen chloride in ethanol (20 ml) and the mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (50 ml) and basified with a saturated aqueous sodium hydrogen carbonate solution (50 ml). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (25 ml x 1). The combined organic layers were washed with brine (75 ml x 1) and dried over magnesium sulfate. Filtration followed by evaporation gave ethyl [4-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]phenoxy]acetate (1.08 g) as a pale yellow crystalline solid.

25
30 (+)APCI-MS (m/z): 378 (M+H)⁺Preparation 66

To a solution of 1,1-dimethyl-2-phenylethylamine (10 g) and triethylamine (12.1 ml) in tetrahydrofuran (5 ml) was added trifluoroacetic anhydride (10.4 ml) under ice-cooling

35

and the mixture was stirred at the same temperature for 2 hours. The resulting mixture was poured into saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo, and the residue was triturated with diisopropyl ether to give N-(1,1-dimethyl-2-phenylethyl)-2,2,2-trifluoroacetamide (16.3 g) as a colorless powder.

MS (m/z): 268 (M+Na)

Preparation 67

To a solution of N-(1,1-dimethyl-2-phenylethyl)-2,2,2-trifluoroacetamide (15.46 g) in chloroform (100 ml) was added dropwise chlorosulfonic acid (68.3 ml) under ice-cooling and the mixture was stirred at the same temperature for 2 hours. To the resulting mixture was added dropwise water under ice-cooling, and extracted with chloroform. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo, and the residue was triturated with diisopropyl ether to give 4-[2-methyl-2-[(trifluoroacetyl)amino]propyl]benzenesulfonyl chloride (15 g) as a colorless powder.

NMR (CDCl₃, δ): 1.43 (6H, s), 3.26 (2H, s), 7.30-7.40 (2H, m), 7.90-8.05 (2H, m)

Preparation 68

To a solution of 4-[2-methyl-2-[(trifluoroacetyl)amino]propyl]benzenesulfonyl chloride (8.16 g) and methoxybenzene (3.1 ml) in 1,2-dichloroethane (90 ml) was added trichloroaluminium (4.11 g) at room temperature and the mixture was stirred at 90°C for 20 hours. The resulting mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel

(hexane:ethyl acetate = 1:1) to give 2,2,2-trifluoro-N-[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1,1-dimethylethyl]-acetamide (2.15 g) as a colorless powder.

MS (m/z): 438 (M+Na)

5

Preparation 69

To a solution of 2,2,2-trifluoro-N-[2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1,1-dimethylethyl]acetamide (510 mg) in ethanol (5 ml) was added 1N sodium hydroxide solution (2.0 ml) at room temperature and the mixture was stirred at 80°C for 4 hours. The resulting mixture was poured into water and extracted with chloroform. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by a column chromatography on silica gel (hexane:ethyl acetate = 1:1) to give 1-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-2-methyl-2-propanamine (310 mg) as a colorless powder.

NMR (CDCl₃, δ): 1.10 (6H, s), 2.69 (2H, s), 3.86 (3H, s), 6.92-7.00 (2H, m), 7.20-7.35 (2H, m), 7.80-7.95 (4H, m)

20

Preparation 70

To a solution of 2,2,2-trifluoro-N-[2-[4-[(4-hydroxyphenyl)sulfonyl]phenyl]-1,1-dimethylethyl]acetamide (950 mg) and potassium carbonate (360 mg) in N,N-dimethylformamide (5 ml) was added ethyl bromoacetate (0.289 ml) at room temperature and the mixture was stirred at room temperature for 18 hours. The resulting mixture was poured into saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 1:1) to give ethyl [4-[[4-[2-methyl-2-[(trifluoroacetyl)amino]-

30

35

propyl]phenyl]sulfonyl]phenoxy]acetate (870 mg) as a colorless powder.

MS (m/z): 486 (M-H)

5 Preparation 71

To a solution of ethyl [4-[[4-[2-methyl-2-
[(trifluoroacetyl)amino]propyl]phenyl]sulfonyl]phenoxy]-
acetate (950 mg) in ethanol (5 ml) was added 1N sodium
hydroxide solution (2.0 ml) at room temperature and the
10 mixture was stirred at 80°C for 4 hours. The resulting
mixture was evaporated in vacuo. To the residue was added
4N hydrogen chloride in ethanol (5.0 ml) at room temperature
and the mixture was stirred at the same temperature for 18
hours. The reaction mixture was evaporated in vacuo. The
15 residue was poured into saturated aqueous sodium hydrogen
carbonate solution, and extracted with chloroform. The
organic layer was washed with brine, dried over magnesium
sulfate, and evaporated in vacuo to give ethyl [4-[[4-(2-
amino-2-methylpropyl)phenyl]sulfonyl]phenoxy]acetate (710
20 mg) as a colorless oil.

MS (m/z): 392 (M+H)

Preparation 72

The following compounds were obtained according to a
25 similar manner to that of Preparation 68.

(1) N-[(1R)-2-[4-[(3-Chloro-4-methoxyphenyl)sulfonyl]-
phenyl]-1-methylethyl]-2,2,2-trifluoroacetamide

30 NMR (CDCl₃, δ): 1.20 (3H, d, J=3Hz), 2.80-3.00 (2H, m),
3.95 (3H, s), 4.20-4.40 (1H, m), 6.92-7.00 (2H, m),
7.20-7.35 (2H, m), 7.80-7.95 (4H, m)

(2) 2,2,2-Trifluoro-N-[2-[4-[(4-methoxy-3-
methylphenyl)sulfonyl]phenyl]ethyl]acetamide

35 MS (m/z): 438 (M+H)

- (3) 2,2,2-Trifluoro-N-[2-[4-[(3-fluoro-4-methoxyphenyl)sulfonyl]phenyl]ethyl]acetamide
MS (m/z): 406 (M+H)

5

Preparation 73

The following compounds were obtained according to a similar manner to that of Preparation 70.

- 10 (1) Ethyl [2-methyl-4-[[4-[2-[(trifluoroacetyl)amino]-ethyl]phenyl]sulfonyl]phenoxy]acetate
MS (m/z): 474 (M+H)
- (2) Ethyl [2-methyl-4-[[4-[2-[(trifluoroacetyl)amino]-ethyl]phenyl]sulfonyl]phenoxy]acetate
15 MS (m/z): 474 (M+H)
- (3) Ethyl [2-chloro-4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-propyl]phenyl]sulfonyl]phenoxy]acetate
20 MS (m/z): 508 (M+H)
- (4) Ethyl [3-[[4-[(2R)-2-[(trifluoroacetyl)amino]propyl]-phenyl]sulfonyl]phenoxy]acetate
MS (m/z): 474 (M+H)

25

Preparation 74

The following compounds were obtained according to a similar manner to that of Preparation 71.

- 30 (1) Ethyl [4-[[4-(2-aminoethyl)phenyl]sulfonyl]-2-methylphenoxy]acetate
MS (m/z): 378 (M+H)
- (2) Ethyl [4-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-2-chlorophenoxy]acetate
35

MS (m/z): 412 (M+H)

(3) Ethyl [4-[[4-(2-aminoethyl)phenyl]sulfonyl]-2-fluorophenoxy]acetate

5 MS (m/z): 382 (M+H)

(4) Ethyl [3-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-phenoxy]acetate

MS (m/z): 378 (M+H)

10

Preparation 75

The following compound was obtained according to a similar manner to that of Preparation 66.

15 2,2,2-Trifluoro-N-(2-phenylethyl)acetamide

NMR (CDCl₃, δ): 2.89 (2H, t, J=7Hz), 3.64 (2H, q, J=7Hz), 7.20-7.40 (5H, m)

Preparation 76

20 The following compound was obtained according to a similar manner to that of Preparation 67.

4-[2-[(Trifluoroacetyl)amino]ethyl]benzenesulfonyl chloride

25 NMR (DMSO-d₆, δ): 2.83 (2H, t, J=7Hz), 3.40 (2H, q, J=7Hz), 7.10-7.20 (2H, m), 7.40-7.60 (2H, m)

Preparation 77

To a solution of 2,2,2-trifluoro-N-[(1R)-1-methyl-2-phenylethyl]acetamide (485 mg) and 3-methoxybenzenesulfonyl chloride (390 mg) in 1,2-dichloroethane (7.0 ml) was added copper(II) trifluoromethanesulfonate (152 mg) and trichloroaluminium (475 mg) at room temperature and the mixture was refluxed for 7 hours. The resulting mixture was
35 evaporated and partitioned between ethyl acetate and water.

The organic layer was separated, washed with water and brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give 2,2,2-trifluoro-N-
5 ((1R)-2-[4-[(3-methoxyphenyl)sulfonyl]phenyl]-1-methylethyl)acetamide (205 mg) as a colorless oil.

MS (m/z): 402 (M+H)

Example 36

10 A mixture of (R)-4-[[4-[2-[N-benzyl-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenol (1.31 g), triethylamine (3.3 ml) and 10% palladium on activated carbon (50% wet, 0.65 g) in a mixture of methanol (13 ml) and chlorobenzene (13 ml) was stirred at room
15 temperature in the presence of hydrogen at an atmospheric pressure for 5 hours. After filtration, the filtrate was evaporated under reduced pressure. The residue was dissolved into a mixture of ethyl acetate and saturated aqueous sodium hydrogen carbonate. After separation, the
20 organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:methanol = 20:1 to 8:1) to give (R)-4-[[4-[2-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-
25 sulfonyl]phenol (789 mg).

NMR (DMSO-d₆, δ): 2.55-2.85 (6H, m), 4.55-4.6 (1H, m),
6.9-6.95 (2H, m), 7.2-7.8 (4H, m)

(+)ESI-MS (m/z): 432, 434 (M+H)⁺

30 Example 37

Under nitrogen at room temperature, to a solution of (R)-4-[[4-[2-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-ethyl]phenyl]sulfonyl]phenol (1.0 g) in tetrahydrofuran (8 ml) was added di-tert-butyl dicarbonate (0.56 g) in
35 tetrahydrofuran (2 ml), and the mixture was stirred at the

same temperature for 12 hours. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 2:1 to 1:1) to give tert-butyl (R)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(4-hydroxyphenyl)sulfonyl]phenyl]ethyl]carbamate (1.1 g).

NMR (CDCl₃, δ): 1.2-1.5 (9H, m), 2.6-2.95 (2H, m), 3.15-3.6 (4H, m), 4.8-4.95 (1H, m), 6.8-6.95 (2H, m), 7.15-7.45 (6H, m), 7.7-7.9 (2H, m)
(+)ESI-MS (m/z): 554, 556 (M+Na)⁺

Example 38

Under nitrogen at 5°C, to a solution of tert-butyl (R)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(4-hydroxyphenyl)sulfonyl]phenyl]ethyl]carbamate (100 mg) in N,N-dimethylformamide (2 ml) was added sodium hydride (60% in oil, 8.3 mg), and the mixture was stirred at the same temperature for 1 hour. To this one was added isopropyl bromoacetate (0.027 ml) and the mixture was stirred at the same temperature for 2 hours. The resulting mixture was poured into saturated aqueous sodium hydrogen carbonate and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 2:1 to 1:1) to give isopropyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]phenoxy]acetate (106 mg).

NMR (CDCl₃, δ): 1.2-1.45 (15H, m), 2.65-2.9 (2H, m), 3.2-3.45 (4H, m), 4.61 (2H, s), 4.8-4.9 (1H, m), 5.05-5.2 (1H, m), 6.9-6.95 (2H, m), 7.15-7.4 (6H,

m), 7.75-7.9 (4H, m)
(+)ESI-MS (m/z): 654, 656 (M+Na)⁺

Example 39

- 5 At room temperature, to a solution of isopropyl (R)-[4-
[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
(103 mg) in ethyl acetate (1 ml) was added 4N hydrogen
chloride in 1,4-dioxane (1 ml), and the mixture was stirred
10 at the same temperature for 1.5 hours to give a precipitate.
The precipitate was collected by filtration and washed with
ethyl acetate, followed by dryness to give isopropyl (R)-[4-
[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-
phenyl]sulfonyl]phenoxy]acetate hydrochloride (66 mg).
15 NMR (DMSO-d₆, δ): 1.21 (6H, d, J=6.4Hz), 2.95-3.5 (6H,
m), 4.87 (2H, s), 4.85-5.05 (2H, m), 7.05-7.15 (2H,
m), 7.3-7.55 (6H, m), 7.85-7.95 (4H, m)
(+)ESI-MS (m/z): 532, 534 (M-HCl+H)⁺

20 Example 40

The following compounds were obtained according to a
similar manner to that of Example 38.

- (1) Propyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-
25 chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-
sulfonyl]phenoxy]acetate
NMR (CDCl₃, δ): 0.91 (3H, t, J=7.4Hz), 1.2-1.5 (9H, m),
1.55-1.8 (2H, m), 2.7-2.9 (2H, m), 3.2-3.45 (4H,
m), 4.1-4.2 (2H, m), 4.65 (2H, s), 4.8-4.9 (1H, m),
30 6.9-7.0 (2H, m), 7.15-7.4 (6H, m), 7.8-7.9 (4H, m)
(+)ESI-MS (m/z): 654, 656 (M+Na)⁺
- (2) tert-Butyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-
35 (3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-
sulfonyl]phenoxy]acetate

NMR (CDCl₃, δ): 1.25-1.45 (9H, m), 1.48 (9H, s), 2.65-2.9 (2H, m), 3.2-3.45 (4H, m), 4.54 (2H, s), 4.8-4.9 (1H, m), 6.9-7.0 (2H, m), 7.15-7.4 (6H, m), 7.8-7.9 (4H, m)

5 (+)ESI-MS (m/z): 668, 670 (M+Na)⁺

(3) Cyclohexyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]phenoxy]acetate

10 NMR (CDCl₃, δ): 1.2-1.95 (19H, m), 2.65-2.9 (2H, m), 3.15-3.45 (4H, m), 4.63 (2H, s), 4.8-4.95 (2H, m), 6.9-7.0 (2H, m), 7.1-7.4 (6H, m), 7.75-7.9 (4H, m)
(+)ESI-MS (m/z): 694, 696 (M+Na)⁺

15 Example 41

The following compounds were obtained according to a similar manner to that of Example 39.

(1) Propyl (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate hydrochloride

20 NMR (DMSO-d₆, δ): 0.82 (3H, t, J=7.4Hz), 1.5-1.7 (2H, m), 2.9-3.5 (6H, m), 4.06 (2H, t, J=6.6Hz), 4.85-5.0 (3H, m), 7.05-7.2 (2H, m), 7.3-7.55 (6H, m), 7.8-7.95 (4H, m)

25 (+)ESI-MS (m/z): 532, 534 (M-HCl+H)⁺

(2) tert-Butyl (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate hydrochloride

30 NMR (DMSO-d₆, δ): 1.41 (9H, s), 2.95-3.3 (6H, m), 4.78 (2H, s), 4.9-5.0 (1H, m), 7.05-7.15 (2H, m), 7.3-7.55 (6H, m), 7.85-7.95 (4H, m)

(+)ESI-MS (m/z): 546, 548 (M+HCl+H)⁺

(3) Cyclohexyl (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate hydrochloride

5 NMR (DMSO-d₆, δ): 1.05-1.85 (10H, m), 2.8-3.4 (6H, m),
4.65-5.0 (4H, m), 7.05-7.2 (2H, m), 7.25-7.55 (6H, m), 7.8-7.95 (4H, m)

(+)ESI-MS (m/z): 572, 574 (M+HCl+H)⁺

Example 42

10 Under nitrogen at room temperature, to a solution of tert-butyl (R)-N-[2-[3-chlorophenyl]-2-hydroxyethyl]-N-[2-[4-[(4-hydroxyphenyl)sulfonyl]phenyl]ethyl]carbamate (900 mg) in N,N-dimethylformamide (10 ml) was added powdered potassium carbonate (257 mg) and ethyl bromoacetate (0.21 ml), and the mixture was stirred at 60°C for 1.5 hours. The
15 resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced
20 pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 2:1 to 1:2) to give ethyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]acetate (1.0 g).

25 NMR (CDCl₃, δ): 1.25-1.5 (12H, m), 2.65-2.95 (2H, m),
3.15-3.5 (4H, m), 4.2-4.3 (2H, m), 4.64 (2H, s),
5.85-5.95 (1H, m), 6.9-6.95 (2H, m), 7.15-7.4 (6H, m), 7.8-7.9 (4H, m)

(+)ESI-MS (m/z): 640, 642 (M+H)⁺

30

Example 43

At room temperature, to a solution of ethyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
35 (374 mg) in ethanol (10 ml) was added aqueous 1N sodium

hydroxide (0.61 ml), and the mixture was stirred at the same temperature for 1.5 hours. The resulting mixture was evaporated under reduced pressure and dried to give sodium (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]acetate (372 mg).

NMR (DMSO-d₆, δ): 1.05-1.35 (9H, m), 2.7-2.9 (2H, m), 3.1-3.5 (4H, m), 4.18 (2H, s), 4.65-4.8 (1H, m), 6.9-6.95 (2H, m), 7.15-7.45 (6H, m), 7.75-7.85 (4H, m)
(+)ESI-MS (m/z): 588, 590 (M-Na-N)⁻

Example 44

Under nitrogen at room temperature, to a solution of sodium (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]acetate (60 mg) in N,N-dimethylformamide (2 ml) were added sodium iodide (22 mg) and 2-bromoethanol (0.010 ml), and the mixture was stirred at 60°C for 1 hour. The resulting mixture was poured into saturated aqueous sodium hydrogen carbonate and the aqueous mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure, followed by dryness to give 2-hydroxyethyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate (56 mg).

NMR (CDCl₃, δ): 1.25-1.5 (9H, m), 2.65-3.0 (2H, m), 3.1-3.6 (4H, m), 3.85-3.9 (2H, m), 4.3-4.35 (2H, m), 4.71 (2H, s), 4.85-4.9 (1H, m), 6.9-7.0 (2H, m), 7.1-7.4 (6H, m), 7.75-7.9 (4H, m)
(+)ESI-MS (m/z): 656, 658 (M+Na)⁺

Example 45

Under nitrogen at room temperature, to a solution of 2-

hydroxyethyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]acetate (53 mg) in dichloromethane (3 ml) was added trifluoroacetic acid (0.5 ml), and the mixture was stirred
5 at the same temperature for 45 minutes. The resulting mixture was poured into saturated aqueous sodium hydrogen carbonate and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and
10 evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:methanol = 20:1 to 10:1), followed by treatment with 4N hydrogen chloride in 1,4-dioxane and dryness to give 2-hydroxyethyl (R)-[4-[[4-[2-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-ethyl]phenyl]sulfonyl]phenoxy]acetate hydrochloride (24 mg).
15

NMR (DMSO-d₆, δ): 2.9-3.4 (6H, m), 3.5-3.7 (2H, m),
4.05-4.2 (2H, m), 4.8-5.0 (3H, m), 7.05-7.2 (2H, m), 7.3-7.6 (6H, m), 7.8-8.0 (4H, m)
(+)ESI-MS (m/z): 534, 536 (M-HCl+H)⁺

20

Example 46

The following compound was obtained according to a similar manner to that of Example 42.

25 2-Ethoxy-1-(ethoxymethyl)ethyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]phenoxy]acetate

NMR (CDCl₃, δ): 1.15-1.2 (6H, m), 1.3-1.4 (9H, m),
2.65-2.95 (2H, m), 3.2-3.6 (12H, m), 4.70 (2H, s),
30 4.85-4.9 (1H, s), 5.25-5.3 (1H, m), 6.9-6.95 (2H, m), 7.1-7.4 (6H, m), 7.8-7.9 (4H, m)
(+)ESI-MS (m/z): 742, 744 (M+Na)⁺

Example 47

35 The following compound was obtained according to a

similar manner to that of Example 44.

2-Pyridylmethyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-
N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-

5 ethyl]phenyl]sulfonyl]phenoxy]acetate

NMR (CDCl₃, δ): 1.25-1.5 (9H, m), 2.65-2.95 (2H, m),
3.1-3.6 (4H, m), 4.77 (2H, s), 4.8-4.9 (1H, m),
5.33 (2H, s), 6.95-7.0 (2H, m), 7.1-7.4 (8H, m),
7.65-7.75 (1H, m), 7.8-7.9 (4H, m), 8.6-8.65 (1H,
10 m)

(+)ESI-MS (m/z): 703, 705 (M+Na)⁺

Example 48

The following compounds were obtained according to a
15 similar manner to that of Example 45.

(1) 2-Ethoxy-1-(ethoxymethyl)ethyl (R)-[4-[[4-[2-[[2-(3-
chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-
sulfonyl]phenoxy]acetate hydrochloride

20 NMR (DMSO-d₆, δ): 1.04 (6H, t, J=7.0Hz), 2.9-3.6 (14H,
m), 4.85-5.2 (4H, m), 7.05-7.2 (2H, m), 7.3-7.6
(6H, m), 7.8-8.0 (4H, m)

(+)ESI-MS (m/z): 620, 622 (M-HCl+H)⁺

25 (2) 2-Pyridylmethyl (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-
acetate dihydrochloride

NMR (DMSO-d₆, δ): 2.95-3.4 (6H, m), 4.9-5.0 (1H, m),
5.06 (2H, s), 5.27 (2H, s), 7.1-7.25 (2H, m), 7.3-
30 7.55 (8H, m), 7.8-7.95 (5H, m), 8.55-8.6 (1H, m)

(+)ESI-MS (m/z): 581, 583 (M-2HCl+H)⁺

Example 49

Under nitrogen at 5°C, to a solution of ethyl (R)-[4-
35 [[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-

hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate (92 mg) in tetrahydrofuran (4 ml) was added sodium borohydride (19 mg), followed by methanol (2 ml) dropwise. The mixture was stirred at room temperature for 12 hours. The resulting mixture was poured into saturated aqueous sodium hydrogen carbonate and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate = 1:1 to 1:2) to give tert-butyl (R)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-(2-hydroxyethyl)phenyl]-sulfonyl]phenyl]ethyl]carbamate (71 mg).

NMR (CDCl₃, δ): 1.2-1.5 (9H, m), 2.65-2.9 (2H, m), 3.1-3.5 (4H, m), 3.9-4.0 (2H, m), 4.05-4.15 (2H, m), 4.8-4.9 (1H, m), 6.9-7.0 (2H, m), 7.1-7.4 (6H, m)
(+)ESI-MS (m/z): 598, 600 (M+Na)⁺

Example 50

At room temperature, to a solution of tert-butyl (R)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-(2-hydroxyethoxy)phenyl]sulfonyl]phenyl]ethyl]carbamate (67 mg) in ethyl acetate (1 ml) was added 4N hydrogen chloride in 1,4-dioxane (1 ml), and the mixture was stirred at the same temperature for 1.5 hours. The resulting mixture was poured into saturated aqueous sodium hydrogen carbonate and the aqueous mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform:methanol = 20:1 to 10:1), followed by treatment with 4N hydrogen chloride in 1,4-dioxane and dryness to give (R)-1-(3-chlorophenyl)-2-[[2-[4-[[4-(2-hydroxyethoxy)phenyl]-sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride (36 mg).

NMR (DMSO-d₆, δ): 2.9-3.5 (6H, m), 3.65-3.8 (2H, m),

4.0-4.15 (2H, m), 4.85-5.0 (1H, m), 7.05-7.2 (2H, m), 7.3-7.6 (6H, m), 7.8-7.95 (4H, m)
(+)ESI-MS (m/z): 476, 478 (M-HCl+H)⁺

5 Example 51

The following compounds were obtained according to a similar manner to that of Example 6.

(1) Ethyl 3-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate
10 NMR (CDCl₃, δ): 1.40 (3H, t, J=7Hz), 2.45-3.00 (6H, m), 3.54 (1H, d, J=13Hz), 3.62 (1H, br s), 3.89 (1H, d, J=13Hz), 4.40 (2H, q, J=7Hz), 4.60 (1H, dd, J=10, 4Hz), 7.00-7.40 (11H, m), 7.58 (1H, t, J=8Hz),
15 7.84 (2H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.22 (1H, d, J=8Hz), 8.59 (1H, s)
(+)APCI-MS (m/z): 578 (M+H)⁺

(2) Ethyl 4-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate
20 NMR (CDCl₃, δ): 1.38 (3H, t, J=7Hz), 2.45-3.00 (6H, m), 3.54 (1H, d, J=13Hz), 3.60 (1H, br s), 3.90 (1H, d, J=13Hz), 4.38 (2H, q, J=7Hz), 4.59 (1H, dd, J=10, 4Hz), 7.05-7.45 (11H, m), 7.83 (2H, d, J=8Hz),
25 7.98 (2H, d, J=8Hz), 8.14 (2H, d, J=8Hz)
(+)APCI-MS (m/z): 578 (M+H)⁺

Example 52

To a solution of ethyl 3-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate (182 mg) in chlorobenzene (1.8 ml) - methanol (1.8 ml) was added triethylamine (0.36 ml), and the solution was hydrogenated (1 atm) over 10% palladium on carbon (43 mg) at room temperature for 3 hours. After the catalyst was
35 filtered off, the filtrate was concentrated and purified by

column chromatography (silica gel, chloroform/methanol) to give ethyl 3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate (107 mg) as an oil.

- 5 NMR (CDCl₃, δ): 1.41 (3H, t, J=7Hz), 2.68 (1H, dd, J=12, 9Hz), 2.75-3.05 (5H, m), 4.40 (2H, q, J=7Hz), 4.65 (1H, dd, J=9, 4Hz), 7.15-7.30 (3H, m), 7.30-7.40 (3H, m), 7.59 (1H, t, J=7.8Hz), 7.89 (2H, d, J=8Hz), 8.12 (1H, ddd, J=7.8, 1.8, 1.3Hz), 8.23 (1H, dt, J=7.8, 1.3Hz), 8.58 (1H, t, J=1.3Hz)
- 10 (+)APCI-MS (m/z): 488 (M+H)⁺

Example 53

- Ethyl 3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate (28 mg) was dissolved in 4N hydrogen chloride/ethanol (0.6 ml), and the solution was evaporated to give ethyl 3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoate hydrochloride (19 mg) as a white powder.

- 20 NMR (DMSO-d₆, δ): 1.34 (3H, t, J=7Hz), 2.85-3.40 (6H, m), 4.36 (2H, q, J=7Hz), 4.96 (1H, m), 6.31 (1H, d, J=4Hz, OH), 7.25-7.50 (4H, m), 7.54 (2H, d, J=8Hz), 7.80 (1H, t, J=8Hz), 7.98 (2H, d, J=8Hz), 8.23 (2H, d, J=8Hz), 8.40 (1H, s), 8.92 (2H, br s)
- 25 (+)APCI-MS (m/z): 488 (M+H)⁺

Example 54

- To a solution of ethyl 3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate (56 mg) in ethanol (0.57 ml) was added 1N sodium hydroxide solution (0.35 ml), and the mixture was stirred at room temperature for 2 hours. After the solvent was evaporated, 1N hydrochloric acid (1 ml) was added to the residue, and the mixture was triturated with acetonitrile to give 3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-
- 30
- 35

amino]ethyl]phenyl]sulfonyl]benzoic acid hydrochloride (31 mg) as a white powder.

NMR (DMSO-d₆, δ): 2.85-3.50 (6H, m), 4.98 (1H, m), 6.32 (1H, d, J=4Hz, OH), 7.25-7.50 (4H, m), 7.54 (2H, d, J=8Hz), 7.77 (1H, t, J=8Hz), 7.98 (2H, d, J=8Hz), 8.21 (2H, d, J=8Hz), 8.38 (1H, s), 8.94 (2H, br s), 13.60 (1H, br s)

(+)APCI-MS (m/z): 458 (M-H)⁻

10 Example 55

The following compounds were obtained according to a similar manner to that of Preparation 30.

- 15 (1) Ethyl 3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoate

NMR (CDCl₃, δ): 1.33 (9H, s), 1.41 (3H, t, J=7Hz), 2.55-3.00 (2H, m), 3.10-3.60 (4H, m), 4.24 (1H, br s, OH), 4.41 (2H, q, J=7Hz), 4.85 (1H, m), 7.10-7.40 (6H, m), 7.57 (1H, t, J=8Hz), 7.88 (2H, d, J=8Hz), 8.09 (1H, d, J=8Hz), 8.21 (1H, d, J=8Hz), 8.57 (1H, s)

(+)APCI-MS (m/z): 610 (M+Na)⁺

- 25 (2) Ethyl 4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoate

NMR (CDCl₃, δ): 1.35 (9H, s), 1.39 (3H, t, J=7Hz), 2.55-3.00 (2H, m), 3.10-3.60 (4H, m), 4.24 (1H, br s, OH), 4.39 (2H, q, J=7Hz), 4.84 (1H, m), 7.00-7.35 (6H, m), 7.86 (2H, d, J=8Hz), 7.98 (2H, d, J=8Hz), 8.13 (2H, d, J=8Hz)

(+)APCI-MS (m/z): 610 (M+Na)⁺

- 35 (3) Ethyl 4-[[4-[(2R)-2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-

(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoate

NMR (CDCl₃, δ): 1.23 (9H, s), 1.25 (3H, d, J=6Hz), 1.39 (3H, t, J=7Hz), 2.50-3.70 (4H, m), 4.00-4.25 (1H, m), 4.39 (2H, q, J=7Hz), 4.67 (1H, m), 5.21 (1H, br s), 7.05-7.45 (6H, m), 7.86 (2H, d, J=8Hz), 7.97 (2H, d, J=8Hz), 8.11 (2H, d, J=8Hz)
(+)APCI-MS (m/z): 624 (M+Na)⁺

10 Example 56

To a solution of ethyl 3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]benzoate (3.06 g) in 1,4-dioxane (31 ml) was added 1N sodium hydroxide solution (6.8 ml), and the mixture was stirred at room temperature for 2.5 hours. After the solution was neutralized with 10% citric acid, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated to give 3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoic acid (3.05 g) as a white solid.

NMR (DMSO-d₆, δ): 1.02, 1.18 (total 9H, a pair of s), 2.60-3.00 (2H, m), 3.00-3.70 (4H, m), 4.73 (1H, m), 5.58 (1H, br s), 7.05-7.60 (6H, m), 7.75 (1H, t, J=8Hz), 7.90 (2H, d, J=8Hz), 8.19 (2H, d, J=8Hz), 8.37 (1H, s), 13.41 (1H, br s)
(-)APCI-MS (m/z): 558 (M-H)⁻

30 Example 57

To a solution of 3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoic acid (84 mg) and 1-hydroxybenzotriazole (24 mg) in N,N-dimethylformamide (0.84 ml) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (37

mg), and the mixture was stirred at room temperature for 1 hour. Ammonia solution (28%, 0.84 ml) was added to the mixture and the mixture was stirred at the same temperature for 2 hours. The mixture was partitioned between
5 hexane/ethyl acetate (1/3) and water. The organic layer was separated, washed successively with sodium hydrogen carbonate solution and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by column chromatography (silica gel,
10 hexane/ethyl acetate) to give tert-butyl N-[2-[4-[[3-(aminocarbonyl)phenyl]sulfonyl]phenyl]ethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (80 mg) as a white amorphous powder.

15 NMR (CDCl₃, δ): 1.36 (9H, s), 2.60-3.60 (6H, m), 4.36 (1H, br s), 4.62 (1H, m), 5.77 (1H, br s), 6.35 (1H, br s), 7.05-7.40 (6H, m), 7.57 (1H, t, J=8Hz), 7.89 (2H, d, J=8Hz), 7.98 (1H, d, J=8Hz), 8.07 (1H, d, J=8Hz), 8.29 (1H, s)
(+)APCI-MS (m/z): 581 (M+Na)⁺

20

Example 58

The following compounds were obtained according to a similar manner to that of Example 33.

25 (1) 3-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]benzamide hydrochloride
NMR (DMSO-d₆, δ): 2.90-3.35 (6H, m), 5.00 (1H, m),
7.30-7.50 (4H, m), 7.54 (2H, d, J=8Hz), 7.65 (1H, br s), 7.72 (1H, t, J=8Hz), 7.97 (2H, d, J=8Hz),
30 8.10 (1H, d, J=8Hz), 8.16 (1H, d, J=8Hz), 8.31 (1H, br s), 8.42 (1H, s), 8.96 (1H, br s), 9.29 (1H, br s)
(+)APCI-MS (m/z): 459 (M+H)⁺

35 (2) 4-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-

amino]ethyl]phenyl]sulfonyl]benzamide hydrochloride

NMR (DMSO-d₆, δ): 2.85-3.35 (6H, m), 5.00 (1H, dd, J=8, 2Hz), 7.25-7.50 (4H, m), 7.53 (2H, d, J=8Hz), 7.63 (1H, br s), 7.96 (2H, d, J=8Hz), 7.96-8.12 (4H, m), 8.20 (1H, br s), 8.96 (1H, br s), 9.26 (1H, br s)
(+)APCI-MS (m/z): 459 (M+H)⁺

(3) 4-[[4-[(2R)-2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzamide hydrochloride

NMR (DMSO-d₆, δ): 1.09 (3H, d, J=6Hz), 2.65-3.70 (5H, m), 5.02 (1H, m), 6.35 (1H, br s), 7.30-7.60 (6H, m), 7.64 (1H, br s), 7.94-8.12 (4H, m), 7.97 (2H, d, J=8Hz), 8.19 (1H, br s), 8.83 (1H, br s), 9.27 (1H, br s)
(+)APCI-MS (m/z): 473 (M+H)⁺

(4) 4-[[4-[(2R)-2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoic acid hydrochloride

NMR (DMSO-d₆, δ): 1.09 (3H, d, J=6Hz), 2.60-3.70 (5H, m), 5.03 (1H, m), 6.36 (1H, br d, J=3Hz), 7.25-7.65 (6H, m), 7.97 (2H, d, J=8Hz), 8.00-8.21 (4H, m), 8.84 (1H, br s), 9.31 (1H, br s), 13.52 (1H, br s)
(-)APCI-MS (m/z): 472 (M-H)⁻

Example 59

To a solution of ethyl 3-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoate (8.25 g) in ethyl acetate (41 ml) was added 4N hydrogen chloride/ethyl acetate (10.7 ml). After the solvent was evaporated, the residue was dissolved in chlorobenzene (58 ml) - ethanol (25 ml), and the solution was hydrogenated (1 atm) over 10% palladium on carbon (409

mg) at room temperature for 1 hour. After the catalyst was filtered off, the filtrate was concentrated to give ethyl 3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-ethyl]phenyl]sulfonyl]benzoate hydrochloride (6.87 g) as a white solid.

NMR (DMSO- d_6 , δ): 1.34 (3H, t, $J=7$ Hz), 2.85-3.40 (6H, m), 4.36 (2H, q, $J=7$ Hz), 4.98 (1H, m), 6.32 (1H, d, $J=4$ Hz, OH), 7.25-7.50 (4H, m), 7.54 (2H, d, $J=8$ Hz), 7.80 (1H, t, $J=8$ Hz), 7.98 (2H, d, $J=8$ Hz), 8.23 (2H, d, $J=8$ Hz), 8.40 (1H, s), 8.99 (2H, br s)
(+)APCI-MS (m/z): 488 (M+H)⁺

Example 60

To a suspension of ethyl 3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate hydrochloride (6.86 g) in tetrahydrofuran (34 ml) were added 1N sodium hydroxide solution (13.5 ml) and di-tert-butyl dicarbonate (3.18 g), and the mixture was stirred at room temperature for 1 hour. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed successively with water, brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give ethyl 3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate (7.75 g) as a colorless oil.

NMR (CDCl₃, δ): 1.33 (9H, s), 1.41 (3H, t, $J=7$ Hz), 2.55-3.00 (2H, m), 3.10-3.60 (4H, m), 4.26 (1H, br s, OH), 4.41 (2H, q, $J=7$ Hz), 4.85 (1H, m), 7.05-7.40 (6H, m), 7.57 (1H, t, $J=8$ Hz), 7.88 (2H, d, $J=8$ Hz), 8.10 (1H, d, $J=8$ Hz), 8.21 (1H, d, $J=8$ Hz), 8.57 (1H, s)
(+)APCI-MS (m/z): 610 (M+Na)⁺

Example 61

The following compound was obtained according to a similar manner to that of Example 52.

5 Ethyl 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate
NMR (CDCl₃, δ): 1.39 (3H, t, J=7Hz), 2.66 (1H, dd, J=12, 9Hz), 2.70-3.10 (5H, m), 4.39 (2H, q, J=7Hz), 4.63 (1H, dd, J=9, 4Hz), 7.10-7.45 (6H, m), 7.87 (2H, d, J=8Hz), 8.00 (2H, d, J=8Hz), 8.15 (2H, d, J=8Hz)
10 (+)APCI-MS (m/z): 488 (M+H)⁺

Example 62

15 The following compound was obtained according to a similar manner to that of Example 53.

Ethyl 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate hydrochloride
20 NMR (DMSO-d₆, δ): 1.31 (3H, t, J=7Hz), 2.9-3.35 (6H, m), 4.34 (2H, q, J=7Hz), 4.95 (1H, m), 6.32 (1H, d, J=4Hz, OH), 7.25-7.50 (4H, m), 7.54 (2H, d, J=8Hz), 7.96 (2H, d, J=8Hz), 8.03-8.21 (4H, m), 8.91 (2H, br s)
25 (+)APCI-MS (m/z): 488 (M+H)⁺

Example 63

The following compounds were obtained according to a similar manner to that of Example 54.

30 (1) 4-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoic acid hydrochloride
NMR (DMSO-d₆, δ): 2.90-3.35 (6H, m), 4.93 (1H, m), 6.27 (1H, br s, OH), 7.30-7.50 (4H, m), 7.53 (2H, d, J=8Hz), 7.96 (2H, d, J=8Hz), 8.00-8.20 (4H, m),
35

8.75 (2H, br s)

(-)APCI-MS (m/z): 458 (M-H)⁻

5 (2) 4-[[4-[(2R)-2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoic acid hydrochloride

NMR (DMSO-d₆, δ): 1.02 (3H, d, J=6Hz), 2.55-3.45 (5H, m), 4.92 (1H, m), 7.20-7.55 (6H, m), 7.87 (2H, d, J=8Hz), 7.97 (2H, d, J=8Hz), 8.09 (2H, d, J=8Hz)

10 (-)APCI-MS (m/z): 472 (M-H)⁻

Example 64

The following compounds were obtained according to a similar manner to that of Example 56.

15

(1) 4-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoic acid

20 NMR (DMSO-d₆, δ): 1.07, 1.19 (total 9H, a pair of s), 2.65-3.00 (2H, m), 3.00-3.60 (4H, m), 4.72 (1H, m), 5.58 (1H, br s), 7.10-7.60 (6H, m), 7.89 (2H, d, J=8Hz), 7.96-8.20 (4H, m), 13.55 (1H, br s)

(-)APCI-MS (m/z): 558 (M-H)⁻

25 (2) 4-[[4-[(2R)-2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoic acid

30 NMR (CDCl₃, δ): 1.23 (9H, s), 1.25 (3H, d, J=6Hz), 2.10-3.70 (5H, m), 4.00-4.25 (1H, m), 4.66 (1H, m), 7.05-7.50 (6H, m), 7.88 (2H, d, J=8Hz), 8.01 (2H, d, J=8Hz), 8.16 (2H, d, J=8Hz)

(-)APCI-MS (m/z): 572 (M-H)⁻

Example 65

35

The following compound was obtained according to a

similar manner to that of Example 57.

- (1) tert-Butyl N-[2-[4-[[4-(aminocarbonyl)phenyl]sulfonyl]-phenyl]ethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate
- 5 NMR (DMSO-d₆, δ): 1.02, 1.19 (total 9H, a pair of s),
2.65-3.60 (6H, m), 4.73 (1H, m), 5.58 (1H, br s),
7.10-7.50 (6H, m), 7.62 (1H, br s), 7.89 (2H, d,
J=8Hz), 7.92-8.12 (4H, m), 8.16 (1H, br s)
- 10 (+)APCI-MS (m/z): 581 (M+Na)⁺
- (2) tert-Butyl N-[(1R)-2-[4-[[4-(aminocarbonyl)phenyl]-sulfonyl]phenyl]-1-methylethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate
- 15 NMR (CDCl₃, δ): 1.24 (3H, d, J=6Hz), 1.26 (9H, s),
2.50-3.70 (4H, m), 3.95-4.25 (1H, m), 4.62 (1H, m),
5.20 (1H, br s), 5.79 (1H, br s), 6.10 (1H, br s),
7.10-7.45 (6H, m), 7.86 (2H, d, J=8Hz), 7.86 (2H,
d, J=8Hz), 7.98 (2H, d, J=8Hz)
- 20 (+)APCI-MS (m/z): 595 (M+Na)⁺

Example 66

To a solution of ethyl 4-[[4-[(2R)-2-aminopropyl]-phenyl]sulfonyl]benzoate (1.06 g) in dimethyl sulfoxide (8.5 ml) was added N,O-bis(trimethylsilyl)acetamide (0.46 ml) at room temperature. After 15 minutes, (R)-2-(3-chlorophenyl)-oxirane (621 mg) was added to the mixture, and the mixture was heated to 80°C for 44.5 hours before allowed to cool to room temperature. To the solution was added 1 M

25 tetrabutylammonium fluoride in tetrahydrofuran (1.3 ml) and the mixture was stirred at room temperature for 1.5 hours. The mixture was partitioned between hexane/ethyl acetate (1/3) and water. The organic layer was separated, washed successively with water, brine, dried over magnesium sulfate,

35 and filtered. The filtrate was concentrated and the residue

was purified by column chromatography (silica gel, chloroform/methanol) to give ethyl 4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoate (409 mg) as a pale yellow solid.

5 NMR (CDCl₃, δ): 1.05 (3H, d, J=6Hz), 1.38 (3H, t, J=7Hz), 2.50-3.10 (5H, m), 4.39 (2H, q, J=7Hz), 4.53 (1H, dd, J=9, 4Hz), 7.05-7.40 (6H, m), 7.87 (2H, d, J=8Hz), 8.00 (2H, d, J=8Hz), 8.15 (2H, d, J=8Hz)
10 (+)APCI-MS (m/z): 502 (M+H)⁺

Example 67

To a solution of ethyl [4-[[4-(2-aminoethyl)phenyl]-sulfonyl]-2-chlorophenoxy]acetate (388 mg) in ethanol (8.0 ml) was added (2R)-2-(3-chlorophenyl)oxirane (166 mg) and the solution was refluxed for 13 hours. After cooling to room temperature, the solvent was removed by evaporation. The residue was chromatographed on silica gel (eluent: chloroform/methanol) to give ethyl [2-chloro-4-[[4-[2-
20 [[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]sulfonyl]phenoxy]acetate (115 mg) as a white foam.
(+)APCI-MS (m/z): 552 (M+H)⁺

Example 68

25 Ethyl [2-chloro-4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate (64.0 mg) was suspended in 4N hydrogen chloride in ethanol (500 μ l) and the mixture was stirred at room temperature for 1 hour. The precipitates were collected by filtration,
30 washed with ethanol, and dried under reduced pressure to give ethyl [2-chloro-4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate hydrochloride (54.0 mg) as a white solid.

35 NMR (CDCl₃, δ): 1.20 (3H, t, J=7.1Hz), 2.84-3.42 (6H, m), 4.16 (2H, q, J=7.1Hz), 4.94-4.99 (1H, m), 5.05

(2H, s), 6.30 (1H, d, J=4.0Hz), 7.26-7.53 (7H, m),
7.84-8.03 (4H, m), 8.89 (2H, br s)
(+)APCI-MS (m/z): 552 (M+H)⁺

5 Example 69

To a solution of ethyl [2-chloro-4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]acetate (50.0 mg) in ethanol (1.5 ml) was added 1N sodium hydroxide solution (181 μ l) at room temperature and
10 the solution was stirred for 3.5 hours. To the solution was added 1N hydrochloric acid (362 μ l) and the solution was stirred for 5 minutes. The solvent was removed by evaporation to give a white solid. The solid was applied on a solid phase extraction cartridge (BOND ELUT C18, 20 ml
15 VARIAN) and eluted with water (20 ml). Further elution with methanol/1N hydrochloric acid (90/10) gave [2-chloro-4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]sulfonyl]phenoxy]acetic acid hydrochloride (52.8 mg) as a white solid.

20 NMR (CDCl₃, δ): 2.94-3.18 (6H, m), 4.85 (2H, s), 4.96-5.05 (1H, m), 7.19-7.51 (7H, m), 7.83-8.03 (4H, m)
(-)APCI-MS (m/z): 522 (M-H)⁻

Example 70

25 To a suspension of 4-[[4-(2-aminoethyl)phenyl]-sulfonyl]-2-chlorophenol (579 mg) in dimethyl sulfoxide (2.9 ml) was added (2R)-2-(3-chlorophenyl)oxirane (287 mg) and the mixture was stirred at 80°C for 48 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate
30 (30 ml) and washed with water (30 ml x 1). The aqueous layer was extracted with ethyl acetate (15 ml x 2). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo to give brown foam (827 mg). The crude product was chromatographed on silica gel
35 (eluent: chloroform/methanol) to give a white solid (209 mg).

The solid was suspended in 4N hydrogen chloride in ethyl acetate (1 ml) and stirred for 5 minutes. The solvent was removed by evaporation to give 2-chloro-4-[[4-[2-[[{(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]phenol hydrochloride (208 mg) as a white solid.

5 NMR (CDCl₃, δ): 2.97-3.18 (6H, m), 4.98-5.03 (1H, m), 6.34 (1H, d, J=3.9Hz), 7.20 (1H, d, J=8.6Hz), 7.33-7.46 (4H, m), 7.50 (2H, d, J=8.1Hz), 7.74 (1H, dd, J=2.3, 8.6Hz), 7.89 (1H, s), 7.92 (2H, d, J=8.1Hz), 8.96 (1H, br s), 9.23 (1H, br s), 11.7 (1H, br s)

10 (+)APCI-MS (m/z): 466 (M+H)⁺

Example 71

15 The following compounds were obtained according to a similar manner to that of Example 67.

(1) (1R)-1-(3-Chlorophenyl)-2-[[{(1R)-2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1-methylethyl]amino]-ethanol

20 (+)APCI-MS (m/z): 460 (M+H)⁺

(2) [4-[[4-[(2R)-2-[[{(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenoxy]-acetate

25 (+)APCI-MS (m/z): 532 (M+H)⁺

(3) Ethyl [4-[[4-[2-[[{(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]sulfonyl]-phenoxy]acetate

30 MS (m/z): 547 (M+H)

Example 72

The following compounds were obtained according to a similar manner to that of Example 68.

35

(1) (1R)-1-(3-Chlorophenyl)-2-[[[(1R)-2-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1-methylethyl]amino]-ethanol hydrochloride

5 NMR (CDCl₃, δ): 1.09 (3H, d, J=6.3Hz), 2.78 (1H, dd, J=10.7, 12.7Hz) 3.11-3.49 (3H, m), 3.83 (3H, s), 5.02-5.07 (1H, m), 6.36 (1H, d, J=4.0Hz), 7.13 (2H, d, J=8.9Hz), 7.37-7.51 (6H, m), 7.85-7.91 (4H, m), 8.84 (1H, br s), 9.36 (1H, br s)
10 (+)APCI-MS (m/z): 460 (M+H)⁺

(2) [4-[[4-[(2R)-2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenoxy]-acetate hydrochloride

15 NMR (CDCl₃, δ): 1.09 (3H, d, J=6.4Hz), 1.19 (3H, t, J=7.1Hz), 2.79 (1H, dd, J=10.7, 12.8Hz), 3.06-3.21 (2H, m), 3.30-3.51 (2H, m), 4.16 (2H, q, J=7.1Hz), 4.91 (2H, s), 5.05-5.08 (1H, m), 6.36 (1H, d, J=4.0Hz), 7.13 (2H, d, J=8.9Hz), 7.38-7.51 (6H, m),
20 7.87-7.91 (4H, m), 8.87 (1H, br s), 9.44 (1H, br s)
(+)APCI-MS (m/z): 532 (M+H)⁺

Example 73

25 To a solution of ethyl [4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-phenoxy]acetate (176 mg) in ethanol (1.8 ml) was added 1N sodium hydroxide solution (0.331 ml) at room temperature and the mixture was stirred overnight. The precipitates were
30 collected by filtration, washed with ethanol, and dried under reduced pressure to give sodium [4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]phenoxy]acetate (140 mg) as a white crystalline solid.

35 NMR (CDCl₃, δ): 0.88 (3H, d, J=6.2Hz), 2.53-2.84 (5H,

m), 4.18 (2H, s), 4.55 (1H, dd, J=5.7, 10.0Hz),
5.40 (1H, d, J=4.2Hz), 6.93 (2H, d, J=8.9Hz),
7.23-7.31 (3H, m), 7.34-7.36 (3H, m), 7.76 (2H, d,
J=8.4Hz), 7.77 (2H, d, J=8.9Hz)

5 (-)APCI-MS (m/z): 552 (M-Na)⁺

Example 74

A solution of 1-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-
2-methyl-2-propanamide (310 mg), (2R)-2-(3-chlorophenyl)-
10 oxirane (150 mg) in ethanol (10 ml) was refluxed for 20
hours. The mixture was evaporated in vacuo. A mixture of
residue was chromatographed (chloroform-methanol) over
silica gel and triturated with 4N hydrochloride in 1,4-
dioxane to give (1R)-1-(3-chlorophenyl)-2-[[2-[4-[(4-
15 methoxyphenyl)sulfonyl]phenyl]-1,1-dimethylethyl]amino]-
ethanol hydrochloride (95 mg) as a colorless powder.

NMR (CD₃OD, δ): 1.3 (6H, s), 3.10-3.40 (4H, m), 3.85
(3H, s), 4.90-5.00 (1H, m), 7.00-7.10 (2H, m),
7.30-7.50 (6H, m), 7.80-7.95 (4H, m)

20 MS (m/z): 474 (M+H)

Example 75

The following compounds were obtained according to a
similar manner to that of Example 23.

25

(1) Sodium [4-[[4-[2-[[{(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]-2-methylpropyl]phenyl]sulfonyl]-
phenoxy]acetate

30 NMR (DMSO-d₆, δ): 0.89 (3H, s), 0.91 (3H, s), 2.60-2.80
(4H, m), 4.24 (2H, s), 4.50-4.60 (1H, m), 6.90-
7.00 (2H, m), 7.10-7.40 (6H, m), 7.70-7.90 (4H, m)

MS (m/z): 516 (M-H)

35

(2) Sodium [2-chloro-4-[[4-[(2R)-2-[[{(2R)-2-(3-
chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-

sulfonyl]phenoxy]acetate

MS (m/z): 536 (M-H)

- 5 (3) Sodium [4-[[4-[2-[[{(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-methylphenoxy]acetate
- NMR (DMSO-d₆, δ): 2.17 (3H, s), 2.70-2.90 (6H, m), 4.20 (2H, s), 4.60-4.70 (1H, m), 6.80-6.90 (1H, m), 7.20-7.40 (6H, m), 7.7-7.90 (4H, m)
- 10 MS (m/z): 502 (M-H)

- (4) Sodium [4-[[4-[2-[[{(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-fluorophenoxy]acetate
- 15 NMR (DMSO-d₆, δ): 2.70-2.90 (6H, m), 4.27 (2H, s), 4.60-4.70 (1H, m), 6.80-7.90 (11H, m)
- MS (m/z): 506 (M-H)

- 20 (5) Sodium [3-[[4-[(2R)-2-[[{(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenoxy]acetate
- NMR (DMSO-d₆, δ): 0.89 (2H, d, J=6.2Hz), 2.62-2.65 (3H, m), 2.80-2.85 (2H, m), 4.15 (2H, s), 4.55 (1H, t, J=6.2Hz), 7.03-7.08 (1H, m), 7.27-7.48 (9H, m), 7.78-7.82 (2H, d, J=8.3Hz)
- 25 MS (m/z): 502 (M-H)

Example 76

- 30 Ethyl [4-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-2-chlorophenoxy]acetate (107 mg), (2R)-2-(3-chlorophenyl)-oxirane (48.2 mg) and bis(trimethylsilyl)acetamide (0.032 ml) in dimethyl sulfoxide (5 ml) was refluxed for 20 hours. To the reaction mixture were added acetic acid (0.5 ml) and water (0.5 ml) and stirred for 1 hour. The resulting
- 35 mixture was poured into water and extracted with ethyl

acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed (chloroform-methanol) over silica gel to give ethyl [2-chloro-4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]phenoxy]acetate (100 mg) as a colorless powder.

MS (m/z): 566 (M+H)

Example 77

The following compounds were obtained according to a similar manner to that of Example 76.

(1) Ethyl [4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-methylphenoxy]acetate
MS (m/z): 532 (M+H)

(2) Ethyl [4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-fluorophenoxy]acetate
MS (m/z): 532 (M+H)

Example 78

Ethyl [3-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-phenoxy]acetate (145 mg) and (2R)-2-(3-chlorophenyl)oxirane (65 mg) in ethanol (2.5 ml) was refluxed for 6 hours. The mixture was evaporated. The residue was purified by column chromatography on silica gel (chloroform/methanol = 100/3) to give ethyl [3-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenoxy]acetate (90 mg) as a colorless oil.

NMR (CDCl₃, δ): 1.06 (2H, d, J=6.2Hz), 1.28 (3H, t, J=7.0Hz), 2.60-2.74 (2H, m), 2.77-2.99 (3H, m), 4.24 (2H, q, J=7.0Hz), 4.54 (1H, m), 4.64 (2H, s), 7.11-7.55 (10H, m), 7.85 (2H, d, J=8.3Hz)

MS (m/z): 533 (M+H)

Example 79

Ethyl [3-[[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenoxy]acetate (50 mg) was triturated with 4N hydrochloride in ethyl acetate (1.0 ml) to give ethyl [3-[[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenoxy]acetate hydrochloride (50 mg) as a colorless powder.

MS (m/z): 533 (M+H)

Example 80

To a solution of ethyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]phenoxy]acetate (277 mg) in methanol (3 mL) was added ammonia (2 M in methanol, 1 mL) at room temperature, and the mixture was sealed at the same temperature for 4.5 days. The resulting mixture was evaporated under reduced pressure. The residue was dissolved into a mixture of water and ethyl acetate. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was dried in vacuo to give (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetamide (248 mg).

NMR (DMSO-d₆, δ): 1.05-1.25 (9H, m), 2.75-2.9 (2H, m), 3.1-3.5 (4H, m), 4.35 (2H, s), 4.65-4.8 (1H, m), 7.05-7.1 (2H, m), 7.15-7.45 (6H, m), 7.75-7.9 (4H, m)

(+)ESI-MS (m/z): 611, 613 (M+Na)⁺

Example 81

The following compound was obtained according to a similar manner to that of Example 39.

(R)-2-[4-[[4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]phenoxy]acetamide hydrochloride

- 5 NMR (DMSO- d_6 , δ): 2.9-3.5 (6H, m), 4.55 (2H, s), 4.85-5.0 (1H, m), 7.11 (2H, d, $J = 8.9$ Hz), 7.3-7.65 (6H, m), 7.8-7.95 (4H, m)
(+)ESI-MS (m/z): 489, 491 (M-HCl+H)⁺

10 Preparation 78

- Under nitrogen at 5°C, to a solution of tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-hydroxyphenyl]sulfonyl]phenyl]ethyl]carbamate (241 mg) in N,N-dimethylformamide (5 ml) was added sodium hydride
15 (60% in oil, 40 mg), and the mixture was stirred at the same temperature for 50 minutes. To this one was added ethyl 2-bromo-2-methylpropionate (0.146 ml) and the mixture was stirred at room temperature for 12 hours. The resulting mixture was poured into water and the aqueous mixture was
20 extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 2 : 1 to 1 : 2) to give ethyl (R)-2-[4-
25 [[4-[2-[5-(3-chlorophenyl)-2-oxo-1,3-oxazolidin-3-yl]ethyl]phenyl]sulfonyl]phenoxy]-2-methylpropanoate (43 mg).

- NMR (CDCl₃, δ): 1.20 (3H, t, $J=7.1$ Hz), 1.62 (6H, s),
2.85-4.05 (6H, m), 4.21 (2H, q, $J=7.1$ Hz), 5.3-5.7
30 (1H, m), 6.8-6.9 (2H, m), 7.05-7.4 (6H, m), 7.75-7.85 (4H, m)
(+)ESI-MS (m/z): 594, 596 (M+Na)⁺

Preparation 79

- 35 The following compound was obtained according to a

similar manner to that of Preparation 78.

Ethyl 2-[3-[[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)-
amino]ethyl]phenyl]thio]phenoxy]-2-methylpropanoate
5 (+)APCI-MS (m/z): 450 (M-Boc+H)⁺

Preparation 80

The following compounds were obtained according to a
similar manner to that of Preparation 18.

10

(1) Ethyl 2-[3-[[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)-
amino]ethyl]phenyl]sulfonyl]phenoxy]-2-methylpropanoate
(+)ESI-MS (m/z): 604 (M+Na)⁺

15

(2) tert-Butyl N-benzyl-N-[2-[2-[(3-
hydroxyphenyl)sulfonyl]phenyl]ethyl]carbamate
MS (m/z): 468 (M+H)

20

(3) tert-Butyl [2-[6-[(4-methoxyphenyl)sulfonyl]-3-
pyridyl]ethyl]carbamate
(+)ESI-MS (m/z): 415 (M+Na)⁺

25

(4) tert-Butyl [2-[6-[(4-hydroxyphenyl)sulfonyl]-3-
pyridyl]ethyl]carbamate
(+)ESI-MS (m/z): 401 (M+Na)⁺

30

(5) tert-Butyl N-benzyl-N-[2-[3-[(4-
methoxyphenyl)sulfonyl]phenyl]ethyl]carbamate
MS (m/z): 504 (M+Na)

(6) tert-Butyl N-benzyl-N-[2-[3-[(3-
hydroxyphenyl)sulfonyl]phenyl]ethyl]carbamate
MS (m/z): 468 (M+H)

35

(7) tert-Butyl N-benzyl-N-[(1S)-2-hydroxy-1-[4-[(4-

hydroxyphenyl)sulfonyl]benzyl]ethyl]carbamate

NMR (CDCl₃, δ): 1.42 (9H, s), 3.01 (2H, m), 3.63 (3H, m), 3.90-4.20 (2H, m), 4.25 (1H, br d, J=14Hz), 6.87 (2H, d, J=9Hz), 6.90-7.40 (8H, m), 7.75 (2H, d, J=8Hz), 7.77 (2H, d, J=9Hz)
(+)ESI-MS (m/z): 520 (M+Na)⁺.

(8) 2,2,2-Trifluoro-N-[2-[4-[(4-hydroxyphenyl)sulfonyl]-phenyl]-1,1-dimethylethyl]acetamide

NMR (CDCl₃, δ): 1.38 (6H, s), 3.15 (2H, s), 5.82 (1H, br s), 6.91 (2H, d, J=9Hz), 7.22 (2H, d, J=8Hz), 7.82 (2H, d, J=9Hz), 7.83 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 424 (M+Na)⁺

(9) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(3-methoxyphenyl)sulfonyl]phenyl]-1-methylethyl]acetamide

NMR (CDCl₃, δ): 1.21 (3H, d, J=7Hz), 2.83 (1H, dd, J=14 and 7Hz), 2.97 (1H, dd, J=14 and 6Hz), 3.85 (3H, s), 4.27 (1H, m), 6.09 (1H, br d, J=7Hz), 7.02-7.18 (1H, m), 7.20-7.68 (5H, m), 7.89 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 424 (M+Na)⁺

(10) 2,2,2-Trifluoro-N-[(1S)-2-[4-[(4-hydroxyphenyl)sulfonyl]phenyl]-1-methylethyl]acetamide

NMR (DMSO-d₆, δ): 1.14 (3H, d, J=7Hz), 2.70-2.97 (2H, m), 4.08 (1H, m), 6.90 (2H, d, J=9Hz), 7.40 (2H, d, J=8Hz), 7.73 (2H, d, J=9Hz), 7.79 (2H, d, J=8Hz), 9.30 (1H, br d, J=8Hz), 10.64 (1H, br s)
(+)ESI-MS (m/z): 410 (M+Na)⁺

(11) Ethyl 4-[[4-[[N-benzyl-N-(tert-butoxycarbonyl)amino]-methyl]phenyl]sulfonyl]benzoate

NMR (CDCl₃, δ): 1.39 (3H, t, J=7Hz), 1.47 (9H, s), 4.36 (4H, br s), 4.40 (2H, q, J=7Hz), 7.03-7.45 (7H, m), 7.84 (2H, d, J=8Hz), 8.00 (2H, d, J=8Hz), 8.16 (2H,

d, J=8Hz)

(+)ESI-MS (m/z): 532 (M+Na)⁺

(12) tert-Butyl N-benzyl-N-[4-[(4-hydroxyphenyl)sulfonyl]-
benzyl]carbamate

NMR (CDCl₃, δ): 1.48 (9H, s), 4.36 (2H, br s), 4.40 (2H, br s), 6.89 (2H, d, J=9Hz), 7.05-7.45 (7H, m), 7.76 (2H, d, J=8Hz), 7.83 (2H, d, J=8Hz)

(+)ESI-MS (m/z): 476 (M+Na)⁺

Preparation 81

The following compounds were obtained according to a similar manner to that of Preparation 32.

(1) Ethyl 2-[3-[[4-[2-(benzylamino)ethyl]phenyl]-sulfonyl]phenoxy]-2-methylpropanoate
(+)APCI-MS (m/z): 482 (M+H)⁺

(2) 3-[[2-[2-(Benzylamino)ethyl]phenyl]sulfonyl]phenol
MS (m/z): 368 (M+H)

(3) N-Benzyl-2-[3-[(4-methoxyphenyl)sulfonyl]phenyl]-ethanamine
MS (m/z): 382 (M+H)

(4) 3-[[3-[2-(Benzylamino)ethyl]phenyl]sulfonyl]phenol
MS (m/z): 368 (M+H)

(5) Ethyl [4-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-phenoxy]acetate
MS (m/z): 454 (M+H)

(6) 4-[[4-[(2S)-2-(Benzylamino)-3-hydroxypropyl]phenyl]-sulfonyl]phenol
NMR (DMSO-d₆, δ): 2.58-2.86 (2H, m), 3.15-3.45 (3H, m),

121

3.57 (2H, s), 6.92 (2H, d, J=9Hz), 7.15 (5H, m),
7.39 (2H, d, J=8Hz), 7.76 (2H, d, J=9Hz), 7.77 (2H,
d, J=8Hz).

(+)ESI-MS (m/z): 398 (M+H)⁺

5

- (7) Ethyl 4-[[4-[(2R)-2-(benzylamino)propyl]phenyl]-
sulfonyl]benzoate

NMR (DMSO-d₆, δ): 0.92 (3H, d, J=6Hz), 1.31 (3H, t,
J=7Hz), 2.40-3.00 (3H, m), 3.67 (1H, d, J=13Hz),
3.71 (1H, d, J=13Hz), 4.34 (2H, q, J=7Hz), 7.17
(5H, m), 7.43 (2H, d, J=8Hz), 7.87 (2H, d, J=8Hz),
8.10 (2H, d, J=8Hz), 8.13 (2H, d, J=8Hz)

10

(+)ESI-MS (m/z): 438 (M+H)⁺

- 15 (8) Ethyl 3-[[3-[2-(benzylamino)ethyl]phenyl]sulfonyl]-
benzoate

NMR (CDCl₃, δ): 1.40 (3H, t, J=7Hz), 2.90 (4H, s), 3.80
(2H, s), 4.40 (2H, q, J=7Hz), 7.12-7.53 (7H, m),
7.57 (1H, t, J=8Hz), 7.70-7.90 (2H, m), 8.10 (1H,
d, J=8Hz), 8.22 (1H, d, J=8Hz), 8.59 (1H, s)

20

(+)ESI-MS (m/z): 424 (M+H)⁺

- (9) Ethyl 4-[[3-[2-(benzylamino)ethyl]phenyl]sulfonyl]-
benzoate

25

NMR (CDCl₃, δ): 1.39 (3H, t, J=7Hz), 2.90 (4H, s), 3.80
(2H, s), 4.39 (2H, q, J=7Hz), 7.13-7.55 (7H, m),
7.70-7.88 (2H, m), 7.99 (2H, d, J=8Hz), 8.14 (2H,
d, J=8Hz)

(+)ESI-MS (m/z): 424 (M+H)⁺

30

- (10) Ethyl 4-[[4-[(benzylamino)methyl]phenyl]sulfonyl]-
benzoate

NMR (CDCl₃, δ): 1.38 (3H, t, J=7Hz), 3.78 (2H, s), 3.85
(2H, s), 4.39 (2H, q, J=7Hz), 7.15-7.45 (5H, m),
7.52 (2H, d, J=8Hz), 7.90 (2H, d, J=8Hz), 7.99 (2H,

35

d, J=8Hz), 8.15 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 410 (M+H)⁺

(11) Ethyl 4-[[4-[3-(benzylamino)propyl]phenyl]sulfonyl]-
5 benzoate
NMR (DMSO-d₆, δ): 1.31 (3H, t, J=7Hz), 1.70 (2H,
quintet, J=7Hz), 2.32 (1H, br s), 2.44 (2H, t,
J=7Hz), 2.69 (2H, t, J=7Hz), 3.64 (2H, s), 4.34
(2H, q, J=7Hz), 7.10-7.38 (5H, m), 7.45 (2H, d,
10 J=8Hz), 7.86 (2H, d, J=8Hz), 8.09 (2H, d, J=8Hz),
8.13 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 438 (M+H)⁺

(12) 4-[[4-[(Benzylamino)methyl]phenyl]sulfonyl]phenol
15 NMR (DMSO-d₆, δ): 3.66 (2H, s), 3.73 (2H, s), 6.92 (2H,
d, J=9Hz), 7.10-7.45 (5H, m), 7.55 (2H, d, J=8Hz),
7.76 (2H, d, J=9Hz), 7.83 (2H, d, J=8Hz), 10.50
(1H, br s)
(+)ESI-MS (m/z): 354 (M+H)⁺

20
(13) 2-[6-[(4-Methoxyphenyl)sulfonyl]-3-pyridyl]ethanamine
(+)ESI-MS (m/z): 293 (M+H)⁺

Preparation 82

25 Under nitrogen at room temperature, to a solution of
2,2,2-trifluoro-N-[2-(4-mercaptophenyl)ethyl]acetamide (1.1
g) in N,N-dimethylformamide (23 ml) were added 6-
chloronicotinic acid (765 mg) and potassium carbonate (1.34
g), and the mixture was stirred at 100°C for 27 hours. The
30 resulting mixture was poured into 0.1N hydrochloric acid and
the aqueous mixture was extracted with ethyl acetate. The
organic layer was washed with 0.1N hydrochloric acid two
times, dried over anhydrous magnesium sulfate and evaporated
under reduced pressure. The residue was dissolved into 7N
35 hydrogen chloride in ethanol (40 ml), and the mixture was

refluxed for 11 hours. The resulting mixture was evaporated under reduced pressure. The residue was dissolved into a mixture of saturated aqueous sodium bicarbonate and ethyl acetate. After separation, the organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure. To a mixture of the residue in a mixture of tetrahydrofuran (30 ml) and water (30 ml) was added di-tert-butyl dicarbonate (4.62 g) in tetrahydrofuran (5 ml) with being adjusted to about pH 8.5 by 1N sodium hydroxide at room temperature, and the mixture was stirred at the same temperature for 12 hours. The resulting mixture was diluted with ethyl acetate, and separated. The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 5 : 1 to 2 : 1) to give ethyl 6-[[4-[2-[(tert-butoxycarbonyl)-amino]ethyl]phenyl]thio]nicotinate (1.0 g).

NMR (CDCl₃, δ): 1.37 (3H, t, J=7.1Hz), 1.4-1.55 (9H, m), 2.86 (2H, t, J=7.1Hz), 3.35-3.5 (2H, m), 4.37 (2H, q, J=7.1Hz), 6.85-6.9 (1H, m), 7.25-7.35 (2H, m), 7.5-7.6 (2H, m), 8.02 (1H, dd, J=2.4, 8.5Hz), 9.00 (1H, d, J=1.7Hz)

(+)ESI-MS (m/z): 425 (M+Na)⁺

25 Preparation 83

Under nitrogen at 5°C, to a solution of ethyl 6-[[4-[2-[(tert-butoxycarbonyl)amino]ethyl]phenyl]thio]nicotinate (960 mg) in dichloromethane (20 ml) was added m-chloroperbenzoic acid (1.23 g), and the mixture was stirred at room temperature for 2 hours. The resulting mixture was poured into aqueous sodium hydrogensulfite and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium bicarbonate two times and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The

residue was purified by column chromatography on silica gel (hexane: ethyl acetate = 2 : 1 to 1 : 1) to give ethyl 6-[[4-[2-[(tert-butoxycarbonyl)amino]ethyl]phenyl]sulfonyl]-nicotinate (786 mg).

- 5 NMR (CDCl₃, δ): 1.3-1.5 (12H, m), 2.87 (2H, t, J=6.9Hz), 3.3-3.5 (2H, m), 4.43 (2H, q, J=7.1Hz), 7.37 (2H, d, J=8.3Hz), 8.00 (2H, d, J=8.3Hz), 8.27 (1H, d, J=7.9Hz), 8.52 (1H, dd, J=2.0, 8.1Hz), 9.22 (1H, m)
- 10 (+)ESI-MS (m/z): 457 (M+Na)⁺

Preparation 84

- To a solution of ethyl 6-[[4-[2-[(tert-butoxycarbonyl)-amino]ethyl]phenyl]sulfonyl]nicotinate (754 mg) in ethyl acetate (5 ml) was added 4N hydrogen chloride in ethyl acetate (5 ml) at room temperature, and the mixture was stirred at the same temperature for 2 hours. The resulting mixture was evaporated under reduced pressure. The residue was dissolved into a mixture of saturated aqueous sodium bicarbonate and chloroform. After separation, the organic layer was dried over anhydrous magnesium sulfate, evaporated under reduced pressure and dried in vacuo to give ethyl 6-[[4-(2-aminoethyl)phenyl]sulfonyl]nicotinate (656 mg).
- 20

- 25 NMR (DMSO-d₆, δ): 1.32 (3H, t, J=7.1Hz), 2.6-3.0 (4H, m), 4.37 (2H, q, J=7.1Hz), 7.45-7.5 (2H, m), 7.85-7.95 (2H, m), 8.3-8.35 (1H, m), 8.55-8.6 (1H, m), 9.1 (1H, m)
- (+)ESI-MS (m/z): 335 (M+H)⁺

Preparation 85

- Under nitrogen at room temperature, to a solution of ethyl 6-[[4-(2-aminoethyl)phenyl]sulfonyl]nicotinate (646 mg) in chloroform (10 ml) was added benzaldehyde (0.206 ml), and the mixture was stirred at the same temperature for 20 minutes. The resulting mixture was evaporated under reduced
- 35

pressure. Under nitrogen at 5°C, to a solution of the residue in tetrahydrofuran (6 ml) was added sodium borohydride (80 mg), followed by ethanol (6 ml) dropwise and the mixture was stirred at room temperature for 12 hours.

- 5 The resulting mixture was poured into saturated aqueous bicarbonate and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified
10 by column chromatography on silica gel (chloroform : methanol = 50 : 1 to 10 : 1) to give ethyl 6-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]nicotinate (135 mg).

NMR (CDCl₃, δ): 1.39 (3H, t, J=7.1Hz), 2.8-3.1 (4H, m),
3.78 (2H, s), 4.42 (2H, q, J=7.1Hz), 7.15-8.6 (11H,
15 m), 9.21 (1H, m)

(+)ESI-MS (m/z): 425 (M+H)⁺

Preparation 86

- To a solution of ethyl [4-[[5-[2-[(tert-
20 butoxycarbonyl)amino]ethyl]-2-pyridyl]sulfonyl]phenoxy]-acetate (260 mg) in tetrahydrofuran (1.5 ml) was added 3.95N hydrogen chloride in ethanol (1.5 ml), and the mixture was stirred at room temperature for 12 hours. The mixture was evaporated under reduced pressure. The residue was
25 dissolved in dichloromethane (40 ml) and methanol (5 ml), and washed with saturated aqueous sodium bicarbonate. The aqueous layer was extracted with dichloromethane (20 ml) and methanol (2 ml). The combined organic layers were dried
over magnesium sulfate and evaporated under reduced pressure
30 to give ethyl [4-[[5-(2-aminoethyl)-2-pyridinyl]sulfonyl]-phenoxy]acetate (215 mg) a colorless oil.

(+)ESI-MS (m/z): 365 (M+H)⁺

Preparation 87

- 35 Under nitrogen at room temperature, to a suspension of

sodium borohydride (9.75 g) in tetrahydrofuran (300 ml) was added 4-iodo-L-phenylalanine (30 g, J. Org. Chem. 59(15), 4206(1994)). The mixture was cooled to 5°C, and concentrated sulfuric acid (7.2 ml) in diethyl ether (10 ml) was added dropwise. The mixture was stirred at room temperature for 24 hours. To the resulting mixture was added methanol (10 ml) carefully, followed by 5N sodium hydroxide (300 ml). After removal of tetrahydrofuran by evaporation, the residual aqueous solution was refluxed for 3 hours. To the resulting mixture were added dichloromethane, tetrahydrofuran and water. After separation, the aqueous layer was extracted with dichloromethane three times. The combined organic layer was dried over anhydrous magnesium sulfate, evaporated under reduced pressure and dried in vacuo to give (S)-2-amino-3-(4-iodophenyl)-1-propanol (22.3 g).

NMR (CDCl₃, δ): 2.4-2.55 (1H, m), 2.6-2.8 (1H, m), 3.0-3.15 (1H, m), 3.3-3.45 (1H, m), 3.55-3.7 (1H, m), 6.95 (2H, d, J=8.2Hz), 7.63 (2H, d, J=8.2Hz)
(+)ESI-MS (m/z): 278 (M+H)⁺

Preparation 88

Under nitrogen at room temperature, to a solution of (S)-2-amino-3-(4-iodophenyl)-1-propanol (1.0 g) in dichloromethane (20 ml) was added benzaldehyde (0.385 ml), and the mixture was stirred at the same temperature for 1 hour. The resulting mixture was evaporated under reduced pressure. Under nitrogen at room temperature, to a solution of the residue in a mixture of dichloromethane (10 ml) and ethanol (20 ml) was added sodium borohydride (150 mg) carefully and the mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated to about 5 ml under reduced pressure. The residue was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried

over anhydrous magnesium sulfate, evaporated under reduced pressure and dried in vacuo to give (S)-2-(benzylamino)-3-(4-iodophenyl)-1-propanol (1.17 g).

5 NMR (CDCl₃, δ): 2.6-3.1 (3H, m), 3.25-3.4 (1H, m),
3.55-3.7 (1H, m), 3.77 (2H, s), 6.85-6.95 (2H, m),
7.1-7.4 (5H, m), 7.55-7.7 (2H, m)
(+)ESI-MS (m/z): 367 (M+H)⁺

Preparation 89

10 To a solution of 3-(trifluoromethyl)benzaldehyde (5 g) in tetrahydrofuran (50 ml) was added potassium tert-butoxide (3.87 g) on ice-cooling and the mixture was stirred at the same temperature for 1 hour. To the mixture was added methyltriphenylphosphonium bromide (12.3 g) and the mixture
15 was stirred at room temperature for 18 hours. The resulting mixture was poured into saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo to give 1-(trifluoromethyl)-3-
20 vinylbenzene (2.18 g) as colorless oil.

MS (m/z): 173 (M+H)

Preparation 90

To a solution of AD mix-beta (17.78 g) (J. Org. Chem.
25 Vol. 57, No 10, 1992 2768-2771) in tert-butanol (60 ml) and water (60 ml) was added 1-(trifluoromethyl)-3-vinylbenzene (2.18 g) on ice-cooling and the mixture was stirred at the same temperature for 4 hours. To the mixture was added sodium sulfite (19 g). The resulting mixture was poured
30 into saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo to give (1R)-1-[3-(trifluoromethyl)phenyl]-1,2-ethanediol (2.5 g) as colorless oil.

35 NMR (CDCl₃, δ): 3.63 (1H, dd, J=8, 11Hz), 3.80 (1H, dd,

J=3.5, 11Hz), 4.9 (1H, dd, J=3.5, 8), 7.40-7.70 (4H, m)

Preparation 91

5 The following compound was obtained according to a similar manner to that of Preparation 89.

3-Vinylbenzonitrile

NMR (DMSO-d₆, δ): 5.40 (1H, d, J=11Hz), 6.00 (1H, d, J=17Hz), 6.70 (1H, dd, J=11, 17Hz), 7.30-8.00 (4H, m)

10

Preparation 92

The following compounds were obtained according to a similar manner to that of Preparation 90.

15

(1) 3-[(1R)-1,2-Dihydroxyethyl]benzonitrile

NMR (DMSO-d₆, δ): δ: 3.40-3.55 (2H, m), 6.70 (1H, t, J=5Hz), 7.50-2.70 (4H, m)

20

(2) (1R)-1-(4-Chlorophenyl)-1,2-ethanediol

NMR (CDCl₃, δ): 3.50-3.80 (2H, m), 4.70-4.85 (1H, m), 7.20-7.40 (4H, m)

25 Preparation 93

Trimethylsilyl chloride (0.369 ml) was added to the solution of (1R)-1-[3-(trifluoromethyl)phenyl]-1,2-ethanediol (500 mg) and trimethyl orthoacetate (0.367 ml) in dichloromethane (10 ml) on ice-cooling. The solution was stirred for 1 hour and evaporated. The crude product was dissolved in dry methanol and potassium carbonate (825 mg) was added. The suspension was stirred vigorously for 100 minutes, then filtered and the residue was washed with dichloromethane. The filtrate was washed with brine, dried over magnesium sulfate, and evaporated in vacuo to give

30

35

(2R)-2-[3-(trifluoromethyl)phenyl]oxirane (320 mg) as a colorless oil.

NMR (CDCl₃, δ): 2.80-2.84 (1H, m), 3.10-3.20 (1H, m),
3.90-3.95 (1H, m), 7.40-7.70 (4H, m)

5

Preparation 94

The following compounds were obtained according to a similar manner to that of Preparation 28.

- 10 (1) Ethyl 4-[[4-[(2R)-2-(benzylamino)propyl]phenyl]-
sulfonyl]benzoate
MS (m/z): 438 (M+H)
- (2) N-Benzyl-2-[2-[(3-methoxyphenyl)thio]phenyl]ethanamine
15 MS (m/z): 350 (M+H)
- (3) A mixture of N-benzyl-2-[4-[(4-methoxy-3,5-
dimethylphenyl)sulfonyl]phenyl]ethanamine and
N-benzyl-2-[4-[(3-methoxy-2,4-dimethylphenyl)sulfonyl]-
20 phenyl]ethanamine
MS (m/z): 410 (M+H)
- (4) Methyl 4-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-
benzoate
25 MS (m/z): 410 (M+H)
- (5) N-Benzyl-2-[3-[(4-methoxyphenyl)thio]phenyl]ethanamine
MS (m/z): 350 (M+H)
- 30 (6) N-Benzyl-2-[3-[(3-methoxyphenyl)sulfonyl]phenyl]-
ethanamine
MS (m/z): 350 (M+H)
- (7) (2R)-N-Benzyl-1-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-
35 2-propanamine

NMR (CDCl₃, δ): 1.06 (3H, d, J=6Hz), 2.50-3.05 (3H, m),
3.73 (1H, d, J=13Hz), 3.82 (1H, d, J=13Hz), 3.84
(3H, s), 6.96 (2H, d, J=9Hz), 7.10-7.40 (7H, m),
7.81 (2H, d, J=8Hz), 7.87 (2H, d, J=9Hz)

5 (+)ESI-MS (m/z): 396 (M+H)⁺

(8) N-Benzyl-3-[4-[(4-methoxyphenyl)sulfonyl]phenyl]-1-propanamine

NMR (CDCl₃, δ): 1.79 (2H, quintet, J=7Hz), 2.64 (2H, t,
10 J=7Hz), 2.70 (2H, t, J=7Hz), 3.76 (2H, s), 3.84
(3H, s), 6.96 (2H, d, J=9Hz), 7.15-7.45 (7H, m),
7.80 (2H, d, J=8Hz), 7.87 (2H, d, J=9Hz)

(+)ESI-MS (m/z): 396 (M+H)⁺

15 (9) Ethyl 4-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-2-fluorobenzoate

(+)APCI-MS (m/z): 442 (M+H)⁺

20 (10) Methyl 4-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-2-chlorobenzoate

(+)APCI-MS (m/z): 444 (M+H)⁺

(11) Ethyl 4-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-2-methylbenzoate

25 (+)APCI-MS (m/z): 438 (M+H)⁺

(12) Ethyl 4'-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-2'-chloro-1,1'-biphenyl-4-carboxylate

NMR (CDCl₃, δ): 1.41 (3H, t, J=7.1Hz), 1.52 (1H, br),
30 2.83-2.94 (4H, m), 3.79 (2H, s), 4.41 (2H, q,
J=7.1Hz), 7.25-7.48 (10H, m), 7.86-7.92 (3H, m),
8.05-8.14 (3H, m)

(+)APCI-MS (m/z): 534 (M+H)⁺

35 (13) Ethyl 4'-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-2'-

chloro-1,1'-biphenyl-3-carboxylate

NMR (CDCl₃, δ): 1.39 (3H, t, J=7.1Hz), 1.51 (1H, br),
2.83-2.94 (4H, m), 3.80 (2H, m), 4.39 (2H, q,
J=7.1Hz), 7.25-7.58 (10H, m), 7.86-7.92 (3H, m),
8.05-8.12 (3H, m)
(+)APCI-MS (m/z): 534 (M+H)⁺

Preparation 95

The following compounds were obtained according to a
similar manner to that of Preparation 93.

(1) 3-[(2R)-2-Oxiranyl]benzonitrile

NMR (CDCl₃, δ): 2.70-2.80 (1H, m), 3.10-3.20 (1H, m),
3.90-4.10 (1H, m), 7.40-7.70 (4H, m)

(2) (2R)-2-(4-Chlorophenyl)oxirane

NMR (CDCl₃, δ): 2.75 (1H, dd, J=2.5, 5.5Hz), 3.14 (1H,
dd, J=4.0, 5.5Hz), 3.80-3.86 (1H, m), 7.18-7.40
(4H, m)

Preparation 96

The following compounds were obtained according to a
similar manner to that of Preparation 68.

(1) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(4-methoxy-3-methylphenyl)sulfonyl]phenyl]-1-methylethyl]-acetamide

MS (m/z): 416 (M+H)

(2) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(3-fluoro-4-methoxyphenyl)sulfonyl]phenyl]-1-methylethyl]-acetamide

MS (m/z): 442 (M+Na)

(3) A mixture of 2,2,2-trifluoro-N-[2-[4-[(4-methoxy-3,5-

dimethylphenyl)sulfonyl]phenyl]ethyl]acetamide and
2,2,2-trifluoro-N-[2-[4-[(3-methoxy-2,4-
dimethylphenyl)sulfonyl]phenyl]ethyl]acetamide
MS (m/z): 416 (M+H)

5

- (4) 2,2,2-Trifluoro-N-[3-[4-[(4-methoxyphenyl)sulfonyl]-
phenyl]propyl]acetamide

NMR (CDCl₃, δ): 1.91 (2H, quintet, J=7Hz), 2.70 (2H, t,
J=7Hz), 3.37 (2H, q, J=7Hz), 3.84 (3H, s), 6.41
10 (1H, br s), 6.96 (2H, d, J=9Hz), 7.28 (2H, d,
J=8Hz), 7.83 (2H, d, J=8Hz), 7.86 (2H, d, J=9Hz)
(+)ESI-MS (m/z): 424 (M+Na)⁺

15

By-product: 2,2,2-Trifluoro-N-[3-[4-[(2-methoxyphenyl)-
sulfonyl]phenyl]propyl]acetamide

20

NMR (CDCl₃, δ): 1.93 (2H, quintet, J=7Hz), 2.73 (2H, t,
J=7Hz), 3.39 (2H, q, J=7Hz), 3.77 (3H, s), 6.40
(1H, br s), 6.91 (1H, d, J=8Hz), 7.10 (1H, dd, J=8
and 7Hz), 7.28 (2H, d, J=8Hz), 7.54 (1H, ddd, J=8,
7 and 2Hz), 7.89 (2H, d, J=8Hz), 8.14 (1H, dd, J=8
and 2Hz)
(+)ESI-MS (m/z): 424 (M+Na)⁺

Preparation 97

25

The following compounds were obtained according to a
similar manner to that of Preparation 34.

30

- (1) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(4-hydroxy-3-
methylphenyl)sulfonyl]phenyl]-1-methylethyl]-
acetamide

MS (m/z): 399 (M-H)

35

- (2) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(3-fluoro-4-
hydroxyphenyl)sulfonyl]phenyl]-1-methylethyl]-
acetamide

MS (m/z): 403 (M-H)

(3) 3-[[2-[2-(Benzylamino)ethyl]phenyl]thio]phenol

MS (m/z): 336 (M+H)

5

(4) A mixture of 4-[[4-[2-(benzylamino)ethyl]phenyl]-sulfonyl]-2,6-dimethylphenol and 3-[[4-[2-(benzylamino)ethyl]phenyl]sulfonyl]-2,6-dimethylphenol

MS (m/z): 396 (M+H)

10

(5) 3-[[3-[2-(Benzylamino)ethyl]phenyl]thio]phenol

MS (m/z): 336 (M+H)

(6) 4-[[3-[2-(Benzylamino)ethyl]phenyl]sulfonyl]phenol

15

MS (m/z): 368 (M+H)

(7) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(3-hydroxyphenyl)-sulfonyl]phenyl]-1-methylethyl]acetamide

20

NMR (CDCl₃, δ): 1.24 (3H, d, J=7Hz), 2.73-3.07 (2H, m),
4.27 (1H, m), 6.18 (1H, br s), 6.22 (1H, br s),
6.95-7.12 (1H, m), 7.20-7.65 (5H, m), 7.87 (2H, d,
J=8Hz)

(-)-ESI-MS (m/z): 386 (M-H)⁻

25 (8) 4-[4-[(2R)-2-[(Benzylamino)propyl]phenyl]sulfonyl]-phenol

NMR (DMSO-d₆, δ): 0.93 (3H, d, J=6Hz), 2.40-3.00 (3H, m),
3.72 (1H, d, J=14Hz), 3.76 (1H, d, J=14Hz),
6.92 (2H, d, J=9Hz), 7.06-7.36 (5H, m), 7.38 (2H, d, J=8Hz),
7.76 (2H, d, J=9Hz), 7.78 (2H, d, J=8Hz)

30

(+)-ESI-MS (m/z): 382 (M+H)⁺

(9) 4-[[4-[(Benzylamino)methyl]phenyl]thio]phenol

35

NMR (DMSO-d₆, δ): 4.08 (2H, s), 4.12 (2H, s), 6.87 (2H,

d, J=9Hz), 7.10 (2H, d, J=8Hz), 7.20-7.60 (9H, m),
9.46 (1H, br s), 10.00 (1H, br s)
(-)ESI-MS (m/z): 320 (M-H)⁻

- 5 (10) 4-[[4-[3-(Benzylamino)propyl]phenyl]sulfonyl]phenol
NMR (CDCl₃, δ): 1.81 (2H, quintet, J=7Hz), 2.67 (2H, t,
J=7Hz), 2.69 (2H, t, J=7Hz), 3.79 (2H, s), 6.78
(2H, d, J=9Hz), 7.15-7.40 (7H, m), 7.76 (2H, d,
J=9Hz), 7.77 (2H, d, J=8Hz)
10 (+)ESI-MS (m/z): 382 (M+H)⁺

Preparation 98

The following compounds were obtained according to a
similar manner to that of Preparation 71.

15

- (1) Ethyl [4-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-2-
fluorophenoxy]acetate
MS (m/z): 396 (M+H)
20 (2) Ethyl [4-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-2-
methylphenoxy]acetate
MS (m/z): 392 (M+H)
(3) A mixture of 2-[4-[(4-methoxy-3,5-dimethylphenyl)-
25 sulfonyl]phenyl]ethanamine and 2-[4-[(3-methoxy-2,4-
dimethylphenyl)sulfonyl]phenyl]ethanamine
MS (m/z): 320 (M+H)

Preparation 99

- 30 The following compounds were obtained according to a
similar manner to that of Preparation 16.

- (1) 2-[(3-Methoxyphenyl)thio]benzaldehyde
MS (m/z): 267 (M+Na)

35

(2) 3-[(3-Methoxyphenyl)sulfonyl]benzaldehyde
MS (m/z): 267 (M+Na)

5 (3) 3-[(4-Methoxyphenyl)thio]benzaldehyde
MS (m/z): 267 (M+Na)

Preparation 100

The following compounds were obtained according to a similar manner to that of Preparation 24.

10

(1) 1-[(3-Methoxyphenyl)thio]-2-(2-nitroethenyl)benzene
MS (m/z): 310 (M+Na)

15 (2) Methyl 3-[[3-(2-nitroethenyl)phenyl]thio]phenyl ether
NMR (CDCl₃, δ): 3.80 (3H, s), 6.90-7.00 (3H, m), 7.20-7.50 (7H, m), 7.90 (1H, d, J=13Hz)

(3) Methyl 4-[[3-(2-nitroethenyl)phenyl]thio]phenyl ether
NMR (CDCl₃, δ): 3.80 (3H, s), 6.90-7.00 (3H, m), 7.20-7.50 (7H, m), 7.90 (1H, d, J=13Hz)

20

Preparation 101

The following compounds were obtained according to a similar manner to that of Preparation 26.

25

(1) 2-[2-[(3-Methoxyphenyl)thio]phenyl]ethanamine
MS (m/z): 260 (M+H)

30 (2) 2-[3-[(3-Methoxyphenyl)sulfonyl]phenyl]ethanamine
MS (m/z): 260 (M+H)

(3) 2-[3-[(4-Methoxyphenyl)thio]phenyl]ethanamine
MS (m/z): 260 (M+H)

35 Preparation 102

The following compounds were obtained according to a similar manner to that of Preparation 30.

- 5 (1) tert-Butyl N-benzyl-N-[2-[2-[(3-hydroxyphenyl)thio]-phenyl]ethyl]carbamate
MS (m/z): 436 (M+H)
- 10 (2) tert-Butyl N-benzyl-N-[2-[3-[(4-methoxyphenyl)thio]-phenyl]ethyl]carbamate
NMR (CDCl₃, δ): 1.55 (9H, s), 2.50-2.70 (2H, m), 3.20-3.40 (2H, m), 3.80 (3H, s), 4.30-4.40 (2H, m), 6.90-7.50 (8H, m)
MS (m/z): 472 (M+Na)
- 15 (3) tert-Butyl N-benzyl-N-[2-[3-[(3-hydroxyphenyl)thio]-phenyl]ethyl]carbamate
MS (m/z): 436 (M+H)
- 20 (4) tert-Butyl N-benzyl-N-[(1S)-2-hydroxy-1-(4-iodobenzyl)ethyl]carbamate
NMR (CDCl₃, δ): 1.45 (9H, s), 2.60-3.10 (2H, m), 3.45-3.80 (4H, m), 4.00 (1H, m), 4.30 (1H, br d, J=15Hz), 6.85 (2H, d, J=8Hz), 7.05-7.40 (5H, m), 7.56 (2H, d, J=8Hz)
25 (+)ESI-MS (m/z): 490 (M+Na)⁺
- 30 (5) tert-Butyl N-benzyl-N-[(1R)-2-[4-[(4-hydroxyphenyl)-sulfonyl]phenyl]-1-methylethyl]carbamate
NMR (CDCl₃, δ): 1.13 (3H, d, J=7Hz), 1.28 (9H, s), 2.55-3.10 (2H, m), 4.11 (1H, br m), 4.25 (2H, br s), 6.86 (2H, d, J=9Hz), 6.86 (1H, br s), 7.00-7.40 (7H, m), 7.76 (2H, d, J=9Hz), 7.76 (2H, d, J=8Hz)
35 (+)ESI-MS (m/z): 504 (M+Na)⁺

Preparation 103

[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-ethyl]benzene (30 g) and carbonyldiimidazole (26.5 g) in tetrahydrofuran (300 ml) was refluxed for 4 hours. The
5 resulting mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo to give (5R)-5-(3-chlorophenyl)-3-(2-phenylethyl)-1,3-oxazolidin-2-one (28 g) as a colorless oil.

10 MS (m/z): 324 (M+Na)

Preparation 104

The following compounds were obtained according to a similar manner to that of Preparation 67.

15

- (1) 4-[2-[(5R)-5-(3-Chlorophenyl)-2-oxo-1,3-oxazolidin-3-yl]ethyl]benzenesulfonyl chloride.

NMR (CDCl₃, δ): 3.00 (2H, t, J=6Hz), 3.25 (1H, dd, J=6, 8Hz), 3.50-3.90 (3H, m), 5.30-5.45 (1H, m), 7.10-
20 7.40 (6H, m), 7.90-8.00 (2H, m)

- (2) 4-[3-[(Trifluoroacetyl)amino]propyl]benzenesulfonyl chloride

NMR (CDCl₃, δ): 1.99 (2H, quintet, J=7Hz), 2.81 (2H, t, J=7Hz), 3.44 (2H, q, J=7Hz), 6.36 (1H, br s), 7.44
25 (2H, d, J=8Hz), 7.97 (2H, d, J=8Hz)

Preparation 105

To a stirred suspension of zinc powder (1.14 g) and
30 dichlorodimethylsilane (2.12 ml) in 1,2-dichloroethane (20 ml) was successively added the mixed solution of 4-[2-[(5R)-5-(3-chlorophenyl)-2-oxo-1,3-oxazolidin-3-yl]ethyl]-benzenesulfonyl chloride (2.0 g) and dimethylacetamide (1.9 ml) in 1,2-dichloroethane (10 ml). The mixture was stirred
35 for 1 hour at room temperature. After the solution was

filtered and evaporated, methanol (10 ml) was added to the residue and then evaporated. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give (5R)-5-(3-chlorophenyl)-3-[2-(4-mercaptophenyl)ethyl]-1,3-oxazolidin-2-one (800 mg) as a colorless oil.

MS (m/z): 356 (M+Na)

Preparation 106

To a solution of (5R)-5-(3-chlorophenyl)-3-[2-(4-mercaptophenyl)ethyl]-1,3-oxazolidin-2-one (200 mg) in ethanol (3 ml) was added 3N sodium hydroxide (3.0 ml) at room temperature and the mixture was stirred at 80°C for 4 hours. The resulting mixture was evaporated in vacuo. To the residue was added 3N hydrogen chloride (3.0 ml) and di-tert-butyl dicarbonate (131 mg) at room temperature and the mixture was stirred at the same temperature for 18 hours. The reaction mixture was evaporated in vacuo. The residue was poured into saturated aqueous sodium bicarbonate solution, and extracted with chloroform. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo to give tert-butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-(4-mercaptophenyl)ethyl]-carbamate (276 mg) as a colorless oil.

MS (m/z): 408 (M+H)

Preparation 107

To a solution of (1R)-2-chloro-1-(6-chloro-3-pyridyl)ethanol (2.3 g) (W099/32475) in 1N sodium hydroxide (24 ml), water (24 ml) and diethyl ether (24 ml) was stirred at room temperature for 1 hour. The resulting mixture was poured into saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo to give 2-chloro-5-[(2R)-2-oxiranyll]pyridine (2.12 g) as a colorless oil.

NMR (DMSO- d_6 , δ): 2.80 (1H, dd, $J=2$, 5Hz), 3.20 (1H, dd, $J=4$, 5Hz), 3.80-3.90 (1H, m), 7.30-7.50 (2H, m), 8.30 (1H, d, $J=2$ Hz)

5 Preparation 108

The following compound was obtained according to a similar manner to that of Preparation 105.

2,2,2-Trifluoro-N-[2-(4-mercaptophenyl)ethyl]acetamide
10 NMR (DMSO- d_6 , δ): 2.70-2.90 (2H, m), 3.30-3.40 (2H, m),
5.31 (1H, s), 7.00-7.40 (6H, m)
MS (m/z): 372 (M+Na)

Preparation 109

15 Under nitrogen atmosphere,
tris(dibenzylideneacetone)dipalladium(0) (910 mg) and bis(2-diphenylphosphinophenyl)ether (1.11 g) were dissolved in toluene (93 ml) at room temperature. After 5 minutes, to the solution were added tert-butyl N-benzyl-N-[(1S)-2-
20 hydroxy-1-(4-iodobenzyl)ethyl]carbamate (9.31 g), 4-mercaptophenol (2.82 g), and potassium tert-butoxide (2.48 g), and the mixture was heated to 100°C for 2 hours. After being allowed to cool to room temperature, the mixture was filtered to remove the insoluble matter, concentrated, and
25 the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give tert-butyl N-benzyl-N-[(1S)-2-hydroxy-1-[4-[(4-hydroxyphenyl)thio]benzyl]ethyl]-carbamate (6.35 g) as a viscous oil.

30 NMR (CDCl₃, δ): 1.44 (9H, s), 2.60-3.10 (2H, m), 3.40-4.20 (5H, m), 4.36 (1H, br d, $J=15$ Hz), 6.09 (1H, br s), 6.79 (2H, d, $J=9$ Hz), 6.90-7.45 (11H, m)
(+)ESI-MS (m/z): 488 (M+Na)⁺

Preparation 110

35 To a solution of 2,2,2-trifluoro-N-(2-phenyl-1,1-

dimethylethyl)acetamide (19.85 g) in acetic acid (135 ml) -
water (27 ml) - sulfuric acid (4.1 ml) were added iodine
(8.26 g) and periodic acid dihydrate (3.71 g) at room
temperature, and the mixture was heated to 60°C for 10 hours.
5 After being allowed to cool to room temperature, the mixture
was partitioned between hexane/ethyl acetate and water. The
organic layer was separated, washed successively with water,
sodium sulfite solution, water, and brine, dried over
magnesium sulfate, and filtered. The filtrate was
10 concentrated and the residue was recrystallized from
diisopropyl ether (26 ml) - hexane (78 ml) to give 2,2,2-
trifluoro-N-[2-(4-iodophenyl)-1,1-dimethylethyl]acetamide
(16.42 g) as a white powder.

NMR (CDCl₃, δ): 1.40 (6H, s), 3.02 (2H, s), 5.79 (1H,
15 br s), 6.86 (2H, d, J=8Hz), 7.63 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 394 (M+Na)⁺

Preparation 111

The following compounds were obtained according to a
20 similar manner to that of Preparation 109.

- (1) 2,2,2-Trifluoro-N-[2-[4-[(4-hydroxyphenyl)thio]phenyl]-
1,1-dimethylethyl]acetamide
NMR (CDCl₃, δ): 1.39 (6H, s), 2.99 (2H, s), 5.24 (1H,
25 s), 5.84 (1H, br s), 6.84 (2H, d, J=9Hz), 6.98 (2H,
d, J=8Hz), 7.10 (2H, d, J=8Hz), 7.37 (2H, d,
J=9Hz)
(+)ESI-MS (m/z): 392 (M+Na)⁺
- 30 (2) 3-[[4-[2-Methyl-2-[(trifluoroacetyl)amino]propyl]-
phenyl]thio]benzoic acid
NMR (CDCl₃, δ): 1.42 (6H, s), 3.08 (2H, s), 5.86 (1H,
br s), 7.10 (2H, d, J=8Hz), 7.26-7.60 (4H, m),
7.84-8.03 (2H, m)
35 (-)ESI-MS (m/z): 396 (M-H)⁻

- (3) 2,2,2-Trifluoro-N-[(1R)-2-[4-[(3-methoxyphenyl)thio]-phenyl]-1-methylethyl]acetamide
NMR (CDCl₃, δ): 1.22 (3H, d, J=7Hz), 2.68-2.98 (2H, m),
5 3.76 (3H, s), 4.24 (1H, m), 6.08 (1H, br d, J=6Hz),
6.70-6.98 (3H, m), 7.11 (2H, d, J=8Hz), 7.21 (1H,
t, J=8Hz), 7.32 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 392 (M+Na)⁺
- 10 (4) 2,2,2-Trifluoro-N-[(1S)-2-[4-[(4-hydroxyphenyl)thio]-phenyl]-1-methylethyl]acetamide
NMR (CDCl₃, δ): 1.20 (3H, d, J=7Hz), 2.60-2.92 (2H, m),
4.25 (1H, m), 5.16 (1H, s), 6.06 (1H, br d, J=7Hz),
6.83 (2H, d, J=9Hz), 7.03 (2H, d, J=8Hz), 7.12 (2H,
15 d, J=8Hz), 7.36 (2H, d, J=9Hz)
(+)ESI-MS (m/z): 378 (M+Na)⁺
- (5) tert-Butyl N-benzyl-N-[2-[4-[(4-hydroxyphenyl)-thio]phenyl]ethyl]carbamate
20 NMR (CDCl₃, δ): 1.45 (9H, s), 2.71 (2H, br s), 3.35 (2H,
br s), 4.36 (2H, br s), 5.62 (1H, br s), 6.81 (2H,
d, J=8Hz), 6.90-7.40 (11H, m)
(+)ESI-MS (m/z): 458 (M+Na)⁺

25 Preparation 112

The following compounds were obtained according to a similar manner to that of Preparation 2.

- (1) 4-[[4-[2-Methyl-2-[(trifluoroacetyl)amino]propyl]-phenyl]sulfonyl]phenyl trifluoromethanesulfonate
30 NMR (CDCl₃, δ): 1.40 (6H, s), 3.18 (2H, s), 5.78 (1H,
br s), 7.28 (2H, d, J=8Hz), 7.42 (2H, d, J=9Hz),
7.88 (2H, d, J=8Hz), 8.06 (2H, d, J=9Hz)
(-)APCI-MS (m/z): 532 (M-H)⁻

- (2) 3-[[4-[(2R)-2-[(2,2,2-Trifluoroacetyl)amino]propyl]-phenyl]sulfonyl]phenyl trifluoromethanesulfonate
NMR (CDCl₃, δ): 1.22 (3H, d, J=7Hz), 2.86 (1H, dd, J=14 and 7Hz), 2.98 (1H, dd, J=14 and 6Hz), 4.27 (1H, m), 6.08 (1H, br d, J=7Hz), 7.36 (2H, d, J=8Hz), 7.40-7.60 (1H, m), 7.63 (1H, t, J=8Hz), 7.78-8.05 (4H, m)
(+)ESI-MS (m/z): 542 (M+Na)⁺
- 10 (3) 4-[[4-[(2S)-2-[(2,2,2-Trifluoroacetyl)amino]propyl]-phenyl]sulfonyl]phenyl trifluoromethanesulfonate
NMR (CDCl₃, δ): 1.23 (3H, d, J=7Hz), 2.86 (1H, dd, J=13 and 7Hz), 2.99 (1H, dd, J=13 and 6Hz), 4.28 (1H, m), 6.08 (1H, br d, J=7Hz), 7.36 (2H, d, J=8Hz), 7.41 (2H, d, J=9Hz), 7.90 (2H, d, J=8Hz), 8.03 (2H, d, J=9Hz)
(+)ESI-MS (m/z): 542 (M+Na)⁺
- 20 (4) 4-[[4-[(2R)-2-[N-Benzyl-N-(tert-butoxycarbonyl)amino]-propyl]phenyl]sulfonyl]phenyl trifluoromethanesulfonate
NMR (CDCl₃, δ): 1.14 (3H, d, J=7Hz), 1.30 (9H, s), 2.50-3.15 (2H, m), 4.03 (1H, br m), 4.23 (2H, br s), 7.00-7.40 (7H, m), 7.40 (2H, d, J=9Hz), 7.80 (2H, d, J=8Hz), 8.04 (2H, d, J=9Hz)
(+)ESI-MS (m/z): 636 (M+Na)⁺
- 25 (5) 3-[[3-[2-[N-Benzyl-N-(tert-butoxycarbonyl)amino]ethyl]-phenyl]sulfonyl]phenyl trifluoromethanesulfonate
NMR (CDCl₃, δ): 1.42 (9H, s), 2.84 (2H, br s), 3.38 (2H, br s), 4.35 (2H, br s), 7.05-8.00 (13H, m)
(+)ESI-MS (m/z): 621 (M+Na)⁺
- 30 (6) 4-[[3-[2-[N-Benzyl-N-(tert-butoxycarbonyl)amino]-ethyl]phenyl]sulfonyl]phenyl trifluoromethanesulfonate
NMR (CDCl₃, δ): 1.42 (9H, s), 2.85 (2H, m), 3.40 (2H,
- 35

m), 4.35 (2H, br s), 7.05-7.52 (9H, m), 7.60-7.90
(2H, m), 8.03 (2H, d, J=9Hz)
(+)ESI-MS (m/z): 622 (M+Na)⁺

- 5 (7) 4-[[4-[[N-Benzyl-N-(tert-butoxycarbonyl)amino]-
methyl]phenyl]thio]phenyl trifluoromethanesulfonate
NMR (CDCl₃, δ): 1.49 (9H, s), 4.11 (2H, br s), 4.14 (2H,
br s), 7.05-7.48 (13H, m)
(+)ESI-MS (m/z): 576 (M+Na)⁺
- 10 (8) 4-[[4-[3-[N-Benzyl-N-(tert-butoxycarbonyl)amino]-
propyl]phenyl]sulfonyl]phenyl trifluoromethanesulfonate
NMR (CDCl₃, δ): 1.43 (9H, s), 1.78 (2H, quintet, J=7Hz),
2.60 (2H, t, J=7Hz), 3.22 (2H, br s), 4.40 (2H, s),
15 7.10-7.40 (7H, m), 7.40 (2H, d, J=9Hz), 7.83 (2H,
d, J=8Hz), 8.03 (2H, d, J=9Hz)
(+)ESI-MS (m/z): 636 (M+Na)⁺
- 20 (9) 2-Fluoro-4-[[4-[2-[(trifluoroacetyl)amino]ethyl]-
phenyl]sulfonyl]phenyl trifluoromethanesulfonate
(+)APCI-MS (m/z): 546 (M+Na)⁺
- 25 (10) 2-Chloro-4-[[4-[2-[(trifluoroacetyl)amino]ethyl]-
phenyl]sulfonyl]phenyl trifluoromethanesulfonate
(+)APCI-MS (m/z): 562 (M+Na)⁺
- 30 (11) 2-Methyl-4-[[4-[2-[(trifluoroacetyl)amino]ethyl]-
phenyl]sulfonyl]phenyl trifluoromethanesulfonate
(+)APCI-MS (m/z): 542 (M+Na)⁺
- (12) 2-Fluoro-4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-
propyl]phenyl]sulfonyl]phenyl trifluoromethanesulfonate
(+)APCI-MS (m/z): 560 (M+Na)⁺
- 35 (13) 2-Chloro-4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-

propyl]phenyl]sulfonyl]phenyl trifluoromethanesulfonate

NMR (CDCl₃, δ): 1.24 (3H, d, J=6.8Hz), 2.87 (1H, dd, J=7.3, 13.5Hz), 3.00 (1H, dd, J=6.2, 13.5Hz), 4.28 (1H, heptuplet, J=7.0Hz), 6.13 (1H, d, J=7.6Hz), 7.38 (2H, d, J=8.4Hz), 7.49 (1H, d, J=8.7Hz), 7.87-7.92 (3H, m), 8.09 (1H, d, J=2.2Hz)

(+)APCI-MS (m/z): 576 (M+Na)⁺

(14) 2-Methyl-4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-

propyl]phenyl]sulfonyl]phenyl trifluoromethanesulfonate

NMR (CDCl₃, δ): 1.23 (3H, d, J=6.8Hz), 2.43 (3H, s), 2.89 (1H, dd, J=7.2, 13.5Hz), 2.98 (1H, dd, J=6.3, 13.5Hz), 4.28 (1H, heptuplet, J=7.0Hz), 6.20 (1H, d, J=7.8Hz), 7.33-7.40 (3H, m), 7.80-7.92 (4H, m)

(+)APCI-MS (m/z): 556 (M+Na)⁺

(15) 2-Methoxy-5-[[4-[2-[(trifluoroacetyl)amino]ethyl]-

phenyl]sulfonyl]phenyl trifluoromethanesulfonate

(-)APCI-MS (m/z): 534 (M-H)⁺

(16) 2-Methoxy-4-[[4-[2-[(trifluoroacetyl)amino]ethyl]-

phenyl]sulfonyl]phenyl trifluoromethanesulfonate

(+)APCI-MS (m/z): 558 (M+Na)⁺

25 Preparation 113

The following compounds were obtained according to a similar manner to that of Preparation 52.

(1) Ethyl 4-[[4-[2-methyl-2-[(trifluoroacetyl)amino]-

propyl]phenyl]sulfonyl]benzoate

NMR (CDCl₃, δ): 1.39 (6H, s), 1.39 (3H, t, J=7Hz), 3.17 (2H, s), 4.39 (2H, q, J=7Hz), 5.78 (1H, br s), 7.26 (2H, d, J=8Hz), 7.88 (2H, d, J=8Hz), 8.01 (2H, d, J=9Hz), 8.16 (2H, d, J=9Hz)

(+)ESI-MS (m/z): 480 (M+Na)⁺

- (2) Ethyl 3-[[4-[(2R)-2-[(trifluoroacetyl)amino]propyl]-phenyl]sulfonyl]benzoate

NMR (CDCl₃, δ): 1.21 (3H, d, J=7Hz), 1.41 (3H, t, J=7Hz), 2.84 (1H, dd, J=14 and 7Hz), 2.98 (1H, dd, J=14 and 6Hz), 4.27 (1H, m), 4.41 (2H, q, J=7Hz), 6.11 (1H, br d, J=8Hz), 7.33 (2H, d, J=8Hz), 7.60 (1H, t, J=8Hz), 7.92 (2H, d, J=8Hz), 8.11 (1H, d, J=8Hz), 8.24 (1H, d, J=8Hz), 8.58 (1H, s)

(+)ESI-MS (m/z): 466 (M+Na)⁺

- (3) Ethyl 4-[[4-[(2S)-2-[(trifluoroacetyl)amino]propyl]-phenyl]sulfonyl]benzoate

NMR (CDCl₃, δ): 1.21 (3H, d, J=7Hz), 1.39 (3H, t, J=7Hz), 2.83 (1H, dd, J=14 and 7Hz), 2.98 (1H, dd, J=14 and 6Hz), 4.26 (1H, m), 4.39 (2H, q, J=7Hz), 6.09 (1H, br d, J=7Hz), 7.33 (2H, d, J=8Hz), 7.90 (2H, d, J=8Hz), 7.99 (2H, d, J=8Hz), 8.16 (2H, d, J=8Hz)

(+)ESI-MS (m/z): 466 (M+Na)⁺

- (4) Ethyl 4-[[4-[(2R)-2-[N-benzyl-N-(tert-butoxycarbonyl)amino]propyl]phenyl]sulfonyl]benzoate

NMR (CDCl₃, δ): 1.13 (3H, d, J=7Hz), 1.31 (9H, s), 1.38 (3H, t, J=7Hz), 2.55-3.15 (2H, m), 4.00 (1H, br m), 4.21 (2H, br s), 4.39 (2H, q, J=7Hz), 6.95-7.40 (7H, m), 7.80 (2H, d, J=8Hz), 7.99 (2H, d, J=8Hz), 8.14 (2H, d, J=8Hz)

(+)ESI-MS (m/z): 560 (M+Na)⁺

- (5) Ethyl 3-[[3-[2-[N-benzyl-N-(tert-butoxycarbonyl)amino]-ethyl]phenyl]sulfonyl]benzoate

NMR (CDCl₃, δ): 1.40 (3H, t, J=7Hz), 1.42 (9H, s), 2.82 (2H, br s), 3.37 (2H, br s), 4.33 (2H, br s), 4.40 (2H, q, J=7Hz), 7.08-7.50 (7H, m), 7.50-7.90 (3H,

m), 8.09 (1H, d, J=8Hz), 8.23 (1H, d, J=8Hz), 8.58 (1H, s)

(+)ESI-MS (m/z): 546 (M+Na)⁺

- 5 (6) Ethyl 4-[[4-[[N-benzyl-N-(tert-butoxycarbonyl)amino]-methyl]phenyl]thio]benzoate

NMR (CDCl₃, δ): 1.37 (3H, t, J=7Hz), 1.50 (9H, s), 4.36 (2H, q, J=7Hz), 4.40 (4H, br s), 7.10-7.40 (9H, m), 7.43 (2H, d, J=8Hz), 7.91 (2H, d, J=8Hz)

10 (+)ESI-MS (m/z): 500 (M+Na)⁺

- (7) Ethyl 4-[[4-[3-[N-benzyl-N-(tert-butoxycarbonyl)amino]-propyl]phenyl]sulfonyl]benzoate

NMR (CDCl₃, δ): 1.39 (3H, t, J=7Hz), 1.43 (9H, s), 1.77 (2H, quintet, J=7Hz), 2.59 (2H, t, J=7Hz), 3.21 (2H, br s), 4.39 (2H, q, J=7Hz), 4.40 (2H, s), 7.10-7.40 (7H, m), 7.83 (2H, d, J=8Hz), 7.98 (2H, d, J=8Hz), 8.14 (2H, d, J=8Hz)

15 (+)ESI-MS (m/z): 560 (M+Na)⁺

20

- (8) Ethyl 2-fluoro-4-[[4-[2-[(trifluoroacetyl)amino]-ethyl]phenyl]sulfonyl]benzoate

(+)APCI-MS (m/z): 470 (M+Na)⁺

- 25 (9) Ethyl 2-chloro-4-[[4-[2-[(trifluoroacetyl)amino]-ethyl]phenyl]sulfonyl]benzoate

(+)APCI-MS (m/z): 486 (M+Na)⁺

- (10) Ethyl 2-methyl-4-[[4-[2-[(trifluoroacetyl)amino]-ethyl]phenyl]sulfonyl]benzoate

30 (+)APCI-MS (m/z): 466 (M+Na)⁺

- (11) Ethyl 2-fluoro-4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-propyl]phenyl]sulfonyl]benzoate

35 (+)APCI-MS (m/z): 484 (M+Na)⁺

- (12) Ethyl 2-chloro-4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-propyl]phenyl]sulfonyl]benzoate
(+)APCI-MS (m/z): 500 (M+Na)⁺
- 5 (13) Ethyl 2-methyl-4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-propyl]phenyl]sulfonyl]benzoate
(+)APCI-MS (m/z): 480 (M+Na)⁺
- 10 (14) Ethyl 2-methoxy-5-[[4-[2-[(trifluoroacetyl)amino]-ethyl]phenyl]sulfonyl]benzoate
NMR (CDCl₃, δ): 1.39 (3H, t, J=7.1Hz), 2.95 (3H, t, J=7.1Hz), 3.56-3.66 (2H, m), 3.95 (3H, s), 4.37 (2H, q, J=7.1Hz), 6.36 (1H, br), 7.06 (1H, d, J=8.9Hz), 7.33 (2H, d, J=8.3Hz), 7.88 (2H, d, J=8.3Hz), 8.02 (1H, dd, J=2.5, 8.8Hz), 8.31 (1H, d, J=2.5Hz)
(+)APCI-MS (m/z): 482 (M+Na)⁺
- 15 (15) Ethyl 2-methoxy-4-[[4-[2-[(trifluoroacetyl)amino]-ethyl]phenyl]sulfonyl]benzoate
NMR (CDCl₃, δ): 1.36 (3H, t, J=7.1Hz), 2.96 (2H, t, J=7.1Hz), 3.56-3.67 (2H, m), 3.95 (3H, s), 4.36 (2H, q, J=7.1Hz), 6.37 (1H, br), 7.35 (2H, d, J=8.3Hz), 7.47-7.52 (2H, m), 7.81 (1H, d, J=8.2Hz), 7.90 (2H, d, J=8.3Hz)
(+)APCI-MS (m/z): 482 (M+Na)⁺
- 20 (16) Ethyl 4-[[3-[2-[N-benzyl-N-(tert-butoxycarbonyl)amino]-ethyl]phenyl]sulfonyl]benzoate
NMR (CDCl₃, δ): 1.38 (3H, t, J=7Hz), 1.43 (9H, s), 2.83 (2H, m), 3.37 (2H, m), 4.30 (2H, br s), 4.39 (2H, q, J=7Hz), 7.05-7.50 (7H, m), 7.60-7.85 (2H, m), 7.98 (2H, d, J=8Hz), 8.15 (2H, d, J=8Hz).
(+)ESI-MS (m/z): 546 (M+Na)⁺
- 25
30
35

Preparation 114

To a suspension of ethyl 4-[[4-[2-methyl-2-
[(trifluoroacetyl)amino]propyl]phenyl]sulfonyl]benzoate (970
5 mg) in ethanol (9.7 ml) was added 1N sodium hydroxide
solution (5.1 ml), and the mixture was heated to reflux for
4 hours. After the mixture was allowed to cool to room
temperature, the solvent was evaporated and the residual
solid was dried in vacuo. To the solid was added 4M
10 hydrogen chloride/ethanol (9.7 ml), and the mixture was
stirred at room temperature for 8 days. The solvent was
evaporated, and the residue was partitioned between ethyl
acetate/methanol and sodium bicarbonate solution. The
organic layer was separated, washed with brine, and dried
15 over magnesium sulfate. Filtration followed by evaporation
gave ethyl 4-[[4-(2-amino-2-ethylpropyl)phenyl]sulfonyl]-
benzoate (579 mg) as a pale yellow solid.

NMR (DMSO-d₆, δ): 1.06 (6H, s), 1.31 (3H, t, J=7Hz),
2.77 (2H, s), 4.34 (2H, q, J=7Hz), 4.84 (2H, br s),
20 7.34 (2H, d, J=8Hz), 7.92 (2H, d, J=8Hz), 8.00-
8.25 (4H, m)

(+)ESI-MS (m/z): 362 (M+H)⁺

Preparation 115

25 To a solution of 3-[[4-[2-methyl-2-[(trifluoroacetyl)-
amino]propyl]phenyl]thio]benzoic acid (789 mg) in ethyl
acetate (16 ml) - water (12 ml) were added
tetrabutylammonium hydrogensulfate (134 mg) and OXONE (2.57
g), and the mixture was heated to 70°C for 5 hours. After
30 being allowed to cool to room temperature, the mixture was
partitioned between ethyl acetate and water. The organic
layer was separated, washed successively with water, sodium
hydrogensulfite solution and brine, dried over magnesium
sulfate, and filtered. The filtrate was concentrated to
35 give 3-[[4-[2-methyl-2-[(trifluoroacetyl)amino]propyl]-

phenyl]sulfonyl]benzoic acid (833 mg) as a pale yellow solid.

NMR (DMSO- d_6 , δ): 1.28 (6H, s), 3.10 (2H, s), 7.34 (2H, d, $J=8$ Hz), 7.77 (1H, t, $J=8$ Hz), 7.94 (2H, d, $J=8$ Hz), 8.12-8.30 (2H, m), 8.39 (1H, s), 8.67 (1H, br s), 13.60 (1H, br s)

(-)ESI-MS (m/z): 428 ($M-H$)⁻

Preparation 116

To a solution of 3-[[4-[2-methyl-2-[(trifluoroacetyl)-amino]propyl]phenyl]sulfonyl]benzoic acid (818 mg) in ethanol (4.2 ml) was added 1N sodium hydroxide solution (4.1 ml), and the mixture was heated to reflux for 9.5 hours. After being allowed to cool to room temperature, the mixture was concentrated and the residue was neutralized with 1N hydrochloric acid. The precipitate formed was collected by filtration to give 3-[[4-(2-amino-2-methylpropyl)phenyl]sulfonyl]benzoic acid (632 mg) as a pale yellow powder.

NMR (DMSO- d_6 + NaOD, δ): 0.95 (6H, s), 2.63 (2H, s), 7.39 (2H, d, $J=8$ Hz), 7.49 (1H, t, $J=8$ Hz), 7.84 (2H, d, $J=8$ Hz), 7.88 (1H, d, $J=8$ Hz), 8.09 (1H, d, $J=8$ Hz), 8.34 (1H, s)

(-)ESI-MS (m/z): 332 ($M-H$)⁻

Preparation 117

Thionyl chloride (0.20 ml) was added dropwise to ethanol (3.1 ml) at 0°C. To the solution was added 3-[[4-(2-amino-2-methylpropyl)phenyl]sulfonyl]benzoic acid (622 mg), and the mixture was stirred at room temperature for 41.5 hours. The solvent was evaporated, and the residue was partitioned between ethyl acetate/methanol and sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate. Filtration followed by evaporation gave ethyl 3-[[4-(2-amino-2-methylpropyl)phenyl]sulfonyl]benzoate (551 mg) as a brown oil.

NMR (DMSO- d_6 , δ): 0.97 (6H, s), 1.34 (3H, t, $J=7$ Hz),
2.66 (2H, s), 4.36 (2H, q, $J=7$ Hz), 7.46 (2H, d,
 $J=8$ Hz), 7.79 (1H, t, $J=8$ Hz), 7.91 (2H, d, $J=8$ Hz),
8.15-8.31 (2H, m), 8.39 (1H, s)

5 (+)APCI-MS (m/z): 362 ($M+H$)⁺

Preparation 118

The following compounds were obtained according to a
similar manner to that of Preparation 110.

10

- (1) 2,2,2-Trifluoro-N-[(1R)-2-(4-iodophenyl)-1-methylethyl]acetamide

NMR (CDCl₃, δ): 1.21 (3H, d, $J=7$ Hz), 2.74 (1H, dd, $J=14$
and 7Hz), 2.85 (1H, dd, $J=14$ and 6Hz), 4.26 (1H,
15 m), 6.04 (1H, br s), 6.92 (2H, d, $J=8$ Hz), 7.65 (2H,
d, $J=8$ Hz)

(+)ESI-MS (m/z): 380 ($M+Na$)⁺

20

- (2) 2,2,2-Trifluoro-N-[(1S)-2-(4-iodophenyl)-1-methylethyl]acetamide

NMR (CDCl₃, δ): 1.21 (3H, d, $J=7$ Hz), 2.73 (1H, dd, $J=14$
and 7Hz), 2.85 (1H, dd, $J=14$ and 6Hz), 4.25 (1H,
m), 6.04 (1H, br s), 6.92 (2H, d, $J=8$ Hz), 7.65 (2H,
d, $J=8$ Hz)

25

(-)ESI-MS (m/z): 356 ($M-H$)⁻

- (3) 2,2,2-Trifluoro-N-[2-(4-iodophenyl)ethyl]acetamide

NMR (CDCl₃, δ): 2.84 (2H, t, $J=7$ Hz), 3.59 (2H, q,
 $J=7$ Hz), 6.33 (1H, br s), 6.94 (2H, d, $J=8$ Hz), 7.66
30 (2H, d, $J=8$ Hz)

(+)ESI-MS (m/z): 366 ($M+Na$)⁺

Preparation 119

The following compound was obtained according to a
35 similar manner to that of Preparation 114.

Ethyl 3-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-benzoate

5 NMR (DMSO- d_6 , δ): 0.93 (3H, d, $J=7$ Hz), 1.34 (3H, t, $J=7$ Hz), 2.50-2.72 (2H, m), 2.90-3.13 (1H, m), 3.33 (2H, br s), 4.36 (2H, q, $J=7$ Hz), 7.45 (2H, d, $J=8$ Hz), 7.79 (1H, t, $J=8$ Hz), 7.90 (2H, d, $J=8$ Hz), 8.13-8.33 (2H, m), 8.39 (1H, s)
(+)ESI-MS (m/z): 348 (M+H)⁺

10

Preparation 120

The following compound was obtained according to a similar manner to that of Preparation 116.

15 4-[[4-[(2S)-2-Aminopropyl]phenyl]sulfonyl]benzoic acid
NMR (DMSO- d_6 + NaOD, δ): 0.91 (3H, d, $J=7$ Hz), 2.47-2.69 (2H, m), 2.97 (1H, m), 7.42 (2H, d, $J=8$ Hz), 7.83 (2H, d, $J=8$ Hz), 7.84 (2H, d, $J=8$ Hz), 7.99 (2H, d, $J=8$ Hz)
20 (+)ESI-MS (m/z): 342 (M+Na)⁺

Preparation 121

The following compound was obtained according to a similar manner to that of Preparation 117.

25

Ethyl 4-[[4-[(2S)-2-aminopropyl]phenyl]sulfonyl]-benzoate

30 NMR (DMSO- d_6 , δ): 0.93 (3H, d, $J=7$ Hz), 1.31 (3H, t, $J=7$ Hz), 1.99 (2H, br s), 2.50-2.72 (2H, m), 3.02 (1H, m), 4.34 (2H, q, $J=7$ Hz), 7.46 (2H, d, $J=8$ Hz), 7.89 (2H, d, $J=8$ Hz), 8.00-8.22 (4H, m)
(+)ESI-MS (m/z): 348 (M+H)⁺

Preparation 122

35 The following compounds were obtained according to a

similar manner to that of Example 60.

- (1) tert-Butyl N-benzyl-N-[2-[3-[(4-hydroxyphenyl)-sulfonyl]phenyl]ethyl]carbamate
5 NMR (CDCl₃, δ): 1.43 (9H, s), 2.82 (2H, m), 3.36 (2H, m), 4.30 (2H, s), 6.75-7.50 (10H, m), 7.55-7.90 (4H, m)
(+)ESI-MS (m/z): 490 (M+Na)⁺
- 10 (2) tert-Butyl N-benzyl-N-[4-[(4-hydroxyphenyl)thio]benzyl]carbamate
NMR (CDCl₃, δ): 1.48 (9H, s), 4.28 (2H, br s), 4.35 (2H, br s), 5.78 (1H, br s), 6.82 (2H, d, J=8Hz), 6.95-7.45 (11H, m)
15 (+)ESI-MS (m/z): 444 (M+Na)⁺
- (3) tert-Butyl N-benzyl-N-[3-[4-[(4-hydroxyphenyl)-sulfonyl]phenyl]propyl]carbamate
NMR (CDCl₃, δ): 1.43 (9H, s), 1.80 (2H, quintet, J=7Hz),
20 2.54 (2H, t, J=7Hz), 3.19 (2H, br s), 4.39 (2H, s), 6.90 (2H, d, J=9Hz), 7.05-7.45 (7H, m), 7.77 (2H, d, J=9Hz), 7.77 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 504 (M+Na)⁺
- 25 (4) tert-Butyl [2-(4-iodophenyl)ethyl]carbamate
NMR (CDCl₃, δ): 1.43 (9H, s), 2.74 (2H, t, J=7Hz), 3.34 (2H, q, J=7Hz), 4.51 (1H, br s), 6.94 (2H, d, J=8Hz), 7.62 (2H, d, J=8Hz)
30 (+)ESI-MS (m/z): 370 (M+Na)⁺

Preparation 123

A solution of 4-[(4-methoxyphenyl)thio]benzaldehyde (4.88 g) and benzylamine (2.4 ml) in dichloromethane (49 ml) was stirred at room temperature for 2 hours. The mixture was evaporated, and the residual solid was suspended in

ethanol (49 ml) - tetrahydrofuran (12 ml). Sodium borohydride (750 mg) was slowly added to the suspension, and the mixture was stirred at room temperature for 1 hour. The mixture was poured onto water and partitioned between
5 hexane/ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, ethyl acetate) to give N-benzyl-N-[4-[(4-methoxyphenyl)thio]-
10 benzyl]amine (6.26 g) as a colorless oil.

NMR (CDCl₃, δ): 3.75 (2H, s), 3.79 (2H, s), 3.82 (3H, s), 6.88 (2H, d, J=9Hz), 7.08-7.50 (11H, m)
(+)ESI-MS (m/z): 336 (M+H)⁺

15 Preparation 124

The following compound was obtained according to a similar manner to that of Preparation 69.

3-[4-[(4-Methoxyphenyl)sulfonyl]phenyl]-1-propanamine
20 NMR (CDCl₃, δ): 1.75 (2H, quintet, J=7Hz), 2.68 (2H, t, J=7Hz), 2.72 (2H, t, J=7Hz), 3.84 (3H, s), 6.96 (2H, d, J=9Hz), 7.28 (2H, d, J=8Hz), 7.81 (2H, d, J=8Hz), 7.87 (2H, d, J=9Hz)
(+)ESI-MS (m/z): 306 (M+H)⁺

25

Preparation 125

To an ice-cooled suspension of sodium hydride (60% in mineral oil, 441 mg) in N,N-dimethylformamide (17 ml) was added tert-butyl [2-(4-iodophenyl)ethyl]carbamate (3.47 g),
30 and the mixture was heated to 40°C for 20 minutes. After the mixture was cooled with ice again, benzyl bromide (1.3 ml) was added, and the resulting suspension was stirred at room temperature for 2.5 hours and partitioned between hexane/ethyl acetate and water. The organic layer was
35 separated, washed successively with water and brine, dried

over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give tert-butyl N-benzyl-N-[2-(4-iodophenyl)ethyl]carbamate (3.14 g) as a viscous oil.

NMR (CDCl₃, δ): 1.45 (9H, s), 2.71 (2H, br s), 3.35 (2H, br s), 4.38 (2H, br s), 6.88 (2H, br s), 7.10-7.40 (5H, m), 7.58 2H, d, J=8Hz)
(+)ESI-MS (m/z): 460 (M+Na)⁺

Preparation 126

The following compounds were obtained according to a similar manner to that of Preparation 70.

- (1) Ethyl [4-[[4-[2-[N-benzyl-N-(tert-butoxycarbonyl)-amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
MS (m/z): 576 (M+Na)
- (2) Ethyl [2-methyl-4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-propyl]phenyl]sulfonyl]phenoxy]acetate
MS (m/z): 488 (M+H)
- (3) Ethyl [2-fluoro-4-[[4-[(2R)-2-[(trifluoroacetyl)amino]-propyl]phenyl]sulfonyl]phenoxy]acetate
MS (m/z): 492 (M+H)
- (4) Ethyl 4-[[4-[2-[(5R)-5-(3-chlorophenyl)-2-oxo-1,3-oxazolidin-3-yl]ethyl]phenyl]thio]butanoate
MS (m/z): 448 (M+H)
- (5) Methyl 4-[[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-thio]methyl]benzoate
MS (m/z): 556 (M+H)

Preparation 127

To a suspension of ethyl 2-fluoro-4-[[4-[2-
[(trifluoroacetyl)amino]ethyl]phenyl]sulfonyl]benzoate (2.95
g) in ethanol (30 ml) was added 1N sodium hydroxide solution
5 (16.5 ml) and the resulting solution was stirred at room
temperature for 24 hours. To the solution was added 1N
hydrochloric acid (16.5 ml) and the solvent was removed by
evaporation. To the residue was added 7N hydrogen chloride
in ethanol (30 ml) and the resulting suspension was refluxed
10 for 24 hours. After cooling to room temperature, the
solvent was removed by evaporation and the residual solid
was partitioned between ethyl acetate (30 ml) and water (30
ml). The mixture was basified with a saturated aqueous
sodium bicarbonate solution and the organic layer was
15 separated. The extract was washed with water (30 ml), dried
over magnesium sulfate, and concentrated in vacuo to give
ethyl 4-[[4-(2-aminoethyl)phenyl]sulfonyl]-2-fluorobenzoate
(1.44 g) as a yellow paste.

(+)APCI-MS (m/z): 352 (M+H)⁺

20

Preparation 128

To a solution of ethyl 2-chloro-4-[[4-[2-
[(trifluoroacetyl)amino]ethyl]phenyl]sulfonyl]benzoate (2.93
g) in ethanol (30 ml) was added 1N sodium hydroxide solution
25 (15.8 ml) and the solution was stirred at room temperature
for 19 hours. To the solution was added 1N hydrochloric
acid (15.8 ml) and the solvent was removed by evaporation.
To the residual yellow solid was added 7N hydrogen chloride
in ethanol (30 ml) and the suspension was refluxed for 13
30 hours. After cooling to room temperature, the solvent was
removed by evaporation and the residual solid was dissolved
in water (30 ml). The solution was basified with saturated
aqueous sodium bicarbonate (30 ml) and extracted with
chloroform (60 ml). The extract was dried over magnesium
35 sulfate, filtered, and concentrated in vacuo to give ethyl

4-[[4-(2-aminoethyl)phenyl]sulfonyl]-2-chlorobenzoate (2.18 g) as an orange paste.

(+)APCI-MS (m/z): 368 (M+H)⁺

5 Preparation 129

The following compounds were obtained according to a similar manner to that of Preparation 128.

- (1) Ethyl 4-[[4-(2-aminoethyl)phenyl]sulfonyl]-2-methylbenzoate
10 (M+H)⁺ 348 (M+H)⁺
- (2) Ethyl 4-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-2-fluorobenzoate
15 (M+H)⁺ 366 (M+H)⁺
- (3) Ethyl 4-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-2-chlorobenzoate
20 (M+H)⁺ 382 (M+H)⁺
- (4) Ethyl 4-[[4-[(2R)-2-aminopropyl]phenyl]sulfonyl]-2-methylbenzoate
(M+H)⁺ 362 (M+H)⁺
- (5) Ethyl 4'-[[4-(2-aminoethyl)phenyl]sulfonyl]-2'-chloro-1,1'-biphenyl-4-carboxylate
25 (M+H)⁺ 444 (M+H)⁺
- (6) Ethyl 4'-[[4-(2-aminoethyl)phenyl]sulfonyl]-2'-chloro-1,1'-biphenyl-3-carboxylate
30 (M+H)⁺ 444 (M+H)⁺

Preparation 130

To a solution of 2-chloro-4-[[4-[2-[(trifluoroacetyl)-amino]ethyl]phenyl]sulfonyl]phenyl trifluoromethanesulfonate
35

(1.00 g) and (4-methoxycarbonylphenyl)boronic acid (433 mg) in 1,2-dimethoxyethane (10 ml) were added successively tetrakis(triphenylphosphine)palladium (107 mg) and 2N aqueous sodium carbonate solution (1.95 ml). The mixture was stirred at 80°C for 4 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (20 ml) and washed with water (20 ml) and brine (20 ml), and dried over magnesium sulfate. Filtration followed by evaporation gave a crude product, which was chromatographed on silica gel (eluent: hexane/ethyl acetate = 2/1) to give methyl 2'-chloro-4'-[[4-[2-[(trifluoroacetyl)amino]ethyl]-phenyl]sulfonyl]-1,1'-biphenyl-4-carboxylate (727 mg).

NMR (CDCl₃, δ): 2.98 (2H, t, J=7.1Hz), 3.58-3.68 (2H, m), 3.95 (3H, m), 6.50 (1H, br), 7.37-7.50 (5H, m), 7.85-7.96 (3H, m), 8.04-8.13 (3H, m)

(+)APCI-MS (m/z): 548 (M+Na)⁺

Preparation 131

The following compound was obtained according to a similar manner to that of Preparation 130.

Methyl 2'-chloro-4'-[[4-[2-[(trifluoroacetyl)amino]ethyl]phenyl]sulfonyl]-1,1'-biphenyl-3-carboxylate

NMR (CDCl₃, δ): 2.98 (2H, t, J=7.1Hz), 3.58-3.68 (2H, m), 3.92 (3H, s), 6.49 (1H, br), 7.37-7.60 (5H, m), 7.85-7.96 (3H, m), 8.05-8.11 (3H, m)

(+)APCI-MS (m/z): 548 (M+Na)⁺

Preparation 132

To a suspension of 4-[2-[(trifluoroacetyl)amino]ethyl]benzenesulfonyl chloride (10.0 g) in 1,2-dichloroethane (50 ml) were added successively 1,2-dimethoxybenzene (5.22 ml) and aluminum trichloride (6.34 g) and the mixture was refluxed for 18 hours. An additional portion of aluminum trichloride (8.45 g) was added and the mixture was refluxed

for 7 hours. The mixture was quenched by addition of water (200 ml) and extracted with ethyl acetate (200 ml, 100 ml). The combined extracts were washed with brine (300 ml) and dried over magnesium sulfate. Filtration followed by
5 evaporation gave a dark purple paste, which was chromatographed on silica gel (eluent: hexane/ethyl acetate) to give the coupling products. The products were dissolved in dichloromethane (100 ml). To the solution was added 1.0 M solution of boron tribromide (83 ml) at 0°C and the mixture
10 was warmed to room temperature. After stirring for 12 hours, the solvent was removed by evaporation. The residue was suspended in ethyl acetate (100 ml) and carefully basified with saturated aqueous sodium bicarbonate (150 ml) under cooling at 0°C. The aqueous layer was separated and
15 extracted with ethyl acetate (50 ml). The combined organic layers were dried over magnesium sulfate, filtered, and evaporated to give a brown solid, which was chromatographed on silica gel (eluent: hexane/ethyl acetate) to give N-[2-[4-[(3,4-dihydroxyphenyl)sulfonyl]phenyl]ethyl]-2,2,2-
20 trifluoroacetamide (5.29 g) as a light brown solid.
(+)APCI-MS (m/z): 412 (M+Na)⁺

Preparation 133

To a solution of N-[2-[4-[(3,4-dihydroxyphenyl)-
25 sulfonyl]phenyl]ethyl]-2,2,2-trifluoroacetamide (1.00 g) in N,N-dimethylformamide (10 ml) was added potassium carbonate (powder, 390 mg) and the mixture was cooled to 0°C. To the mixture was added iodomethane (208 μ l) and the whole was stirred at 0°C for 20 minutes. The mixture was warmed to
30 room temperature and stirred for 2 hours. The mixture was quenched by addition of water (20 ml) and extracted with ethyl acetate (20 ml and 5 ml). The combined extracts were washed with water (25 ml x 2) and brine (25 ml x 1), and dried over magnesium sulfate. Filtration followed by
35 evaporation gave a crude oil, which was chromatographed on

silica gel (eluent: hexane/ethyl acetate) to give 2,2,2-trifluoro-N-[2-[4-[(3-hydroxy-4-methoxyphenyl)sulfonyl]-phenyl]ethyl]acetamide (185 mg) as a pale yellow solid.
(+)APCI-MS (m/z): 426 (M+Na)⁺

5

Preparation 134

A solution of ethyl 2-methoxy-5-[[4-[2-[(trifluoroacetyl)amino]ethyl]phenyl]sulfonyl]benzoate (113 mg) in 7N hydrogen chloride in ethanol (2.0 ml) was refluxed
10 for 14 hours. After cooling to room temperature, the solvent was removed by evaporation and the residue was dissolved in water (2.0 ml). The solution was basified with saturated aqueous sodium bicarbonate (5 ml) and extracted
with chloroform (5 ml x 3). The extracts were dried over
15 magnesium sulfate, filtered, and concentrated in vacuo to give ethyl 5-[[4-(2-aminoethyl)phenyl]sulfonyl]-2-methoxybenzoate (84.6 mg) as a white crystalline solid.

NMR (CDCl₃, δ): 1.38 (3H, t, J=7.1Hz), 1.50 (2H, br),
2.80 (2H, t, J=6.6Hz), 2.98 (2H, t, J=6.6Hz), 3.94
20 (3H, s), 4.37 (2H, q, J=7.1Hz), 7.05 (1H, d, J=8.8Hz), 7.34 (2H, d, J=8.4Hz), 7.86 (2H, d, J=8.4Hz), 8.03 (1H, dd, J=2.4, 8.8Hz), 8.32 (1H, d, J=2.4Hz)

(+)APCI-MS (m/z): 364 (M+H)⁺

25

Preparation 135

The following compounds were obtained according to a similar manner to that of Preparation 133.

30 (1) N-[2-[4-[[4-(Benzyloxy)-3-hydroxyphenyl]sulfonyl]-phenyl]ethyl]-2,2,2-trifluoroacetamide
(+)APCI-MS (m/z): 502 (M+Na)⁺

(2) N-[2-[4-[[4-(Benzyloxy)-3-methoxyphenyl]sulfonyl]-phenyl]ethyl]-2,2,2-trifluoroacetamide
35

(+)APCI-MS (m/z): 494 (M+H)⁺

Preparation 136

To a solution of N-[2-[4-[[4-(benzyloxy)-3-methoxyphenyl]sulfonyl]phenyl]ethyl]-2,2,2-trifluoroacetamide (505 mg) in methanol (10 ml) was added 10% palladium on activated carbon (50% wet, 50 mg) and the mixture was hydrogenated (1 atm) for 1 hour. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to give 2,2,2-trifluoro-N-[2-[4-[(4-hydroxy-3-methoxyphenyl)sulfonyl]phenyl]ethyl]acetamide (436 mg) as white foam.

(-)APCI-MS (m/z): 402 (M-H)⁻

15 Preparation 137

The following compound was obtained according to a similar manner to that of Preparation 134.

Ethyl 5-[[4-(2-aminoethyl)phenyl]sulfonyl]-2-methoxybenzoate

20 NMR (CDCl₃, δ): 1.36 (3H, t, J=7.1Hz), 1.43 (2H, br), 2.77-2.85 (2H, m), 2.95-3.02 (2H, m), 3.95 (3H, s), 4.36 (2H, q, J=7.1Hz), 7.35 (2H, d, J=8.3Hz), 7.47-7.54 (2H, m), 7.80 (1H, d, J=7.9Hz), 7.86 (2H, d, J=8.3Hz)

25 (+)APCI-MS (m/z): 364 (M+H)⁺

Preparation 138

30 The following compounds were obtained according to a similar manner to that of Example 76.

(1) (1R)-1-(3-Chlorophenyl)-2-[[2-[3-[(4-methoxyphenyl)thio]phenyl]ethyl]amino]ethanol

35 NMR (MeOD-d₄, δ): 2.50-2.90 (6H, m), 3.80 (3H, s), 4.60-4.80 (1H, m), 6.80-7.50 (12H, m)."

MS (m/z): 414 (M+H)

(2) 2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-ethyl]benzene

5 NMR (DMSO-d₆, δ): 2.95-3.30 (6H, m), 5.00-5.10 (1H, m),
7.20-7.60 (9H, m)

Preparation 139

The following compound was obtained according to a
10 similar manner to that of Example 50.

4-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]thio]butanoic acid hydrochloride

15 NMR (DMSO-d₆, δ): 1.60-1.80 (2H, m), 2.30-2.40 (2H, m),
2.80-3.30 (8H, m), 4.90-5.00 (1H, m), 7.10-7.45
(8H, m)

MS (m/z): 394 (M+H)

Preparation 140

20 The following compound was obtained according to a
similar manner to that of Preparation 106.

4-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-

25 thio]butanoic acid

MS (m/z): 494 (M+H)

Preparation 141

To a solution of N-[2-(2-chlorophenyl)ethyl]-2,2,2-
30 trifluoroacetamide (1.5 g) and 3-nitrobenzenesulfonyl
chloride (1.19 g) in 1,2-dichloroethane (12 ml) was added
trichloroaluminium (1.8 g) at room temprature and the
mixture was refluxed for 24 hours. The resulting mixture
was evaporated and partitioned between ethyl acetate and
35 water. The organic layer was seperated, washed with water

and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give N-[2-[2-chloro-4-[(3-nitrophenyl)sulfonyl]phenyl]-ethyl]-2,2,2-trifluoroacetamide (530 mg) as a yellow solid.

(+)ESI-MS m/z: 459 (M+Na)⁺

Preparation 142

The following compound was obtained according to a similar manner to that of Preparation 67.

3-Chloro-4-[2-[(trifluoroacetyl)amino]ethyl]-benzenesulfonyl chloride

NMR (CDCl₃, δ): 3.15 (2H, t, J=7.0Hz), 3.66-3.76 (2H, m), 6.47 (1H, br), 7.63-7.67 (1H, m), 7.86-7.92 (2H, m)

Preparation 143

The following compound was obtained according to a similar manner to that of Preparation 68.

N-[2-[2-Chloro-4-[(4-methoxyphenyl)sulfonyl]phenyl]-ethyl]-2,2,2-trifluoroacetamide

(+)ESI-MS m/z: 444 (M+Na)⁺

Preparation 144

A suspension of N-[2-[2-chloro-4-[(3-nitrophenyl)sulfonyl]phenyl]ethyl]-2,2,2-trifluoroacetamide (520 mg) in methanol (5 ml) and tetrahydrofuran (5 ml) was hydrogenated over palladium on carbon (10 % w/w, 50 % wet, 220 mg) under hydrogen atmosphere for 2.5 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give N-[2-[4-[(3-aminophenyl)sulfonyl]phenyl]ethyl]-2,2,2-trifluoroacetamide (490 mg) as a yellow oil.

(-)ESI-MS (m/z): 371 (M-H)⁻

Preparation 145

To a solution of N-[2-[4-[(3-aminophenyl)sulfonyl]-phenyl]ethyl]-2,2,2-trifluoroacetamide (200 mg), 4-
5 dimethylaminopyridine (33 mg) and N,N-diisopropylethylamine (0.2 ml) in dichloromethane (3.0 ml) was added acetic anhydride (0.25 ml), and the mixture was stirred at room temperature for 2 hours. The mixture was diluted with dichloromethane, washed with saturated aqueous sodium
10 bicarbonate and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1/2) to give N-[2-[4-[(3-(acetylamino)phenyl)sulfonyl]-phenyl]ethyl]-2,2,2-trifluoroacetamide (127 mg) as a
15 colorless oil.

(+)ESI-MS (m/z): 437 (M+Na)⁺

Preparation 146

To a solution of 3-chloro-4-[2-[(trifluoroacetyl)-(20
amino]ethyl]benzenesulfonyl chloride (600 mg) and ethyl phenoxyacetate (500 mg) in 1,2-dichloroethane (5.0 ml) was added trichloroaluminium (1.4 g) at room temperature and the mixture was refluxed for 8 hours. The resulting mixture was partitioned between ethyl acetate and water. The organic
25 layer was separated, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was suspended in 3.95N hydrogen chloride in ethanol (2.5 ml) and stirred for 3 hours. The solvent was removed by evaporation. The residue was purified by column
30 chromatography on silica gel (hexane/ethyl acetate = 2/1) to give ethyl [4-[(3-chloro-4-[2-[(trifluoroacetyl)amino]-ethyl]phenyl)sulfonyl]phenoxy]acetate (205 mg) as a white solid.

(+)ESI-MS (m/z): 516 (M+Na)⁺

Preparation 147

The following compound was obtained according to a similar manner to that of Preparation 71.

- 5 Ethyl [4-[[4-(2-aminoethyl)-3-chlorophenyl]-sulfonyl]phenoxy]acetate
(+)ESI-MS (m/z): 398 (M+H)⁺

Preparation 148

- 10 A suspension of N-[2-[2-chloro-4-[(3-nitrophenyl)sulfonyl]phenyl]ethyl]-2,2,2-trifluoroacetamide (360 mg) and formaldehyde (37% w/w solution in water, 180 μ l) in methanol (3.5 ml) and tetrahydrofuran (1.5 ml) was hydrogenated over palladium on carbon (10 % w/w, 50 % wet, 15 220 mg) under hydrogen atmosphere at 50°C for 6 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give N-[2-[4-[[3-(dimethylamino)phenyl]sulfonyl]phenyl]-20 ethyl]-2,2,2-trifluoroacetamide (146 mg) as a colorless oil.
(+)ESI-MS (m/z): 423 (M+Na)⁺

Preparation 149

- To a solution of tert-butyl 2-(1-oxido-3-pyridyl)-25 ethylcarbamate (480 mg) in toluene (5.0 ml) was added diethylcarbamoyl chloride under 5°C. The mixture was stirred at the same temperature for 5 minutes. A solution of triethylamine (0.55 ml) and 3-methoxybenzenethiol (424 mg) in toluene (1.0 ml) was added to the mixture. The reaction 30 mixture was refluxed for 4 hours. The resulting mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with an aqueous solution of sodium hydroxide (1N) and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue 35 was purified by column chromatography on silica gel

165

(hexane/ethyl acetate = 4/1) to give tert-butyl 2-[6-[(4-methoxyphenyl)thio]-3-pyridyl]ethylcarbamate (149 mg) as a white solid.

(+)ESI-MS (m/z): 361 (M+H)⁺

5

Preparation 150

The following compound was obtained according to a similar manner to that of Preparation 149.

10 tert-Butyl 2-[6-[(4-hydroxyphenyl)thio]-3-pyridyl]ethylcarbamate

(+)ESI-MS (m/z): 347 (M+H)⁺

Preparation 151

15 The following compound was obtained according to a similar manner to that of Preparation 70.

Ethyl [4-[[5-[2-[(tert-butoxycarbonyl)amino]ethyl]-2-pyridyl]sulfonyl]phenoxy]acetate

20 (+)ESI-MS (m/z): 465 (M+H)⁺

Preparation 152

The following compounds were obtained according to a similar manner to that of Preparation 63.

25

(1) N-[3-[[4-(2-Aminoethyl)phenyl]sulfonyl]phenyl]-N,N-dimethylamine

(+)ESI-MS (m/z): 305 (M+H)⁺

30 (2) N-[3-[[4-(2-Aminoethyl)phenyl]sulfonyl]phenyl]acetamide
(+)ESI-MS (m/z): 319 (M+H)⁺

(3) 2-[2-Chloro-4-[(4-methoxyphenyl)sulfonyl]phenyl]-ethanamine

35 (+)ESI-MS (m/z): 326 (M+H)⁺

Example 82

To a solution of ethyl (R)-[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[2-(3-chlorophenyl)-2-hydroxy-ethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate (231 mg)
5 in methanol (3 ml) was added 40% methylamine in methanol (0.5 ml) at room temperature, and the mixture was sealed at the same temperature for 12 hours. The resulting mixture was evaporated under reduced pressure. The residue was
10 dissolved into a mixture of water and ethyl acetate. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was dried in vacuo to give
tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-
15 [4-[[4-[2-(methylamino)-2-oxoethoxy]phenyl]sulfonyl]-phenyl]ethyl]carbamate (198 mg).

NMR (CDCl₃, δ): 1.25-1.45 (9H, m), 2.7-2.9 (2H, m),
2.92 (3H, d, J=2.5Hz), 3.1-3.55 (4H, m), 4.50 (2H,
s), 4.8-4.85 (1H, m), 6.97 (2H, d, J=4.5Hz), 7.1-
20 7.4 (6H, m), 7.8-7.9 (4H, m)
(+)ESI-MS (m/z): 625, 627 (M+Na)⁺

Example 83

At room temperature, to a solution of tert-butyl N-
25 [(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-[2-(methylamino)-2-oxoethoxy]phenyl]sulfonyl]phenyl]ethyl]-carbamate (195 mg) in ethyl acetate (2 ml) was added 4N hydrogen chloride in 1,4-dioxane (2 ml), and the mixture was
stirred at the same temperature for 2 hours to give a
30 precipitate. The precipitate was collected by filtration and washed with ethyl acetate, followed by dryness to give
(R)-2-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-ethyl]phenyl]sulfonyl]phenoxy]-N-methylacetamide
hydrochloride (170 mg).

35 NMR (DMSO-d₆, δ): 2.63 (3H, d, J=4.6Hz), 2.9-3.3 (6H,

m), 4.58 (2H, s), 4.9-5.05 (1H, m), 7.05-7.2 (2H, m), 7.3-7.55 (6H, m), 7.8-7.95 (4H, m)
(+)ESI-MS (m/z): 503, 505 (M-HCl+H)⁺

5 Example 84

Under nitrogen at 5°C, to a solution of sodium [4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate (65 mg) in N,N-dimethylformamide (2 ml) were added dimethylamine hydrochloride (9.6 mg), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (23 mg) and 1-hydroxybenzotriazole (16 mg), and the mixture was stirred at room temperature overnight. The resulting mixture was poured into saturated aqueous sodium bicarbonate and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate= 1 : 2 to 1 : 10) to give tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-[2-(dimethylamino)-2-oxoethoxy]phenyl]sulfonyl]phenyl]ethyl]carbamate (55 mg).

NMR (CDCl₃, δ): 1.2-1.5 (9H, m), 2.65-2.9 (2H, m), 2.97 (3H, s), 3.06 (3H, s), 3.1-3.45 (4H, m), 4.73 (2H, s), 4.8-4.95 (1H, m), 6.9-7.0 (2H, m), 7.15-7.4 (6H, m), 7.75-7.9 (4H, m)

(+)ESI-MS (m/z): 639, 641 (M+Na)⁺

Example 85

30 The following compound was obtained according to a similar manner to that of Example 83.

(R)-2-[4-[[4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-N,N-dimethylacetamide hydrochloride

NMR (DMSO- d_6 , δ): 2.81 (3H, s), 2.9-3.45 (9H, m), 4.85-5.0 (3H, m), 7.0-7.15 (2H, m), 7.3-7.55 (6H, m), 7.8-7.95 (4H, m)
(+)ESI-MS (m/z): 517, 519 (M-HCl+H)⁺

5

Example 86

To a solution of ethyl (R)-2-[4-[[4-[2-[5-(3-chlorophenyl)-2-oxo-1,3-oxazolidin-3-yl]ethyl]phenyl]-sulfonyl]phenoxy]-2-methylpropanoate (41 mg) was added 3N sodium hydroxide (3 ml) at room temperature, and the mixture was refluxed for 7 hours. The resulting mixture was cooled to 5°C, and to this one was added concentrated hydrochloric acid (0.75 ml). Ethanol was removed by evaporation under reduced pressure. To the residue was added 1N hydrochloric acid to give a precipitate. The precipitate was collected and washed with water, followed by dryness in vacuo to give (R)-2-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-ethyl]phenyl]sulfonyl]phenoxy]-2-methylpropanoic acid hydrochloride (46 mg).

20 NMR (DMSO- d_6 , δ): 1.55 (6H, s), 2.8-3.5 (6H, m), 4.85-4.95 (1H, m), 6.85-7.0 (2H, m), 7.3-7.55 (6H, m), 7.8-7.95 (4H, m)
(-)ESI-MS (m/z): 516, 518 (M-HCl-H)⁻

25 Example 87

A mixture of (R)-2-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-2-methylpropanoic acid hydrochloride (29 mg), and 4N hydrogen chloride in ethanol (5 ml) was stirred at room temperature for 6 days. The mixture was evaporated under reduced pressure and dried to give ethyl (R)-2-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-2-methylpropanoate hydrochloride (22 mg).

35 NMR (DMSO- d_6 , δ): 1.11 (3H, t, J=7.1Hz), 1.57 (6H, s), 2.8-3.55 (6H, m), 4.15 (2H, q, J=7.1Hz), 4.85-5.0

(1H, m), 6.85-7.0 (2H, m), 7.3-7.55 (6H, m), 7.8-7.95 (4H, m)

(+)ESI-MS (m/z): 546, 548 (M-HCl+H)⁺

5 Example 88

Under nitrogen at 5°C, to a solution of (R)-4-[[4-[2-[N-benzyl-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]sulfonyl]phenol (400 mg) in N,N-dimethylformamide (10 ml) was added sodium hydride (60% in oil, 34 mg), and the
10 mixture was stirred at the same temperature for 1.5 hours. To this one was added bromoacetonitrile (0.059 ml) and the mixture was stirred at room temperature for 12 hours. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer
15 was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 2 : 1 to 1 : 1) to give (R)-[4-[[4-[2-[N-benzyl-N-[2-(3-chlorophenyl)-2-
20 hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetonitrile (322 mg).

NMR (CDCl₃, δ): 2.5-2.9 (6H, m), 3.5-3.95 (2H, m),
4.55-4.65 (1H, m), 4.80 (2H, s), 7.0-7.35 (11H, m),
7.75-7.9 (2H, m), 7.9-8.0 (2H, m)

25 (+)ESI-MS (m/z): 561, 563 (M+H)⁺

Example 89

Under nitrogen at room temperature, to a solution of (R)-[4-[[4-[2-[N-benzyl-N-[2-(3-chlorophenyl)-2-
30 hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetonitrile (320 mg) in N,N-dimethylformamide (5 ml) were added ammonium chloride (153 mg) and sodium azide (185 mg), and the mixture was stirred at 100°C for 4 hours. To the resulting mixture was added water at room temperature and
35 the mixture was stirred for 30 minutes to give a precipitate.

The precipitate was collected and washed with water, followed by dryness in vacuo to give (R)-2-[N-benzyl-N-[2-[4-[[4-(1H-tetrazol-5-ylmethoxy)phenyl]sulfonyl]phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol (311 mg).

- 5 NMR (DMSO-d₆, δ): 2.65-2.9 (6H, m), 3.7-3.9 (2H, m),
 4.65-4.8 (1H, m), 5.54 (2H, s), 7.05-7.4 (13H, m),
 7.7-8.0 (4H, m)
 (-)ESI-MS (m/z): 602, 604 (M-H)⁻

10 Example 90

- A mixture of (R)-2-[N-benzyl-N-[2-[4-[[4-(1H-tetrazol-5-ylmethoxy)phenyl]sulfonyl]phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol (302 mg), triethylamine (2 ml) and 10% palladium on activated carbon (50% wet, 100 mg) in a mixture
15 of methanol (8 ml) and chlorobenzene (8 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 6 hours. After filtration, the filtrate was evaporated under reduced pressure. The residue was dissolved into methanol and added 10% hydrogen chloride
20 in methanol. The mixture was evaporated under reduced pressure. The residue was purified by reversed phase chromatography (water : methanol = 9 : 1 to 0 : 1), followed by treatment with 10% hydrogen chloride in methanol, evaporation under reduced pressure and dryness in vacuo to
25 give (R)-1-(3-chlorophenyl)-2-[[2-[4-[[4-(1H-tetrazol-5-ylmethoxy)phenyl]sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride (83 mg).

- NMR (DMSO-d₆, δ): 3.0-3.3 (6H, m), 4.95-5.0 (1H, m),
 5.60 (2H, s), 7.25-7.3 (2H, m), 7.35-7.55 (6H, m),
30 7.9-7.95 (4H, m)
 (-)ESI-MS (m/z): 512, 514 (M-HCl-H)⁻

Example 91

- Under nitrogen at 5°C, to a solution of tert-butyl N-
35 [(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(4-

hydroxyphenyl)sulfonyl]phenyl]ethyl]carbamate (236 mg) in N,N-dimethylformamide (5 ml) was added sodium hydride (60% in oil, 20 mg), and the mixture was stirred at the same temperature for 50 minutes. To this one was added ethyl
5 bromodifluoroacetate (0.063 ml) and the mixture was stirred at room temperature for 6 days. The resulting mixture was poured into water and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate and evaporated under
10 reduced pressure. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 3 : 1 to 2 : 1) to give tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-(difluoromethoxy)phenyl]sulfonyl]-phenyl]ethyl]carbamate (109 mg).

15 NMR (DMSO-d₆, δ): 1.2-1.5 (9H, m), 2.7-3.6 (6H, m), 4.8-4.95 (1H, m), 6.55 (1H, t, J=72.5Hz), 7.15-7.45 (8H, m), 7.8-8.0 (4H, m)
(+)ESI-MS (m/z): 604, 606 (M+Na)⁺

20 Example 92

To a solution of tert-butyl N-[(R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-(difluoromethoxy)-phenyl]sulfonyl]phenyl]ethyl]carbamate (106 mg) in ethyl acetate (1 ml) was added 4N hydrogen chloride in 1,4-dioxane
25 (1 ml) at room temperature, and the mixture was stirred at the same temperature for 1.5 hours. The resulting mixture was evaporated under reduced pressure. The residue was dissolved into a mixture of saturated aqueous sodium bicarbonate and ethyl acetate. After separation, the
30 organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform : methanol = 20 : 1 to 15 : 1) to give (R)-1-(3-chlorophenyl)-2-[[2-[4-[[4-(difluoromethoxy)phenyl]sulfonyl]phenyl]ethyl]amino]ethanol
35

(68 mg).

NMR (DMSO- d_6 , δ): 2.55-2.9 (6H, m), 4.5-4.65 (1H, m),
7.0-7.75 (9H, m), 7.8-7.9 (2H, m), 7.95-8.05 (2H,
m)

5 (+)ESI-MS (m/z): 482, 484 (M+H)⁺

Example 93

To a solution of (R)-1-(3-chlorophenyl)-2-[[2-[4-[[4-(difluoromethoxy)phenyl]sulfonyl]phenyl]ethyl]amino]ethanol
10 (34 mg) in ethanol (2 ml) was added 4N hydrogen chloride in ethanol (0.5 ml), and the mixture was evaporated under reduced pressure, followed by dryness in vacuo to give (R)-1-(3-chlorophenyl)-2-[[2-[4-[[4-(difluoromethoxy)phenyl]sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride (36 mg).

15 NMR (DMSO- d_6 , δ): 2.9-3.4 (6H, m), 4.9-5.0 (1H, m),
7.0-7.75 (9H, m), 7.9-8.1 (4H, m)
(+)ESI-MS (m/z): 482, 484 (M-HCl+H)⁺

Example 94

20 The following compound was obtained according to a similar manner to that of Example 93.

Ethyl (R)-2-[3-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-2-methylpropanoate hydrochloride

25 NMR (DMSO- d_6 , δ): 1.11 (3H, t, J=7.1Hz), 2.95-3.3 (6H, m), 4.13 (2H, q, J=7.1Hz), 4.9-5.0 (1H, m), 7.05-7.15 (1H, m), 7.2-7.6 (9H, m), 7.85-7.95 (2H, m)
(+)ESI-MS (m/z): 546, 548 (M-HCl+H)⁺

30

Example 95

The following compounds were obtained according to a similar manner to that of Example 6.

35 (1) Ethyl (R)-2-[3-[[4-[2-[N-benzyl-N-[2-(3-chlorophenyl)-

2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy}-2-methylpropanoate

NMR (CDCl₃, δ): 1.21 (3H, t, J=7.1Hz), 1.59 (6H, s),
2.5-2.9 (6H, s), 3.5-3.95 (2H, s), 4.20 (2H, q,
J=7.1Hz), 4.55-4.65 (1H, m), 6.95-7.0 (1H, m),
7.1-7.45 (13H, m), 7.5-7.55 (1H, m), 7.75-7.85 (2H,
m)

(+)APCI-MS (m/z): 636, 638 (M+H)⁺

10 (2) (S)-1-[N-Benzyl-N-[2-[4-[(3,4-dimethoxyphenyl)-sulfonyl]phenyl]ethyl]amino]-3-(4-fluorophenoxy)-2-propanol

NMR (CDCl₃, δ): 2.65-2.9 (6H, m), 3.5-4.0 (11H, m),
6.75-7.0 (5H, m), 7.1-7.3 (7H, m), 7.35 (1H, m),
7.5-7.55 (1H, m), 7.75-7.8 (2H, m)

15 (+)ESI-MS (m/z): 580 (M+H)⁺

(3) (S)-1-[N-Benzyl-N-[2-[4-[(3,4-dimethoxyphenyl)-sulfonyl]phenyl]ethyl]amino]-3-(1H-indol-4-yloxy)-2-propanol

20 NMR (CDCl₃, δ): 2.65-2.9 (6H, m), 3.55-3.85 (2H, m),
3.89 (3H, s), 3.90 (3H, s), 4.05-4.2 (3H, m),
6.45-6.65 (2H, m), 6.85-7.55 (13H, m), 7.7-7.8 (2H,
m)

25 (+)ESI-MS (m/z): 601 (M+H)⁺

(4) Ethyl (R)-6-[[4-[2-[N-benzyl-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-nicotinate

30 NMR (CDCl₃, δ): 1.39 (3H, t, J=7.1Hz), 2.5-2.95 (6H, m),
3.5-3.95 (2H, m), 4.42 (2H, q, J=7.1Hz), 6.55-6.65
(1H, m), 7.1-7.4 (11H, m), 7.95 (1H, d, J=8.3Hz),
8.25 (1H, d, J=7.8Hz), 8.50 (1H, dd, J=2.2, 8.3Hz),
9.2 (1H, m)

35 (+)ESI-MS (m/z): 579, 581 (M+H)⁺

- (5) Methyl 4-[[4-[(2R)-2-[N-benzyl-N-[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoate
5 MS (m/z): 579 (M+H)
- (6) Methyl 4-[[4-[2-[N-benzyl-N-[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-benzoate
10 MS (m/z): 565 (M+H)
- (7) 4-[[4-[2-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-dimethylphenol
15 MS (m/z): 550 (M+H)
- (8) 3-[[2-[2-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenol
20 MS (m/z): 522 (M+H)
- (9) (2S)-1-[N-Benzyl-N-[2-[3-[(4-methoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-3-phenoxy-2-propanol
MS (m/z): 532 (M+H)
- (10) 4-[[3-[2-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenol
25 MS (m/z): 522 (M+)
- (11) 3-[[3-[2-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenol
30 MS (m/z): 522 (M+H)
- (12) Ethyl [4-[[4-[2-[N-benzyl-N-[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]acetate
35

MS (m/z): 609 (M+H)

- (13) 4-[[4-[(2S)-2-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]sulfonyl]-phenol
5 NMR (DMSO-d₆, δ): 2.60-2.90 (5H, m), 3.18-3.35 (1H, m), 3.35-3.55 (1H, m), 3.67 (1H, d, J=14Hz), 3.75 (1H, d, J=14Hz), 4.37 (1H, br s, OH), 4.47 (1H, m), 5.02 (1H, br s, OH), 6.83-7.40 (13H, m), 7.71 (2H, d, J=8Hz), 7.77 (2H, d, J=8Hz), 10.62 (1H, br s)
10 (+)ESI-MS (m/z): 552 (M+H)⁺
- (14) Ethyl 4-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]sulfonyl]-benzoate
15 NMR (CDCl₃, δ): 1.04 (3H, s), 1.06 (3H, s), 1.39 (3H, t, J=7Hz), 2.50-3.05 (4H, m), 4.40 (2H, q, J=7Hz), 4.58 (1H, dd, J=8 and 4Hz), 7.10-7.45 (6H, m), 7.85 (2H, d, J=8Hz), 8.01 (2H, d, J=8Hz), 8.17 (2H, d, J=8Hz)
20 (+)ESI-MS (m/z): 516 (M+H)⁺
- (15) Ethyl 3-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]sulfonyl]-benzoate
25 NMR (CDCl₃, δ): 1.04 (3H, s), 1.06 (3H, s), 1.41 (3H, t, J=7Hz), 2.62-2.82 (2H, m), 2.63 (1H, dd, J=12 and 8Hz), 2.94 (1H, dd, J=12 and 4Hz), 4.42 (2H, q, J=7Hz), 4.58 (1H, dd, J=8 and 4Hz), 7.10-7.45 (6H, m), 7.61 (1H, t, J=8Hz), 7.87 (2H, d, J=8Hz), 8.13 (1H, d, J=8Hz), 8.24 (1H, d, J=8Hz), 8.60 (1H, s)
30 (+)ESI-MS (m/z): 516 (M+H)⁺
- (16) Ethyl 3-[[4-[(2R)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
35

NMR (CDCl₃, δ): 1.05 (3H, d, J=6Hz), 1.41 (3H, t, J=7Hz), 2.52-3.02 (5H, m), 4.40 (2H, q, J=7Hz), 4.54 (1H, dd, J=8 and 4Hz), 7.06-7.42 (6H, m), 7.59 (1H, t, J=8Hz), 7.89 (2H, d, J=8Hz), 8.12 (1H, d, J=8Hz), 8.23 (1H, d, J=8Hz), 8.59 (1H, s)
5 (+)ESI-MS (m/z): 502 (M+H)⁺

(17) Ethyl 4-[[4-[(2S)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
10 NMR (CDCl₃, δ): 1.04 (3H, d, J=6Hz), 1.38 (3H, t, J=7Hz), 2.45-3.06 (5H, m), 4.39 (2H, q, J=7Hz), 4.59 (1H, dd, J=8 and 4Hz), 7.07-7.42 (6H, m), 7.86 (2H, d, J=8Hz), 8.00 (2H, d, J=8Hz), 8.16 (2H, d, J=8Hz)
15 (+)ESI-MS (m/z): 502 (M+H)⁺

(18) Ethyl 4-[[4-[(2R)-2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoate
20 NMR (CDCl₃, δ): 1.02 (3H, d, J=7Hz), 1.38 (3H, t, J=7Hz), 2.40-2.95 (4H, m), 3.00-3.26 (1H, m), 3.49 (1H, d, J=13Hz), 3.50 (1H, br s), 3.80 (1H, d, J=13Hz), 4.39 (2H, q, J=7Hz), 4.55 (1H, dd, J=10 and 4Hz), 6.90-7.40 (11H, m), 7.78 (2H, d, J=8Hz),
25 8.01 (2H, d, J=8Hz), 8.17 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 592 (M+H)⁺

(19) Ethyl 3-[[3-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate
30 NMR (CDCl₃, δ): 1.39 (3H, t, J=7Hz), 2.40-3.00 (6H, m), 3.57 (1H, d, J=13Hz), 3.91 (1H, d, J=13Hz), 4.38 (2H, q, J=7Hz), 4.52 (1H, dd, J=8 and 4Hz), 7.00-7.39 (10H, m), 7.43 (1H, t, J=8Hz), 7.55 (1H, t, J=8Hz), 7.68-7.88 (2H, m), 8.09 (1H, d, J=8Hz),
35 8.20 (1H, d, J=8Hz), 8.59 (1H, s)

(+)ESI-MS (m/z): 578 (M+H)⁺

(20) Ethyl 4-[[3-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate

5 NMR (CDCl₃, δ): 1.38 (3H, t, J=7Hz), 2.40-3.00 (6H, m),
3.53 (1H, br s, OH), 3.57 (1H, d, J=13Hz), 3.92
(1H, d, J=13Hz), 4.38 (2H, q, J=7Hz), 4.52 (1H, dd,
J=10 and 4Hz), 7.02-7.50 (11H, m), 7.65-7.88 (2H,
m), 7.98 (2H, d, J=8Hz), 8.11 (2H, d, J=8Hz)

10 (+)ESI-MS (m/z): 578 (M+H)⁺

(21) Ethyl 4-[[4-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]methyl]phenyl]sulfonyl]benzoate

15 NMR (CDCl₃, δ): 1.38 (3H, t, J=7Hz), 2.58 (1H, dd, J=13
and 9Hz), 2.64 (1H, dd, J=13 and 4Hz), 3.45 (1H,
br s, OH), 3.50 (1H, d, J=13Hz), 3.55 (1H, d,
J=14Hz), 3.84 (1H, d, J=13Hz), 3.89 (1H, d,
J=14Hz), 4.39 (2H, q, J=7Hz), 4.68 (1H, dd, J=9
and 4Hz), 6.95-7.45 (9H, m), 7.44 (2H, d, J=8Hz),
20 7.91 (2H, d, J=8Hz), 8.00 (2H, d, J=8Hz), 8.16 (2H,
d, J=8Hz)

(+)ESI-MS (m/z): 564 (M+H)⁺

(22) Ethyl 4-[[4-[3-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate

25 NMR (CDCl₃, δ): 1.39 (3H, t, J=7Hz), 1.80 (2H, quintet,
J=7Hz), 2.35-2.80 (6H, m), 3.48 (1H, d, J=13Hz),
3.87 (1H, d, J=13Hz), 3.90 (1H, br s), 4.39 (2H, q,
J=7Hz), 4.60 (1H, dd, J=10 and 4Hz), 7.05-7.42
30 (11H, m), 7.82 (2H, d, J=8Hz), 7.99 (2H, d, J=8Hz),
8.15 (2H, d, J=8Hz)

(+)ESI-MS (m/z): 592 (M+H)⁺

(23) Ethyl 4-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-

35

fluorobenzoate

(+)APCI-MS (m/z): 596 (M+H)⁺

- 5 (24) Methyl 4-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-chlorobenzoate
(+)APCI-MS (m/z): 598 (M+H)⁺

- 10 (25) Ethyl 4-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-methylbenzoate
(+)APCI-MS (m/z): 592 (M+H)⁺

- 15 (26) Ethyl 4-[[4-[[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-2-fluorobenzoate
(+)APCI-MS (m/z): 520 (M+H)⁺

- 20 (27) Ethyl 2-chloro-4-[[4-[[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
(+)APCI-MS (m/z): 536 (M+H)⁺

- 25 (28) Ethyl 4-[[4-[[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-2-methylbenzoate
(+)APCI-MS (m/z): 516 (M+H)⁺

- 30 (29) Ethyl 4'-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2'-chloro-1,1'-biphenyl-4-carboxylate
(+)APCI-MS (m/z): 688 (M+H)⁺

- 35 (30) Ethyl 4'-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2'-chloro-1,1'-biphenyl-3-carboxylate

(+)APCI-MS (m/z): 688 (M+H)⁺

(31) 4-[[4-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]methyl]phenyl]sulfonyl]phenol

5 NMR (CDCl₃, δ): 2.58 (1H, dd, J=13 and 9Hz), 2.65 (1H, dd, J=13 and 4Hz), 3.50 (1H, d, J=13Hz), 3.54 (1H, d, J=14Hz), 3.84 (1H, d, J=13Hz), 3.88 (1H, d, J=14Hz), 4.66 (1H, dd, J=9 and 4Hz), 6.88 (2H, d, J=9Hz), 6.93-7.55 (11H, m), 7.81 (2H, d, J=9Hz),
10 7.86 (2H, d, J=8Hz)

(+)ESI-MS (m/z): 508 (M+H)⁺

(32) 4-[[4-[3-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenol

15 NMR (CDCl₃, δ): 1.80 (2H, quintet, J=7Hz), 2.30-2.80 (6H, m), 3.48 (1H, d, J=13Hz), 3.87 (1H, d, J=13Hz), 4.59 (1H, dd, J=10 and 4Hz), 6.88 (2H, d, J=9Hz), 7.05-7.48 (11H, m), 7.78 (2H, d, J=8Hz),
20 7.79 (2H, d, J=9Hz)

(+)ESI-MS (m/z): 536 (M+H)⁺

(33) 3-[[4-[2-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-dimethylphenol

25 MS (m/z): 550 (M+H)

Example 96

A mixture of ethyl (R)-2-[3-[[4-[2-[N-benzyl-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]-2-methylpropanoate (613 mg) and 10% palladium on
30 activated carbon (50% wet, 300 mg) in a mixture of ethanol (6 ml) and chlorobenzene (6 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 2 hours. After filtration, the filtrate was
35 evaporated under reduced pressure. The residue was

dissolved into a mixture of saturated aqueous sodium bicarbonate and ethyl acetate. After separation, the organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (chloroform : methanol = 30 : 1 to 20 : 1) to give ethyl (R)-2-[3-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]phenoxy]-2-methylpropanoate (275 mg).

NMR (DMSO- d_6 , δ): 1.11 (3H, t, $J=7.1$ Hz), 1.54 (6H, s),
2.55-2.85 (6H, m), 4.11 (2H, q, $J=7.1$ Hz), 4.5-4.65
(1H, m), 7.05-7.6 (10H, m), 7.75-7.85 (2H, m)
(+)ESI-MS (m/z): 546, 548 (M+H)⁺

Example 97

To a solution of ethyl (R)-2-[3-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-2-methylpropanoate (138 mg) in ethanol (5 ml) was added 1N sodium hydroxide (0.25 ml) at room temperature, and the mixture was stirred at 60°C for 5 hours. The resulting mixture was evaporated under reduced pressure and dried in vacuo to give sodium 2-[3-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-2-methylpropanoate (128 mg).

NMR (DMSO- d_6 , δ): 1.36 (6H, s), 2.5-2.85 (6H, m), 4.5-4.65 (1H, m), 7.0-7.05 (1H, m), 7.15-7.45 (9H, m),
7.75-7.85 (2H, m)
(+)ESI-MS (m/z): 540, 542 (M+H)⁺

Example 98

The following compounds were obtained according to a similar manner to that of Example 35.

- (1) (S)-1-[[2-[4-[(3,4-Dimethoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-(4-fluorophenoxy)-2-propanol hydrochloride

NMR (DMSO- d_6 , δ): 2.9-3.3 (6H, m), 3.82 (3H, s), 3.83 (3H, s), 3.9-3.95 (2H, m), 4.1-4.2 (1H, m), 6.9-7.2 (5H, m), 7.35-7.6 (4H, m), 7.9-7.95 (2H, m)
(+)ESI-MS (m/z): 490 (M-HCl+H)⁺

5

(2) (S)-1-[[2-[4-[(3,4-Dimethoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-(1H-indol-4-yloxy)-2-propanol hydrochloride

10 NMR (DMSO- d_6 , δ): 3.0-3.5 (6H, m), 3.81 (3H, s), 3.82 (3H, s), 3.9-4.5 (3H, m), 6.45-6.8 (2H, m), 6.95-7.25 (4H, m), 7.35-7.55 (4H, m), 7.85-7.95 (2H, m)
(+)ESI-MS (m/z): 511 (M+H)⁺

Example 99

15 To a solution of ethyl (R)-6-[[4-[2-[N-benzyl-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]nicotinate (93 mg) in ethyl acetate (3 ml) was added 4N hydrogen chloride in ethyl acetate (0.12 ml) at room temperature, and the mixture was evaporated under reduced
20 pressure. A mixture of the residue and 10% palladium on activated carbon (50% wet, 185 mg) in a mixture of ethanol (0.9 ml) and chlorobenzene (2.1 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 37 hours. After the catalyst was filtered off,
25 the filtrate was evaporated under reduced pressure. The residue was dissolved into a mixture of saturated aqueous sodium bicarbonate and ethyl acetate. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure.
30 The residue was purified by column chromatography on silica gel (chloroform : methanol = 20 : 1 to 15 : 1) to give ethyl (R)-6-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]nicotinate (33 mg).

35 NMR (CDCl₃, δ): 1.40 (3H, t, J=7.1Hz), 2.67 (1H, dd, J=8.9, 12.3Hz), 2.8-3.05 (5H, m), 4.43 (2H, q,

J=7.1Hz), 4.63 (1H, dd, J=3.6, 8.8Hz), 7.15-7.3
(6H, m), 7.95-8.05 (2H, m), 8.25-8.3 (1H, m), 8.52
(1H, dd, J=2.0, 8.1Hz), 9.2 (1H, m)
(+)ESI-MS (m/z): 488, 490 (M+H)⁺

5

Example 100

At room temperature, to a solution of ethyl (R)-[4-[[4-
[2-[N-benzyl-N-[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-
ethyl]phenyl]sulfonyl]phenoxy]acetate (5.55 g) in ethyl
10 acetate (56 ml) was added 4N hydrogen chloride in ethyl
acetate (3.4 ml), and the mixture was evaporated under
reduced pressure and dried in vacuo. A mixture of the
residue and 10% palladium on activated carbon (50% wet, 0.28
g) in a mixture of ethanol (17 ml) and chlorobenzene (39 ml)
15 was stirred at room temperature in the presence of hydrogen
at an atmospheric pressure for 1.2 hours to give
precipitates. To the reaction mixture was added ethanol to
dissolve the precipitates. After removal of 10% palladium
on activated carbon by filtration, the filtrate was
20 evaporated under reduced pressure. The residue was
dissolved into a mixture of saturated aqueous sodium
bicarbonate and ethyl acetate. After separation, the
organic layer was washed with brine, dried over magnesium
sulfate and evaporated under reduced pressure. The residue
25 was purified by column chromatography on silica gel
(chloroform : methanol = 30 : 1 to 20 : 1) to give ethyl
(R)-[4-[[4-[2-[2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
(4.25 g).

30 NMR (CDCl₃, δ): 1.29 (3H, t, J=7.2Hz), 2.6-3.0 (6H, m),
4.26 (2H, q, J=7.2Hz), 4.6-4.7 (3H, m), 6.9-7.0
(2H, m), 7.15-7.4 (6H, m), 7.8-7.9 (4H, m)
(+)ESI-MS (m/z): 518, 520 (M+H)⁺

35 Example 101

To a solution of sodium (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]acetate (1.38 g) in methanol (10 ml) was added 1N hydrochloric acid (2.7 ml) at room temperature, and the mixture was stirred at the same temperature for 1 hour to give a precipitate. The precipitate was collected and washed with methanol, followed by dryness in vacuo to give (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-ethyl]phenyl]sulfonyl]phenoxy]acetic acid (1.23 g).

10 NMR (DMSO-d₆, δ): 2.7-3.1 (6H, m), 4.52 (1H, s), 4.75-4.85 (1H, m), 6.9-7.1 (2H, m), 7.25-7.5 (6H, m), 7.75-7.9 (4H, m)

(-)ESI-MS (m/z): 488, 490 (M-H)⁻

15 Example 102

The following compounds were obtained according to a similar manner to that of Example 4.

- (1) Ethyl 4-[[4-[(2R)-2-[N-benzyl-N-[(2R)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]propyl]phenyl]-sulfonyl]benzoate
- 20 MS (m/z): 626 (M+H)
- (2) Ethyl 4-[[4-[(2R)-2-[N-benzyl-N-[(2R)-2-(3-cyanophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoate
- 25 MS (m/z): 583 (M+H)
- (3) Methyl 4-[[4-[(2R)-2-[N-benzyl-N-[(2R)-2-(4-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoate
- 30 MS (m/z): 579 (M+H)
- (4) Methyl 4-[[4-[2-[N-benzyl-N-[(2R)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]ethyl]phenyl]-
- 35

sulfonyl]benzoate

MS (m/z): 598 (M+H)

- 5 (5) Methyl 4-[[4-[2-[N-benzyl-N-[(2R)-2-(3-cyanophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate
MS (m/z): 555 (M+H)

- 10 (6) Methyl 4-[[4-[2-[N-benzyl-N-[(2R)-2-(4-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate
MS (m/z): 565 (M+H)

Example 103

The following compounds were obtained according to a similar manner to that of Example 17.

15

- (1) Methyl 4-[[4-[2-[(2R)-2-(4-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate
MS (m/z): 474 (M+H)
- 20 (2) Methyl 4-[[4-[(2R)-2-[(2R)-2-(4-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
MS (m/z): 489 (M+H)
- 25 (3) Methyl 4-[[4-[2-[(2R)-2-(3-cyanophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate
MS (m/z): 465 (M+H)
- 30 (4) Methyl 4-[[4-[2-[(2R)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]ethyl]phenyl]sulfonyl]benzoate
MS (m/z): 508 (M+H)
- 35 (5) Ethyl [3-[[2-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate

MS (m/z): 519 (M+H)

- (6) Ethyl 4-[[4-[(2R)-2-[[[(2R)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]propyl]phenyl]-sulfonyl]benzoate

MS (m/z): 536 (M+H)

- (7) Ethyl 4-[[4-[(2R)-2-[[[(2R)-2-(3-cyanophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate

MS (m/z): 493 (M+H)

- (8) Ethyl (2S)-2-[4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-propanoate

MS (m/z): 532 (M+H)

- (9) Ethyl (2S)-2-[4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-propanoate

MS (m/z): 532 (M+H)

- (10) Ethyl [4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-dimethylphenoxy]acetate

MS (m/z): 546 (M+H)

- (11) Ethyl [3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-dimethylphenoxy]acetate

MS (m/z): 546 (M+H)

- (12) Ethyl [4-[[3-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]acetate

MS (m/z): 518 (M+H)

- (13) Ethyl [3-[3-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
5 MS (m/z): 518 (M+H)
- (14) (2S)-1-[[2-[3-[(4-Methoxyphenyl)sulfonyl]phenyl]ethyl]amino]-3-phenoxy-2-propanol hydrochloride
NMR (MeOD-d₄, δ): 3.05-3.40 (6H, m), 3.85 (3H, s),
10 4.00-4.10 (2H, m), 4.20-4.40 (1H, m), 7.00-7.30 (7H, m), 7.60-7.90 (4H, m)
MS (m/z): 442 (M+H)
- (15) (1R)-1-(3-Chlorophenyl)-2-[[2-[3-[(3-methoxyphenyl)sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride
15 NMR (MeOD-d₄, δ): 3.10-3.40 (6H, m), 3.85 (3H, s),
4.90-5.00 (1H, m), 7.00-7.90 (12H, m)
MS (m/z): 446 (M+H)
- (16) Ethyl [4-[4-(2-aminoethyl)phenyl]sulfonyl]phenoxy]acetate
20 MS (m/z): 364 (M+H)
- (17) (1R)-1-(3-Chlorophenyl)-2-[[2-[4-[[3-(2-hydroxyethoxy)phenyl]sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride
25 NMR (DMSO-d₆, δ): 3.0-3.4 (6H, m), 3.67-3.75 (2H, m),
4.01-4.09 (2H, m), 4.87-4.98 (1H, m), 6.3-6.33 (1H, br), 7.22-7.26 (1H, m), 7.35-7.53 (9H, m), 7.93-
30 7.97 (2H, m), 8.96-9.26 (1H, br)
(+)ESI-MS (m/z): 476(M-HCl+H)⁺
- (18) Ethyl 3-[3-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]propanoate hydrochloride
35

NMR (DMSO-d₆, δ): 1.18 (3H, t, J=7.0Hz), 2.79 (2H, t, J=5.9Hz), 2.96-3.31 (6H, m), 4.10 (2H, q, J=7.0Hz), 4.26 (2H, t, J=5.9Hz), 4.89-4.95 (1H, m), 6.26-6.28 (1H, m), 7.22-7.54 (10H, m), 7.96 (2H, d, J=8.2Hz), 8.73 (1H, br)
5 (+)ESI-MS (m/z): 532 (M-HCl+H)⁺

Example 104

The following compounds were obtained according to a
10 similar manner to that of Example 23.

- (1) Sodium 4-[[4-[(2R)-2-[[[(2R)-2-(4-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
NMR (DMSO-d₆, δ): 2.50-2.90 (6H, m), 4.50-4.60 (1H, m),
15 7.30-7.50 (6H, m), 7.80 (4H, d, J=8Hz), 8.00 (2H, d, J=8Hz)
MS (m/z): 258 (M-H)
- (2) Sodium 4-[[4-[2-[[[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]-amino]ethyl]phenyl]sulfonyl]benzoate
20 NMR (DMSO-d₆, δ): 2.50-2.80 (6H, m), 4.60-4.70 (1H, m), 7.20-8.50 (12H, m)
MS (m/z): 472 (M-H)
- (3) Sodium 4-[[4-[(2R)-2-[[[(2R)-2-hydroxy-2-(3-pyridyl)-ethyl]amino]propyl]phenyl]sulfonyl]benzoate
25 NMR (DMSO-d₆, δ): 0.90 (3H, d, J=5Hz), 2.50-3.00 (5H, m), 4.60-4.70 (1H, m), 7.20-7.40 (3H, m), 7.79-8.10 (7H, m), 8.40-8.60 (2H, m)
30 MS (m/z): 439 (M-H)
- (4) Sodium 4-[[4-[2-[[[(2R)-2-(4-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
NMR (DMSO-d₆, δ): 0.86 (3H, d, J=6Hz), 2.50-2.90 (5H, m),
35 4.50-4.65 (1H, m), 7.30-7.50 (6H, m), 7.80 (4H,

d, J=8Hz), 7.90 (2H, d, J=8Hz)

MS (m/z): 472 (M-H)

5 (5) Sodium 4-[[4-[2-[[{(2R)-2-(3-cyanophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate
NMR (DMSO-d₆, δ): 2.60-2.80 (6H, m), 4.60-4.80 (1H, m),
7.40-8.10 (12H, m)
MS (m/z): 451 (M+H)

10 (6) Sodium 4-[[4-[2-[[{(2R)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]ethyl]phenyl]-sulfonyl]benzoate
NMR (DMSO-d₆, δ): 2.50-2.80 (6H, m), 4.60-4.70 (1H, m),
7.30-8.05 (12H, m)
15 MS (m/z): 494 (M+H)

(7) Sodium 4-[[4-[2-[[{(2R)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]propyl]phenyl]-sulfonyl]benzoate
20 NMR (DMSO-d₆, δ): 0.87 (3H, d, J=6Hz), 2.60-2.80 (5H, m), 4.60-4.70 (1H, m), 7.10-8.00 (12H, m)
MS (m/z): 506 (M-H)

(8) Sodium [3-[[2-[2-[[{(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate
25 NMR (DMSO-d₆, δ): 2.50-2.70 (2H, m), 2.80-3.00 (4H, m), 4.50-4.60 (1H, m), 7.10-7.80 (11H, m), 8.00-8.08 (1H, m)
30 MS (m/z): 490 (M+H)

(9) Sodium 4-[[4-[2-[[{(2R)-2-(3-cyanophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
35 NMR (DMSO-d₆, δ): 0.88 (3H, d, J=3Hz), 2.50-2.80 (5H, m), 4.60-4.70 (1H, m), 7.30-8.00 (12H, m)

MS (m/z): 463 (M-H)

- (10) Sodium (2S)-2-[4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]propanoate

NMR (DMSO-d₆, δ): 1.35 (3H, d, J=6Hz), 2.50-2.80 (6H, m), 4.30 (1H, q, J=6Hz), 6.90 (1H, d, J=8Hz), 7.20-7.40 (6H, m), 7.70-7.80 (4H, m)

MS (m/z): 502 (M-H)

- (11) Sodium (2R)-2-[4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-propanoate

NMR (DMSO-d₆, δ): 1.37 (3H, d, J=6Hz), 2.50-2.80 (6H, m), 4.30 (1H, q, J=6Hz), 6.90 (1H, d, J=8Hz), 7.20-7.40 (6H, m), 7.70-7.80 (4H, m)

MS (m/z): 502 (M-H)

- (12) Sodium [4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-2-methylphenoxy]acetate

NMR (DMSO-d₆, δ): 0.85 (3H, d, J=6Hz), 2.18 (3H, s), 2.50-2.90 (5H, m), 4.23 (2H, s), 4.40-4.60 (1H, m), 6.70-6.80 (1H, m), 7.20-7.40 (6H, m), 7.70-7.80 (4H, m)

MS (m/z): 516 (M-H)

- (13) Sodium [4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-2-fluorophenoxy]acetate

NMR (DMSO-d₆, δ): 0.90 (3H, d, J=6H), 2.50-2.90 (5H, m), 4.25 (2H, s), 4.50-4.60 (1H, m), 6.90-8.00 (11H, m)

MS (m/z): 520 (M-H)

- (14) Sodium [4-[[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-dimethylphenoxy]acetate
NMR (DMSO-d₆, δ): 2.26 (6H, s), 2.50-2.90 (6H, m), 3.90 (2H, s), 4.50-4.60 (1H, m), 7.10-7.90 (10H, m)
MS (m/z): 518 (M+H)
- (15) Sodium [3-[[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-dimethylphenoxy]acetate
NMR (DMSO-d₆, δ): 2.25 (3H, s), 2.27 (3H, s), 2.50-2.90 (6H, m), 3.80 (2H, s), 4.50-4.60 (1H, m), 7.10-7.90 (10H, m)
MS (m/z): 518 (M+H)
- (16) Sodium [4-[[3-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
NMR (MeOD-d₄, δ): 2.70-3.10 (6H, m), 4.40 (2H, s), 4.70-4.80 (1H, m), 7.00-7.10 (2H, m), 7.20-7.60 (6H, m), 7.80-7.90 (4H, m)
MS (m/z): 488 (M-H)
- (17) Sodium [3-[[3-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
NMR (MeOD-d₄, δ): 2.70-3.10 (6H, m), 4.40 (2H, s), 4.70-4.80 (1H, m), 7.00-7.60 (10H, m), 7.80-7.90 (2H, m)
MS (m/z): 488 (M-H)
- (18) Sodium [4-[[4-[2-[[(2R)-2-hydroxy-2-(3-pyridyl)-ethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
NMR (DMSO-d₆, δ): 2.50-2.80 (6H, m), 4.19 (2H, s), 4.60-4.70 (1H, m), 6.90-7.00 (2H, m), 7.10-7.90

(9H, m), 8.40-8.60 (1H, m)

MS (m/z): 478 (M+Na)

(19) Sodium [4-[[4-[2-[[[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate

NMR (DMSO-d₆, δ): 2.70-2.90 (6H, m), 4.20 (2H, s), 4.60-4.70 (1H, m), 6.90-7.00 (2H, m), 7.10-7.50 (3H, m), 7.70-7.90 (5H, m), 8.30-8.40 (1H, m)

MS (m/z): 512 (M+Na)

(20) Sodium [4-[[4-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]methyl]phenyl]sulfonyl]phenoxy]-acetate

NMR (DMSO-d₆, δ): 2.60 (2H, d, AB of ABX), 3.76 (2H, s), 4.09 (2H, s), 4.65 (1H, t, X of ABX), 5.50 (1H, br s, OH), 6.93 (2H, d, J=9Hz), 7.10-7.50 (4H, m), 7.49 (2H, d, J=8Hz), 7.77 (2H, d, J=9Hz), 7.82 (2H, d, J=8Hz)

(+)ESI-MS (m/z): 476 (free, M+H)⁺

(21) Sodium [4-[[4-[3-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenoxy]-acetate

NMR (DMSO-d₆, δ): 1.66 (2H, quintet, J=7Hz), 2.37-2.77 (6H, m), 4.18 (2H, s), 4.60 (1H, m), 5.44 (1H, br s, OH), 6.92 (2H, d, J=9Hz), 7.12-7.50 (6H, m), 7.77 (2H, d, J=9Hz), 7.78 (2H, d, J=8Hz)

(+)ESI-MS (m/z): 504 (free, M+H)⁺

(22) Sodium [4-[[3-chloro-4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate

NMR (DMSO-d₆, δ): 3.02-3.35 (6H, m), 4.01 (2H, s), 4.52-4.62 (1H, m), 5.62 (1H, br), 6.89-6.94 (2H,

m), 7.19-7.36 (4H, m), 7.55-7.90 (5H, m)
(-)ESI-MS (m/z): 522, 524 (M-Na-H)⁻

(23) Sodium [4-[[5-[2-[[[(2R)-2-(3-chlorophenyl)-2-
5 hydroxyethyl]amino]ethyl]-2-pyridyl]sulfonyl]-
phenoxy]acetate
NMR (DMSO-d₆, δ): 2.60-2.76 (6H, m), 4.18 (2H, s),
4.56-4.59 (1H, m), 5.46 (1H, br), 6.92-6.95 (2H,
m), 7.24-7.36 (4H, m), 7.75-7.79 (2H, m), 7.88-
10 7.91 (1H, m), 8.01-8.03 (1H, m), 8.53 (1H, s)
(-)ESI-MS (m/z): 489 (M-Na-H)⁻

Example 105

Methyl 4-[[4-[(2R)-2-[N-benzyl-N-[(2R)-2-(6-chloro-3-
15 pyridyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-
benzoate (480 mg), ammonium formate (200 mg) and palladium
on carbon powder (120 mg) in methanol (5 ml) was refluxed
for 30 minutes. The reaction mixture was filtrated and
poured into water and extracted with ethyl acetate. The
20 organic layer was washed with brine, dried over magnesium
sulfate, and evaporated in vacuo. A mixture of the residue
was chromatographed (chloroform-methanol) over silica gel to
give methyl 4-[[4-[(2R)-2-[[[(2R)-2-hydroxy-2-(3-
pyridyl)ethyl]amino]propyl]phenyl]sulfonyl]benzoate (150 mg)
25 as a colorless foam.

MS (m/z): 455 (M+H)

Example 106

The following compound was obtained according to a
30 similar manner to that of Example 105.

Methyl 4-[[4-[2-[[[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]-
amino]ethyl]phenyl]sulfonyl]benzoate

MS (m/z): 441 (M+H)

Example 107

The following compounds were obtained according to a similar manner to that of Preparation 70.

- 5 (1) Ethyl [3-[[2-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate
MS (m/z): 609 (M+H)
- 10 (2) Ethyl (2R)-2-[4-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]phenoxy]propanoate
MS (m/z): 622 (M+H)
- 15 (3) (1R)-2-[N-Benzyl-N-[2-[3-[(3-methoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol
MS (m/z): 536 (M+H)
- 20 (4) Ethyl [4-[[4-[(2S)-2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]sulfonyl]phenoxy]acetate
NMR (CDCl₃, δ): 1.28 (3H, t, J=7Hz), 2.53-3.23 (5H, m),
3.40-3.70 (2H, m), 3.70 (1H, d, J=13Hz), 3.85 (1H, d, J=13Hz), 4.26 (2H, q, J=7Hz), 4.49 (1H, dd, J=8
25 and 4Hz), 4.65 (2H, s), 6.96 (2H, d, J=9Hz), 7.00-7.40 (11H, m), 7.78 (2H, d, J=8Hz), 7.87 (2H, d, J=9Hz)
(+)ESI-MS (m/z): 638 (M+H)⁺
- 30 (5) Ethyl [4-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-dimethylphenoxy]acetate
MS (m/z): 636 (M+H)
- 35 (6) Ethyl [3-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-

hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-
dimethylphenoxy]acetate
MS (m/z): 636 (M+H)

- 5 (7) Ethyl (2S)-2-[4-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]phenoxy]propanoate
MS (m/z): 622 (M+H)
- 10 (8) Ethyl [3-[[3-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate
MS (m/z): 608 (M+H)
- 15 (9) Ethyl [4-[[3-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate
MS (m/z): 608 (M+H)

20 Example 108

The following compounds were obtained according to a similar manner to that of Example 76.

- 25 (1) Ethyl [4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-2-methylphenoxy]acetate
MS (m/z): 546 (M+H)
- 30 (2) Ethyl [4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-2-fluorophenoxy]acetate
MS (m/z): 550 (M+H)
- 35 (3) Ethyl [4-[[4-[2-[[[(2R)-2-[6-chloro-3-pyridyl]-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-

acetate

MS (m/z): 519 (M+H)

Example 109

5 [4-[[4-[2-[[{(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]-2-methylpropyl]phenyl]sulfonyl]phenoxy]acetate (50
mg) was triturated with 4N hydrochloric acid in 1,4-dioxane
(1.0 ml) to give [4-[[4-[2-[[{(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]-2-methylpropyl]phenyl]sulfonyl]phenoxy]-
10 acetate hydrochloride (50 mg) as a colorless powder.

NMR (CDCl₃, δ): 1.04 (3H, s), 1.07 (3H, s), 1.30 (3H, t,
J=7Hz), 2.50-3.10 (4H, m), 3.85 (3H, s), 4.30 (2H,
q, J=7Hz), 4.40-4.55 (1H, m), 4.66 (2H, s), 6.90-
7.00 (2H, m), 7.10-7.40 (6H, m), 7.70-7.90 (4H, m)

15 MS (m/z): 547 (M+H)

Example 110

The following compounds were obtained according to a
similar manner to that of Example 109.

20

(1) Ethyl [2-chloro-4-[[4-[(2R)-2-[[{(2R)-2-(3-
chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-
sulfonyl]phenoxy]acetate hydrochloride

25 NMR (DMSO-d₆, δ): 1.10 (3H, d, J=3Hz), 1.17 (3H, t,
J=3Hz), 2.70-2.80 (1H, m), 3.00-3.40 (4H, m), 4.10
(2H, q, J=3Hz), 4.90-5.10 (3H, m), 7.10-7.40 (7H
m), 7.70-7.90 (4H, m)

MS (m/z): 566 (M+H)

30 (2) Ethyl [4-[[4-[2-[[{(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-
methylphenoxy]acetate hydrochloride

35 NMR (DMSO-d₆, δ): 1.10 (3H, t, J=3Hz), 2.23 (3H, s),
3.00-3.40 (6H, m), 4.10 (2H, q, J=3Hz), 4.90-5.10
(3H, m), 7.00-7.40 (7H, m), 7.70-7.90 (4H, m)

MS (m/z): 532 (M+H)

- (3) Ethyl [4-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-fluorophenoxy]acetate hydrochloride

MS (m/z): 536 (M+H)

- (4) Ethyl (2R)-2-[4-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-propanoate hydrochloride

NMR (DMSO-d₆, δ): 1.20 (3H, t, J=7Hz), 1.50 (3H, d, J=7Hz), 2.90-3.20 (6H, m), 4.23 (2H, q, J=7Hz), 4.90-5.00 (1H, m), 5.10 (1H, q, J=7Hz), 6.35 (1H, d, J=4Hz), 7.05 (1H, d, J=8Hz), 7.30-7.50 (6H, m), 7.80-7.90 (4H, m)

MS (m/z): 532 (M+H)

- (5) Ethyl [4-[[4-[(2R)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-2-fluorophenoxy]acetate hydrochloride

NMR (DMSO-d₆, δ): 1.10-1.20 (6H, m), 2.80-3.50 (5H, m), 4.20 (2H, q, J=7Hz), 5.00 (2H, s), 5.10-5.20 (1H, m), 7.20-8.00 (11H, m)

MS (m/z): 550 (M+H)

- (6) Ethyl [4-[[4-[(2R)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-2-methylphenoxy]acetate hydrochloride

NMR (DMSO-d₆, δ): 1.10 (3H, d, J=7Hz), 1.20 (3H, t, J=7Hz), 2.23 (3H, s), 2.60-3.20 (5H, m), 4.23 (2H, q, J=7Hz), 4.94 (2H, s), 5.10-5.20 (1H, m), 7.05 (1H, d, J=8Hz), 7.30-7.50 (6H, m), 7.80-7.90 (4H, m)

MS (m/z): 546 (M+H)

- (7) Ethyl [4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-dimethylphenoxy]acetate hydrochloride
NMR (DMSO-d₆, δ): 1.20 (3H, t, J=7Hz), 2.29 (6H, s),
5 2.90-3.30 (6H, m), 4.20 (2H, q, J=7Hz), 4.50 (2H, s), 5.00-5.10 (1H, m), 7.20-7.90 (10H, m)
MS (m/z): 546 (M+H)
- (8) Ethyl [3-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2,6-dimethylphenoxy]acetate hydrochloride
NMR (DMSO-d₆, δ): 1.20 (3H, t, J=7Hz), 2.28 (3H, s),
10 2.30 (3H, s), 2.90-3.30 (6H, m), 4.20 (2H, q, J=7Hz), 4.50 (2H, s), 5.00-5.10 (1H, m), 7.30-7.90
15 (10H, m)
MS (m/z): 546 (M+H)
- (9) Ethyl [4-[[3-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate hydrochloride
NMR (DMSO-d₆, δ): 1.20 (3H, t, J=7Hz), 3.00-3.40 (6H, m), 4.20 (2H, q, J=7Hz), 3.80 (3H, s), 4.90 (2H, s), 4.90-5.05 (1H, m), 7.00-7.10 (2H, m), 7.30-7.60 (6H, m), 7.80-7.90 (4H, m)
20 25 MS (m/z): 518 (M+H)
- (10) Ethyl [3-[[3-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate hydrochloride
NMR (DMSO-d₆, δ): 1.25 (3H, t, J=7Hz), 3.00-3.50 (6H, m), 4.20 (2H, q, J=7Hz), 3.80 (3H, s), 4.90 (2H, s), 4.90-5.05 (1H, m), 7.00-7.10 (2H, m), 7.30-7.60 (6H, m), 7.80-7.90 (4H, m)
30 35 MS (m/z): 518 (M+H)

Example 111

The following compound was obtained according to a similar manner to that of Example 43.

- 5 4-[[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-methyl]benzoic acid
MS (m/z): 574 (M+H)

10 Example 112

The following compounds were obtained according to a similar manner to that of Example 50.

- (1) 4-[[[4-[2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]methyl]benzoic acid
15 hydrochloride
NMR (DMSO-d₆, δ): 2.80-3.50 (6H, m), 4.90 (2H, s),
5.00-5.10 (1H, m), 7.20-8.20 (13H, m)
MS (m/z): 474 (M+H)
- 20 (2) 4-[[4-[2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]butanoic acid hydrochloride
NMR (DMSO-d₆, δ): 1.60-1.80 (2H, m), 2.30-2.40 (2H, m),
3.00-3.40 (8H, m), 5.00-5.10 (1H, m), 7.30-7.70
25 (6H, m), 7.90 (2H, d, J=8Hz)
MS (m/z): 426 (M+H)

Example 113

- A solution of N-benzyl-2-[3-[(4-methoxyphenyl)-sulfonyl]phenyl]ethanamine (141 mg), (2R)-2-(3-chlorophenyl)oxirane (57.1 mg) in ethanol (5 ml) was
30 refluxed for 20 hours and evaporated in vacuo. To the residue were added 10% palladium on activated carbon (50% wet, 20 mg), methanol (3.0 ml) and chlorobenzene (3.0 ml)
35 and then stirred at room temperature in the presence of

hydrogen at an atmospheric pressure for 1 hour. After filtration, the filtrate was evaporated in vacuo. To the residue was added 4N hydrogen chloride in 1,4-dioxane (1.0 ml), and the mixture was stirred at room temperature for 1
5 hour and evaporated in vacuo to give (1R)-1-(3-chlorophenyl)-2-[[2-[3-[(4-methoxyphenyl)sulfonyl]phenyl]-ethyl]amino]ethanol hydrochloride (50 mg) as a colorless foam.

NMR (MeOD-d₄, δ): 3.00-3.50 (6H, m), 3.80 (3H, s),
10 4.90-5.00 (1H, m), 7.00-7.10 (2H, m), 7.30-7.60
(6H, m), 7.80-8.00 (4H, m)
MS (m/z): 446 (M+H)

Example 114

15 The following compound was obtained according to a similar manner to that of Example 8.

Ethyl [4-[[4-[2-[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]-amino]ethyl]phenyl]sulfonyl]phenoxy]acetate

20 NMR (CDCl₃, δ): 1.25 (3H, t, J=9Hz), 2.60-3.00 (6H, m),
4.25 (2H, q, J=9Hz), 4.60-4.70 (3H, m), 6.90-7.00
(2H, m), 7.20-7.30 (3H, m), 7.70-7.90 (5H, m),
8.50-8.60 (1H, m)

Example 115

25 4-[[4-[2-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenol (180 mg), N-(2-bromoethyl)phthalimide (96 mg) and potassium carbonate (57.2 mg) in N,N-dimethylformamide (5 ml) was stirred for 20
30 hours. The resulting mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. To the residue was added hydrazine (20.7 mg),
methanol (3 ml) and tetrahydrofuran (3 ml) and refluxed for
35 4 hours. The resulting mixture was poured into water and

extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue, 10 % palladium on carbon (50 % wet, 30 mg) and 4N hydrogen chloride in 1,4-dioxane (1 ml) in
5 methanol was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 2 hours. After filtration, the filtrate was evaporated in vacuo to give (1R)-2-[[2-[4-[[4-(2-aminoethoxy)phenyl]sulfonyl]phenyl]-ethyl]amino]-1-(3-chlorophenyl)ethanol dihydrochloride (50
10 mg) as a colorless powder.

NMR (DMSO- d_6 , δ): 2.90-3.30 (8H, m), 4.20-4.40 (2H, m),
4.90-5.00 (1H, m), 7.10-7.50 (8H, m), 7.70-7.90
(4H, m)

MS (m/z): 475 (M+H)

15

Example 116

To a mixture of 3-[[4-[2-[N-(tert-butoxycarbonyl)-N-
[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-
20 sulfonyl]benzoic acid (1.60 g), N,O-dimethylhydroxylamine hydrochloride (321 mg), and 1-hydroxybenzotriazole (391 mg) in dichloromethane (16 ml) - N,N-dimethylformamide (0.8 ml) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (490 mg), and the mixture was stirred at room temperature
25 for 17.5 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed successively with sodium bicarbonate solution and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column
30 chromatography (silica gel, hexane/ethyl acetate) to give tert-butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[3-[methoxy(methyl)amino]carbonyl]phenyl]sulfonyl]-phenyl]ethyl]carbamate (1.13 g) as a white amorphous powder.

NMR (CDCl₃, δ): 1.36 (9H, s), 2.50-3.60 (6H, m), 3.36
35 (3H, s), 3.52 (3H, s), 4.25 (1H, br s, OH), 4.87

(1H, m), 7.05-7.42 (6H, m), 7.53 (1H, t, J=8Hz),
7.86 (2H, d, J=8Hz), 7.86 (1H, d, J=8Hz), 8.01 (1H,
d, J=8Hz), 8.25 (1H, s)
(+)ESI-MS (m/z): 625 (M+Na)⁺

5

Example 117

To an ice-cooled solution of tert-butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[3-[methoxy(methyl)-amino]carbonyl]phenyl]sulfonyl]phenyl]ethyl]carbamate (1.12
10 g) in tetrahydrofuran (9 ml) was added lithium aluminum
hydride (72 mg), and the mixture was stirred at room
temperature for 6.5 hours. After the mixture was diluted
with ether (9 ml) and cooled with ice, sodium fluoride (320
mg) was added. Water (0.36 ml) was added to the mixture
15 with vigorous stirring, and the precipitate formed was
removed by filtration. The filtrate was concentrated and
the residue was purified by column chromatography (silica
gel, hexane/ethyl acetate) to give tert-butyl N-[(2R)-2-(3-
chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[3-formylphenyl]-
20 sulfonyl]phenyl]ethyl]carbamate (779 mg) as a viscous oil.
NMR (CDCl₃, δ): 1.34 (9H, s), 2.50-3.70 (6H, m), 4.21
(1H, br s, OH), 4.82 (1H, m), 7.00-7.50 (6H, m),
7.67 (1H, t, J=8Hz), 7.89 (2H, d, J=8Hz), 8.05 (1H,
d, J=8Hz), 8.17 (1H, d, J=8Hz), 8.40 (1H, s),
25 10.04 (1H, s)
(+)ESI-MS (m/z): 566 (M+Na)⁺

Example 118

To a mixture of tert-butyl N-[(2R)-2-(3-chlorophenyl)-
30 2-hydroxyethyl]-N-[2-[4-[3-formylphenyl]sulfonyl]phenyl]-
ethyl]carbamate (243 mg) and methyl
(triphenylphosphoranylidene)acetate (227 mg) in
tetrahydrofuran (1.9 ml) was heated to 60°C for 1.5 hours.
After being cooled to room temperature, the mixture was
35 concentrated and the residue was purified by column

chromatography (silica gel, hexane/ethyl acetate) to give methyl (2E)-3-[3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]phenyl]-2-propenoate (211 mg) as a white amorphous powder.

NMR (CDCl₃, δ): 1.33 (9H, s), 2.60-3.60 (6H, m), 3.82 (3H, s), 4.23 (1H, br s, OH), 4.85 (1H, m), 6.50 (1H, d, J=16Hz), 7.08-7.42 (6H, m), 7.50 (1H, t, J=8Hz), 7.66 (1H, d, J=16Hz), 7.66 (1H, d, J=8Hz), 7.87 (2H, d, J=8Hz), 7.91 (1H, d, J=8Hz), 8.05 (1H, s)
(+)ESI-MS (m/z): 622 (M+Na)⁺

Example 119

The following compounds were obtained according to a similar manner to that of Example 56.

(1) (2E)-3-[3-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]phenyl]-2-propenoic acid
NMR (CDCl₃, δ): 1.34 (9H, s), 2.60-3.60 (6H, m), 4.85 (1H, m), 6.51 (1H, d, J=16Hz), 7.05-7.45 (6H, m), 7.52 (1H, t, J=8Hz), 7.69 (1H, d, J=8Hz), 7.74 (1H, d, J=16Hz), 7.88 (2H, d, J=8Hz), 7.94 (1H, d, J=8Hz), 8.07 (1H, s)
(+)ESI-MS (m/z): 608 (M+Na)⁺

(2) [[3-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoyl]amino]acetic acid
NMR (DMSO-d₆, δ): 1.02, 1.19 (total 9H, a pair of s), 2.70-2.95 (2H, m), 3.08-3.60 (4H, m), 3.95 (2H, d, J=6Hz), 4.75 (1H, m), 5.59 (1H, br s, OH), 7.15-7.50 (6H, m), 7.73 (1H, t, J=8Hz), 7.90 (2H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.15 (1H, d, J=8Hz),

8.43 (1H, s), 9.19 (1H, br t, J=6Hz), 12.70 (1H, br s)

(-)ESI-MS (m/z): 615 (M-H)⁻

- 5 (3) [[4-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoyl]amino]acetic acid

NMR (DMSO-d₆, δ): 1.06, 1.19 (total 9H, a pair of s),
2.70-2.95 (2H, m), 3.10-3.60 (4H, m), 3.93 (2H, d,
10 J=6Hz), 4.73 (1H, m), 5.59 (1H, br s, OH), 7.15-
7.49 (6H, m), 7.89 (2H, m), 8.04 (4H, m), 9.07 (1H,
t, J=6Hz), 12.50 (1H, br s)

(-)ESI-MS (m/z): 615 (M-H)⁻

- 15 (4) [[4-[[4-[(2R)-2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoyl]amino]acetic acid

NMR (CDCl₃, δ): 1.22 (3H, d, J=6Hz), 1.26 (9H, s),
2.50-3.60 (4H, m), 3.95-4.21 (1H, m), 4.21 (2H, d,
20 J=5Hz), 4.62 (1H, m), 6.92 (1H, br t, J=5Hz),
7.08-7.42 (6H, m), 7.85 (2H, d, J=8Hz), 7.85 (2H,
d, J=8Hz), 7.95 (2H, d, J=8Hz)

(-)ESI-MS (m/z): 629 (M-H)⁻

- 25 (5) 3-[[3-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoyl]amino]propanoic acid

NMR (DMSO-d₆, δ): 1.02, 1.08 (total 9H, a pair of s),
2.62-2.98 (2H, m), 3.00-3.70 (8H, m), 4.73 (1H, m),
30 5.58 (1H, br s, OH), 7.08-7.52 (6H, m), 7.70 (1H,
t, J=8Hz), 7.89 (2H, d, J=8Hz), 8.07 (1H, d,
J=8Hz), 8.11 (1H, d, J=8Hz), 8.39 (1H, s), 8.87
(1H, br t, J=5Hz), 12.30 (1H, br s)

(-)ESI-MS (m/z): 629 (M-H)⁻

- (6) [[3-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoyl](methyl)amino]acetic acid
NMR (DMSO-d₆, δ): 1.05, 1.20 (total 9H, a pair of s),
5 2.65-3.60 (6H, m), 2.90, 2.99 (total 3H, a pair of s), 3.88, 4.15 (total 2H, a pair of s), 4.73 (1H, m), 5.58 (1H, br s, OH), 7.10-8.15 (12H, m), 13.10 (1H, br s)
(-)ESI-MS (m/z): 629 (M-H)⁻
- (7) (2S)-2-[[3-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoyl]amino]propanoic acid
NMR (DMSO-d₆, δ): 1.02, 1.19 (total 9H, a pair of s),
15 1.41 (3H, d, J=7Hz), 2.65-3.70 (6H, m), 4.44 (1H, quintet, J=7Hz), 4.73 (1H, m), 5.59 (1H, br s, OH), 7.10-7.55 (6H, m), 7.72 (1H, t, J=8Hz), 7.90 (2H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.17 (1H, d, J=8Hz), 8.45 (1H, s), 9.02 (1H, br d, J=7Hz),
20 12.65 (1H, br s)
(-)ESI-MS (m/z): 629 (M-H)⁻
- (8) (2R)-2-[[3-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoyl]amino]propanoic acid
NMR (DMSO-d₆, δ): 1.02, 1.18 (total 9H, a pair of s),
25 1.41 (3H, d, J=7Hz), 2.65-3.65 (6H, m), 4.44 (1H, quintet, J=7Hz), 4.74 (1H, m), 5.59 (1H, br s, OH), 7.10-7.55 (6H, m), 7.72 (1H, t, J=8Hz), 7.90 (2H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.17 (1H, d, J=8Hz), 8.45 (1H, s), 9.02 (1H, br d, J=7Hz),
30 12.60 (1H, br s)
(-)ESI-MS (m/z): 629 (M-H)⁻
- (9) [[4-[[4-[(2R)-2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-

chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-
sulfonyl]benzoyl](methyl)amino]acetic acid

NMR (DMSO-d₆, δ): 1.11, 1.21 (total 9H, a pair of s),
1.19 (3H, d, J=7Hz), 2.60-3.70 (4H, m), 2.86, 2.97
(total 3H, a pair of s), 3.87, 4.15 (total 2H, a
pair of s), 3.94 (1H, m), 4.68, 4.82 (total 1H, a
pair of m), 5.55 (1H, br s, OH), 7.05-7.70 (8H, m),
7.75-8.12 (4H, m), 12.80 (1H, br s)
(-)ESI-MS (m/z): 643 (M-H)⁻

Example 120

The following compounds were obtained according to a
similar manner to that of Example 33.

- (1) (2E)-3-[3-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenyl]-2-
propenoic acid hydrochloride
NMR (DMSO-d₆, δ): 2.90-3.55 (6H, m), 4.99 (1H, m), 6.32
(1H, br s, OH), 6.71 (1H, d, J=16Hz), 7.22-7.80
(8H, m), 7.80-8.15 (4H, m), 8.27 (1H, s), 9.34 (2H,
br d)
(-)ESI-MS (m/z): 484 (free, M-H)⁻
- (2) (5Z)-5-[3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzylidene]-
1,3-thiazolidine-2,4-dione hydrochloride
NMR (DMSO-d₆, δ): 2.80-3.75 (6H, m), 4.99 (1H, m), 6.32
(1H, br s, OH), 7.20-7.65 (6H, m), 7.65-8.10 (6H,
m), 8.16 (1H, s), 8.93 (1H, br s), 9.20 (1H, br s),
12.77 (1H, br s)
(-)ESI-MS (m/z): 541 (free, M-H)⁻
- (3) 3-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-N,N-
dimethylbenzamide hydrochloride

NMR (DMSO-d₆, δ): 2.80-3.40 (6H, m), 2.86 (3H, s), 2.99 (3H, s), 5.02 (1H, m), 6.35 (1H, br s), 7.30-7.50 (4H, m), 7.54 (2H, d, J=8Hz), 7.62-7.80 (2H, m), 7.85-8.10 (4H, m), 8.98 (1H, br s), 9.33 (1H, br s)

5

(+)ESI-MS (m/z): 487 (free, M+H)⁺

(4) 4-[[4-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-N,N-dimethylbenzamide hydrochloride

10

NMR (DMSO-d₆, δ): 2.83 (3H, s), 2.90-3.35 (6H, m), 2.98 (3H, s), 5.02 (1H, m), 7.26-7.54 (4H, m), 7.54 (2H, d, J=8Hz), 7.62 (2H, d, J=8Hz), 7.96 (2H, d, J=8Hz), 8.01 (2H, d, J=8Hz), 8.99 (1H, br s), 9.36 (1H, br s)

15

(+)ESI-MS (m/z): 487 (free, M+H)⁺

(5) 3-[[4-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-N-methylbenzamide hydrochloride

20

NMR (DMSO-d₆, δ): 2.80 (3H, d, J=4Hz), 2.90-3.30 (6H, m), 5.00 (1H, m), 6.35 (1H, br s, OH), 7.32-7.49 (4H, m), 7.54 (2H, d, J=8Hz), 7.72 (1H, t, J=8Hz), 7.97 (2H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.13 (1H, d, J=8Hz), 8.39 (1H, s), 8.83 (1H, q, J=4Hz), 8.95 (1H, br s), 9.26 (1H, br s)

25

(+)ESI-MS (m/z): 473 (free, M+H)⁺

(6) 4-[[4-[(2R)-2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-N-methylbenzamide hydrochloride

30

NMR (DMSO-d₆, δ): 1.09 (3H, d, J=6Hz), 2.60-3.65 (5H, m), 2.78 (3H, d, J=5Hz), 5.04 (1H, m), 6.35 (1H, br s, OH), 7.30-7.62 (6H, m), 7.96 (2H, d, J=8Hz), 8.03 (4H, s), 8.71 (1H, br q, J=5Hz), 8.83 (1H, br s), 9.32 (1H, br s)

35

(+)ESI-MS (m/z): 487 (free, M+H)⁺

- (7) 4-[[4-[(2R)-2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-N,N-dimethylbenzamide hydrochloride

NMR (DMSO-d₆, δ): 1.10 (3H, d, J=6Hz), 2.63-3.67 (5H, m), 2.83 (3H, s), 2.98 (3H, s), 5.06 (1H, m), 6.36 (1H, br s, OH), 7.30-7.65 (6H, m), 7.62 (2H, d, J=8Hz), 7.97 (2H, d, J=8Hz), 8.01 (2H, d, J=8Hz), 8.85 (1H, br s), 9.41 (1H, br s)

(+)ESI-MS (m/z): 501 (free, M+H)⁺

- (8) 1-[3-[[4-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]-4-piperidinol hydrochloride

NMR (DMSO-d₆, δ): 1.15-2.00 (4H, m), 2.70-4.10 (12H, m), 5.01 (1H, m), 6.35 (1H, br s, OH), 7.20-7.80 (8H, m), 7.80-8.15 (4H, m), 8.96 (1H, br s), 9.27 (1H, br s)

(+)ESI-MS (m/z): 543 (free, M+H)⁺

- (9) 1-[4-[[4-[(2R)-2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoyl]-4-piperidinol hydrochloride

NMR (DMSO-d₆, δ): 1.10 (3H, d, J=6Hz), 1.15-1.95 (4H, m), 2.65-4.10 (10H, m), 4.81 (1H, br s, OH), 5.01 (1H, m), 6.34 (1H, br s, OH), 7.25-7.70 (8H, m), 7.85-8.15 (4H, m), 8.80 (1H, br s), 9.15 (1H, br s)

(+)ESI-MS (m/z): 557 (free, M+H)⁺

- (10) 3-[[4-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-N-(5-methyl-1,3-thiazol-2-yl)benzamide hydrochloride

NMR (DMSO-d₆, δ): 2.38 (3H, s), 2.90-3.35 (6H, m), 5.01

(1H, m), 6.56 (1H, br s), 7.26 (1H, s), 7.30-7.52
(4H, m), 7.55 (2H, d, J=8Hz), 7.78 (1H, t, J=8Hz),
8.01 (2H, d, J=8Hz), 8.18 (1H, d, J=8Hz), 8.34 (1H,
d, J=8Hz), 8.65 (1H, s), 8.98 (1H, br s), 9.32 (1H,
br s)

(+)ESI-MS (m/z): 556 (free, M+H)⁺

(11) 4-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]ethyl]phenyl]sulfonyl]-N-(5-methyl-1,3-thiazol-2-
yl)benzamide hydrochloride

NMR (DMSO-d₆, δ): 2.37 (3H, s), 2.90-3.33 (6H, m), 4.97
(1H, m), 6.30 (1H, br s, OH), 7.24 (1H, s), 7.31-
7.49 (4H, m), 7.55 (2H, d, J=8Hz), 7.99 (2H, d,
J=8Hz), 8.10 (2H, d, J=8Hz), 8.24 (2H, d, J=8Hz),
8.89 (1H, br s), 9.11 (1H, br s)

(+)ESI-MS (m/z): 556 (free, M+H)⁺

(12) 3-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]ethyl]phenyl]sulfonyl]-N-(1H-tetrazol-5-
yl)benzamide hydrochloride

NMR (DMSO-d₆, δ): 2.90-3.30 (6H, m), 4.98 (1H, m), 6.34
(1H, br s, OH), 7.31-7.49 (4H, m), 7.55 (2H, d,
J=8Hz), 7.83 (1H, t, J=8Hz), 8.02 (2H, d, J=8Hz),
8.23 (1H, d, J=8Hz), 8.34 (1H, d, J=8Hz), 8.68 (1H,
s), 8.88 (1H, br s), 9.15 (1H, br s), 12.83 (1H,
br s)

(-)ESI-MS (m/z): 525 (free, M-H)⁻

(13) 4-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]ethyl]phenyl]sulfonyl]-N-(1H-tetrazol-5-
yl)benzamide hydrochloride

NMR (DMSO-d₆, δ): 2.90-3.30 (6H, m), 4.97 (1H, m), 6.34
(1H, br s, OH), 7.31-7.49 (4H, m), 7.55 (2H, d,
J=8Hz), 8.00 (2H, d, J=8Hz), 8.14 (2H, d, J=8Hz),
8.25 (2H, d, J=8Hz), 8.89 (1H, br s), 9.10 (1H, br

s), 12.71 (1H, br s)

(-)ESI-MS (m/z): 525 (free, M-H)⁻

- 5 (14) Ethyl [[3-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]-amino]acetate hydrochloride

10 NMR (DMSO-d₆, δ): 1.21 (3H, t, J=7Hz), 2.93-3.30 (6H, m), 4.02 (2H, d, J=5Hz), 4.12 (2H, q, J=7Hz), 4.99 (1H, m), 6.33 (1H, br s, OH), 7.30-7.50 (4H, m), 7.54 (2H, d, J=8Hz), 7.76 (1H, t, J=8Hz), 7.98 (2H, d, J=8Hz), 8.15 (1H, d, J=8Hz), 8.17 (1H, d, J=8Hz), 8.43 (1H, s), 8.93 (1H, br s), 9.10 (1H, br s), 9.35 (1H, t, J=5Hz)

(+)ESI-MS (m/z): 545 (free, M+H)⁺

15

- (15) [[3-[[4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]benzoyl]amino]acetic acid hydrochloride

20 NMR (DMSO-d₆, δ): 2.90-3.30 (6H, m), 3.95 (2H, d, J=6Hz), 4.97 (1H, m), 6.32 (1H, br s, OH), 7.31-7.49 (4H, m), 7.54 (2H, d, J=8Hz), 7.76 (1H, t, J=8Hz), 7.98 (2H, d, J=8Hz), 8.14 (1H, d, J=8Hz), 8.17 (1H, d, J=8Hz), 8.44 (1H, s), 9.00 (2H, br s), 9.24 (1H, br t, J=6Hz), 12.50 (1H, br s)

25 (-)ESI-MS (m/z): 515 (free, M-H)⁻

- (16) Ethyl [[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]-amino]acetate hydrochloride

30 NMR (DMSO-d₆, δ): 1.19 (3H, t, J=7Hz), 2.93-3.30 (6H, m), 4.00 (2H, d, J=6Hz), 4.11 (2H, q, J=7Hz), 4.98 (1H, m), 6.33 (1H, br s, OH), 7.31-7.49 (4H, m), 7.54 (2H, d, J=8Hz), 7.97 (2H, d, J=8Hz), 8.06 (2H, d, J=8Hz), 8.08 (2H, d, J=8Hz), 9.00 (2H, br s), 9.23 (1H, t, J=6Hz)

35

(+)ESI-MS (m/z): 545 (free, M+H)⁺

(17) [[4-[[4-[2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]amino]acetic acid hydrochloride

5 NMR (DMSO-d₆, δ): 2.92-3.32 (6H, m), 3.93 (2H, d, J=6Hz), 4.97 (1H, m), 6.32 (1H, br s, OH), 7.31-7.49 (4H, m), 7.53 (2H, d, J=8Hz), 7.96 (2H, d, J=8Hz), 8.05 (2H, d, J=8Hz), 8.07 (2H, d, J=8Hz),
10 9.05 (2H, br s), 9.11 (1H, br t, J=5Hz), 12.45 (1H, br s)

(-)ESI-MS (m/z): 515 (free, M-H)⁻

(18) Ethyl [[4-[[4-[(2R)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoyl]amino]acetate hydrochloride

15 NMR (DMSO-d₆, δ): 1.09 (3H, d, J=6Hz), 1.19 (3H, t, J=7Hz), 2.65-3.65 (5H, m), 4.01 (2H, d, J=6Hz), 4.11 (2H, q, J=7Hz), 5.04 (1H, m), 6.25 (1H, br s, OH), 7.25-7.65 (6H, m), 7.57 (2H, d, J=8Hz), 8.05
20 (2H, d, J=8Hz), 8.10 (2H, d, J=8Hz), 8.84 (1H, br s), 9.24 (1H, br t, J=6Hz), 9.28 (1H, br s)

(+)ESI-MS (m/z): 559 (free, M+H)⁺

25 (19) [[4-[[4-[(2R)-2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoyl]amino]acetic acid hydrochloride

NMR (DMSO-d₆, δ): 1.09 (3H, d, J=6Hz), 2.65-3.65 (5H, m), 3.93 (2H, d, J=6Hz), 5.06 (1H, m), 6.35 (1H, br s, OH), 7.27-7.62 (6H, m), 7.97 (2H, d, J=8Hz),
30 8.07 (4H, s), 9.14 (1H, br t, J=6Hz), 9.30 (2H, br s)

(-)ESI-MS (m/z): 529 (free, M-H)⁻

35 (20) Ethyl 3-[[3-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-

hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]-
amino]propanoate hydrochloride

5 NMR (DMSO-d₆, δ): 1.16 (3H, t, J=7Hz), 2.60 (2H, t, J=6Hz), 2.90-3.40 (6H, m), 3.51 (2H, q, J=6Hz), 4.07 (2H, q, J=7Hz), 5.01 (1H, m), 6.34 (1H, br s, OH), 7.20-7.53 (4H, m), 7.54 (2H, d, J=8Hz), 7.73 (1H, t, J=8Hz), 7.97 (2H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.13 (1H, d, J=8Hz), 8.39 (1H, s), 8.96 (1H, br t, J=6Hz), 9.12 (2H, br s)
10 (+)ESI-MS (m/z): 559 (free, M+H)⁺

(21) 3-[[3-[[4-[2-[[2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]benzoyl]amino]propanoic acid hydrochloride

15 NMR (DMSO-d₆, δ): 2.54 (2H, t, J=6Hz), 2.80-3.80 (8H, m), 5.01 (1H, m), 6.35 (1H, br s, OH), 7.20-7.55 (4H, m), 7.54 (2H, d, J=8Hz), 7.72 (1H, t, J=8Hz), 7.97 (2H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.14 (1H, d, J=8Hz), 8.40 (1H, s), 8.94 (1H, br t, J=6Hz), 8.96 (1H, br s), 9.27 (1H, br s), 12.40 (1H, br s)
20 (-)ESI-MS (m/z): 529 (free, M-H)⁻

(22) Ethyl [[3-[[4-[2-[[2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]-(methyl)amino]acetate hydrochloride

25 NMR (DMSO-d₆, δ): 1.14, 1.24 (total 3H, a pair of t, J=7Hz), 2.80-3.40 (6H, m), 2.92, 3.01 (total 3H, a pair of s), 4.09, 4.17 (total 2H, a pair of q, J=7Hz), 4.02, 4.24 (total 2H, a pair of s), 5.02 (1H, m), 6.35 (1H, br s, OH), 7.20-8.20 (12H, m), 9.00 (1H, br s), 9.34 (1H, br s)
30 (+)ESI-MS (m/z): 559 (free, M+H)⁺

(23) [[3-[[4-[2-[[2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]benzoyl] (methyl)amino]-

35

acetic acid hydrochloride

NMR (DMSO-d₆, δ): 2.70-3.70 (6H, m), 2.91, 3.00 (3H, total 3H, a pair of s), 3.90, 4.17 (2H, total 2H, a pair of s), 5.03 (1H, m), 6.35 (1H, br s, OH),
5 7.15-8.30 (12H, m), 9.04 (1H, br s), 9.39 (1H, br s), 12.99 (1H, br s)

(-)ESI-MS (m/z): 529 (free, M-H)⁻

(24) Ethyl (2S)-2-[[3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]amino]propanoate hydrochloride
10

NMR (DMSO-d₆, δ): 1.19 (3H, t, J=7Hz), 1.42 (3H, d, J=7Hz), 2.85-3.40 (6H, m), 4.11 (2H, q, J=7Hz), 4.47 (1H, quintet, J=7Hz), 5.00 (1H, m), 6.34 (1H, br s, OH),
15 7.20-7.55 (4H, m), 7.54 (2H, d, J=8Hz), 7.75 (1H, t, J=8Hz), 7.98 (2H, d, J=8Hz), 8.14 (1H, d, J=8Hz), 8.19 (1H, d, J=8Hz), 8.44 (1H, s), 9.09 (2H, br s), 9.17 (1H, br d, J=7Hz)

(+)ESI-MS (m/z): 559 (free, M+H)⁺

20

(25) (2S)-2-[[3-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]-amino]propanoic acid hydrochloride

NMR (DMSO-d₆, δ): 1.42 (3H, d, J=7Hz), 2.85-3.75 (6H, m), 4.44 (1H, quintet, J=7Hz), 5.02 (1H, m), 6.35 (1H, br s, OH), 7.15-7.60 (4H, m), 7.55 (2H, d, J=8Hz), 7.75 (1H, t, J=8Hz), 7.98 (2H, d, J=8Hz), 8.14 (1H, d, J=8Hz), 8.20 (1H, d, J=8Hz), 8.46 (1H, s), 9.08 (1H, br d, J=7Hz), 9.13 (2H, br s), 12.65 (1H, br s)
25
30

(-)ESI-MS (m/z): 629 (free, M-H)⁻

(26) Methyl (2R)-2-[[3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]-amino]propanoate hydrochloride
35

NMR (DMSO- d_6 , δ): 1.43 (3H, d, $J=7$ Hz), 2.85-3.50 (6H, m), 3.65 (3H, s), 4.50 (1H, quintet, $J=7$ Hz), 5.02 (1H, m), 6.36 (1H, br s, OH), 7.20-7.55 (4H, m), 7.55 (2H, d, $J=8$ Hz), 7.75 (1H, t, $J=8$ Hz), 7.98 (2H, d, $J=8$ Hz), 8.14 (1H, d, $J=8$ Hz), 8.20 (1H, d, $J=8$ Hz), 8.46 (1H, s), 9.00 (1H, br s), 9.21 (1H, br d, $J=7$ Hz), 9.34 (1H, br s)
(+)ESI-MS (m/z): 545 (free, $M+H$)⁺

10 (27) (2R)-2-[[[3-[[4-[2-[[[2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]-amino]propanoic acid hydrochloride

15 NMR (DMSO- d_6 , δ): 1.42 (3H, d, $J=7$ Hz), 2.80-3.75 (6H, m), 4.45 (1H, quintet, $J=7$ Hz), 5.03 (1H, m), 6.35 (1H, br s, OH), 7.15-7.58 (4H, m), 7.55 (2H, d, $J=8$ Hz), 7.75 (1H, t, $J=8$ Hz), 7.98 (2H, d, $J=8$ Hz), 8.14 (1H, d, $J=8$ Hz), 8.20 (1H, d, $J=8$ Hz), 8.46 (1H, s), 9.09 (1H, br d, $J=7$ Hz), 9.20 (2H, br s), 12.60 (1H, br s)

20 (-)ESI-MS (m/z): 529 (free, $M-H$)⁻

(28) Ethyl [[4-[[4-[(2R)-2-[[[2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoyl]-(methyl)amino]acetate hydrochloride

25 NMR (DMSO- d_6 , δ): 1.09 (3H, d, $J=6$ Hz), 1.22 (3H, t, $J=7$ Hz), 2.65-3.65 (5H, m), 2.89, 2.98 (3H, total 3H, a pair of s), 4.01, 4.23 (2H, total 3H, a pair of s), 4.15 (2H, q, $J=7$ Hz), 5.01 (1H, m), 6.34 (1H, br s, OH), 7.30-7.65 (6H, m), 7.64 (2H, d, $J=8$ Hz), 7.97 (2H, d, $J=8$ Hz), 8.05 (2H, d, $J=8$ Hz), 8.82 (1H, br s), 9.14 (1H, br s)

30 (+)ESI-MS (m/z): 573 (free, $M+H$)⁺

35 (29) [[4-[[4-[(2R)-2-[[[2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoyl]-

(methyl)amino]acetic acid hydrochloride

NMR (DMSO-d₆, δ): 1.10 (3H, d, J=6Hz), 2.65-3.80 (5H, m), 2.88, 2.98 (total 3H, a pair of s), 3.91, 4.15 (total 2H, a pair of s), 5.06 (1H, m), 6.37 (1H, br s, OH), 7.25-7.75 (8H, m), 7.82-8.22 (4H, m), 8.95 (1H, br s), 9.40 (1H, br s), 12.75 (1H, br s)
(-)ESI-MS (m/z): 543 (free, M-H)⁻

(30) Sodium [4-[[4-[(2S)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]sulfonyl]-phenoxy]acetate

NMR (DMSO-d₆, δ): 2.70-2.90 (5H, m), 3.00-3.55 (2H, m), 4.17 (2H, s), 4.58 (1H, m), 4.58 (1H, br s, OH), 5.43 (1H, br s, OH), 6.82 (2H, d, J=9Hz), 7.10-7.60 (6H, m), 7.76 (2H, d, J=9Hz), 7.76 (2H, d, J=8Hz)

(-)ESI-MS (m/z): 518 (free, M-H)⁻

Example 121

A solution of (2E)-3-[3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenyl]-2-propenoic acid (99 mg) in ethanol (5 ml) was hydrogenated (2 atm) over platinum(IV) oxide (10 mg) at room temperature for 4 hours. The catalyst was filtered off and the filtrate was evaporated to give 3-[3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenyl]propanoic acid (106 mg) as a white amorphous powder.

NMR (CDCl₃, δ): 1.33 (9H, s), 2.50-3.60 (6H, m), 2.68 (2H, t, J=7Hz), 2.98 (2H, t, J=7Hz), 4.77 (1H, m), 7.00-7.50 (8H, m), 7.65-8.00 (4H, m)
(+)ESI-MS (m/z): 610 (M+Na)⁺

Example 122

3-[3-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-

chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-
phenyl]propanoic acid (87 mg) and 4N hydrogen chloride in
1,4-dioxane (1.7 ml) were mixed and stirred at room
temperature for 8.5 hours. The solvent was evaporated and
5 the residue was triturated with diisopropyl ether - hexane
to give ethyl 3-[3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenyl]propanoate
hydrochloride (67 mg) as a white powder.

10 NMR (DMSO-d₆, δ): 1.10 (3H, t, J=7Hz), 2.65 (2H, t,
J=7Hz), 2.80-3.45 (6H, m), 2.93 (2H, t, J=7Hz),
4.00 (2H, q, J=7Hz), 4.98 (1H, m), 6.32 (1H, d,
J=4Hz, OH), 7.25-7.68 (8H, m), 7.68-8.05 (4H, m),
8.99 (2H, br s)
(+)ESI-MS (m/z): 516 (free, M+H)⁺

15

Example 123

The following compounds were obtained according to a
similar manner to that of Example 54.

20 (1) 3-[3-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenyl]-
propanoic acid hydrochloride

25 NMR (DMSO-d₆, δ): 2.57 (2H, t, J=7Hz), 2.60-3.60 (6H,
m), 2.91 (2H, t, J=7Hz), 4.97 (1H, m), 6.33 (1H,
br s, OH), 7.20-8.00 (12H, m), 8.90 (1H, br s),
9.00 (1H, br s), 12.15 (1H, br s)
(+)ESI-MS (m/z): 488 (free, M+H)⁺

30 (2) 4-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-
2-methylpropyl]phenyl]sulfonyl]benzoic acid hydrochloride

NMR (DMSO-d₆, δ): 1.21 (6H, s), 2.90-3.35 (4H, m), 4.99
(1H, m), 6.36 (1H, br s), 7.30-7.60 (6H, m), 7.96
(2H, d, J=8Hz), 8.00-8.22 (4H, m), 9.25 (2H, br s)
(+)ESI-MS (m/z): 488 (free, M+H)⁺

35

- (3) 3-[[4-[2-[[2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]-2-methylpropyl]phenyl]sulfonyl]benzoic acid hydrochloride

NMR (DMSO- d_6 , δ): 1.21 (6H, s), 2.90-3.40 (4H, m), 5.01 (1H, m), 6.34 (1H, br s), 7.25-7.65 (6H, m), 7.78 (1H, t, $J=8\text{Hz}$), 7.98 (2H, d, $J=8\text{Hz}$), 8.10-8.34 (2H, m), 8.40 (1H, s), 8.70 (1H, br s), 9.30 (1H, br s), 13.63 (1H, br s)

(-)ESI-MS (m/z): 486 (free, $M-H$)⁻

- (4) 3-[[4-[(2R)-2-[[2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoic acid hydrochloride

NMR (DMSO- d_6 , δ): 1.10 (3H, d, $J=6\text{Hz}$), 2.65-3.65 (5H, m), 5.10 (1H, m), 6.39 (1H, br s), 7.22-7.65 (6H, m), 7.78 (1H, t, $J=8\text{Hz}$), 7.99 (2H, d, $J=8\text{Hz}$), 8.10-8.34 (2H, m), 8.40 (1H, t, $J=7\text{Hz}$), 8.93 (1H, br s), 9.61 (1H, br s), 13.60 (1H, br s)

(+)ESI-MS (m/z): 474 (free, $M+H$)⁺

- (5) 4-[[4-[(2S)-2-[[2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoic acid hydrochloride

NMR (DMSO- d_6 , δ): 0.91 (3H, d, $J=6\text{Hz}$), 2.45-3.10 (5H, m), 4.66 (1H, m), 7.10-7.53 (6H, m), 7.83 (2H, d, $J=8\text{Hz}$), 7.87 (2H, d, $J=8\text{Hz}$), 8.02 (2H, d, $J=8\text{Hz}$)

(+)ESI-MS (m/z): 474 (free, $M+H$)⁺

- (6) 4-[[4-[(2R)-2-[[2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoic acid hydrochloride

NMR (DMSO- d_6 , δ): 1.09 (3H, d, $J=6\text{Hz}$), 2.65-3.65 (5H, m), 5.02 (1H, m), 6.37 (1H, br s, OH), 7.25-7.65 (6H, m), 7.97 (2H, d, $J=8\text{Hz}$), 8.00-8.21 (4H, m), 9.15 (2H, br s)

(-)ESI-MS (m/z): 472 (free, $M-H$)⁻

Example 124

The mixture of tert-butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(3-formylphenyl)sulfonyl]phenyl]-ethyl]carbamate (217 mg), 2,4-thiazolidinedione (60 mg), and ammonium acetate (68 mg) in acetic acid (0.23 ml) - benzene (4.4 ml) was heated to reflux for 11 hours. After being allowed to cool to room temperature, the mixture was partitioned between ethyl acetate and sodium bicarbonate solution. The organic layer was separated, washed successively with water and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give tert-butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(3-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl)sulfonyl]phenyl]-ethyl]carbamate (161 mg) as a white amorphous powder.

NMR (CDCl₃, δ): 1.35 (9H, s), 2.60-3.60 (6H, m), 4.24 (1H, br s, OH), 4.84 (1H, m), 7.08-7.48 (6H, m), 7.50-7.72 (2H, m), 7.81 (1H, s), 7.89 (2H, d, J=8Hz), 7.90-8.10 (2H, m), 9.60 (1H, br s)
(-)ESI-MS (m/z): 641 (M-H)⁻

Example 125

The following compounds were obtained according to a similar manner to that of Example 57.

(1) tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[(3-[(dimethylamino)carbonyl]phenyl)sulfonyl]phenyl]ethyl]carbamate

NMR (CDCl₃, δ): 1.38 (9H, s), 2.60-3.55 (6H, m), 2.95 (3H, s), 3.11 (3H, s), 4.28 (1H, br s, OH), 4.86 (1H, br s), 7.10-7.42 (6H, m), 7.45-7.68 (2H, m), 7.84 (2H, d, J=8Hz), 7.90-8.02 (2H, m)
(+)ESI-MS (m/z): 609 (M+Na)⁺

- (2) tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-[(dimethylamino)carbonyl]phenyl]sulfonyl]phenyl]ethyl]carbamate
- 5 NMR (DMSO- d_6 , δ): 1.05, 1.19 (total 9H, a pair of s),
2.65-3.60 (6H, m), 2.82 (3H, s), 2.98 (3H, s),
4.73 (1H, m), 5.58 (1H, br s, OH), 7.10-7.50 (6H,
m), 7.60 (2H, d, $J=8\text{Hz}$), 7.89 (2H, d, $J=8\text{Hz}$), 7.98
(2H, d, $J=8\text{Hz}$)
- 10 (+)ESI-MS (m/z): 609 ($M+\text{Na}$)⁺
- (3) tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[3-[(methylamino)carbonyl]phenyl]sulfonyl]phenyl]ethyl]carbamate
- 15 NMR (CDCl_3 , δ): 1.36 (9H, s), 2.65-3.00 (2H, m), 3.00
(3H, d, $J=5\text{Hz}$), 3.08-3.60 (4H, m), 4.39 (1H, br s,
OH), 4.59 (1H, m), 6.36 (1H, br s), 7.05-7.40 (6H,
m), 7.55 (1H, t, $J=8\text{Hz}$), 7.88 (2H, d, $J=8\text{Hz}$), 7.94
(1H, br q, $J=8\text{Hz}$), 8.03 (1H, d, $J=8\text{Hz}$), 8.19 (1H,
20 s)
- (+)ESI-MS (m/z): 595 ($M+\text{Na}$)⁺
- (4) tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[(1R)-1-methyl-2-[4-[[4-[(methylamino)carbonyl]phenyl]sulfonyl]phenyl]ethyl]carbamate
- 25 NMR (CDCl_3 , δ): 1.24 (3H, d, $J=6\text{Hz}$), 1.26 (9H, s),
2.50-3.65 (4H, m), 3.00 (3H, d, $J=5\text{Hz}$), 3.92-4.28
(1H, m), 4.60 (1H, m), 5.21 (1H, br s, OH), 6.17
(1H, br q, $J=5\text{Hz}$), 7.05-7.45 (6H, m), 7.80 (2H, d,
30 $J=8\text{Hz}$), 7.82 (2H, d, $J=8\text{Hz}$), 7.96 (2H, d, $J=8\text{Hz}$)
- (+)ESI-MS (m/z): 609 ($M+\text{Na}$)⁺
- (5) tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[(1R)-2-[4-[[4-[(dimethylamino)carbonyl]phenyl]sulfonyl]phenyl]-1-methylethyl]carbamate
- 35

NMR (CDCl₃, δ): 1.23 (3H, d, J=7Hz), 1.28 (9H, s),
2.50-3.70 (4H, m), 2.91 (3H, s), 3.11 (3H, s),
4.00-4.28 (1H, m), 4.73 (1H, m), 5.22 (1H, br s,
OH), 7.10-7.47 (6H, m), 7.49 (2H, d, J=8Hz), 7.84
5 (2H, d, J=8Hz), 7.96 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 623 (M+Na)⁺.

Example 126

To a mixture of 3-[[4-[2-[N-(tert-butoxycarbonyl)-N-
10 [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-
sulfonyl]benzoic acid (168 mg), 4-hydroxypiperidine (34 mg),
and 1-hydroxybenzotriazole (44 mg) in N,N-dimethylformamide
(1.3 ml) was added 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (75 mg), and the mixture was
15 stirred at room temperature for 48.5 hours. The mixture was
partitioned between hexane/ethyl acetate and water. The
organic layer was separated, washed successively with water
and brine, dried over magnesium sulfate, and filtered. The
filtrate was concentrated and the residue was purified by
20 column chromatography (silica gel, ethyl acetate/methanol)
to give tert-butyl N-[(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl]-N-[2-[4-[[3-[(4-hydroxy-1-piperidiny)]-
carbonyl]phenyl]sulfonyl]phenyl]ethyl]carbamate (188 mg) as
a white amorphous powder.

25 NMR (CDCl₃, δ): 1.38 (9H, s), 1.50-2.20 (4H, m), 2.50-
3.75 (10H, m), 4.01 (1H, m), 4.12 (1H, br s, OH),
4.86 (1H, m), 7.05-8.10 (12H, m)
(+)ESI-MS (m/z): 665 (M+Na)⁺

30 Example 127

The following compounds were obtained according to a
similar manner to that of Example 126.

(1) tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-
35 N-[(1R)-2-[4-[[4-[(4-hydroxy-1-piperidiny)]carbonyl]-

phenyl]sulfonyl]phenyl]-1-methylethyl]carbamate

NMR (CDCl₃, δ): 1.24 (3H, d, J=6Hz), 1.25 (9H, s),
1.50-2.10 (4H, m), 2.50-3.70 (8H, m), 4.00 (1H, m),
4.14 (1H, m), 4.15 (1H, br s, OH), 4.74 (1H, m),
5.26 (1H, br s, OH), 7.10-7.45 (6H, m), 7.47 (2H,
d, J=8Hz), 7.85 (2H, d, J=8Hz), 7.96 (2H, d,
J=8Hz)

(+)ESI-MS (m/z): 679 (M+Na)⁺

- 10 (2) tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-
N-[2-[4-[[3-[(5-methyl-1,3-thiazol-2-yl)amino]-
carbonyl]phenyl]sulfonyl]phenyl]ethyl]carbamate

NMR (CDCl₃, δ): 1.37 (9H, s), 2.39 (3H, s), 2.60-3.70
(6H, m), 4.35 (1H, br s, OH), 4.68 (1H, m), 6.84
(1H, br s), 7.02-7.46 (7H, m), 7.63 (1H, t, J=8Hz),
7.89 (2H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.16 (1H,
d, J=8Hz), 8.44 (1H, s)

(-)ESI-MS (m/z): 654 (M-H)⁻

- 20 (3) tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-
N-[2-[4-[[4-[(5-methyl-1,3-thiazol-2-yl)amino]-
carbonyl]phenyl]sulfonyl]phenyl]ethyl]carbamate

NMR (CDCl₃, δ): 1.36 (9H, s), 2.38 (3H, s), 2.60-3.60
(6H, m), 4.25 (1H, br s, OH), 4.81 (1H, m), 6.77
(1H, s), 7.06-7.50 (7H, m), 7.89 (2H, d, J=8Hz),
8.03 (4H, s)

(-)ESI-MS (m/z): 654 (M-H)⁻

- 30 (4) Ethyl 4-[[4-[(2R)-2-[(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
hydrochloride

NMR (DMSO-d₆, δ): 1.09 (3H, d, J=6Hz), 1.31 (3H, t,
J=7Hz), 2.65-3.65 (5H, m), 4.34 (2H, q, J=7Hz),
5.02 (1H, m), 6.34 (1H, br s, OH), 7.28-7.62 (6H,
m), 7.96 (2H, d, J=8Hz), 8.11 (2H, d, J=8Hz), 8.14

(2H, d, J=8Hz), 8.81 (1H, br s), 9.23 (1H, br s)
(+)ESI-MS (m/z): 502 (free, M+H)⁺

- (5) Ethyl 4-[[3-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate hydrochloride
NMR (DMSO-d₆, δ): 1.31 (3H, t, J=7Hz), 2.90-3.40 (6H, m), 4.34 (2H, q, J=7Hz), 4.98 (1H, m), 6.35 (1H, br s, OH), 7.28-7.52 (4H, m), 7.55-7.73 (2H, m), 7.80-8.00 (2H, m), 8.12 (2H, d, J=8Hz), 8.14 (2H, d, J=8Hz), 8.91 (1H, br s), 9.12 (1H, br s)
(+)ESI-MS (m/z): 488 (free, M+H)⁺

Example 128

- To a solution of 3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoic acid (83 mg), 5-amino-1H-tetrazole (17 mg), 1-hydroxybenzotriazole (20 mg), and 4-(dimethylamino)pyridine (18 mg) in N,N-dimethylformamide (0.84 ml) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (46 mg), and the mixture was stirred at room temperature for 5 days. The mixture was partitioned between hexane/ethyl acetate and water. The organic layer was separated, washed successively with water and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by gel permeation chromatography to give tert-butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[3-[(1H-tetrazol-5-ylamino)carbonyl]phenyl]sulfonyl]phenyl]ethyl]carbamate (51 mg) as a white amorphous powder.

- NMR (DMSO-d₆, δ): 1.03, 1.18 (total 9H, a pair of s), 2.70-2.95 (2H, m), 3.03-3.60 (4H, m), 4.74 (1H, m), 5.59 (1H, br s, OH), 7.15-7.55 (6H, m), 7.80 (1H, t, J=8Hz), 7.94 (2H, d, J=8Hz), 8.20 (1H, m), 8.32 (1H, d, J=8Hz), 8.66 (1H, s), 12.60 (1H, br s)

(-)ESI-MS (m/z): 625 (M-H)⁻

Example 129

The following compound was obtained according to a similar manner to that of Example 128.

tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[2-[4-[[4-[(1H-tetrazol-5-ylamino)carbonyl]phenyl]sulfonyl]phenyl]ethyl]carbamate

10 NMR (DMSO-d₆, δ): 1.07, 1.20 (total 9H, a pair of s), 2.70-3.00 (2H, m), 3.05-3.60 (4H, m), 4.73 (1H, m), 5.60 (1H, br s, OH), 7.15-7.55 (6H, m), 7.93 (2H, m), 8.10 (2H, m), 8.20 (2H, d, J=8Hz)

(-)ESI-MS (m/z): 625 (M-H)⁻

15

Example 130

To a mixture of 3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]sulfonyl]benzoic acid (112 mg), glycine ethyl ester hydrochloride (32 mg), and 1-hydroxybenzotriazole (29 mg) in N,N-dimethylformamide (1.1 ml) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (45 mg), and the mixture was stirred at room temperature for 15 hours. The mixture was partitioned between hexane/ethyl acetate and water. The organic layer was separated, washed successively with water and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give ethyl [[3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]sulfonyl]benzoyl]amino]acetate (114 mg) as a white amorphous powder.

35 NMR (CDCl₃, δ): 1.32 (3H, t, J=7Hz), 1.36 (9H, s), 2.60-3.60 (6H, m), 4.22 (2H, d, J=5Hz), 4.27 (2H, q, J=7Hz), 4.33 (1H, br s, OH), 4.74 (1H, m), 6.78

(1H, br t, J=5Hz), 7.10-7.40 (6H, m), 7.57 (1H, t, J=8Hz), 7.88 (2H, d, J=8Hz), 7.97 (1H, d, J=8Hz), 8.07 (1H, d, J=8Hz), 8.30 (1H, s)
(+)ESI-MS (m/z): 667 (M+Na)⁺

5

Example 131

The following compounds were obtained according to a similar manner to that of Example 130.

- 10 (1) Ethyl [[4-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoyl]amino]acetate
NMR (CDCl₃, δ): 1.31 (3H, t, J=7Hz), 1.35 (9H, s),
2.60-3.60 (6H, m), 4.22 (2H, d, J=5Hz), 4.25 (1H,
15 br s, OH), 4.26 (2H, q, J=7Hz), 4.82 (1H, m), 6.67
(1H, br t, J=5Hz), 7.08-7.48 (6H, m), 7.86 (2H, d, J=8Hz), 7.89 (2H, d, J=8Hz), 7.99 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 667 (M+Na)⁺
- 20 (2) Ethyl [[4-[[4-[(2R)-2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoyl]amino]acetate
NMR (CDCl₃, δ): 1.24 (3H, d, J=6Hz), 1.26 (9H, s), 1.31
(3H, t, J=7Hz), 2.50-3.65 (4H, m), 4.00-4.26 (1H,
25 m), 4.21 (2H, d, J=5Hz), 4.26 (2H, q, J=7Hz), 4.66
(1H, m), 5.26 (1H, br s, OH), 6.65 (1H, br t, J=5Hz), 7.05-7.50 (6H, m), 7.86 (2H, d, J=8Hz),
7.87 (2H, d, J=8Hz), 7.99 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 681 (M+Na)⁺
- 30 (3) Ethyl 3-[[3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoyl]amino]propanoate
NMR (CDCl₃, δ): 1.28 (3H, t, J=7Hz), 1.36 (9H, s),
35 2.55-3.60 (6H, m), 2.65 (2H, t, J=6Hz), 3.72 (2H,

q, J=6Hz), 4.19 (2H, q, J=7Hz), 4.32 (1H, br s, OH), 4.77 (1H, m), 6.96 (1H, br t, J=6Hz), 7.05-7.42 (6H, m), 7.55 (1H, t, J=8Hz), 7.88 (2H, d, J=8Hz), 7.92 (1H, d, J=8Hz), 8.04 (1H, d, J=8Hz),
5 8.26 (1H, s)

(+)ESI-MS (m/z): 681 (M+Na)⁺

(4) Ethyl [[3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]benzoyl](methyl)amino]acetate

10 NMR (CDCl₃, δ): 1.32 (3H, t, J=7Hz), 1.37 (9H, s), 2.60-3.60 (6H, m), 3.02, 3.13 (total 3H, a pair of s), 3.91 (1H, br s, OH), 4.25 (2H, s), 4.25 (2H, q, J=7Hz), 4.87 (1H, m), 7.05-8.10 (12H, m)

15 (+)ESI-MS (m/z): 681 (M+Na)⁺

(5) Ethyl (2S)-2-[[3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]sulfonyl]benzoyl]amino]propanoate

20 NMR (CDCl₃, δ): 1.32 (3H, t, J=7Hz), 1.36 (9H, s), 1.54 (3H, d, J=7Hz), 2.60-3.60 (6H, m), 4.26 (2H, q, J=7Hz), 4.27 (1H, br s, OH), 4.35 (1H, quintet, J=7Hz), 4.36 (1H, m), 6.83 (1H, br d, J=7Hz), 7.05-7.43 (6H, m), 7.56 (1H, t, J=8Hz), 7.88 (2H, d, J=8Hz), 7.97 (1H, d, J=8Hz), 8.06 (1H, d, J=8Hz), 8.30 (1H, s)

25

(+)ESI-MS (m/z): 681 (M+Na)⁺

(6) Methyl (2R)-2-[[3-[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]sulfonyl]benzoyl]amino]propanoate

30

NMR (CDCl₃, δ): 1.36 (9H, s), 1.54 (3H, d, J=7Hz), 2.55-3.55 (6H, m), 3.80 (3H, s), 4.32 (1H, br s, OH), 4.77 (1H, quintet, J=7Hz), 4.77 (1H, m), 6.81 (1H, br d, J=7Hz), 7.10-7.42 (6H, m), 7.56 (1H, t, J=8Hz),

35

7.88 (2H, d, J=8Hz), 7.97 (1H, d, J=8Hz), 8.06 (1H, d, J=8Hz), 8.30 (1H, s)

(+)ESI-MS (m/z): 667 (M+Na)⁺

5 (7) Ethyl [[4-[[4-[(2R)-2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoyl](methyl)amino]acetate

NMR (CDCl₃, δ): 1.23 (3H, d, J=7Hz), 1.26 (9H, s), 1.27 (3H, t, J=7Hz), 2.50-3.70 (4H, m), 2.97, 3.11 (total 3H, a pair of s), 3.87, 4.25 (total 3H, a pair of s), 4.16 (1H, m), 4.24 (2H, q, J=7Hz), 4.74 (1H, m), 5.26 (1H, br s, OH), 7.10-7.68 (8H, m), 7.75-8.10 (4H, m)

(+)ESI-MS (m/z): 695 (M+Na)⁺

15

Example 132

The following compound was obtained according to a similar manner to that of Example 122.

20 Ethyl (2R)-2-[[3-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoyl]amino]-propanoate hydrochloride

NMR (DMSO-d₆, δ): 1.19 (3H, t, J=7Hz), 1.42 (3H, d, J=7Hz), 2.85-3.55 (6H, m), 4.11 (2H, q, J=7Hz), 4.47 (1H, quintet, J=7Hz), 4.91 (1H, m), 6.33 (1H, br s, OH), 7.20-7.55 (4H, m), 7.54 (2H, d, J=8Hz), 7.75 (1H, t, J=8Hz), 7.98 (2H, d, J=8Hz), 8.14 (1H, d, J=8Hz), 8.19 (1H, d, J=8Hz), 8.44 (1H, s), 9.05 (2H, br s), 9.16 (1H, br d, J=7Hz)

30 (+)ESI-MS (m/z): 559 (free, M+H)⁺

Example 133

At room temperature, to a solution of ethyl (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]phenoxy]acetate (296 mg) in ethanol (5 ml) was

35

added 4N hydrogen chloride in ethanol (1 ml), and the mixture was evaporated under reduced pressure and dried in vacuo to give ethyl (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate
5 hydrochloride (296 mg), which was recrystallized from ethanol.

mp: 198-200°C

NMR (DMSO-d₆, δ): 1.20 (3H, t, J=7.1Hz), 2.95-3.3 (6H, m), 4.16 (2H, q, J=7.1Hz), 4.85-5.0 (1H, m), 4.91 (2H, s), 7.1-7.2 (2H, m), 7.3-7.55 (6H, m), 7.8-
10 7.95 (4H, m)

IR (KBr): 2958, 1762, 1733, 1594, 1295, 1214, 1155, 1108, 1074, 686 cm⁻¹

(+)ESI-MS (m/z): 518, 520 (M-HCl+H)⁺

15 Example 134

A solution of 4-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-fluorobenzoate (251 mg) in 7N hydrogen chloride in ethanol (1.0 ml) was stirred at room temperature for 1 hour. The
20 solvent was removed by evaporation and the residue was dissolved in a mixed solvent of chlorobenzene (1.75 ml) and ethanol (0.75 ml). To the solution was added 10% palladium on activated carbon (50% wet, 25 mg) and the mixture was hydrogenated (1 atm) for 2 hours. The precipitates were
25 dissolved by addition of ethanol and the catalyst was removed by filtration and washed with ethanol. The filtrate was concentrated in vacuo to give ethyl 4-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]-2-fluorobenzoate hydrochloride (219 mg) as an
30 orange solid.

(+)APCI-MS (m/z): 506 (M+H)⁺

Example 135

The following compounds were obtained according to a
35 similar manner to that of Example 134.

- (1) Ethyl [4-[[4-[(2S)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]-sulfonyl]phenoxy]acetate hydrochloride
- 5 NMR (DMSO-d₆, δ): 1.20 (3H, t, J=7Hz), 2.75-3.75 (7H, m), 4.15 (2H, q, J=7Hz), 4.81 (2H, s), 5.02 (1H, m), 5.40 (1H, br s, OH), 6.33 (1H, br s, OH), 7.13 (2H, d, J=9Hz), 7.25-7.65 (6H, m), 7.88 (2H, d, J=9Hz), 7.91 (2H, d, J=8Hz), 8.58 (1H, br s), 9.19 (1H, br s)
- 10 (+)ESI-MS (m/z): 548 (free, M+H)⁺
- (2) Ethyl 3-[[3-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate hydrochloride
- 15 NMR (DMSO-d₆, δ): 1.34 (3H, t, J=7Hz), 2.90-3.50 (6H, m), 4.36 (2H, q, J=7Hz), 5.00 (1H, m), 6.36 (1H, br s, OH), 7.28-8.05 (9H, m), 8.12-8.32 (2H, m), 8.42 (1H, s), 8.91 (1H, br s), 9.18 (1H, br s)
- 20 (+)ESI-MS (m/z): 488 (free, M+H)⁺
- (3) Ethyl 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-methylbenzoate hydrochloride
- 25 (+)APCI-MS (m/z): 502 (M+H)⁺
- (4) Ethyl 2'-chloro-4'-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-1,1'-biphenyl-4-carboxylate hydrochloride
- 30 NMR (DMSO-d₆, δ): 1.34 (3H, t, J=7.1Hz), 2.98-3.20 (6H, m), 4.35 (2H, q, J=7.1Hz), 5.00-5.05 (1H, m), 6.37 (1H, d, J=4.1Hz), 7.31-7.72 (9H, m), 7.99-8.08 (5H, m), 8.18 (1H, d, J=1.7Hz), 9.05 (1H, br), 9.30 (1H, br)
- 35 (+)APCI-MS (m/z): 598 (M+H)⁺

- (5) Ethyl 2'-chloro-4'-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-1,1'-biphenyl-3-carboxylate hydrochloride
- 5 NMR (DMSO- d_6 , δ): 1.31 (3H, t, $J=7.1$ Hz), 2.98-3.20 (6H, m), 4.33 (2H, q, $J=7.1$ Hz), 4.99-5.04 (1H, m), 6.36 (1H, m), 7.31-7.46 (5H, m), 7.55-7.77 (4H, m), 7.98-8.08 (5H, m), 8.18 (1H, d, $J=1.7$ Hz), 9.07 (1H, br), 9.23 (1H, br)
- 10 (+)APCI-MS (m/z): 598 (M+H)⁺
- (6) Ethyl 4-[[4-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]methyl]phenyl]sulfonyl]benzoate hydrochloride
- 15 NMR (DMSO- d_6 , δ): 1.32 (3H, t, $J=7$ Hz), 2.85-3.25 (2H, m), 4.27 (2H, s), 4.34 (2H, q, $J=7$ Hz), 5.01 (1H, m), 6.70 (1H, br s, OH), 7.20-7.50 (4H, m), 7.82 (2H, d, $J=8$ Hz), 8.05 (2H, d, $J=8$ Hz), 8.14 (4H, s), 9.41 (2H, br s)
- 20 (+)ESI-MS (m/z): 474 (free, M+H)⁺
- (7) Ethyl 4-[[4-[3-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate hydrochloride
- 25 NMR (DMSO- d_6 , δ): 1.31 (3H, t, $J=7$ Hz), 1.96 (2H, quintet, $J=7$ Hz), 2.74 (2H, t, $J=7$ Hz), 2.90-3.28 (2H, m), 2.93 (2H, t, $J=7$ Hz), 4.34 (2H, q, $J=7$ Hz), 4.96 (1H, m), 6.29 (1H, br s, OH), 7.25-7.55 (4H, m), 7.51 (2H, d, $J=8$ Hz), 7.93 (2H, d, $J=8$ Hz), 8.10 (2H, d, $J=8$ Hz), 8.14 (2H, d, $J=8$ Hz), 8.89 (2H, br s)
- 30 (+)ESI-MS (m/z): 502 (free, M+H)⁺
- (8) Ethyl [4-[[4-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]methyl]phenyl]sulfonyl]phenoxy]-
- 35

acetate hydrochloride

NMR (DMSO-d₆, δ): 1.20 (3H, t, J=7Hz), 2.80-3.35 (2H, m), 4.15 (2H, q, J=7Hz), 4.26 (2H, br s), 4.92 (2H, s), 5.02 (1H, m), 6.30 (1H, br s, OH), 7.14 (2H, d, J=9Hz), 7.22-7.52 (4H, m), 7.78 (2H, d, J=8Hz), 7.90 (2H, d, J=9Hz), 8.00 (2H, d, J=8Hz), 9.28 (1H, br s), 9.56 (1H, br s)

(+)ESI-MS (m/z): 504 (free, M+H)⁺

- 10 (9) Ethyl [4-[[4-[3-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenoxy]-acetate hydrochloride

NMR (DMSO-d₆, δ): 1.20 (3H, t, J=7Hz), 1.80-2.15 (2H, m), 2.55-3.30 (6H, m), 4.16 (2H, q, J=7Hz), 4.91 (2H, s), 4.97 (1H, m), 6.30 (1H, br s, OH), 7.13 (2H, d, J=9Hz), 7.25-7.60 (6H, m), 7.87 (2H, d, J=9Hz), 7.87 (2H, d, J=8Hz), 8.81 (1H, br s), 9.10 (1H, br s)

(+)APCI-MS (m/z): 532 (free, M+H)⁺

20

Example 136

- To a solution of ethyl 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]sulfonyl]benzoate (67 mg) in ethanol (1.3 ml) was added 4 M hydrogen chloride/ethanol (0.7 ml), and the solvent was evaporated. The residual solid was recrystallized from ethanol (0.7 ml) - hexane (2.1 ml) to give ethyl 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]sulfonyl]benzoate hydrochloride (62 mg) as a white powder.
- 25
30

NMR (DMSO-d₆, δ): 1.21 (6H, s), 1.31 (3H, t, J=7Hz), 2.90-3.30 (4H, m), 4.34 (2H, q, J=7Hz), 4.99 (1H, m), 6.35 (1H, br s), 7.30-7.60 (6H, m), 7.96 (2H, d, J=8Hz), 8.03-8.24 (4H, m), 8.63 (1H, br s), 9.28 (1H, br s)

35

(+)ESI-MS (m/z): 516 (free, M+H)⁺

Example 137

The following compounds were obtained according to a
5 similar manner to that of Example 136.

- (1) Ethyl 3-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]sulfonyl]benzoate hydrochloride

10 NMR (DMSO-d₆, δ): 1.22 (6H, s), 1.34 (3H, t, J=7Hz),
2.90-3.35 (4H, m), 4.27 (2H, q, J=7Hz), 5.04 (1H, m), 6.36 (1H, d, J=4Hz), 7.25-7.65 (6H, m), 7.81 (1H, t, J=8Hz), 7.99 (2H, d, J=8Hz), 8.18-8.32 (2H, m), 8.41 (1H, s), 8.69 (1H, br s), 9.49 (1H, br s)
15 (+)ESI-MS (m/z): 516 (free, M+H)⁺

- (2) Ethyl 3-[[4-[(2R)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate hydrochloride

20 NMR (DMSO-d₆, δ): 1.09 (3H, d, J=6Hz), 1.34 (3H, t, J=7Hz), 2.70-3.65 (5H, m), 4.36 (2H, q, J=7Hz), 5.03 (1H, m), 6.36 (1H, d, J=4Hz), 7.28-7.65 (6H, m), 7.80 (1H, t, J=8Hz), 7.99 (2H, d, J=8Hz), 8.15-8.32 (2H, m), 8.40 (1H, t, J=7Hz), 8.81 (1H, br s), 9.30 (1H, br s)
25 (+)ESI-MS (m/z): 502 (free, M+H)⁺

- (3) Ethyl 4-[[4-[(2S)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate hydrochloride

30 NMR (DMSO-d₆, δ): 1.10 (3H, d, J=6Hz), 1.31 (3H, t, J=7Hz), 2.95-3.60 (5H, m), 4.34 (2H, q, J=7Hz), 5.03 (1H, m), 6.36 (1H, br d, J=4Hz), 7.28-7.65 (6H, m), 7.96 (2H, d, J=8Hz), 8.00-8.24 (4H, m), 8.81 (1H, br s), 9.34 (1H, br s)
35

(+)ESI-MS (m/z): 502 (free, M+H)⁺

Example 138

To a suspension of ethyl 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-benzoate hydrochloride (550 mg) in ethanol (5.5 ml) was added 1N sodium hydroxide solution (2.3 ml), and the mixture was stirred at room temperature for 4 hours. After the solvent was evaporated, the residual solid was washed with water to give sodium 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate (404 mg) as a white powder.

NMR (DMSO-d₆, δ): 1.80 (1H, br s), 2.50-2.90 (6H, m),
4.59 (1H, m), 5.41 (1H, br s), 7.15-7.50 (6H, m),
7.82 (4H, d, J=8Hz), 7.98 (2H, d, J=8Hz)
(-)ESI-MS (m/z): 460 (free, M-H)⁻

Example 139

The following compounds were obtained according to a similar manner to that of Example 138.

(1) Sodium 4-[[4-[3-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
NMR (DMSO-d₆, δ): 1.66 (2H, quintet, J=7Hz), 2.35-2.80
(6H, m), 4.60 (1H, m), 5.44 (1H, br s, OH), 7.15-
7.55 (6H, m), 7.82 (2H, d, J=8Hz), 7.82 (2H, d, J=8Hz), 7.99 (2H, d, J=8Hz)
(+)ESI-MS (m/z): 474 (free, M+H)⁺

(2) Sodium 4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]benzoate
NMR (DMSO-d₆, δ): 0.88 (3H, d, J=6Hz), 1.56 (1H, br s),
2.45-2.95 (5H, m), 4.55 (1H, m), 5.40 (1H, br s),
7.12-7.50 (6H, m), 7.80 (2H, d, J=8Hz), 7.82 (2H, d, J=8Hz), 7.99 (2H, d, J=8Hz)

(+)ESI-MS (m/z): 474 (free, M+H)⁺

(3) Sodium 3-[[3-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate

5 NMR (DMSO-d₆, δ): 2.35-2.95 (6H, m), 4.61 (1H, dd, J=8 and 4Hz), 7.00-7.60 (7H, m), 7.60-7.90 (2H, m), 7.90 (1H, d, J=8Hz), 8.11 (1H, d, J=8Hz), 8.37 (1H, s)

(+)ESI-MS (m/z): 482 (M+H)⁺

10

(4) Sodium 4-[[3-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate

NMR (DMSO-d₆, δ): 2.35-3.00 (6H, m), 4.62 (1H, m), 7.10-7.60 (6H, m), 7.60-8.00 (4H, m), 8.06 (2H, d, J=8Hz)

15

(+)ESI-MS (m/z): 482 (M+H)⁺

Example 140

To a solution of 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-fluorobenzoic acid hydrochloride (150 mg) in ethanol (1.5 ml) was added 1N sodium hydroxide (583 µl) and the solvent was removed by evaporation. The residue was chromatographed on ODS (Daisogel SP-120, eluent: water/methanol) to give sodium 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-fluorobenzoate (132 mg) as a white solid.

(-)APCI-MS (m/z): 476 (M-Na)⁻

Example 141

The following compound was obtained according to a similar manner to that of Example 140.

Methyl 2-chloro-4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoate

35

hydrochloride

(+)APCI-MS (m/z): 508 (M+H)⁺

Example 142

5 To a suspension of ethyl 4-[[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-fluorobenzoate hydrochloride (204 mg) in ethanol (2.0 ml) was added 1N sodium hydroxide solution (0.94 ml) and the resulting solution was stirred at room temperature for 17
10 hours. To the solution were added 1N hydrochloric acid (0.94 ml) and water (4.0 ml). The resulting suspension was stirred for 1 hour and the precipitates were collected by filtration. The precipitates were washed with water and dried under reduced pressure to give 4-[[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-
15 fluorobenzoic acid hydrochloride (161 mg) as a pale yellow solid.

IR (KBr): 3359, 3026, 1630, 1599, 1406, 1369, 1329,
1155, 698 cm⁻¹

20 NMR (DMSO-d₆, δ): 2.84-3.24 (6H, m), 4.94-4.97 (1H, m),
7.26-7.51 (6H, m), 7.67-7.81 (3H, m), 7.92 (2H, d,
J=8.3Hz)

(-)APCI-MS (m/z): 476 (M-H)⁻

25 Example 143

The following compound was obtained according to a similar manner to that of Example 142.

(1) 2-Chloro-4-[[4-[2-[[(2R)-2-(3-chlorophenyl)-2-
30 hydroxyethyl]amino]ethyl]phenyl]sulfonyl]benzoic acid hydrochloride

IR (KBr): 3421, 2952, 1724, 1593, 1576, 1385, 1363,
1308, 1157, 1109, 694 cm⁻¹

35 NMR (DMSO-d₆, δ): 2.95-3.22 (6H, m), 4.98-5.02 (1H, m),
7.32-7.52 (6H, m), 7.62 (1H, d, J=8.0Hz), 7.80-

7.97 (4H, m), 9.52 (2H, br)
(-)APCI-MS (m/z): 492 (M-H)⁻

- (2) 4-[[4-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
5 amino]ethyl]phenyl]sulfonyl]-2-methylbenzoic acid
hydrochloride
IR (KBr): 3417, 3005, 1716, 1597, 1294, 1194, 1155,
1084 cm⁻¹
NMR (DMSO-d₆, δ): 2.95-3.21 (6H, m), 4.97-5.00 (1H, m),
10 7.33-7.55 (6H, m), 7.81-7.97 (5H, m), 10.3 (2H,
br)
(-)APCI-MS (m/z): 472 (M-H)⁻

Example 144

- 15 To a solution of ethyl 4-[[4-[(2R)-2-[[[(2R)-2-(3-
chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-
2-fluorobenzoate (378 mg) in ethanol (3.8 ml) was added 1N
sodium hydroxide (909 μl) and the mixture was stirred at room
temperature overnight. An additional portion of 1N sodium
20 hydroxide (363 μl) was added and the mixture was stirred at
60°C for 3 hours. After cooling to room temperature, the
solvent was removed by evaporation and the residual solid
was chromatographed on ODS (Daisogel SP-120, eluent:
water/methanol) to give sodium 4-[[4-[(2R)-2-[[[(2R)-2-(3-
25 chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-
2-fluorobenzoate (280 mg) as a white solid.

- NMR (DMSO-d₆, δ): 1.00 (3H, d, J=6.2Hz), 2.68 (1H, d,
J=9.5, 12.6Hz), 2.87-3.17 (4H, m), 3.30 (2H, br),
4.94-4.97 (1H, m), 7.35-7.46 (6H, m), 7.65-7.78
30 (3H, m), 7.89 (2H, d, J=8.3Hz)
(-)APCI-MS (m/z): 490 (M-Na)⁻

Example 145

- The following compounds were obtained according to a
35 similar manner to that of Example 144.

- (1) Sodium 2-chloro-4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]-sulfonyl]benzoate
5 NMR (DMSO-d₆, δ): 0.98 (3H, d, J=6.1Hz), 2.67 (1H, dd, J=8.8, 12.7Hz), 2.83-3.35 (6H, m), 4.86-4.89 (1H, m), 7.28-7.53 (7H, m), 7.74-7.90 (4H, m)
(-)APCI-MS (m/z): 506 (M-Na)⁻
- 10 (2) Sodium 4-[[4-[(2R)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]-2-methylbenzoate
NMR (DMSO-d₆, δ): 0.94 (3H, d, J=6.0Hz), 2.61 (1H, dd, J=8.0, 12.8Hz), 2.80-3.17 (4H, m), 4.76 (1H, dd, J=4.2, 7.9Hz), 7.24-7.41 (6H, m), 7.57-7.67 (3H, m), 7.82 (2H, d, J=8.2Hz)
15 (-)APCI-MS (m/z): 486 (M-Na)⁻
- (3) Sodium 2'-chloro-4'-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-1,1'-biphenyl-4-carboxylate
20 NMR (DMSO-d₆, δ): 1.65 (1H, br), 2.61-2.78 (4H, m), 3.08-3.20 (2H, m), 4.60 (1H, br), 5.50 (1H, br), 7.23-7.67 (9H, m), 7.93-8.11 (6H, m)
25 (-)APCI-MS (m/z): 568 (M-Na)⁻
- (4) Sodium 2'-chloro-4'-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-1,1'-biphenyl-3-carboxylate
30 NMR (DMSO-d₆, δ): 2.69-2.90 (6H, m), 4.72-4.78 (1H, m), 7.24-7.71 (9H, m), 7.95-8.03 (5H, m), 7.95-8.03 (5H, m), 8.14 (1H, d, J=1.7Hz)
(+)APCI-MS (m/z): 570 (M+H)⁺

To a solution of ethyl 5-[[4-(2-aminoethyl)phenyl]-sulfonyl]-2-methoxybenzoate (74.6 mg) in dimethyl sulfoxide (1.0 ml) was added N,O-bis(trimethylsilyl)acetamide (25.4 μ l) and the solution was stirred at room temperature for 30 minutes. To the mixture was added (2R)-2-(3-chlorophenyl)oxirane (38.1 mg) and the whole was heated at 80°C for 48 hours. After cooling to room temperature, the mixture was quenched by addition of 5% acetic acid in water (2.0 ml) and stirred for 30 minutes. The mixture was basified with saturated aqueous sodium bicarbonate (5.0 ml) and extracted with ethyl acetate (5.0 ml x 3). The combined extracts were washed with water (10 ml x 2) and brine (10 ml x 1), and dried over magnesium sulfate. Filtration followed by evaporation gave a crude product, which was chromatographed on silica gel (eluent: chloroform/methanol) to give the ethyl 5-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-methoxybenzoate (49.8 mg) as a white solid.

(+)APCI-MS (m/z): 518 (M+H)⁺

Example 147

To a suspension of ethyl 5-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-methoxybenzoate (44.1 mg) in ethanol (0.44 ml) was added 1N sodium hydroxide (85.1 μ l) and the mixture was stirred at room temperature for 5 hours. An additional portion of 1N sodium hydroxide (25.5 μ l) was added and the mixture was stirred for 17 hours. The solvent was removed by evaporation and the residual solid was dried under reduced pressure to give sodium 5-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-methoxybenzoate (46.4 mg) as an orange solid.

NMR (CDCl₃, δ): 1.66 (1H, br), 2.59-2.75 (6H, m), 3.75

(3H, s), 4.59 (1H, br), 5.43 (1H, d, J=4.1Hz),

7.04 (1H, d, J=8.7Hz), 7.21-7.42 (6H, m), 7.58 (1H,

d, J=2.5Hz), 7.68-7.78 (3H, m)
(-)APCI-MS (m/z): 488 (M-Na)⁻

Example 148

5 The following compound was obtained according to a similar manner to that of Example 147.

Sodium 4-[[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-methoxybenzoate
10 NMR (CDCl₃, δ): 1.67 (1H, br), 2.60-2.75 (6H, m), 3.76 (3H, s), 4.59 (1H, br), 5.42 (1H, d, J=3.7Hz), 7.21-7.47 (9H, m), 7.83 (1H, d, J=8.1Hz)
(-)APCI-MS (m/z): 488 (M-Na)⁻

15 Example 149

The following compound was obtained according to a similar manner to that Example 49.

(1R)-2-[N-benzyl-N-[2-[4-[[3-(2-hydroxyethoxy)phenyl]-sulfonyl]phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol
20 (+)ESI-MS (m/z): 566 (M+H)⁺

Example 150

25 The following compounds were obtained according to a similar manner to that of Example 70.

(1) (1R)-2-[[2-[2-Chloro-4-[(4-methoxyphenyl)sulfonyl]-phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol hydrochloride
30 NMR (DMSO-d₆, δ): 3.02-3.35 (6H, m), 3.83 (3H, s), 4.95-4.99 (1H, m), 6.34-6.35 (1H, m), 7.12-7.16 (2H, m), 7.38-7.47 (4H, m), 7.68-7.99 (5H, m), 8.97 (1H, br)
(+)ESI-MS (m/z): 480 (M-HCl+H)⁺

- (2) N-[3-[[4-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]phenyl]acetamide hydrochloride
NMR (DMSO-d₆, δ): 2.05 (3H, s), 3.0-3.4 (6H, m), 4.93-4.99 (1H, m), 6.32-6.34 (1H, m), 7.37-7.85 (12H, m), 8.32 (1H, s), 8.83-8.94 (1H, br), 10.38 (1H, s)
(+)ESI-MS (m/z): 473 (M-HCl+H)⁺
- 10 (3) (1R)-1-(3-Chlorophenyl)-2-[[2-[4-[[3-(dimethylamino)-phenyl]sulfonyl]phenyl]ethyl]amino]ethanol hydrochloride
NMR (DMSO-d₆, δ): 2.48 (3H, s), 2.49 (3H, s), 3.09-3.29 (6H, m), 4.98-5.04 (1H, m), 6.95-6.99 (1H, m), 7.13-7.16 (2H, m), 7.34-7.59 (7H, m), 7.82-7.88 (2H, m), 8.94 (1H, br), 9.26 (1H, br)
15 (+)ESI-MS (m/z): 459 (M-HCl+H)⁺
- 20 (4) (1R)-1-(3-Chlorophenyl)-2-[[2-[6-[(4-methoxyphenyl)-sulfonyl]-3-pyridyl]ethyl]amino]ethanol hydrochloride
NMR (DMSO-d₆, δ): 3.00-3.47 (6H, m), 3.84 (3H, s), 4.95-5.00 (1H, m), 7.16 (2H, d, J=7.0Hz), 7.33-7.45 (4H, m), 7.90 (2H, d, J=7.0Hz), 8.03 (1H, d, J=8.0Hz), 8.15 (1H, d, J=8.0Hz), 8.60 (1H, s), 8.91 (1H, br), 9.15 (1H, br)
25 (+)ESI-MS (m/z): 447 (M-HCl+H)⁺

Example 151

The following compounds were obtained according to a similar manner to that of Example 76.

- (1) Ethyl [4-[[5-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2-pyridyl]sulfonyl]-phenoxy]acetate
35 (+)ESI-MS (m/z): 519 (M+H)⁺

(2) Ethyl [4-[[3-chloro-4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate

5 (+)ESI-MS (m/z): 552 (M+H)⁺

Example 152

The following compound was obtained according to a similar manner to that of Example 79.

10

Ethyl [4-[[5-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2-pyridinyl]sulfonyl]phenoxy]-acetate hydrochloride

15 NMR (DMSO-d₆, δ): 1.20 (3H, t, J=7.0Hz), 2.99-3.36 (6H, m), 4.16 (2H, q, J=7.0Hz), 4.92 (2H, s), 4.90-4.95 (1H, m), 6.27-6.29 (1H, m), 7.14-7.17 (2H, m), 7.36-7.45 (4H, m), 7.87-7.89 (2H, m), 8.01-8.04 (1H, m), 8.16 (1H, d, J=4.0Hz), 8.60 (1H, s), 8.78 (1H, br)

20 (+)ESI-MS (m/z): 519 (M-HCl+H)⁺

Example 153

The following compounds were obtained according to a similar manner to that of Example 42.

25

(1) Ethyl [4-[[4-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]methyl]phenyl]sulfonyl]phenoxy]-acetate

30 NMR (CDCl₃, δ): 1.28 (3H, t, J=7Hz), 2.57 (1H, dd, J=13 and 9Hz), 2.66 (1H, dd, J=13 and 4Hz), 3.50 (1H, br s), 3.50 (1H, d, J=13Hz), 3.55 (1H, d, J=14Hz), 3.84 (1H, d, J=13Hz), 3.89 (1H, d, J=14Hz), 4.26 (2H, q, J=7Hz), 4.65 (2H, s), 4.68 (1H, dd, J=9 and 4Hz), 6.97 (2H, d, J=9Hz), 7.00-7.50 (11H, m),
35 7.87 (2H, d, J=8Hz), 7.89 (2H, d, J=9Hz)

(+)ESI-MS (m/z): 594 (M+H)⁺

(2) Ethyl [4-[[4-[3-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenyl]sulfonyl]phenoxy]-acetate

5 NMR (CDCl₃, δ): 1.29 (3H, t, J=7Hz), 1.80 (2H, quintet, J=7Hz), 2.35-2.80 (6H, m), 3.48 (1H, d, J=13Hz), 3.87 (1H, d, J=13Hz), 4.26 (2H, q, J=7Hz), 4.60 (1H, dd, J=10 and 4Hz), 4.65 (2H, s), 6.96 (2H, d, J=9Hz), 7.08-7.45 (11H, m), 7.79 (2H, d, J=8Hz), 7.87 (2H, d, J=9Hz)

(+)ESI-MS (m/z): 622 (M+H)⁺

Example 154

15 The following compound was obtained according to a similar manner to that of Example 138.

Sodium 4-[[4-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]methyl]phenyl]sulfonyl]benzoate

20 NMR (DMSO-d₆, δ): 2.60 (2H, d, AB of ABX), 3.78 (2H, s), 4.65 (1H, t, X of ABX), 5.45 (1H, br s, OH), 7.15-7.48 (4H, m), 7.52 (2H, d, J=8Hz), 7.83 (2H, d, J=8Hz), 7.86 (2H, d, J=8Hz), 8.00 (2H, d, J=8Hz)

(-)ESI-MS (m/z): 444 (free, M-H)⁻

25

Example 155

To a solution of methyl [3-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-phenoxy]acetate (51 mg) in methanol (1.0 ml) was added 1M ammonia in methanol (2.0 ml), and the mixture was stirred at room temperature for 4 hours. The mixture was evaporated under reduced pressure. The residue was dissolved in dichloromethane (20 ml) and methanol (2.0 ml), and washed with water (5.0 ml). The aqueous layer was extracted with 35 dichloromethane (20 ml). The combined organic layers were

dried over magnesium sulfate and evaporated under reduced pressure. The residue was suspended in 4N hydrogen chloride in ethyl acetate (0.5 ml) and stirred for 5 minutes. The solvent was removed by evaporation to give 2-[3-[[4-[2-
5 [[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]sulfonyl]phenoxy]acetamide hydrochloride (33 mg) as a white foam.

NMR (DMSO- d_6 , δ): 3.05-3.53 (6H, m), 4.53 (2H, s),
4.93-4.98 (1H, m), 6.31-6.33 (1H, m), 7.22-7.26
10 (1H, m), 7.36-7.55 (9H, m), 7.92-7.96 (2H, m),
8.84-8.99 (2H, br)
(+)ESI-MS (m/z): 489 (M-HCl+H)⁺

Example 156

15 Under nitrogen at room temperature, to a solution of 3-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]phenol (210 mg) and β -propiolactone (40 μ l) in tetrahydrofuran (2.5 ml) was added potassium tert-butoxide (50 mg) by portion, and the mixture
20 was stirred at room temperature for 48 hours. To this one was added 3.95N hydrogen chloride in ethanol (1.5 ml), and the mixture was stirred for 12 hours. The resulting mixture was evaporated under reduced pressure. The residue was diluted with ethyl acetate and an aqueous solution of sodium
25 hydroxide (1N). The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (methanol/chloroform = 1/30) to give ethyl 3-[3-[[4-[2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-
30 hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]propanoate (105 mg) as a colorless oil.

(+)ESI-MS (m/z): 622 (M+H)⁺

Example 157

35 The following compounds were obtained according to a

similar manner to that of Preparation 19.

- (1) 4-[[4-[2-[N-(tert-Butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]butanoic acid
5 MS (m/z): 526 (M+H)
- (2) Methyl 4-[[[4-[2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-sulfonyl]methyl]benzoate
10 MS (m/z): 588 (M+H)

Example 158

To a mixture of (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetic acid
15 (102 mg) in a mixture of tetrahydrofuran (20 ml) and water (8 ml) was added saturated aqueous sodium bicarbonate to be adjusted to about pH 8.5, and to this one was added 1-[[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]oxy]-2,5-pyrrolidinedione (68 mg) in tetrahydrofuran (3 ml)
20 controlling the pH at 8.5 at room temperature. The mixture was stirred at the same temperature for 3 hours. The resulting mixture was adjusted to pH 3 with 1N hydrochloric acid, and ethyl acetate was added. After separation, the
25 organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by thin layer silica gel chromatography (chloroform : methanol = 3 : 1) to give (R)-[4-[[4-[2-[N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]amino]ethyl]phenyl]sulfonyl]-
30 phenoxy]acetic acid (86 mg).

NMR (DMSO-d₆, δ): 2.05-2.15 (3H, m), 2.75-3.0 (2H, m),
3.15-3.5 (4H, m), 4.45 (2H, s), 4.6-4.85 (3H, m),
6.99 (2H, d, J=8.5Hz), 7.15-7.5 (6H, m), 7.75-7.9
35 (4H, m)

(-)ESI-MS (m/z): 644, 646 (M-H)⁻

Example 159

The following compound was obtained according to a
5 similar manner to that of Example 146.

Ethyl 4-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-2-methoxybenzoate
(+)APCI-MS (m/z): 518 (M+H)⁺

10

Example 160

To a suspension of ethyl (R)-6-[[4-[2-[[2-(3-
chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]-
nicotinate (31 mg) in ethanol (2 ml) was added 1N sodium
15 hydroxide (0.063 ml) at room temperature, and the mixture was
stirred at the same temperature for 6 hours. The resulting
mixture was evaporated under reduced pressure and dried in
vacuo to give sodium (R)-6-[[4-[2-[[2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]nicotinate (31 mg).

20 NMR (DMSO-d₆, δ): 2.5-2.85 (6H, m), 4.55-4.7 (1H, m),
7.1-7.5 (6H, m), 7.84 (2H, d, J=8.3Hz), 8.09 (1H,
d, J=8.0Hz), 8.34 (1H, dd, J=1.8, 7.9Hz), 8.9 (1H,
m)

(-)ESI-MS (m/z): 459, 461 (M-Na-H)⁻

25

Example 161

4-[[4-[2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]ethyl]phenyl]sulfonyl]benzoic acid hydrochloride (39
mg) and 10% hydrogen chloride in methanol (2 ml) were mixed
30 and stirred at room temperature for 11.5 days. Evaporation
of the solvent gave methyl 4-[[4-[2-[(2R)-2-(3-
chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-
sulfonyl]benzoate hydrochloride (38 mg) as a white powder.

35 NMR (DMSO-d₆, δ): 2.90-3.50 (6H, m), 3.88 (3H, s), 4.91
(1H, m), 6.33 (1H, br s, OH), 7.28-7.52 (4H, m),

WO-02/094770

PCT/JP02/04863

244

7.54 (2H, d, J=8Hz), 7.96 (2H, d, J=8Hz), 7.98-
8.23 (4H, m), 9.05 (2H, br s)
(+)ESI-MS (m/z): 474 (free, M+H)⁺

5

10

15


20

25

30

C L A I M S

1. A compound of the formula [I]:




wherein

R^1 is phenyl, pyridyl, indolyl or carbazolyl, each of which may be substituted with one or two same or different substituent(s) selected from a group consisting of halogen; hydroxy; benzyloxy; nitro; cyano; mono(or di or tri)halo(lower)alkyl; and (lower alkylsulfonyl)amino,

R^2 is hydrogen, [5-(lower alkyl)-2-oxo-1,3-dioxol-4-yl](lower)alkoxycarbony or an amino protective group,


R^3 and R^4 are each independently hydrogen, lower alkyl or hydroxy(lower)alkyl,



R^5 is aryl, ar(lower)alkyl, a heterocyclic group or lower alkyl, each of which may be substituted with one, two or three same or different substituent(s) selected from a group consisting of halogen; hydroxy; cyano; amino(hydroxyimino)methyl; phenyl optionally substituted with carboxy or lower alkoxycarbonyl; phenoxy optionally substituted with halogen; lower alkoxy optionally substituted with hydroxy, amino, cyano, carboxy, carbamoyl, mono(or di)(lower)alkylcarbamoyl, lower alkoxycarbonyl, cyclo(lower)alkyloxycarbonyl,

hydroxy(lower)alkoxycarbonyl,
 di[(lower)alkoxy](lower)alkoxycarbonyl,
 pyridyl(lower)alkoxycarbonyl, phenyl or
 tetrazolyl; mono(or di or tri)halo(lower)alkoxy;
 5 lower alkyl optionally substituted with carboxy,
 lower alkoxycarbonyl, dioxothiazolidinyl or
 dioxothiazolidinylidene; lower alkenyl optionally
 substituted with carboxy or lower alkoxycarbonyl;
 oxadiazolyl optionally substituted with lower
 10 alkyl; tetrazolyl; triazolylthio; lower alkanoyl;
 carboxy; lower alkoxycarbonyl; carbamoyl
 optionally substituted with one or two same or
 different substituent(s) selected from a group
 consisting of lower alkyl, lower alkoxy,
 15 carboxy(lower)alkyl, lower
 alkoxycarbonyl(lower)alkyl, tetrazolyl, thiazolyl
 optionally substituted with lower alkyl, oxazolyl
 optionally substituted with lower alkyl,
 oxadiazolyl, lower alkylsulfonyl and
 20 phenylsulfonyl; (hydroxypiperidino)carbonyl; (2,4-
 dioxo-1,3-thiazolidin-5-ylidene)methyl; and amino
 optionally substituted with one or two same or
 different substituent(s) selected from a group
 consisting of lower alkyl, lower alkanoyl, benzoyl,
 25 pyridylcarbonyl, lower alkylsulfonyl,
 phenylsulfonyl, carbamoyl, lower alkylcarbamoyl,
 phenylcarbamoyl, lower alkoxycarbonyl and
 phenoxycarbonyl,

or



35 in which R⁶ and R⁷ are each independently

hydrogen, carboxy or lower
alkoxycarbonyl,

R⁸ is hydrogen or halogen,

X is a single bond or -O-CH₂-, and

5 n is 0, 1 or 2,
or a salt thereof.

2. A compound of claim 1, wherein

10 R² is hydrogen, [5-(lower alkyl)-2-oxo-1,3-dioxol-4-yl](lower)alkoxycarbonyl, lower alkoxycarbonyl or ar(lower)alkyl.

3. A compound of claim 2, wherein

15 R¹ is phenyl which may be substituted with one or two same or different substituent(s) selected from a group consisting of halogen; hydroxy; benzyloxy; nitro and (lower alkylsulfonyl)amino,


R² is hydrogen or [5-(lower alkyl)-2-oxo-1,3-dioxol-4-yl](lower)alkoxycarbonyl, and

20 R⁵ is phenyl, benzyl, triazolyl, tetrazolyl, quinolyl, thiazolyl, thienyl or lower alkyl, each of which may be substituted with one, two or three same or different substituent(s) selected from a group consisting of halogen; hydroxy; cyano;
25 amino(hydroxyimino)methyl; phenyl optionally substituted with carboxy or lower alkoxycarbonyl; phenoxy optionally substituted with halogen; lower alkoxy optionally substituted with hydroxy, amino, cyano, carboxy, carbamoyl, mono(or
30 di)(lower)alkoxycarbamoyl, lower alkoxycarbonyl, cyclo(lower)alkyloxycarbonyl, hydroxy(lower)alkoxycarbonyl, di[(lower)alkoxy](lower)alkoxycarbonyl, pyridyl(lower)alkoxycarbonyl, phenyl or
35 tetrazolyl; mono(or di or tri)halo(lower)alkoxy;

lower alkyl optionally substituted with carboxy,
 lower alkoxy, carbonyl, dioxothiazolidinyl or
 dioxothiazolidinylidene; lower alkenyl optionally
 substituted with carboxy or lower alkoxy, carbonyl;
 5 oxadiazolyl optionally substituted with lower
 alkyl; tetrazolyl; triazolylthio; lower alkanoyl;
 carboxy; lower alkoxy, carbonyl; carbamoyl
 optionally substituted with one or two same or
 different substituent(s) selected from a group
 10 consisting of lower alkyl, lower alkoxy, carboxy,
 lower alkoxy, carbonyl, thiazolyl optionally
 substituted with lower alkyl, oxazolyl optionally
 substituted with lower alkyl, oxadiazolyl, lower
 alkylsulfonyle and phenylsulfonyle;
 15 (hydroxypiperidino)carbonyl; (2,4-dioxo-1,3-
 thiadiazolidin-5-ylidene)methyl; and amino
 optionally substituted with one or two same or
 different substituent(s) selected from a group
 consisting of lower alkyl, lower alkanoyl, benzoyl,
 20 pyridylcarbonyl, lower alkylsulfonyle,
 phenylsulfonyle, carbamoyl, lower alkylcarbamoyl,
 phenylcarbamoyl, lower alkoxy, carbonyl and
 phenoxy, carbonyl,

or

25




30

in which R⁶ and R⁷ are each independently
 hydrogen, carboxy or lower
 alkoxy, carbonyl.

4. A compound of claim 3, wherein
 35 R¹ is phenyl which may be substituted with halogen,

R^2 is hydrogen,



5 R^5 is phenyl which may be substituted with one, two or
three same or different substituent(s) selected
from a group consisting of halogen; hydroxy;
cyano; amino(hydroxyimino)methyl; phenyl
optionally substituted with carboxy or lower
10 alkoxy carbonyl; phenoxy optionally substituted
with halogen; lower alkoxy optionally substituted
with hydroxy, amino, cyano, carboxy, carbamoyl,
mono(or di)(lower)alkoxy carbamoyl, lower
alkoxy carbonyl, cyclo(lower)alkyloxy carbonyl,
15 hydroxy(lower)alkoxy carbonyl,
di[(lower)alkoxy](lower)alkoxy carbonyl,
pyridyl(lower)alkoxy carbonyl, phenyl or
tetrazolyl; mono(or di or tri)halo(lower)alkoxy;
lower alkyl optionally substituted with carboxy,
20 lower alkoxy carbonyl, dioxothiazolidinyl or
dioxothiazolidinylidene; lower alkenyl optionally
substituted with carboxy or lower alkoxy carbonyl;
oxadiazolyl optionally substituted with lower
alkyl; tetrazolyl; triazolylthio; lower alkanoyl;
25 carboxy; lower alkoxy carbonyl; carbamoyl
optionally substituted with one or two same or
different substituent(s) selected from a group
consisting of lower alkyl, lower alkoxy, carboxy,
lower alkoxy carbonyl, thiazolyl optionally
30 substituted with lower alkyl, oxazolyl optionally
substituted with lower alkyl, oxadiazolyl, lower
alkylsulfonyl or phenylsulfonyl; and amino
optionally substituted with one or two same or
different substituent(s) selected from a group
35 consisting of lower alkyl and lower alkanoyl,


R⁸ is hydrogen,
X is a single bond, and
n is 1.

- 5 5. A compound of claim 4, wherein
R³ and R⁴ are each hydrogen, and
R⁵ is phenyl substituted with lower alkoxy optionally
substituted with a substituent selected from a
group consisting of hydroxy, amino, cyano, carboxy,
10 carbamoyl, mono(or di)(lower)alkoxycarbamoyl,
lower alkoxycarbonyl, cyclo(lower)alkyloxycarbonyl,
hydroxy(lower)alkoxycarbonyl,
di[(lower)alkoxy](lower)alkoxycarbonyl,
pyridyl(lower)alkoxycarbonyl, phenyl and
15 tetrazolyl.
6. A compound of claim 5, which is selected from a group
consisting of
- 20 (1) Isopropyl (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-
hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-
acetate,
- (2) (R)-2-[4-[[4-[2-[[2-(3-Chlorophenyl)-2-
25 hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-N-
methylacetamide,
- (3) [4-[[4-[2-[[(R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]ethyl]phenyl]sulfonyl]phenoxy]acetate,
- 30 (4) (1R)-2-[[2-[4-[[4-(2-Aminoethoxy)phenyl]sulfonyl]-
phenyl]ethyl]amino]-1-(3-chlorophenyl)ethanol,
- (5) Ethyl {4-[[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxy-
35 ethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]acetate,

- (6) 2-Pyridylmethyl (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate,
- (7) 2-Hydroxyethyl (R)-[4-[[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]sulfonyl]phenoxy]-acetate,
- (8) (R)-1-(3-Chlorophenyl)-2-[[2-[4-[[4-(1H-tetrazol-5-ylmethoxy)phenyl]sulfonyl]phenyl]ethyl]amino]ethanol,
- (9) (R)-2-[4-[[4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]sulfonyl]phenoxy]acetamide, and
- (10) (1R)-1-(3-Chlorophenyl)-2-[[2-[4-[[3-(2-hydroxyethoxy)phenyl]sulfonyl]phenyl]ethyl]amino]ethanol
- or a pharmaceutically acceptable salt thereof.
7. A process for preparing a compound of claim 1, or a salt thereof, which comprises,
- (i) reacting a compound [II] of the formula:




wherein R^1 and X are each as defined in claim 1, with a compound [III] of the formula:



wherein R^2 , R^3 , R^4 , \textcircled{R} , R^5 , R^8 and n are each as defined in claim 1,


or a salt thereof, to give a compound [I] of the formula:



wherein R^1 , R^2 , R^3 , R^4 , \textcircled{R} , R^5 , R^8 , X and n are each as defined in claim 1,

or a salt thereof,


(ii) subjecting a compound [Ia] of the formula :



wherein R^1 , R^3 , R^4 , \textcircled{R} , R^5 , R^8 , X and n are each as defined in claim 1, and


R_a^2 is [5-(lower alkyl)-2-oxo-1,3-dioxol-4-yl](lower)alkoxycarbonyl or an amino protective group,

or a salt thereof, to elimination reaction of the amino protective group, to give a compound [Ib] of the formula:



wherein R^1 , R^3 , R^4 , \textcircled{R} , R^5 , R^8 , X and n are each as
defined in claim 1,
or a salt thereof, and

(iii) reacting a compound [Ic] of the formula:




wherein R^1 , R^2 , R^3 , R^4 , \textcircled{R} , R^8 , X and n are each as
defined in claim 1,
with a compound [IV] of the formula:



wherein R^9 is lower alkyl optionally substituted with
hydroxy, amino, cyano, carboxy, carbamoyl,
mono(or di) (lower)alkylcarbamoyl, lower
alkoxycarbonyl, cyclo(lower)alkyloxy-
carbonyl, hydroxy(lower)alkoxycarbonyl,
di[(lower)alkoxy] (lower)alkoxycarbonyl,
pyridyl(lower)alkoxycarbonyl, phenyl or
tetrazolyl, and

Y is halogen,

to give a compound [Id] of the formula:



defined in claim 1, and
R⁹ is as defined above,
or a salt thereof.

- 5 8. A pharmaceutical composition which comprises, as an
active ingredient, a compound of claim 1 or a
pharmaceutically acceptable salt thereof in admixture
with pharmaceutically acceptable carriers or excipients.
- 10 9. Use of a compound of claim 1 or a pharmaceutically
acceptable salt thereof for the manufacture of a
medicament.
- 15 10. A compound of claim 1 or a pharmaceutically acceptable
salt thereof for use as a medicament.
- 20 11. A compound of claim 1 or a pharmaceutically acceptable
salt thereof for use as selective β_3 adrenergic receptor
agonists.
- 25 12. A method for the prophylactic and/or the therapeutic
treatment of pollakiuria or urinary incontinence which
comprises administering a compound of claim 1 or a
pharmaceutically acceptable salt thereof to a human
being or an animal.